advertisement

Oculus

List of abstracts related to

80737 Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial
Fan KR; Baskaran M; Nongpiur ME; Htoon HM; De Leon JMS; Perera SA; Belkin M; Aung T
Acta Ophthalmologica 2019; 97: e827-e832

Listed by Classification


11.14 Investigational drugs; pharmacological experiments (2172 abstracts found)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Yagi-Yaguchi Y
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


85112 Secondary Neuroprotection in Glaucoma Through the Concepts of Complementary Drug Therapy
Erb C
Klinische Monatsblätter für Augenheilkunde 2020; 237: 163-174 (IGR: 21-1)


85085 Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
Montero-Oleas N
BMC complementary medicine and therapies 2020; 20: 12 (IGR: 21-1)


85019 Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
Wisely CE
Advances in Therapy 2020; 37: 1114-1123 (IGR: 21-1)


85228 Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells
Chen W
Frontiers in pharmacology 2020; 11: 302 (IGR: 21-1)


84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Nemoto E
International journal of molecular sciences 2019; 21: (IGR: 21-1)


84522 Once Daily Pregabalin Eye Drops for Management of Glaucoma
Ibrahim MM
ACS nano 2019; 13: 13728-13744 (IGR: 21-1)


85225 Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis
Park CW
EXCLI journal 2020; 19: 187-200 (IGR: 21-1)


84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Rocha LR
Aging Cell 2020; 19: e13089 (IGR: 21-1)


85224 Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
Martin P
Clinical Ophthalmology 2020; 14: 885-896 (IGR: 21-1)


85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Sanz-González SM
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)


84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Yamamoto K
Scientific reports 2019; 9: 19288 (IGR: 21-1)


84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Tan J
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)


84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Caruso C
International Ophthalmology 2019; 0: (IGR: 21-1)


85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Hommer N
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)


84489 New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Mehran NA
Eye 2020; 34: 72-88 (IGR: 21-1)


84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Nguyen Huu VA
Aging Cell 2020; 19: e13089 (IGR: 21-1)


84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Wang X
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)


85085 Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
Arevalo-Rodriguez I
BMC complementary medicine and therapies 2020; 20: 12 (IGR: 21-1)


84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Kokubun T
Scientific reports 2019; 9: 19288 (IGR: 21-1)


84489 New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Sinha S
Eye 2020; 34: 72-88 (IGR: 21-1)


85019 Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
Sheng H
Advances in Therapy 2020; 37: 1114-1123 (IGR: 21-1)


85228 Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells
Yang X
Frontiers in pharmacology 2020; 11: 302 (IGR: 21-1)


85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Kallab M
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)


85224 Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
Cohen A
Clinical Ophthalmology 2020; 14: 885-896 (IGR: 21-1)


85225 Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis
Han CT
EXCLI journal 2020; 19: 187-200 (IGR: 21-1)


84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Kojima S
International journal of molecular sciences 2019; 21: (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Kojima T
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


84522 Once Daily Pregabalin Eye Drops for Management of Glaucoma
Maria DN
ACS nano 2019; 13: 13728-13744 (IGR: 21-1)


85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Raga-Cervera J
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)


84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Pacente L
International Ophthalmology 2019; 0: (IGR: 21-1)


85019 Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
Heah T
Advances in Therapy 2020; 37: 1114-1123 (IGR: 21-1)


84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Cai S
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)


85225 Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis
Sakaguchi Y
EXCLI journal 2020; 19: 187-200 (IGR: 21-1)


84489 New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost
Razeghinejad R
Eye 2020; 34: 72-88 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Higa K
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


84522 Once Daily Pregabalin Eye Drops for Management of Glaucoma
Mishra SR
ACS nano 2019; 13: 13728-13744 (IGR: 21-1)


84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Sato K
Scientific reports 2019; 9: 19288 (IGR: 21-1)


85224 Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
Uddin S
Clinical Ophthalmology 2020; 14: 885-896 (IGR: 21-1)


85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Aguirre Lipperheide M
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)


85228 Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells
Fang J
Frontiers in pharmacology 2020; 11: 302 (IGR: 21-1)


84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Troiano P
International Ophthalmology 2019; 0: (IGR: 21-1)


84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Palomino La Torre C
Aging Cell 2020; 19: e13089 (IGR: 21-1)


85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Szegedi S
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)


85085 Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
Nuñez-González S
BMC complementary medicine and therapies 2020; 20: 12 (IGR: 21-1)


84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Sugiyama T
International journal of molecular sciences 2019; 21: (IGR: 21-1)


85225 Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis
Lee J
EXCLI journal 2020; 19: 187-200 (IGR: 21-1)


85228 Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells
Zhang Y
Frontiers in pharmacology 2020; 11: 302 (IGR: 21-1)


84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
He F
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)


84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Jin D
International journal of molecular sciences 2019; 21: (IGR: 21-1)


85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Zanón-Moreno V
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)


84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Ostacolo C
International Ophthalmology 2019; 0: (IGR: 21-1)


85085 Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
Viteri-García A
BMC complementary medicine and therapies 2020; 20: 12 (IGR: 21-1)


85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Puchner S
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)


84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Akaishi T
Scientific reports 2019; 9: 19288 (IGR: 21-1)


84522 Once Daily Pregabalin Eye Drops for Management of Glaucoma
Guragain D
ACS nano 2019; 13: 13728-13744 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Dogru M
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


85019 Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2
Kim T
Advances in Therapy 2020; 37: 1114-1123 (IGR: 21-1)


84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Xu Q
Aging Cell 2020; 19: e13089 (IGR: 21-1)


85224 Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
Epelbaum L
Clinical Ophthalmology 2020; 14: 885-896 (IGR: 21-1)


84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Takai S
International journal of molecular sciences 2019; 21: (IGR: 21-1)


85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Stjepanek K
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)


85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Chiner V
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)


85224 Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
Josiah S; Josiah S
Clinical Ophthalmology 2020; 14: 885-896 (IGR: 21-1)


84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Jabari M
Aging Cell 2020; 19: e13089 (IGR: 21-1)


84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
D'Andrea L
International Ophthalmology 2019; 0: (IGR: 21-1)


84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Zhang D
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)


85085 Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews
Simancas-Racines D
BMC complementary medicine and therapies 2020; 20: 12 (IGR: 21-1)


84522 Once Daily Pregabalin Eye Drops for Management of Glaucoma
Wang X
ACS nano 2019; 13: 13728-13744 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Ibrahim OM
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


85228 Rho-Associated Protein Kinase Inhibitor Treatment Promotes Proliferation and Phagocytosis in Trabecular Meshwork Cells
Zhu W
Frontiers in pharmacology 2020; 11: 302 (IGR: 21-1)


84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Shimazaki A
Scientific reports 2019; 9: 19288 (IGR: 21-1)


85225 Safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis
Youn HY
EXCLI journal 2020; 19: 187-200 (IGR: 21-1)


84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Nakamura M
Scientific reports 2019; 9: 19288 (IGR: 21-1)


84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Bartollino S
International Ophthalmology 2019; 0: (IGR: 21-1)


84522 Once Daily Pregabalin Eye Drops for Management of Glaucoma
Jablonski MM
ACS nano 2019; 13: 13728-13744 (IGR: 21-1)


85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Bauer M
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)


84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Krawczyk M
Aging Cell 2020; 19: e13089 (IGR: 21-1)


84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Bartollino S
International Ophthalmology 2019; 0: (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Shimizu T
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Li D
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)


84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Maeda M
International journal of molecular sciences 2019; 21: (IGR: 21-1)


85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Ramírez AI
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)


85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Werkmeister RM
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)


84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Weinreb RN
Aging Cell 2020; 19: e13089 (IGR: 21-1)


84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Zhu X
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Tsubota K
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


85017 Effect of an oral supplementation with a formula containing R-lipoic acid in glaucoma patients
Pinazo-Durán MD
Archivos de la Sociedad Española de Oftalmologia 2020; 95: 120-129 (IGR: 21-1)


84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Kohmoto R
International journal of molecular sciences 2019; 21: (IGR: 21-1)


84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Shiga Y
Scientific reports 2019; 9: 19288 (IGR: 21-1)


84662 Intraocular pressure reduction with once-a-day application of a new prostaglandin eye drop: a pilot placebo-controlled study in 12 patients
Costagliola C
International Ophthalmology 2019; 0: (IGR: 21-1)


84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Tsuda S
Scientific reports 2019; 9: 19288 (IGR: 21-1)


84873 The Effects of 3% Diquafosol Sodium Eye Drops on Tear Function and the Ocular Surface of Cu, Zn-Superoxide Dismutase-1 () Knockout Mice Treated with Antiglaucoma Eye Medications
Shimazaki J
Diagnostics (Basel, Switzerland) 2020; 10: (IGR: 21-1)


84802 Early removal of senescent cells protects retinal ganglion cells loss in experimental ocular hypertension
Skowronska-Krawczyk D
Aging Cell 2020; 19: e13089 (IGR: 21-1)


84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Ueki M
International journal of molecular sciences 2019; 21: (IGR: 21-1)


84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Zhou L
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)


85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Schmetterer L; Abensperg-Traun M
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)


84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Omodaka K
Scientific reports 2019; 9: 19288 (IGR: 21-1)


84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Oku H
International journal of molecular sciences 2019; 21: (IGR: 21-1)


84885 C3 Transferase-Expressing scAAV2 Transduces Ocular Anterior Segment Tissues and Lowers Intraocular Pressure in Mouse and Monkey
Fan N; Liu X
Molecular therapy. Methods & clinical development 2020; 17: 143-155 (IGR: 21-1)


84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Saya H
Scientific reports 2019; 9: 19288 (IGR: 21-1)


84795 Effects of Regorafenib, a Multi-Kinase Inhibitor, on Conjunctival Scarring in a Canine Filtration Surgery Model in Comparison with Mitomycin-C
Ikeda T
International journal of molecular sciences 2019; 21: (IGR: 21-1)


85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Garhöfer G
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)


84772 The DNA topoisomerase II inhibitor amsacrine as a novel candidate adjuvant in a model of glaucoma filtration surgery
Nakazawa T
Scientific reports 2019; 9: 19288 (IGR: 21-1)


85010 The Effect of Orally Administered Dronabinol on Optic Nerve Head Blood Flow in Healthy Subjects-A Randomized Clinical Trial
Schmidl D
Clinical Pharmacology and Therapeutics 2020; 0: (IGR: 21-1)


82273 Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595
Bonardi A
Expert Opinion on Therapeutic Patents 2019; 29: 753-759 (IGR: 20-4)


82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 781-792 (IGR: 20-4)


82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Savinainen A
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)


82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Guo Y
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)


82590 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues
Ha JY
Chonnam medical journal 2019; 55: 156-162 (IGR: 20-4)


82315 Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018)
Angeli A
Expert Opinion on Therapeutic Patents 2019; 29: 793-803 (IGR: 20-4)


82239 Leucaena leucocephala (Lam.) galactomannan nanoparticles: Optimization and characterization for ocular delivery in glaucoma treatment
Mittal N
International Journal of Biological Macromolecules 2019; 139: 1252-1262 (IGR: 20-4)


82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Chițu I
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)


82535 Rho-kinase inhibitors in the management of glaucoma
Berrino E
Expert Opinion on Therapeutic Patents 2019; 29: 817-827 (IGR: 20-4)


82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Savinainen A
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)


82309 Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension
Heo JH
Journal of managed care & specialty pharmacy 2019; 25: 1001-1010 (IGR: 20-4)


82313 The Neuroprotective Effect of the Adiponectin Receptor Agonist AdipoRon on Glutamate-Induced Cell Death in Rat Primary Retinal Ganglion Cells
Uchida T
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 535-541 (IGR: 20-4)


82614 Sustained scleral stiffening in rats after a single genipin treatment
Hannon BG
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)


82430 Latanoprost uptake and release from commercial contact lenses
Horne RR
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)


82163 Novel therapies for glaucoma: a patent review (2013-2019)
Guglielmi P
Expert Opinion on Therapeutic Patents 2019; 29: 769-780 (IGR: 20-4)


82244 Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Millar JC
Experimental Eye Research 2019; 188: 107763 (IGR: 20-4)


82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Krishnan A
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)


82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Quaranta L
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Fernández-Albarral JA
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82877 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Aillegas NA
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-4)


82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Aihara M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)


82222 Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
Sheppard JD
Clinical Ophthalmology 2019; 13: 1279-1288 (IGR: 20-4)


82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Choi KJ
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)


82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Lanza M
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)


82728 Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension
Sinha S
Expert Opinion in Pharmacotherapy 2020; 21: 39-45 (IGR: 20-4)


82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Fakhraie G
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)


82430 Latanoprost uptake and release from commercial contact lenses
Rich JT
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)


82222 Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
Singh IP
Clinical Ophthalmology 2019; 13: 1279-1288 (IGR: 20-4)


82728 Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension
Lee D
Expert Opinion in Pharmacotherapy 2020; 21: 39-45 (IGR: 20-4)


82163 Novel therapies for glaucoma: a patent review (2013-2019)
Carradori S
Expert Opinion on Therapeutic Patents 2019; 29: 769-780 (IGR: 20-4)


82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Lu F
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)


82273 Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 753-759 (IGR: 20-4)


82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Na YJ
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)


82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Mehrabian Z
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)


82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Altamimi ASA
Expert Opinion on Therapeutic Patents 2019; 29: 781-792 (IGR: 20-4)


82590 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues
Sung MS
Chonnam medical journal 2019; 55: 156-162 (IGR: 20-4)


82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Riva I
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)


82309 Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension
Rascati KL
Journal of managed care & specialty pharmacy 2019; 25: 1001-1010 (IGR: 20-4)


82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Mirghorbani M
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)


82315 Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 - 2018)
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 793-803 (IGR: 20-4)


82239 Leucaena leucocephala (Lam.) galactomannan nanoparticles: Optimization and characterization for ocular delivery in glaucoma treatment
Kaur G
International Journal of Biological Macromolecules 2019; 139: 1252-1262 (IGR: 20-4)


82244 Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Savinainen A
Experimental Eye Research 2019; 188: 107763 (IGR: 20-4)


82535 Rho-kinase inhibitors in the management of glaucoma
Supuran CT
Expert Opinion on Therapeutic Patents 2019; 29: 817-827 (IGR: 20-4)


82877 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Tártara LI
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-4)


82614 Sustained scleral stiffening in rats after a single genipin treatment
Schwaner SA
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)


82313 The Neuroprotective Effect of the Adiponectin Receptor Agonist AdipoRon on Glutamate-Induced Cell Death in Rat Primary Retinal Ganglion Cells
Ueta T
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 535-541 (IGR: 20-4)


82244 Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Savinainen A
Experimental Eye Research 2019; 188: 107763 (IGR: 20-4)


82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Voinea LM
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)


82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Kocab AJ
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)


82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Gironi Carnevale UA
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Ramírez AI
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Prusakiewicz JJ
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)


82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Zacks DN
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)


82728 Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension
Kolomeyer NN
Expert Opinion in Pharmacotherapy 2020; 21: 39-45 (IGR: 20-4)


82313 The Neuroprotective Effect of the Adiponectin Receptor Agonist AdipoRon on Glutamate-Induced Cell Death in Rat Primary Retinal Ganglion Cells
Honjo M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 535-541 (IGR: 20-4)


82244 Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Josiah S
Experimental Eye Research 2019; 188: 107763 (IGR: 20-4)


82614 Sustained scleral stiffening in rats after a single genipin treatment
Boazak EM
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)


82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Oswald J
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)


82877 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Caballero G
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-4)


82728 Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension
Kolomeyer NN
Expert Opinion in Pharmacotherapy 2020; 21: 39-45 (IGR: 20-4)


82244 Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Josiah S
Experimental Eye Research 2019; 188: 107763 (IGR: 20-4)


82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Kawata H
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)


82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Katz LJ
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)


82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Mele L
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)


82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Jung WH
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)


82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Biagioli E
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
de Hoz R
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Istrate S
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)


82587 Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Carta F
Expert Opinion on Therapeutic Patents 2019; 29: 781-792 (IGR: 20-4)


82590 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues
Park SW
Chonnam medical journal 2019; 55: 156-162 (IGR: 20-4)


82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Johnson MA
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)


82430 Latanoprost uptake and release from commercial contact lenses
Bradley MW
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)


82309 Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension
Wilson JP
Journal of managed care & specialty pharmacy 2019; 25: 1001-1010 (IGR: 20-4)


82163 Novel therapies for glaucoma: a patent review (2013-2019)
Campestre C
Expert Opinion on Therapeutic Patents 2019; 29: 769-780 (IGR: 20-4)


82244 Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice
Pang IH
Experimental Eye Research 2019; 188: 107763 (IGR: 20-4)


82309 Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension
Lawson KA
Journal of managed care & specialty pharmacy 2019; 25: 1001-1010 (IGR: 20-4)


82877 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Campana V
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-4)


82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Marshak-Rothstein A
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)


82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Bifani Sconocchia M
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
López-Villarín N
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Mollazadeh A
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)


82430 Latanoprost uptake and release from commercial contact lenses
Pitt WG
Journal of Biomaterials Science, Polymer Edition 2020; 31: 1-19 (IGR: 20-4)


82163 Novel therapies for glaucoma: a patent review (2013-2019)
Poce G
Expert Opinion on Therapeutic Patents 2019; 29: 769-780 (IGR: 20-4)


82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Park SB
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)


82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Vrapciu A
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)


82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Albers DS
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)


82728 Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension
Myers JS
Expert Opinion in Pharmacotherapy 2020; 21: 39-45 (IGR: 20-4)


82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Tanaka Y
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)


82313 The Neuroprotective Effect of the Adiponectin Receptor Agonist AdipoRon on Glutamate-Induced Cell Death in Rat Primary Retinal Ganglion Cells
Aihara M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 535-541 (IGR: 20-4)


82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Spencer E
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)


82614 Sustained scleral stiffening in rats after a single genipin treatment
Gerberich BG
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)


82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Ciuluvică RC
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)


82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Kang S
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)


82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Lou Z
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)


82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Rulli E
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)


82877 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Allemandi DA
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-4)


82309 Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension
Richards KM
Journal of managed care & specialty pharmacy 2019; 25: 1001-1010 (IGR: 20-4)


82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Gregory-Ksander M
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)


82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Bartollino S
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)


82614 Sustained scleral stiffening in rats after a single genipin treatment
Winger EJ
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Salobrar-García E
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82728 Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension
Razeghinejad R
Expert Opinion in Pharmacotherapy 2020; 21: 39-45 (IGR: 20-4)


82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Vahedian Z
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)


82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Yamamura K
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)


82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Bartollino S
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)


82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Rich CC
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)


82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Odani-Kawabata N
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)


82614 Sustained scleral stiffening in rats after a single genipin treatment
Prausnitz MR
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)


82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Nam HJ
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)


82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Cohen ML
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)


82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Baumgartner RA
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)


82608 Morphological and Functional Evaluation of Oral Citicoline Therapy in Chronic Open-Angle Glaucoma Patients: A Pilot Study With a 2-Year Follow-Up
Costagliola C
Frontiers in pharmacology 2019; 10: 1117 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
López-Cuenca I
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Poli D
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)


82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Tudosescu R
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)


82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Zarei R
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)


82309 Comparison of Prostaglandin Analog Treatment Patterns in Glaucoma and Ocular Hypertension
Nair R
Journal of managed care & specialty pharmacy 2019; 25: 1001-1010 (IGR: 20-4)


82877 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Palma SD
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-4)


82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Legramandi L
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)


82739 Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
Shams NK
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 542-550 (IGR: 20-4)


82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Eslami Y
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)


82614 Sustained scleral stiffening in rats after a single genipin treatment
Ethier CR
Journal of the Royal Society, Interface / the Royal Society 2019; 16: 20190427 (IGR: 20-4)


82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Bernstein SL
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)


82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Rashidzadeh H
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)


82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Ahn JH
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Licastro E
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Kim KY
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)


82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Mohammadi M
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)


82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Josiah S
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Inarejos-García AM
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82641 Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey
Josiah S
Experimental Eye Research 2019; 189: 107836 (IGR: 20-4)


82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol

Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Almodóvar P
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Hamzeh N
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Pinazo-Durán MD
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82505 Cystoid macular edema with prostaglandin analogue use after uneventful cataract surgery in glaucoma patients
Masoomi A
Journal of Cataract and Refractive Surgery 2019; 45: 1436-1445 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Ramírez JM; Salazar JJ
International journal of molecular sciences 2019; 20: (IGR: 20-4)


81455 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Angel Aillegas N
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-3)


80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Aihara M
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)


80599 Neuroprotective effects of topical coenzyme Q10 + vitamin E in mechanic optic nerve injury model
Ekicier Acar S
European Journal of Ophthalmology 2019; 0: 1120672119833271 (IGR: 20-3)


80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Woodward DF
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)


80720 Causative glaucoma treatment: promising targets and delivery systems
Mietzner R
Drug Discovery Today 2019; 24: 1606-1613 (IGR: 20-3)


81435 The effects of prostaglandins and endocannabinoids on iris arterial vascularization in Wistar rats - Experimental analysis
Coman IC
Romanian journal of ophthalmology 2019; 63: 135-141 (IGR: 20-3)


80599 Neuroprotective effects of topical coenzyme Q10 + vitamin E in mechanic optic nerve injury model
Sarıcaoğlu MS
European Journal of Ophthalmology 2019; 0: 1120672119833271 (IGR: 20-3)


81435 The effects of prostaglandins and endocannabinoids on iris arterial vascularization in Wistar rats - Experimental analysis
Al Hammoud M
Romanian journal of ophthalmology 2019; 63: 135-141 (IGR: 20-3)


81455 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Tártara LI
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-3)


80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Lu F
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)


80720 Causative glaucoma treatment: promising targets and delivery systems
Breunig M
Drug Discovery Today 2019; 24: 1606-1613 (IGR: 20-3)


80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Wang JW
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)


81435 The effects of prostaglandins and endocannabinoids on iris arterial vascularization in Wistar rats - Experimental analysis
Tudosescu R
Romanian journal of ophthalmology 2019; 63: 135-141 (IGR: 20-3)


80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Coleman RA
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)


80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Kawata H
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)


81455 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Caballero G
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-3)


80599 Neuroprotective effects of topical coenzyme Q10 + vitamin E in mechanic optic nerve injury model
Çolak A
European Journal of Ophthalmology 2019; 0: 1120672119833271 (IGR: 20-3)


80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Coleman RA
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)


80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Woodrooffe AJ
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)


81435 The effects of prostaglandins and endocannabinoids on iris arterial vascularization in Wistar rats - Experimental analysis
Iancu R
Romanian journal of ophthalmology 2019; 63: 135-141 (IGR: 20-3)


81455 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Campana V
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-3)


80599 Neuroprotective effects of topical coenzyme Q10 + vitamin E in mechanic optic nerve injury model
Aktaş Z
European Journal of Ophthalmology 2019; 0: 1120672119833271 (IGR: 20-3)


80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Woodrooffe AJ
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)


80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Iwata A
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)


80599 Neuroprotective effects of topical coenzyme Q10 + vitamin E in mechanic optic nerve injury model
Sepici Dinçel A
European Journal of Ophthalmology 2019; 0: 1120672119833271 (IGR: 20-3)


80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Clark KL; Clark KL
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)


80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Liu K
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)


81455 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Allemandi DA
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-3)


81435 The effects of prostaglandins and endocannabinoids on iris arterial vascularization in Wistar rats - Experimental analysis
Barac C
Romanian journal of ophthalmology 2019; 63: 135-141 (IGR: 20-3)


80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Odani-Kawabata N
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)


81435 The effects of prostaglandins and endocannabinoids on iris arterial vascularization in Wistar rats - Experimental analysis
Popa CA
Romanian journal of ophthalmology 2019; 63: 135-141 (IGR: 20-3)


81455 Antioxidant status in rabbit aqueous humor after instillation of ascorbyl laurate-based nanostructures
Palma SD
Pharmacological Reports 2019; 71: 794-797 (IGR: 20-3)


80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Stamer WD
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)


80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Tao G
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)


80575 Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Shams NK
Journal of Glaucoma 2019; 28: 375-385 (IGR: 20-3)


80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Fan S
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)


80927 A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method
Toris CB
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 265-277 (IGR: 20-3)


79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Kahook MY
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Hu C
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79787 Evidence on neuroprotective properties of coenzyme Q10 in the treatment of glaucoma
Martucci A
Neural Regeneration Research 2019; 14: 197-200 (IGR: 20-2)


79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Kang X
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)


79393 Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval
Duggan S
Drugs 2018; 78: 1925-1929 (IGR: 20-2)


79713 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma
Lin C
Eye 2019; 33: 777-784 (IGR: 20-2)


79411 RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis
Dang Y
Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257: 101-109 (IGR: 20-2)


80056 Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension
Fingeret M
Clinical and Experimental Optometry 2019; 102: 541-550 (IGR: 20-2)


79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Shen Y
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)


79713 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma
Wu F
Eye 2019; 33: 777-784 (IGR: 20-2)


79411 RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis
Wang C
Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257: 101-109 (IGR: 20-2)


79787 Evidence on neuroprotective properties of coenzyme Q10 in the treatment of glaucoma
Nucci C
Neural Regeneration Research 2019; 14: 197-200 (IGR: 20-2)


80056 Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension
Gaddie IB
Clinical and Experimental Optometry 2019; 102: 541-550 (IGR: 20-2)


79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Serle JB
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Sun J
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79713 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma
Zheng T
Eye 2019; 33: 777-784 (IGR: 20-2)


79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Mah FS
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)


80056 Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension
Bloomenstein M
Clinical and Experimental Optometry 2019; 102: 541-550 (IGR: 20-2)


79411 RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis
Shah P
Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257: 101-109 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Zhang Y
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Zhao H
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Chen J
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79713 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma
Wang X
Eye 2019; 33: 777-784 (IGR: 20-2)


79411 RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis
Waxman S
Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257: 101-109 (IGR: 20-2)


79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Kim T
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)


79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Wang Z
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)


79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Raizman MB
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)


79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Guan W
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)


79411 RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis
Loewen RT
Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257: 101-109 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Lei Y
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79713 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma
Chen Y
Eye 2019; 33: 777-784 (IGR: 20-2)


79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Heah T
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)


79411 RKI-1447, a Rho kinase inhibitor, causes ocular hypotension, actin stress fiber disruption, and increased phagocytosis
Loewen NA
Graefe's Archive for Clinical and Experimental Ophthalmology 2019; 257: 101-109 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Sun X
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79713 Kaempferol attenuates retinal ganglion cell death by suppressing NLRP1/NLRP3 inflammasomes and caspase-8 via JNK and NF-κB pathways in acute glaucoma
Wu X
Eye 2019; 33: 777-784 (IGR: 20-2)


79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Ge R
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)


79521 Local Delivery and Sustained-Release of Nitric Oxide Donor Loaded in Mesoporous Silica Particles for Efficient Treatment of Primary Open-Angle Glaucoma
Deng Y
Advanced healthcare materials 2018; 7: e1801047 (IGR: 20-2)


79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Wang R
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)


79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Ramirez-Davis N; Kopczynski CC
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)


79820 Anti-scarring effect of rapamycin in rabbits following glaucoma filtering surgery
Tai X
Journal of Southern Medical University 2018; 38: 1389-1394 (IGR: 20-2)


79961 Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2)
Usner DW; Novack GD;
American Journal of Ophthalmology 2019; 200: 130-137 (IGR: 20-2)


78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Moshirfar M
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)


79189 SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
Ashwinbalaji S
Scientific reports 2018; 8: 15472 (IGR: 20-1)


79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Pitha I
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)


79141 Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
Komizo T
Japanese Journal of Ophthalmology 2019; 63: 40-45 (IGR: 20-1)


78899 Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma
Matsou A
Expert Opinion on Investigational Drugs 2018; 27: 777-785 (IGR: 20-1)


78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Weinreb RN
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)


79132 Rho-kinase (ROCK) Inhibitors- A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Abbhi V
Current Medicinal Chemistry 2018; 0: (IGR: 20-1)


78351 Glaucoma Drugs in the Pipeline
Kaufman PL
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 345-351 (IGR: 20-1)


79189 SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
Senthilkumari S
Scientific reports 2018; 8: 15472 (IGR: 20-1)


78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Liebmann JM
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)


79132 Rho-kinase (ROCK) Inhibitors- A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Piplani P
Current Medicinal Chemistry 2018; 0: (IGR: 20-1)


78351 Glaucoma Drugs in the Pipeline
Mohr ME
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 345-351 (IGR: 20-1)


78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Parker L
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)


79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Oglesby E
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)


79141 Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
Ono T
Japanese Journal of Ophthalmology 2019; 63: 40-45 (IGR: 20-1)


78899 Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma
Anastasopoulos E
Expert Opinion on Investigational Drugs 2018; 27: 777-785 (IGR: 20-1)


79141 Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
Yagi A
Japanese Journal of Ophthalmology 2019; 63: 40-45 (IGR: 20-1)


78351 Glaucoma Drugs in the Pipeline
Riccomini SP
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 345-351 (IGR: 20-1)


79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Chow A
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)


79189 SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
Gowripriya C
Scientific reports 2018; 8: 15472 (IGR: 20-1)


78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Cioffi GA
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)


78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Birdsong OC
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)


79141 Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
Miyata K
Japanese Journal of Ophthalmology 2019; 63: 40-45 (IGR: 20-1)


79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Kimball E
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)


78351 Glaucoma Drugs in the Pipeline
Rasmussen CA
Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018; 7: 345-351 (IGR: 20-1)


78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Goldberg I
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)


79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Kimball E
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)


78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Ronquillo YC
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)


79189 SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
Krishnadas S; Gabelt BAT
Scientific reports 2018; 8: 15472 (IGR: 20-1)


78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Hofstedt D
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)


79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Pease ME
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)


79141 Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma
Aihara M
Japanese Journal of Ophthalmology 2019; 63: 40-45 (IGR: 20-1)


78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Brandt JD; Johnson CA
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)


78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Shah TJ
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)


79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Schaub J; Schaub J
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)


79189 SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
Kaufman PL
Scientific reports 2018; 8: 15472 (IGR: 20-1)


79096 Rho-Kinase Inhibition Reduces Myofibroblast Differentiation and Proliferation of Scleral Fibroblasts Induced by Transforming Growth Factor β and Experimental Glaucoma
Quigley H
Translational vision science & technology 2018; 7: 6 (IGR: 20-1)


79189 SB772077B, A New Rho Kinase Inhibitor Enhances Aqueous Humour Outflow Facility in Human Eyes
Muthukkaruppan V
Scientific reports 2018; 8: 15472 (IGR: 20-1)


78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Gomez AT
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)


78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Zangwill LM
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)


78782 Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature
Hoopes PCS
Medical hypothesis, discovery and innovation in ophthalmology 2018; 7: 101-111 (IGR: 20-1)


78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Schneider S; Badger H; Bejanian M
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)


78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Iwamura R
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)


78148 Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision
Sharif NA
Neural Regeneration Research 2018; 13: 1145-1150 (IGR: 19-4)


78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Fuwa M
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)


78116 Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Tanna AP
Ophthalmology 2018; 125: 1741-1756 (IGR: 19-4)


78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Jacob TF
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)


78293 Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension
Kopczynski CC
Drugs of Today 2018; 54: 467-478 (IGR: 19-4)


78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Iwamura R
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)


78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Mahalingam K
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)


78256 Old and New Drug Classes Expanding To Include Glaucoma Treatments
Kish T
P and T 2018; 43: 489-502 (IGR: 19-4)


78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Singh V
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)


78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Chaurasia AK
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)


78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Tanaka M
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)


78293 Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension
Heah T
Drugs of Today 2018; 54: 467-478 (IGR: 19-4)


78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Toris CB
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)


78116 Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Johnson M
Ophthalmology 2018; 125: 1741-1756 (IGR: 19-4)


78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Okanari E
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)


78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Dixit M
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)


78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Gowtham L
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)


78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Fan S; Taniguchi T
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)


78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Gupta S
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)


78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Ginsburg-Shmuel T
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)


78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Kirihara T
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)


78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Fonseca B
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)


78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Somarajan BI
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)


78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Odani-Kawabata N
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)


78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Ichikawa M
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)


78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Velpandian T
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)


78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Pintor J
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)


78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Shams N
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)


78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Odani-Kawabata N
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)


78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Yoneda K
Journal of Medicinal Chemistry 2018; 61: 6869-6891 (IGR: 19-4)


78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Sihota R
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)


78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Iwamura R
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)


78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Youdim MBH
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)


78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Iwamura R
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)


78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Major DT
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)


78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Yoneda K
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)


78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Gupta V
Indian Journal of Ophthalmology 2018; 66: 1104-1108 (IGR: 19-4)


78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Weinreb O
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)


78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Matsugi T; Shams NK
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)


78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Fischer B
Purinergic signalling 2018; 14: 271-284 (IGR: 19-4)


78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Zhang JZ
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537 (IGR: 19-4)


77175 Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil
Inoue K
Japanese Journal of Ophthalmology 2018; 62: 508-516 (IGR: 19-3)


76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Stack T
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779 (IGR: 19-3)


76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Zhang QL
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)


77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Miller S
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)


76424 The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells
Gu L
Neuroscience Letters 2018; 670: 89-93 (IGR: 19-3)


77101 Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
Hoy SM
Drugs 2018; 78: 773-780 (IGR: 19-3)


76694 Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats
Hampel U
International Ophthalmology 2019; 39: 847-851 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Stacy R
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


77039 The nitric oxide-guanylate cyclase pathway and glaucoma
Wareham LK
Nitric oxide : biology and chemistry 2018; 77: 75-87 (IGR: 19-3)


76816 Neuroprotective Effects of Psalmotoxin-1, an Acid-Sensing Ion Channel (ASIC) Inhibitor, in Ischemia Reperfusion in Mouse Eyes
Dibas A
Current Eye Research 2018; 43: 921-933 (IGR: 19-3)


76503 Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma
Honjo M
Japanese Journal of Ophthalmology 2018; 62: 109-126 (IGR: 19-3)


76553 The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
Kazemi A
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 380-386 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Prasanna G
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


76551 Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma
Kusuhara S
Graefe's Archive for Clinical and Experimental Ophthalmology 2018; 256: 809-814 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Stacy R
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Impagnatiello F
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ferrara L
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


76816 Neuroprotective Effects of Psalmotoxin-1, an Acid-Sensing Ion Channel (ASIC) Inhibitor, in Ischemia Reperfusion in Mouse Eyes
Millar C
Current Eye Research 2018; 43: 921-933 (IGR: 19-3)


76694 Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats
Träger K
International Ophthalmology 2019; 39: 847-851 (IGR: 19-3)


76424 The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells
Kwong JMK
Neuroscience Letters 2018; 670: 89-93 (IGR: 19-3)


76503 Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma
Tanihara H
Japanese Journal of Ophthalmology 2018; 62: 109-126 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Huttner K
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76551 Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma
Katsuyama A
Graefe's Archive for Clinical and Experimental Ophthalmology 2018; 256: 809-814 (IGR: 19-3)


76553 The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
McLaren JW
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 380-386 (IGR: 19-3)


76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Bastia E
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)


76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Vahabikashi A
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779 (IGR: 19-3)


77175 Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil
Ishida K
Japanese Journal of Ophthalmology 2018; 62: 508-516 (IGR: 19-3)


76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Wang W
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)


77039 The nitric oxide-guanylate cyclase pathway and glaucoma
Buys ES
Nitric oxide : biology and chemistry 2018; 77: 75-87 (IGR: 19-3)


77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Kulkarni S
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)


76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Johnson M
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779 (IGR: 19-3)


76553 The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
Kopczynski CC
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 380-386 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Watts J
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Almirante N
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)


77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Ciesielski A
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)


76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Jiang Y
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)


77039 The nitric oxide-guanylate cyclase pathway and glaucoma
Sappington RM
Nitric oxide : biology and chemistry 2018; 77: 75-87 (IGR: 19-3)


76551 Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma
Matsumiya W
Graefe's Archive for Clinical and Experimental Ophthalmology 2018; 256: 809-814 (IGR: 19-3)


76816 Neuroprotective Effects of Psalmotoxin-1, an Acid-Sensing Ion Channel (ASIC) Inhibitor, in Ischemia Reperfusion in Mouse Eyes
Al-Farra A
Current Eye Research 2018; 43: 921-933 (IGR: 19-3)


77175 Effectiveness and safety of switching from prostaglandin analog monotherapy to prostaglandin/timolol fixed combination therapy or adding ripasudil
Tomita G
Japanese Journal of Ophthalmology 2018; 62: 508-516 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Adams C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


76694 Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats
Liu H
International Ophthalmology 2019; 39: 847-851 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Adams C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


76424 The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells
Yadegari D
Neuroscience Letters 2018; 670: 89-93 (IGR: 19-3)


76694 Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats
Teister J
International Ophthalmology 2019; 39: 847-851 (IGR: 19-3)


76424 The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells
Yu F
Neuroscience Letters 2018; 670: 89-93 (IGR: 19-3)


76551 Efficacy and safety of ripasudil, a Rho-associated kinase inhibitor, in eyes with uveitic glaucoma
Nakamura M
Graefe's Archive for Clinical and Experimental Ophthalmology 2018; 256: 809-814 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ehara T
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
A-Tuya
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)


76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Brambilla S
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)


76552 Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles
Scott E
Journal of Biomedical Materials Research - Part A 2018; 106: 1771-1779 (IGR: 19-3)


76553 The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
Heah TG
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 380-386 (IGR: 19-3)


77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Nikas SP
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Peace J
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76816 Neuroprotective Effects of Psalmotoxin-1, an Acid-Sensing Ion Channel (ASIC) Inhibitor, in Ischemia Reperfusion in Mouse Eyes
Yorio T
Current Eye Research 2018; 43: 921-933 (IGR: 19-3)


76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Dongmei
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Li B
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


76553 The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
Novack GD
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 380-386 (IGR: 19-3)


76694 Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats
Grus F
International Ophthalmology 2019; 39: 847-851 (IGR: 19-3)


77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Mackie K
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Wirta D
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Duquesroix B
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)


76424 The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells
Caprioli J
Neuroscience Letters 2018; 670: 89-93 (IGR: 19-3)


76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Kothe AC
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)


76424 The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells
Piri N
Neuroscience Letters 2018; 670: 89-93 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Yang L
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Li LL
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)


76694 Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats
Prokosch-Willing V
International Ophthalmology 2019; 39: 847-851 (IGR: 19-3)


77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Makriyannis A
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Walters T
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76553 The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
Sit AJ
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 380-386 (IGR: 19-3)


76938 Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
Bergamini MVW
British Journal of Pharmacology 2019; 176: 1079-1089 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Sall K
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Xiang C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Lu ZJ
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)


77159 Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure
Straiker A
Pharmaceuticals (Basel, Switzerland) 2018; 11: (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Seaman J
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Chang H
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ng CTH
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Ni X
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Kim S
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


76619 GRGM-13 comprising 13 plant and animal products, inhibited oxidative stress induced apoptosis in retinal ganglion cells by inhibiting P2RX7/p38 MAPK signaling pathway
Zhang TZ
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2018; 101: 494-500 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Prasanna G
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Towler C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Mogi M
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Topley T
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Adams C
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
McAllister C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Adams C; Yan JH
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ghosh M; Newton R
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Wald M
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Newton R
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
He Y
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Stacy R; Stacy R; Rice DS
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Newton R; Newton R
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Mogi M
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716 (IGR: 19-3)


77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Kolega R; Grosskreutz C
American Journal of Ophthalmology 2018; 192: 113-123 (IGR: 19-3)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Giannaccini M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Weinreb RN
Journal of Glaucoma 2018; 27: 7-15 (IGR: 19-2)


75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Serle JB
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)


75286 Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits
Loma P
Journal of optometry 2018; 11: 69-74 (IGR: 19-2)


75045 Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
Williams PA
Journal of Glaucoma 2017; 26: 1161-1168 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Kim J
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Pfeiffer N
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)


75170 Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules
Yu AK; Datta S
Human Molecular Genetics 2017; 26: 4929-4936 (IGR: 19-2)


75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Voykov B
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)


75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Liebmann JM
Journal of Glaucoma 2018; 27: 7-15 (IGR: 19-2)


75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Katz LJ
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)


75286 Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits
Guzman-Aranguez A
Journal of optometry 2018; 11: 69-74 (IGR: 19-2)


75045 Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
Harder JM
Journal of Glaucoma 2017; 26: 1161-1168 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Usai A
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Kudisch M
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
McLaurin E
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)


75045 Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma
John SWM
Journal of Glaucoma 2017; 26: 1161-1168 (IGR: 19-2)


75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Renieri G
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)


75286 Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits
de Lara MJP
Journal of optometry 2018; 11: 69-74 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
da Silva NRK
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75170 Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules
McMackin MZ
Human Molecular Genetics 2017; 26: 4929-4936 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Chiellini F
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Martin KR
Journal of Glaucoma 2018; 27: 7-15 (IGR: 19-2)


75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Bell K
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Asada H
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75286 Beta2 adrenergic receptor silencing change intraocular pressure in New Zealand rabbits
Pintor J
Journal of optometry 2018; 11: 69-74 (IGR: 19-2)


75170 Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules
Cortopassi GA
Human Molecular Genetics 2017; 26: 4929-4936 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Guadagni V
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Kaufman PL
Journal of Glaucoma 2018; 27: 7-15 (IGR: 19-2)


75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Heah T
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Andreazzoli M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75428 Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings
Vittitow JL
Journal of Glaucoma 2018; 27: 7-15 (IGR: 19-2)


75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Ramirez-Davis N
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)


75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Richter P
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Aya-Shibuya E; Bloomer MM
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Ori M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Weigel M
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)


75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Usner DW; Novack GD
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Pasqualetti M
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Mudumba S
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Thieme H
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Dente L
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)
Kopczynski CC
American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)


75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Wilhelm B
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)


75280 Long-term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti-glaucoma agent
Bhisitkul RB; Desai TA
Journal of Controlled Release 2018; 269: 45-51 (IGR: 19-2)


75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Lorenz K
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)


75444 Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)

American Journal of Ophthalmology 2018; 186: 116-127 (IGR: 19-2)


75226 Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress
Raffa V
Cellular and Molecular Life Sciences 2018; 75: 1255-1267 (IGR: 19-2)


75418 First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Feindor M; Wosikowski K; Janicot M; Päckert D; Römmich R; Mala C; Fettes P; Leo E
PLoS ONE 2017; 12: e0188899 (IGR: 19-2)


74124 ROCK inhibitors for the treatment of ocular diseases
Nourinia R
British Journal of Ophthalmology 2017; 0: (IGR: 19-1)


74182 Targets of Neuroprotection in Glaucoma
He S
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 85-106 (IGR: 19-1)


74543 Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo
Liu H
Investigative Ophthalmology and Visual Science 2017; 58: 5129-5141 (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Kawaguchi I
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74421 Novel therapeutics in glaucoma management
Bucolo C
Current Neuropharmacology 2017; 0: (IGR: 19-1)


74773 Impact of Topically Administered Steroids, Antibiotics, and Sodium Hyaluronate on Bleb-Related Infection Onset: The Japan Glaucoma Society Survey of Bleb-Related Infection Report 4
Sagara H
Journal of Ophthalmology 2017; 2017: 7062565 (IGR: 19-1)


74473 Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway
O'Callaghan J
Expert Opinion on Therapeutic Targets 2017; 21: 1037-1050 (IGR: 19-1)


74710 The Anti-Inflammatory Effect of Ripasudil (K-115), a Rho Kinase (ROCK) Inhibitor, on Endotoxin-Induced Uveitis in Rats
Uchida T
Investigative Ophthalmology and Visual Science 2017; 58: 5584-5593 (IGR: 19-1)


74834 Low density lipoprotein - rosiglitazone - chitosan-calcium alginate/nanoparticles inhibition of human tenon's fibroblasts activation and proliferation
Gong Y
Oncotarget 2017; 8: 105126-105136 (IGR: 19-1)


74145 A novel RIPK1 inhibitor that prevents retinal degeneration in a rat glaucoma model
Do YJ
Experimental Cell Research 2017; 359: 30-38 (IGR: 19-1)


74426 Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis
Nuzzi R
Frontiers in neuroscience 2017; 11: 494 (IGR: 19-1)


74106 The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies
Cavet ME
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 52-60 (IGR: 19-1)


74447 Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro
Gao FJ
Frontiers in molecular neuroscience 2017; 10: 285 (IGR: 19-1)


74591 Relationship between Sigma-1 receptor and BDNF in the visual system
Mysona BA
Experimental Eye Research 2017; 167: 25-30 (IGR: 19-1)


74194 The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss
Blanco R
Experimental Eye Research 2017; 164: 37-45 (IGR: 19-1)


74704 Baicalin alleviates oxidative stress damage in trabecular meshwork cells in vitro
Gong L
Naunyn-Schmiedeberg's archives of pharmacology 2018; 391: 51-58 (IGR: 19-1)


74658 Gastrodin protects retinal ganglion cells through inhibiting microglial-mediated neuroinflammation in an acute ocular hypertension model
Wang JW
International Journal of Ophthalmology 2017; 10: 1483-1489 (IGR: 19-1)


74445 The Antiangiogenesis Effect of Pirfenidone in Wound Healing In Vitro
Liu X
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 693-703 (IGR: 19-1)


74672 Bilberry extract administration prevents retinal ganglion cell death in mice via the regulation of chaperone molecules under conditions of endoplasmic reticulum stress
Nakamura O
Clinical Ophthalmology 2017; 11: 1825-1834 (IGR: 19-1)


74159 Trimetazidine protects retinal ganglion cells from acute glaucoma via the Nrf2/Ho-1 pathway
Wan P
Clinical Science 2017; 131: 2363-2375 (IGR: 19-1)


74535 Resveratrol Ameliorates Retinal Ischemia/Reperfusion Injury in C57BL/6J Mice via Downregulation of Caspase-3
Seong H
Current Eye Research 2017; 42: 1650-1658 (IGR: 19-1)


74342 Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma
Inoue T
Expert Opinion in Pharmacotherapy 2017; 18: 1669-1673 (IGR: 19-1)


74495 Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension
Yasuda M
PLoS ONE 2017; 12: e0185305 (IGR: 19-1)


74703 Norrin protects optic nerve axons from degeneration in a mouse model of glaucoma
Leopold SA
Scientific reports 2017; 7: 14274 (IGR: 19-1)


74512 CRISPR-Cas9-based treatment of myocilin-associated glaucoma
Jain A
Proceedings of the National Academy of Sciences of the United States of America 2017; 114: 11199-11204 (IGR: 19-1)


74704 Baicalin alleviates oxidative stress damage in trabecular meshwork cells in vitro
Zhu J
Naunyn-Schmiedeberg's archives of pharmacology 2018; 391: 51-58 (IGR: 19-1)


74658 Gastrodin protects retinal ganglion cells through inhibiting microglial-mediated neuroinflammation in an acute ocular hypertension model
Liu YM
International Journal of Ophthalmology 2017; 10: 1483-1489 (IGR: 19-1)


74426 Glaucoma: Biological Trabecular and Neuroretinal Pathology with Perspectives of Therapy Innovation and Preventive Diagnosis
Tridico F
Frontiers in neuroscience 2017; 11: 494 (IGR: 19-1)


74106 The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies
DeCory HH
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 52-60 (IGR: 19-1)


74159 Trimetazidine protects retinal ganglion cells from acute glaucoma via the Nrf2/Ho-1 pathway
Su W
Clinical Science 2017; 131: 2363-2375 (IGR: 19-1)


74535 Resveratrol Ameliorates Retinal Ischemia/Reperfusion Injury in C57BL/6J Mice via Downregulation of Caspase-3
Ryu J
Current Eye Research 2017; 42: 1650-1658 (IGR: 19-1)


74342 Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma
Tanihara H
Expert Opinion in Pharmacotherapy 2017; 18: 1669-1673 (IGR: 19-1)


74124 ROCK inhibitors for the treatment of ocular diseases
Nakao S
British Journal of Ophthalmology 2017; 0: (IGR: 19-1)


74495 Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension
Takayama K
PLoS ONE 2017; 12: e0185305 (IGR: 19-1)


74703 Norrin protects optic nerve axons from degeneration in a mouse model of glaucoma
Zeilbeck LF
Scientific reports 2017; 7: 14274 (IGR: 19-1)


74591 Relationship between Sigma-1 receptor and BDNF in the visual system
Zhao J
Experimental Eye Research 2017; 167: 25-30 (IGR: 19-1)


74182 Targets of Neuroprotection in Glaucoma
Stankowska DL
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 85-106 (IGR: 19-1)


74473 Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway
Cassidy PS
Expert Opinion on Therapeutic Targets 2017; 21: 1037-1050 (IGR: 19-1)


74445 The Antiangiogenesis Effect of Pirfenidone in Wound Healing In Vitro
Yang Y
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 693-703 (IGR: 19-1)


74145 A novel RIPK1 inhibitor that prevents retinal degeneration in a rat glaucoma model
Sul JW
Experimental Cell Research 2017; 359: 30-38 (IGR: 19-1)


74672 Bilberry extract administration prevents retinal ganglion cell death in mice via the regulation of chaperone molecules under conditions of endoplasmic reticulum stress
Moritoh S
Clinical Ophthalmology 2017; 11: 1825-1834 (IGR: 19-1)


74512 CRISPR-Cas9-based treatment of myocilin-associated glaucoma
Zode G
Proceedings of the National Academy of Sciences of the United States of America 2017; 114: 11199-11204 (IGR: 19-1)


74194 The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss
Martínez-Navarrete G
Experimental Eye Research 2017; 164: 37-45 (IGR: 19-1)


74421 Novel therapeutics in glaucoma management
Platania CBM
Current Neuropharmacology 2017; 0: (IGR: 19-1)


74773 Impact of Topically Administered Steroids, Antibiotics, and Sodium Hyaluronate on Bleb-Related Infection Onset: The Japan Glaucoma Society Survey of Bleb-Related Infection Report 4
Yamamoto T
Journal of Ophthalmology 2017; 2017: 7062565 (IGR: 19-1)


74834 Low density lipoprotein - rosiglitazone - chitosan-calcium alginate/nanoparticles inhibition of human tenon's fibroblasts activation and proliferation
Yin JY
Oncotarget 2017; 8: 105126-105136 (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Kobayashi A
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74447 Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro
Zhang SH
Frontiers in molecular neuroscience 2017; 10: 285 (IGR: 19-1)


74543 Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo
Anders F
Investigative Ophthalmology and Visual Science 2017; 58: 5129-5141 (IGR: 19-1)


74710 The Anti-Inflammatory Effect of Ripasudil (K-115), a Rho Kinase (ROCK) Inhibitor, on Endotoxin-Induced Uveitis in Rats
Honjo M
Investigative Ophthalmology and Visual Science 2017; 58: 5584-5593 (IGR: 19-1)


74159 Trimetazidine protects retinal ganglion cells from acute glaucoma via the Nrf2/Ho-1 pathway
Zhang Y
Clinical Science 2017; 131: 2363-2375 (IGR: 19-1)


74512 CRISPR-Cas9-based treatment of myocilin-associated glaucoma
Kasetti RB
Proceedings of the National Academy of Sciences of the United States of America 2017; 114: 11199-11204 (IGR: 19-1)


74834 Low density lipoprotein - rosiglitazone - chitosan-calcium alginate/nanoparticles inhibition of human tenon's fibroblasts activation and proliferation
Tong BD
Oncotarget 2017; 8: 105126-105136 (IGR: 19-1)


74145 A novel RIPK1 inhibitor that prevents retinal degeneration in a rat glaucoma model
Jang KH
Experimental Cell Research 2017; 359: 30-38 (IGR: 19-1)


74495 Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension
Kanda T
PLoS ONE 2017; 12: e0185305 (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Higashide T
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74194 The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss
Valiente-Soriano FJ
Experimental Eye Research 2017; 164: 37-45 (IGR: 19-1)


74124 ROCK inhibitors for the treatment of ocular diseases
Zandi S
British Journal of Ophthalmology 2017; 0: (IGR: 19-1)


74421 Novel therapeutics in glaucoma management
Drago F
Current Neuropharmacology 2017; 0: (IGR: 19-1)


74658 Gastrodin protects retinal ganglion cells through inhibiting microglial-mediated neuroinflammation in an acute ocular hypertension model
Zhao XF
International Journal of Ophthalmology 2017; 10: 1483-1489 (IGR: 19-1)


74447 Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro
Xu P
Frontiers in molecular neuroscience 2017; 10: 285 (IGR: 19-1)


74703 Norrin protects optic nerve axons from degeneration in a mouse model of glaucoma
Weber G
Scientific reports 2017; 7: 14274 (IGR: 19-1)


74710 The Anti-Inflammatory Effect of Ripasudil (K-115), a Rho Kinase (ROCK) Inhibitor, on Endotoxin-Induced Uveitis in Rats
Yamagishi R
Investigative Ophthalmology and Visual Science 2017; 58: 5584-5593 (IGR: 19-1)


74672 Bilberry extract administration prevents retinal ganglion cell death in mice via the regulation of chaperone molecules under conditions of endoplasmic reticulum stress
Sato K
Clinical Ophthalmology 2017; 11: 1825-1834 (IGR: 19-1)


74445 The Antiangiogenesis Effect of Pirfenidone in Wound Healing In Vitro
Guo X
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 693-703 (IGR: 19-1)


74535 Resveratrol Ameliorates Retinal Ischemia/Reperfusion Injury in C57BL/6J Mice via Downregulation of Caspase-3
Yoo WS
Current Eye Research 2017; 42: 1650-1658 (IGR: 19-1)


74182 Targets of Neuroprotection in Glaucoma
Ellis DZ
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 85-106 (IGR: 19-1)


74543 Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo
Thanos S
Investigative Ophthalmology and Visual Science 2017; 58: 5129-5141 (IGR: 19-1)


74473 Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway
Humphries P
Expert Opinion on Therapeutic Targets 2017; 21: 1037-1050 (IGR: 19-1)


74773 Impact of Topically Administered Steroids, Antibiotics, and Sodium Hyaluronate on Bleb-Related Infection Onset: The Japan Glaucoma Society Survey of Bleb-Related Infection Report 4
Imaizumi K
Journal of Ophthalmology 2017; 2017: 7062565 (IGR: 19-1)


74591 Relationship between Sigma-1 receptor and BDNF in the visual system
Smith S
Experimental Eye Research 2017; 167: 25-30 (IGR: 19-1)


74445 The Antiangiogenesis Effect of Pirfenidone in Wound Healing In Vitro
Liu L
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 693-703 (IGR: 19-1)


74447 Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro
Yang BQ
Frontiers in molecular neuroscience 2017; 10: 285 (IGR: 19-1)


74672 Bilberry extract administration prevents retinal ganglion cell death in mice via the regulation of chaperone molecules under conditions of endoplasmic reticulum stress
Maekawa S
Clinical Ophthalmology 2017; 11: 1825-1834 (IGR: 19-1)


74591 Relationship between Sigma-1 receptor and BDNF in the visual system
Bollinger KE
Experimental Eye Research 2017; 167: 25-30 (IGR: 19-1)


74159 Trimetazidine protects retinal ganglion cells from acute glaucoma via the Nrf2/Ho-1 pathway
Li Z
Clinical Science 2017; 131: 2363-2375 (IGR: 19-1)


74182 Targets of Neuroprotection in Glaucoma
Krishnamoorthy RR
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 85-106 (IGR: 19-1)


74658 Gastrodin protects retinal ganglion cells through inhibiting microglial-mediated neuroinflammation in an acute ocular hypertension model
Zhang H
International Journal of Ophthalmology 2017; 10: 1483-1489 (IGR: 19-1)


74773 Impact of Topically Administered Steroids, Antibiotics, and Sodium Hyaluronate on Bleb-Related Infection Onset: The Japan Glaucoma Society Survey of Bleb-Related Infection Report 4
Sekiryu T
Journal of Ophthalmology 2017; 2017: 7062565 (IGR: 19-1)


74834 Low density lipoprotein - rosiglitazone - chitosan-calcium alginate/nanoparticles inhibition of human tenon's fibroblasts activation and proliferation
Zeng JX
Oncotarget 2017; 8: 105126-105136 (IGR: 19-1)


74194 The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss
Avilés-Trigueros M
Experimental Eye Research 2017; 164: 37-45 (IGR: 19-1)


74710 The Anti-Inflammatory Effect of Ripasudil (K-115), a Rho Kinase (ROCK) Inhibitor, on Endotoxin-Induced Uveitis in Rats
Aihara M
Investigative Ophthalmology and Visual Science 2017; 58: 5584-5593 (IGR: 19-1)


74535 Resveratrol Ameliorates Retinal Ischemia/Reperfusion Injury in C57BL/6J Mice via Downregulation of Caspase-3
Kim SJ
Current Eye Research 2017; 42: 1650-1658 (IGR: 19-1)


74543 Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo
Mann C
Investigative Ophthalmology and Visual Science 2017; 58: 5129-5141 (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Takeji Y
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74124 ROCK inhibitors for the treatment of ocular diseases
Safi S
British Journal of Ophthalmology 2017; 0: (IGR: 19-1)


74512 CRISPR-Cas9-based treatment of myocilin-associated glaucoma
Ran FA
Proceedings of the National Academy of Sciences of the United States of America 2017; 114: 11199-11204 (IGR: 19-1)


74703 Norrin protects optic nerve axons from degeneration in a mouse model of glaucoma
Seitz R
Scientific reports 2017; 7: 14274 (IGR: 19-1)


74495 Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension
Taguchi M
PLoS ONE 2017; 12: e0185305 (IGR: 19-1)


74421 Novel therapeutics in glaucoma management
Reibaldi M
Current Neuropharmacology 2017; 0: (IGR: 19-1)


74145 A novel RIPK1 inhibitor that prevents retinal degeneration in a rat glaucoma model
Kang NS; Kim YH
Experimental Cell Research 2017; 359: 30-38 (IGR: 19-1)


74512 CRISPR-Cas9-based treatment of myocilin-associated glaucoma
Yan W
Proceedings of the National Academy of Sciences of the United States of America 2017; 114: 11199-11204 (IGR: 19-1)


74703 Norrin protects optic nerve axons from degeneration in a mouse model of glaucoma
Bösl MR
Scientific reports 2017; 7: 14274 (IGR: 19-1)


74672 Bilberry extract administration prevents retinal ganglion cell death in mice via the regulation of chaperone molecules under conditions of endoplasmic reticulum stress
Murayama N
Clinical Ophthalmology 2017; 11: 1825-1834 (IGR: 19-1)


74421 Novel therapeutics in glaucoma management
Bonfiglio V
Current Neuropharmacology 2017; 0: (IGR: 19-1)


74445 The Antiangiogenesis Effect of Pirfenidone in Wound Healing In Vitro
Wu K
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 693-703 (IGR: 19-1)


74159 Trimetazidine protects retinal ganglion cells from acute glaucoma via the Nrf2/Ho-1 pathway
Deng C
Clinical Science 2017; 131: 2363-2375 (IGR: 19-1)


74535 Resveratrol Ameliorates Retinal Ischemia/Reperfusion Injury in C57BL/6J Mice via Downregulation of Caspase-3
Han YS
Current Eye Research 2017; 42: 1650-1658 (IGR: 19-1)


74543 Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo
Liu A
Investigative Ophthalmology and Visual Science 2017; 58: 5129-5141 (IGR: 19-1)


74495 Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension
Someya H
PLoS ONE 2017; 12: e0185305 (IGR: 19-1)


74182 Targets of Neuroprotection in Glaucoma
Yorio T
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 85-106 (IGR: 19-1)


74834 Low density lipoprotein - rosiglitazone - chitosan-calcium alginate/nanoparticles inhibition of human tenon's fibroblasts activation and proliferation
Xiong W
Oncotarget 2017; 8: 105126-105136 (IGR: 19-1)


74447 Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro
Zhang R
Frontiers in molecular neuroscience 2017; 10: 285 (IGR: 19-1)


74194 The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss
Pérez-Rico C
Experimental Eye Research 2017; 164: 37-45 (IGR: 19-1)


74124 ROCK inhibitors for the treatment of ocular diseases
Hafezi-Moghadam A
British Journal of Ophthalmology 2017; 0: (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Sakurai K
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74447 Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro
Cheng Y
Frontiers in molecular neuroscience 2017; 10: 285 (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Kawaguchi C
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74194 The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss
Serrano-Puebla A
Experimental Eye Research 2017; 164: 37-45 (IGR: 19-1)


74445 The Antiangiogenesis Effect of Pirfenidone in Wound Healing In Vitro
Yu M
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 693-703 (IGR: 19-1)


74535 Resveratrol Ameliorates Retinal Ischemia/Reperfusion Injury in C57BL/6J Mice via Downregulation of Caspase-3
Park JM
Current Eye Research 2017; 42: 1650-1658 (IGR: 19-1)


74672 Bilberry extract administration prevents retinal ganglion cell death in mice via the regulation of chaperone molecules under conditions of endoplasmic reticulum stress
Himori N
Clinical Ophthalmology 2017; 11: 1825-1834 (IGR: 19-1)


74512 CRISPR-Cas9-based treatment of myocilin-associated glaucoma
Sharma TP
Proceedings of the National Academy of Sciences of the United States of America 2017; 114: 11199-11204 (IGR: 19-1)


74703 Norrin protects optic nerve axons from degeneration in a mouse model of glaucoma
Jägle H
Scientific reports 2017; 7: 14274 (IGR: 19-1)


74124 ROCK inhibitors for the treatment of ocular diseases
Ahmadieh H
British Journal of Ophthalmology 2017; 0: (IGR: 19-1)


74145 A novel RIPK1 inhibitor that prevents retinal degeneration in a rat glaucoma model
Kim YG
Experimental Cell Research 2017; 359: 30-38 (IGR: 19-1)


74543 Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo
Grus FH
Investigative Ophthalmology and Visual Science 2017; 58: 5129-5141 (IGR: 19-1)


74495 Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension
Takeuchi M
PLoS ONE 2017; 12: e0185305 (IGR: 19-1)


74159 Trimetazidine protects retinal ganglion cells from acute glaucoma via the Nrf2/Ho-1 pathway
Zhuo Y
Clinical Science 2017; 131: 2363-2375 (IGR: 19-1)


74421 Novel therapeutics in glaucoma management
Avitabile T
Current Neuropharmacology 2017; 0: (IGR: 19-1)


74194 The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss
Boya P
Experimental Eye Research 2017; 164: 37-45 (IGR: 19-1)


74421 Novel therapeutics in glaucoma management
Uva M
Current Neuropharmacology 2017; 0: (IGR: 19-1)


74512 CRISPR-Cas9-based treatment of myocilin-associated glaucoma
Bugge K
Proceedings of the National Academy of Sciences of the United States of America 2017; 114: 11199-11204 (IGR: 19-1)


74543 Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo
Pfeiffer N
Investigative Ophthalmology and Visual Science 2017; 58: 5129-5141 (IGR: 19-1)


74625 Rebamipide protects against glaucoma eyedrop-induced ocular surface disorders in rabbits
Sugiyama K
PLoS ONE 2017; 12: e0186714 (IGR: 19-1)


74447 Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro
Zhou XJ
Frontiers in molecular neuroscience 2017; 10: 285 (IGR: 19-1)


74703 Norrin protects optic nerve axons from degeneration in a mouse model of glaucoma
Fuchshofer R
Scientific reports 2017; 7: 14274 (IGR: 19-1)


74535 Resveratrol Ameliorates Retinal Ischemia/Reperfusion Injury in C57BL/6J Mice via Downregulation of Caspase-3
Kang SS
Current Eye Research 2017; 42: 1650-1658 (IGR: 19-1)


74145 A novel RIPK1 inhibitor that prevents retinal degeneration in a rat glaucoma model
Kim E
Experimental Cell Research 2017; 359: 30-38 (IGR: 19-1)


74672 Bilberry extract administration prevents retinal ganglion cell death in mice via the regulation of chaperone molecules under conditions of endoplasmic reticulum stress
Omodaka K; Sogon T
Clinical Ophthalmology 2017; 11: 1825-1834 (IGR: 19-1)


74535 Resveratrol Ameliorates Retinal Ischemia/Reperfusion Injury in C57BL/6J Mice via Downregulation of Caspase-3
Seo SW
Current Eye Research 2017; 42: 1650-1658 (IGR: 19-1)


74703 Norrin protects optic nerve axons from degeneration in a mouse model of glaucoma
Tamm ER
Scientific reports 2017; 7: 14274 (IGR: 19-1)


74543 Hydrogen Sulfide Protects Retinal Ganglion Cells Against Glaucomatous Injury In Vitro and In Vivo
Prokosch-Willing V
Investigative Ophthalmology and Visual Science 2017; 58: 5129-5141 (IGR: 19-1)


74447 Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro
Huang WJ
Frontiers in molecular neuroscience 2017; 10: 285 (IGR: 19-1)


74512 CRISPR-Cas9-based treatment of myocilin-associated glaucoma
Searby CC
Proceedings of the National Academy of Sciences of the United States of America 2017; 114: 11199-11204 (IGR: 19-1)


74194 The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss
Fernández E
Experimental Eye Research 2017; 164: 37-45 (IGR: 19-1)


74447 Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro
Wang M
Frontiers in molecular neuroscience 2017; 10: 285 (IGR: 19-1)


74672 Bilberry extract administration prevents retinal ganglion cell death in mice via the regulation of chaperone molecules under conditions of endoplasmic reticulum stress
Nakazawa T
Clinical Ophthalmology 2017; 11: 1825-1834 (IGR: 19-1)


74703 Norrin protects optic nerve axons from degeneration in a mouse model of glaucoma
Ohlmann A
Scientific reports 2017; 7: 14274 (IGR: 19-1)


74512 CRISPR-Cas9-based treatment of myocilin-associated glaucoma
Fingert JH
Proceedings of the National Academy of Sciences of the United States of America 2017; 114: 11199-11204 (IGR: 19-1)


74194 The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss
Vidal-Sanz M; de la Villa P
Experimental Eye Research 2017; 164: 37-45 (IGR: 19-1)


74447 Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro
Chen JY
Frontiers in molecular neuroscience 2017; 10: 285 (IGR: 19-1)


74512 CRISPR-Cas9-based treatment of myocilin-associated glaucoma
Zhang F; Clark AF
Proceedings of the National Academy of Sciences of the United States of America 2017; 114: 11199-11204 (IGR: 19-1)


74447 Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro
Sun XH
Frontiers in molecular neuroscience 2017; 10: 285 (IGR: 19-1)


74512 CRISPR-Cas9-based treatment of myocilin-associated glaucoma
Sheffield VC
Proceedings of the National Academy of Sciences of the United States of America 2017; 114: 11199-11204 (IGR: 19-1)


74447 Quercetin Declines Apoptosis, Ameliorates Mitochondrial Function and Improves Retinal Ganglion Cell Survival and Function in In Vivo Model of Glaucoma in Rat and Retinal Ganglion Cell Culture In Vitro
Wu JH
Frontiers in molecular neuroscience 2017; 10: 285 (IGR: 19-1)


72791 Quantification of the efficacy of collagen cross-linking agents to induce stiffening of rat sclera
Campbell IC
Journal of the Royal Society, Interface / the Royal Society 2017; 14: (IGR: 18-4)


72668 Peeking into Sigma-1 Receptor Functions Through the Retina
Mavlyutov TA
Adv Exp Med Biol 2017; 964: 285-297 (IGR: 18-4)


72713 An introduction to DARC technology
Ahmad SS
Saudi Journal of Ophthalmology 2017; 31: 38-41 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Adelli GR
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


72679 Toll-like receptor 4 inhibitor protects against retinal ganglion cell damage induced by optic nerve crush in mice
Nakano Y
Journal of Pharmacological Sciences 2017; 133: 176-183 (IGR: 18-4)


72682 Grooved Glaucoma Drainage Devices That Continuously Deliver Cyclosporine A Decrease Postsurgical Scar Formation in Rabbit Eyes
Dai Z
Investigative Ophthalmology and Visual Science 2017; 58: 1692-1701 (IGR: 18-4)


72730 Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations
Andrés-Guerrero V
Advances in Therapy 2017; 34: 1049-1069 (IGR: 18-4)


72716 Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients
Haug NA
Addictive behaviors 2017; 72: 14-20 (IGR: 18-4)


72728 Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study
Matsumura R
Clinical Drug Investigation 2017; 37: 535-539 (IGR: 18-4)


72748 Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma
Lu LJ
The Yale journal of biology and medicine 2017; 90: 111-118 (IGR: 18-4)


72669 The Role of Sigma 1 Receptor as a Neuroprotective Target in Glaucoma
Mysona B
Adv Exp Med Biol 2017; 964: 299-307 (IGR: 18-4)


73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Natesan S
International Journal of Biological Macromolecules 2017; 104: 1837-1845 (IGR: 18-4)


73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Lin CW
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51 (IGR: 18-4)


72755 Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis
Yu-Wai-Man C
Scientific reports 2017; 7: 518 (IGR: 18-4)


72669 The Role of Sigma 1 Receptor as a Neuroprotective Target in Glaucoma
Kansara N
Adv Exp Med Biol 2017; 964: 299-307 (IGR: 18-4)


72716 Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients
Padula CB
Addictive behaviors 2017; 72: 14-20 (IGR: 18-4)


72755 Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis
Spencer-Dene B
Scientific reports 2017; 7: 518 (IGR: 18-4)


72791 Quantification of the efficacy of collagen cross-linking agents to induce stiffening of rat sclera
Hannon BG
Journal of the Royal Society, Interface / the Royal Society 2017; 14: (IGR: 18-4)


72679 Toll-like receptor 4 inhibitor protects against retinal ganglion cell damage induced by optic nerve crush in mice
Shimazawa M
Journal of Pharmacological Sciences 2017; 133: 176-183 (IGR: 18-4)


72682 Grooved Glaucoma Drainage Devices That Continuously Deliver Cyclosporine A Decrease Postsurgical Scar Formation in Rabbit Eyes
Yu X
Investigative Ophthalmology and Visual Science 2017; 58: 1692-1701 (IGR: 18-4)


73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Pandian S
International Journal of Biological Macromolecules 2017; 104: 1837-1845 (IGR: 18-4)


72748 Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma
Tsai JC
The Yale journal of biology and medicine 2017; 90: 111-118 (IGR: 18-4)


73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Sherman B
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Bhagav P
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


72730 Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations
García-Feijoo J
Advances in Therapy 2017; 34: 1049-1069 (IGR: 18-4)


72668 Peeking into Sigma-1 Receptor Functions Through the Retina
Guo LW
Adv Exp Med Biol 2017; 964: 285-297 (IGR: 18-4)


72728 Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study
Inoue T
Clinical Drug Investigation 2017; 37: 535-539 (IGR: 18-4)


73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Ponnusamy C
International Journal of Biological Macromolecules 2017; 104: 1837-1845 (IGR: 18-4)


72748 Novel Pharmacologic Candidates for Treatment of Primary Open-Angle Glaucoma
Liu J
The Yale journal of biology and medicine 2017; 90: 111-118 (IGR: 18-4)


72755 Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis
Lee RM
Scientific reports 2017; 7: 518 (IGR: 18-4)


72730 Targeting Schlemm's Canal in the Medical Therapy of Glaucoma: Current and Future Considerations
Konstas AG
Advances in Therapy 2017; 34: 1049-1069 (IGR: 18-4)


72791 Quantification of the efficacy of collagen cross-linking agents to induce stiffening of rat sclera
Read AT
Journal of the Royal Society, Interface / the Royal Society 2017; 14: (IGR: 18-4)


72728 Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study
Matsumura A
Clinical Drug Investigation 2017; 37: 535-539 (IGR: 18-4)


72679 Toll-like receptor 4 inhibitor protects against retinal ganglion cell damage induced by optic nerve crush in mice
Ojino K
Journal of Pharmacological Sciences 2017; 133: 176-183 (IGR: 18-4)


72669 The Role of Sigma 1 Receptor as a Neuroprotective Target in Glaucoma
Zhao J
Adv Exp Med Biol 2017; 964: 299-307 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Taskar P
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


72682 Grooved Glaucoma Drainage Devices That Continuously Deliver Cyclosporine A Decrease Postsurgical Scar Formation in Rabbit Eyes
Sun J
Investigative Ophthalmology and Visual Science 2017; 58: 1692-1701 (IGR: 18-4)


73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Moore LA
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51 (IGR: 18-4)


72716 Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients
Sottile JE
Addictive behaviors 2017; 72: 14-20 (IGR: 18-4)


73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Laethem CL
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51 (IGR: 18-4)


72728 Efficacy of Ripasudil as a Second-line Medication in Addition to a Prostaglandin Analog in Patients with Exfoliation Glaucoma: A Pilot Study
Tanihara H
Clinical Drug Investigation 2017; 37: 535-539 (IGR: 18-4)


72669 The Role of Sigma 1 Receptor as a Neuroprotective Target in Glaucoma
Bollinger K
Adv Exp Med Biol 2017; 964: 299-307 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Hingorani T
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


72716 Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients
Vandrey R
Addictive behaviors 2017; 72: 14-20 (IGR: 18-4)


73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Palanichamy R
International Journal of Biological Macromolecules 2017; 104: 1837-1845 (IGR: 18-4)


72755 Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis
Hutchings K
Scientific reports 2017; 7: 518 (IGR: 18-4)


72791 Quantification of the efficacy of collagen cross-linking agents to induce stiffening of rat sclera
Sherwood JM
Journal of the Royal Society, Interface / the Royal Society 2017; 14: (IGR: 18-4)


72679 Toll-like receptor 4 inhibitor protects against retinal ganglion cell damage induced by optic nerve crush in mice
Izawa H
Journal of Pharmacological Sciences 2017; 133: 176-183 (IGR: 18-4)


72682 Grooved Glaucoma Drainage Devices That Continuously Deliver Cyclosporine A Decrease Postsurgical Scar Formation in Rabbit Eyes
Sun X
Investigative Ophthalmology and Visual Science 2017; 58: 1692-1701 (IGR: 18-4)


72679 Toll-like receptor 4 inhibitor protects against retinal ganglion cell damage induced by optic nerve crush in mice
Takeuchi H
Journal of Pharmacological Sciences 2017; 133: 176-183 (IGR: 18-4)


73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Muthusamy S
International Journal of Biological Macromolecules 2017; 104: 1837-1845 (IGR: 18-4)


72716 Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients
Heinz AJ
Addictive behaviors 2017; 72: 14-20 (IGR: 18-4)


73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Lu DW
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51 (IGR: 18-4)


72791 Quantification of the efficacy of collagen cross-linking agents to induce stiffening of rat sclera
Schwaner SA
Journal of the Royal Society, Interface / the Royal Society 2017; 14: (IGR: 18-4)


72755 Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis
Lisabeth EM
Scientific reports 2017; 7: 518 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Pettaway S
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Pattabiraman PP
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51 (IGR: 18-4)


73001 Co-encapsulated resveratrol and quercetin in chitosan and peg modified chitosan nanoparticles: For efficient intra ocular pressure reduction
Kandasamy R
International Journal of Biological Macromolecules 2017; 104: 1837-1845 (IGR: 18-4)


72791 Quantification of the efficacy of collagen cross-linking agents to induce stiffening of rat sclera
Ethier CR
Journal of the Royal Society, Interface / the Royal Society 2017; 14: (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Gul W
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


72755 Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis
Treisman R
Scientific reports 2017; 7: 518 (IGR: 18-4)


72679 Toll-like receptor 4 inhibitor protects against retinal ganglion cell damage induced by optic nerve crush in mice
Inoue Y
Journal of Pharmacological Sciences 2017; 133: 176-183 (IGR: 18-4)


72716 Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients
Bonn-Miller MO
Addictive behaviors 2017; 72: 14-20 (IGR: 18-4)


72755 Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis
Bailly M
Scientific reports 2017; 7: 518 (IGR: 18-4)


72679 Toll-like receptor 4 inhibitor protects against retinal ganglion cell damage induced by optic nerve crush in mice
Tsuruma K
Journal of Pharmacological Sciences 2017; 133: 176-183 (IGR: 18-4)


73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Rao PV
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Elsohly MA; Repka MA
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
deLong MA
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51 (IGR: 18-4)


72755 Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis
Larsen SD
Scientific reports 2017; 7: 518 (IGR: 18-4)


72679 Toll-like receptor 4 inhibitor protects against retinal ganglion cell damage induced by optic nerve crush in mice
Hara H
Journal of Pharmacological Sciences 2017; 133: 176-183 (IGR: 18-4)


72828 Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability
Majumdar S
Investigative Ophthalmology and Visual Science 2017; 58: 2167-2179 (IGR: 18-4)


72755 Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis
Neubig RR
Scientific reports 2017; 7: 518 (IGR: 18-4)


73280 Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma
Kopczynski CC
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 40-51 (IGR: 18-4)


72755 Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis
Khaw PT
Scientific reports 2017; 7: 518 (IGR: 18-4)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Chandrawati R
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71291 The selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast regulates extracellular matrix remodeling
Peng J
Biochemical and Biophysical Research Communications 2017; 484: 474-479 (IGR: 18-3)


71312 Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma
Patil A
AAPS PharmSciTech 2017; 18: 2291-2302 (IGR: 18-3)


71590 Safety of Using Matrix Metalloproteinase Inhibitor in Experimental Glaucoma Filtration Surgery
Suh W
J Korean Med Sci 2017; 32: 666-671 (IGR: 18-3)


71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
Maria DN
Pharmaceutical Research 2017; 34: 809-824 (IGR: 18-3)


71547 Oral Delivery of a Synthetic Sterol Reduces Axonopathy and Inflammation in a Rodent Model of Glaucoma
Lambert WS
Frontiers in neuroscience 2017; 11: 45 (IGR: 18-3)


71425 Tetramethylpyrazine nitrone protects retinal ganglion cells against N-methyl-d-aspartate-induced excitotoxicity
Luo X
Journal of Neurochemistry 2017; 141: 373-386 (IGR: 18-3)


71257 Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)
Vicente A
Ophthalmic Research 2017; 57: 201-207 (IGR: 18-3)


71645 Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review
Liu XF
Frontiers in pharmacology 2017; 8: 66 (IGR: 18-3)


71590 Safety of Using Matrix Metalloproteinase Inhibitor in Experimental Glaucoma Filtration Surgery
Han KE
J Korean Med Sci 2017; 32: 666-671 (IGR: 18-3)


71547 Oral Delivery of a Synthetic Sterol Reduces Axonopathy and Inflammation in a Rodent Model of Glaucoma
Carlson BJ
Frontiers in neuroscience 2017; 11: 45 (IGR: 18-3)


71425 Tetramethylpyrazine nitrone protects retinal ganglion cells against N-methyl-d-aspartate-induced excitotoxicity
Yu Y
Journal of Neurochemistry 2017; 141: 373-386 (IGR: 18-3)


71257 Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)
Prud'homme S
Ophthalmic Research 2017; 57: 201-207 (IGR: 18-3)


71312 Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma
Singh S
AAPS PharmSciTech 2017; 18: 2291-2302 (IGR: 18-3)


71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
Abd-Elgawad AH
Pharmaceutical Research 2017; 34: 809-824 (IGR: 18-3)


71645 Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review
Hao JL
Frontiers in pharmacology 2017; 8: 66 (IGR: 18-3)


71291 The selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast regulates extracellular matrix remodeling
Zhou H
Biochemical and Biophysical Research Communications 2017; 484: 474-479 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Chang JY
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71312 Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma
Opere C
AAPS PharmSciTech 2017; 18: 2291-2302 (IGR: 18-3)


71257 Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)
Ferreira J
Ophthalmic Research 2017; 57: 201-207 (IGR: 18-3)


71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
Soliman OA
Pharmaceutical Research 2017; 34: 809-824 (IGR: 18-3)


71645 Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review
Xie T
Frontiers in pharmacology 2017; 8: 66 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Reina-Torres E
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71590 Safety of Using Matrix Metalloproteinase Inhibitor in Experimental Glaucoma Filtration Surgery
Han JR
J Korean Med Sci 2017; 32: 666-671 (IGR: 18-3)


71425 Tetramethylpyrazine nitrone protects retinal ganglion cells against N-methyl-d-aspartate-induced excitotoxicity
Xiang Z
Journal of Neurochemistry 2017; 141: 373-386 (IGR: 18-3)


71291 The selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast regulates extracellular matrix remodeling
Kuang G
Biochemical and Biophysical Research Communications 2017; 484: 474-479 (IGR: 18-3)


71547 Oral Delivery of a Synthetic Sterol Reduces Axonopathy and Inflammation in a Rodent Model of Glaucoma
Formichella CR
Frontiers in neuroscience 2017; 11: 45 (IGR: 18-3)


71645 Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review
Mukhtar NJ
Frontiers in pharmacology 2017; 8: 66 (IGR: 18-3)


71257 Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)
Abegão Pinto L
Ophthalmic Research 2017; 57: 201-207 (IGR: 18-3)


71312 Sustained-Release Delivery System of a Slow Hydrogen Sulfide Donor, GYY 4137, for Potential Application in Glaucoma
Dash A
AAPS PharmSciTech 2017; 18: 2291-2302 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Jumeaux C
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
El-Dahan MS
Pharmaceutical Research 2017; 34: 809-824 (IGR: 18-3)


71425 Tetramethylpyrazine nitrone protects retinal ganglion cells against N-methyl-d-aspartate-induced excitotoxicity
Wu H
Journal of Neurochemistry 2017; 141: 373-386 (IGR: 18-3)


71547 Oral Delivery of a Synthetic Sterol Reduces Axonopathy and Inflammation in a Rodent Model of Glaucoma
Sappington RM
Frontiers in neuroscience 2017; 11: 45 (IGR: 18-3)


71291 The selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast regulates extracellular matrix remodeling
Xie L
Biochemical and Biophysical Research Communications 2017; 484: 474-479 (IGR: 18-3)


71425 Tetramethylpyrazine nitrone protects retinal ganglion cells against N-methyl-d-aspartate-induced excitotoxicity
Ramakrishna S
Journal of Neurochemistry 2017; 141: 373-386 (IGR: 18-3)


71291 The selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast regulates extracellular matrix remodeling
Tian T
Biochemical and Biophysical Research Communications 2017; 484: 474-479 (IGR: 18-3)


71416 Nimodipine Ophthalmic Formulations for Management of Glaucoma
Jablonski MM
Pharmaceutical Research 2017; 34: 809-824 (IGR: 18-3)


71645 Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review
Zhang W
Frontiers in pharmacology 2017; 8: 66 (IGR: 18-3)


71547 Oral Delivery of a Synthetic Sterol Reduces Axonopathy and Inflammation in a Rodent Model of Glaucoma
Ahlem C
Frontiers in neuroscience 2017; 11: 45 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Sherwood JM
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71257 Open-Angle Glaucoma: Drug Development Pipeline during the Last 20 Years (1995-2015)
Stalmans I
Ophthalmic Research 2017; 57: 201-207 (IGR: 18-3)


71645 Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review
Malik TH
Frontiers in pharmacology 2017; 8: 66 (IGR: 18-3)


71425 Tetramethylpyrazine nitrone protects retinal ganglion cells against N-methyl-d-aspartate-induced excitotoxicity
Wang Y
Journal of Neurochemistry 2017; 141: 373-386 (IGR: 18-3)


71291 The selective cysteinyl leukotriene receptor 1 (CysLT1R) antagonist montelukast regulates extracellular matrix remodeling
Liu R
Biochemical and Biophysical Research Communications 2017; 484: 474-479 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Stamer WD
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71547 Oral Delivery of a Synthetic Sterol Reduces Axonopathy and Inflammation in a Rodent Model of Glaucoma
Calkins DJ
Frontiers in neuroscience 2017; 11: 45 (IGR: 18-3)


71425 Tetramethylpyrazine nitrone protects retinal ganglion cells against N-methyl-d-aspartate-induced excitotoxicity
So KF
Journal of Neurochemistry 2017; 141: 373-386 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Zelikin AN
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71645 Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review
Lu CW
Frontiers in pharmacology 2017; 8: 66 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Overby DR
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71645 Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review
Zhou DD
Frontiers in pharmacology 2017; 8: 66 (IGR: 18-3)


71425 Tetramethylpyrazine nitrone protects retinal ganglion cells against N-methyl-d-aspartate-induced excitotoxicity
Zhang Z
Journal of Neurochemistry 2017; 141: 373-386 (IGR: 18-3)


71542 Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma
Stevens MM
Advanced materials (Deerfield Beach, Fla.) 2017; 29: (IGR: 18-3)


71425 Tetramethylpyrazine nitrone protects retinal ganglion cells against N-methyl-d-aspartate-induced excitotoxicity
Xu Y
Journal of Neurochemistry 2017; 141: 373-386 (IGR: 18-3)


69863 Generation of reactive oxygen species in the anterior eye segment. Synergistic codrugs of N-acetylcarnosine lubricant eye drops and mitochondria-targeted antioxidant act as a powerful therapeutic platform for the treatment of cataracts and primary open-an
Babizhayev MA
BBA clinical 2016; 6: 49-68 (IGR: 18-2)


70884 Apelin protects against NMDA-induced retinal neuronal death via an APJ receptor by activating Akt and ERK1/2, and suppressing TNF-α expression in mice
Ishimaru Y
Journal of Pharmacological Sciences 2017; 133: 34-41 (IGR: 18-2)


70538 Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms
Ren R
Investigative Ophthalmology and Visual Science 2016; 57: 6197-6209 (IGR: 18-2)


70513 New classes of glaucoma medications
Schehlein EM
Current Opinions in Ophthalmology 2017; 28: 161-168 (IGR: 18-2)


70625 Integrin α5β1 Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery
Van Bergen T
Investigative Ophthalmology and Visual Science 2016; 57: 6428-6439 (IGR: 18-2)


70466 Critical evaluation of latanoprostene bunod in the treatment of glaucoma
Garcia GA
Clinical Ophthalmology 2016; 10: 2035-2050 (IGR: 18-2)


70151 Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research
Rao PV
Experimental Eye Research 2017; 158: 23-32 (IGR: 18-2)


70180 Tetramethylpyrazine Attenuates Transdifferentiation of TGF-β2-Treated Human Tenon's Fibroblasts
Cai X
Investigative Ophthalmology and Visual Science 2016; 57: 4740-4748 (IGR: 18-2)


70557 Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma
Fonseca B
Purinergic signalling 2017; 13: 171-177 (IGR: 18-2)


70663 Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4
Terao E
Current Eye Research 2016; 0: 1-5 (IGR: 18-2)


70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Miller Ellis E
British Journal of Ophthalmology 2017; 101: 796-800 (IGR: 18-2)


69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
Laties A
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554 (IGR: 18-2)


70044 Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma
Lusthaus JA
Expert Opinion on Investigational Drugs 2016; 25: 1201-1208 (IGR: 18-2)


70838 The arguments for and against cannabinoids application in glaucomatous retinopathy
Panahi Y
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2017; 86: 620-627 (IGR: 18-2)


70146 Apelin-36 is protective against N-methyl-D-aspartic-acid-induced retinal ganglion cell death in the mice
Sakamoto K
European Journal of Pharmacology 2016; 791: 213-220 (IGR: 18-2)


70839 New furoxan derivatives for the treatment of ocular hypertension
Blangetti M
Bioorganic and Medicinal Chemistry Letters 2017; 27: 479-483 (IGR: 18-2)


70193 Dock3-NMDA receptor interaction as a target for glaucoma therapy
Kimura A
Histology and Histopathology 2017; 32: 215-221 (IGR: 18-2)


70072 Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Skaat A
Journal of Glaucoma 2016; 25: e807-e814 (IGR: 18-2)


70195 Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase
Chao HM
Chinese medicine 2016; 11: 39 (IGR: 18-2)


69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Harris A
Journal of Glaucoma 2016; 25: e826-e833 (IGR: 18-2)


70838 The arguments for and against cannabinoids application in glaucomatous retinopathy
Manayi A
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2017; 86: 620-627 (IGR: 18-2)


70466 Critical evaluation of latanoprostene bunod in the treatment of glaucoma
Ngai P
Clinical Ophthalmology 2016; 10: 2035-2050 (IGR: 18-2)


70151 Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research
Pattabiraman PP
Experimental Eye Research 2017; 158: 23-32 (IGR: 18-2)


70625 Integrin α5β1 Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery
Zahn G
Investigative Ophthalmology and Visual Science 2016; 57: 6428-6439 (IGR: 18-2)


70180 Tetramethylpyrazine Attenuates Transdifferentiation of TGF-β2-Treated Human Tenon's Fibroblasts
Yang Y
Investigative Ophthalmology and Visual Science 2016; 57: 4740-4748 (IGR: 18-2)


70884 Apelin protects against NMDA-induced retinal neuronal death via an APJ receptor by activating Akt and ERK1/2, and suppressing TNF-α expression in mice
Sumino A
Journal of Pharmacological Sciences 2017; 133: 34-41 (IGR: 18-2)


70195 Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase
Hu L
Chinese medicine 2016; 11: 39 (IGR: 18-2)


70663 Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4
Nakakura S
Current Eye Research 2016; 0: 1-5 (IGR: 18-2)


69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
Rich CC
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554 (IGR: 18-2)


70193 Dock3-NMDA receptor interaction as a target for glaucoma therapy
Namekata K
Histology and Histopathology 2017; 32: 215-221 (IGR: 18-2)


70513 New classes of glaucoma medications
Novack GD
Current Opinions in Ophthalmology 2017; 28: 161-168 (IGR: 18-2)


69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Ward CL
Journal of Glaucoma 2016; 25: e826-e833 (IGR: 18-2)


70072 Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Jasien JV
Journal of Glaucoma 2016; 25: e807-e814 (IGR: 18-2)


70557 Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma
Martínez-Águila A
Purinergic signalling 2017; 13: 171-177 (IGR: 18-2)


70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Berlin MS
British Journal of Ophthalmology 2017; 101: 796-800 (IGR: 18-2)


70044 Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma
Goldberg I
Expert Opinion on Investigational Drugs 2016; 25: 1201-1208 (IGR: 18-2)


70839 New furoxan derivatives for the treatment of ocular hypertension
Rolando B
Bioorganic and Medicinal Chemistry Letters 2017; 27: 479-483 (IGR: 18-2)


70538 Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms
Li G
Investigative Ophthalmology and Visual Science 2016; 57: 6197-6209 (IGR: 18-2)


70146 Apelin-36 is protective against N-methyl-D-aspartic-acid-induced retinal ganglion cell death in the mice
Murakami Y
European Journal of Pharmacology 2016; 791: 213-220 (IGR: 18-2)


70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Ward CL
British Journal of Ophthalmology 2017; 101: 796-800 (IGR: 18-2)


70146 Apelin-36 is protective against N-methyl-D-aspartic-acid-induced retinal ganglion cell death in the mice
Sawada S
European Journal of Pharmacology 2016; 791: 213-220 (IGR: 18-2)


70839 New furoxan derivatives for the treatment of ocular hypertension
Chegaev K
Bioorganic and Medicinal Chemistry Letters 2017; 27: 479-483 (IGR: 18-2)


69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Rowe-Rendleman CL
Journal of Glaucoma 2016; 25: e826-e833 (IGR: 18-2)


69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
Stoltz R
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554 (IGR: 18-2)


70072 Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Ritch R
Journal of Glaucoma 2016; 25: e807-e814 (IGR: 18-2)


70538 Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms
Le TD
Investigative Ophthalmology and Visual Science 2016; 57: 6197-6209 (IGR: 18-2)


70838 The arguments for and against cannabinoids application in glaucomatous retinopathy
Nikan M
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2017; 86: 620-627 (IGR: 18-2)


70513 New classes of glaucoma medications
Robin AL
Current Opinions in Ophthalmology 2017; 28: 161-168 (IGR: 18-2)


70151 Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research
Kopczynski C
Experimental Eye Research 2017; 158: 23-32 (IGR: 18-2)


70884 Apelin protects against NMDA-induced retinal neuronal death via an APJ receptor by activating Akt and ERK1/2, and suppressing TNF-α expression in mice
Kajioka D
Journal of Pharmacological Sciences 2017; 133: 34-41 (IGR: 18-2)


70195 Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase
Cheng JM
Chinese medicine 2016; 11: 39 (IGR: 18-2)


70663 Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4
Fujisawa Y
Current Eye Research 2016; 0: 1-5 (IGR: 18-2)


70466 Critical evaluation of latanoprostene bunod in the treatment of glaucoma
Mosaed S
Clinical Ophthalmology 2016; 10: 2035-2050 (IGR: 18-2)


70180 Tetramethylpyrazine Attenuates Transdifferentiation of TGF-β2-Treated Human Tenon's Fibroblasts
Chen P
Investigative Ophthalmology and Visual Science 2016; 57: 4740-4748 (IGR: 18-2)


70557 Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma
de Lara MJ
Purinergic signalling 2017; 13: 171-177 (IGR: 18-2)


70625 Integrin α5β1 Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery
Caldirola P
Investigative Ophthalmology and Visual Science 2016; 57: 6428-6439 (IGR: 18-2)


70193 Dock3-NMDA receptor interaction as a target for glaucoma therapy
Guo X
Histology and Histopathology 2017; 32: 215-221 (IGR: 18-2)


70663 Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4
Fujio Y
Current Eye Research 2016; 0: 1-5 (IGR: 18-2)


70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Sharpe JA
British Journal of Ophthalmology 2017; 101: 796-800 (IGR: 18-2)


70838 The arguments for and against cannabinoids application in glaucomatous retinopathy
Vazirian M
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2017; 86: 620-627 (IGR: 18-2)


70839 New furoxan derivatives for the treatment of ocular hypertension
Guglielmo S
Bioorganic and Medicinal Chemistry Letters 2017; 27: 479-483 (IGR: 18-2)


70557 Diadenosine tetraphosphate as a potential therapeutic nucleotide to treat glaucoma
Pintor J
Purinergic signalling 2017; 13: 171-177 (IGR: 18-2)


70193 Dock3-NMDA receptor interaction as a target for glaucoma therapy
Harada C
Histology and Histopathology 2017; 32: 215-221 (IGR: 18-2)


70625 Integrin α5β1 Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery
Fsadni M
Investigative Ophthalmology and Visual Science 2016; 57: 6428-6439 (IGR: 18-2)


70884 Apelin protects against NMDA-induced retinal neuronal death via an APJ receptor by activating Akt and ERK1/2, and suppressing TNF-α expression in mice
Shibagaki F
Journal of Pharmacological Sciences 2017; 133: 34-41 (IGR: 18-2)


70466 Critical evaluation of latanoprostene bunod in the treatment of glaucoma
Lin KY
Clinical Ophthalmology 2016; 10: 2035-2050 (IGR: 18-2)


70146 Apelin-36 is protective against N-methyl-D-aspartic-acid-induced retinal ganglion cell death in the mice
Ushikubo H
European Journal of Pharmacology 2016; 791: 213-220 (IGR: 18-2)


70195 Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase
Liu XQ
Chinese medicine 2016; 11: 39 (IGR: 18-2)


69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
Humbert V
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554 (IGR: 18-2)


70538 Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms
Kopczynski C
Investigative Ophthalmology and Visual Science 2016; 57: 6197-6209 (IGR: 18-2)


70180 Tetramethylpyrazine Attenuates Transdifferentiation of TGF-β2-Treated Human Tenon's Fibroblasts
Ye Y
Investigative Ophthalmology and Visual Science 2016; 57: 4740-4748 (IGR: 18-2)


69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Ouchi T
Journal of Glaucoma 2016; 25: e826-e833 (IGR: 18-2)


69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
Brickman C
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554 (IGR: 18-2)


70193 Dock3-NMDA receptor interaction as a target for glaucoma therapy
Harada T
Histology and Histopathology 2017; 32: 215-221 (IGR: 18-2)


70146 Apelin-36 is protective against N-methyl-D-aspartic-acid-induced retinal ganglion cell death in the mice
Mori A
European Journal of Pharmacology 2016; 791: 213-220 (IGR: 18-2)


70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Jamil A
British Journal of Ophthalmology 2017; 101: 796-800 (IGR: 18-2)


70663 Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4
Matsuya K
Current Eye Research 2016; 0: 1-5 (IGR: 18-2)


69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Wood A
Journal of Glaucoma 2016; 25: e826-e833 (IGR: 18-2)


70180 Tetramethylpyrazine Attenuates Transdifferentiation of TGF-β2-Treated Human Tenon's Fibroblasts
Liu X
Investigative Ophthalmology and Visual Science 2016; 57: 4740-4748 (IGR: 18-2)


70195 Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase
Liu JH
Chinese medicine 2016; 11: 39 (IGR: 18-2)


70538 Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms
Stamer WD
Investigative Ophthalmology and Visual Science 2016; 57: 6197-6209 (IGR: 18-2)


70625 Integrin α5β1 Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery
Caram-Lelham N
Investigative Ophthalmology and Visual Science 2016; 57: 6428-6439 (IGR: 18-2)


70839 New furoxan derivatives for the treatment of ocular hypertension
Lazzarato L
Bioorganic and Medicinal Chemistry Letters 2017; 27: 479-483 (IGR: 18-2)


70884 Apelin protects against NMDA-induced retinal neuronal death via an APJ receptor by activating Akt and ERK1/2, and suppressing TNF-α expression in mice
Yamamuro A
Journal of Pharmacological Sciences 2017; 133: 34-41 (IGR: 18-2)


70180 Tetramethylpyrazine Attenuates Transdifferentiation of TGF-β2-Treated Human Tenon's Fibroblasts
Wu K
Investigative Ophthalmology and Visual Science 2016; 57: 4740-4748 (IGR: 18-2)


69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Fujii A
Journal of Glaucoma 2016; 25: e826-e833 (IGR: 18-2)


70884 Apelin protects against NMDA-induced retinal neuronal death via an APJ receptor by activating Akt and ERK1/2, and suppressing TNF-α expression in mice
Yoshioka Y
Journal of Pharmacological Sciences 2017; 133: 34-41 (IGR: 18-2)


70538 Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms
Gong H
Investigative Ophthalmology and Visual Science 2016; 57: 6197-6209 (IGR: 18-2)


70195 Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase
Pan WH
Chinese medicine 2016; 11: 39 (IGR: 18-2)


70839 New furoxan derivatives for the treatment of ocular hypertension
Durante M
Bioorganic and Medicinal Chemistry Letters 2017; 27: 479-483 (IGR: 18-2)


70237 Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
Harris A
British Journal of Ophthalmology 2017; 101: 796-800 (IGR: 18-2)


69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
McVicar W
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554 (IGR: 18-2)


70663 Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4
Kobayashi Y
Current Eye Research 2016; 0: 1-5 (IGR: 18-2)


70146 Apelin-36 is protective against N-methyl-D-aspartic-acid-induced retinal ganglion cell death in the mice
Nakahara T
European Journal of Pharmacology 2016; 791: 213-220 (IGR: 18-2)


70625 Integrin α5β1 Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery
Vandewalle E
Investigative Ophthalmology and Visual Science 2016; 57: 6428-6439 (IGR: 18-2)


70663 Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4
Tabuchi H
Current Eye Research 2016; 0: 1-5 (IGR: 18-2)


70195 Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase
Zhang XM
Chinese medicine 2016; 11: 39 (IGR: 18-2)


70146 Apelin-36 is protective against N-methyl-D-aspartic-acid-induced retinal ganglion cell death in the mice
Ishii K
European Journal of Pharmacology 2016; 791: 213-220 (IGR: 18-2)


70625 Integrin α5β1 Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery
Moons L
Investigative Ophthalmology and Visual Science 2016; 57: 6428-6439 (IGR: 18-2)


70884 Apelin protects against NMDA-induced retinal neuronal death via an APJ receptor by activating Akt and ERK1/2, and suppressing TNF-α expression in mice
Maeda S
Journal of Pharmacological Sciences 2017; 133: 34-41 (IGR: 18-2)


70180 Tetramethylpyrazine Attenuates Transdifferentiation of TGF-β2-Treated Human Tenon's Fibroblasts
Yu M
Investigative Ophthalmology and Visual Science 2016; 57: 4740-4748 (IGR: 18-2)


69793 Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
Serle JB
Journal of Glaucoma 2016; 25: e826-e833 (IGR: 18-2)


69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
Baumgartner RA
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554 (IGR: 18-2)


70839 New furoxan derivatives for the treatment of ocular hypertension
Masini E
Bioorganic and Medicinal Chemistry Letters 2017; 27: 479-483 (IGR: 18-2)


70625 Integrin α5β1 Inhibition by CLT-28643 Reduces Postoperative Wound Healing in a Mouse Model of Glaucoma Filtration Surgery
Stalmans I
Investigative Ophthalmology and Visual Science 2016; 57: 6428-6439 (IGR: 18-2)


70663 Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4
Yoneda T
Current Eye Research 2016; 0: 1-5 (IGR: 18-2)


70839 New furoxan derivatives for the treatment of ocular hypertension
Almirante N; Bastia E
Bioorganic and Medicinal Chemistry Letters 2017; 27: 479-483 (IGR: 18-2)


70663 Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4
Fukushima A
Current Eye Research 2016; 0: 1-5 (IGR: 18-2)


70839 New furoxan derivatives for the treatment of ocular hypertension
Impagnatiello F
Bioorganic and Medicinal Chemistry Letters 2017; 27: 479-483 (IGR: 18-2)


70663 Time Course of Conjunctival Hyperemia Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4
Kiuchi Y
Current Eye Research 2016; 0: 1-5 (IGR: 18-2)


70839 New furoxan derivatives for the treatment of ocular hypertension
Fruttero R; Gasco A
Bioorganic and Medicinal Chemistry Letters 2017; 27: 479-483 (IGR: 18-2)


68994 Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study
Medeiros FA
American Journal of Ophthalmology 2016; 168: 250-259 (IGR: 18-1)


69373 Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury
Shaw PX
Experimental Eye Research 2017; 158: 33-42 (IGR: 18-1)


69268 Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma
Mao WM
Chinese Journal of Ophthalmology 2016; 52: 471-475 (IGR: 18-1)


69300 The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts
Futakuchi A
Experimental Eye Research 2016; 149: 107-115 (IGR: 18-1)


69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Sato S
Advances in Therapy 2016; 33: 1628-1634 (IGR: 18-1)


69392 Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours
Liu JH
American Journal of Ophthalmology 2016; 169: 249-257 (IGR: 18-1)


69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Shirley Ding SL
Eye 2016; 30: 1293-1309 (IGR: 18-1)


69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Kawase K
Advances in Therapy 2016; 33: 1612-1627 (IGR: 18-1)


69392 Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours
Slight JR
American Journal of Ophthalmology 2016; 169: 249-257 (IGR: 18-1)


69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Hirooka K
Advances in Therapy 2016; 33: 1628-1634 (IGR: 18-1)


69373 Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury
Sang A
Experimental Eye Research 2017; 158: 33-42 (IGR: 18-1)


69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Vittitow JL
Advances in Therapy 2016; 33: 1612-1627 (IGR: 18-1)


69300 The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts
Inoue T
Experimental Eye Research 2016; 149: 107-115 (IGR: 18-1)


68994 Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study
Martin KR
American Journal of Ophthalmology 2016; 168: 250-259 (IGR: 18-1)


69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Leow SN
Eye 2016; 30: 1293-1309 (IGR: 18-1)


69268 Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma
Liu Y
Chinese Journal of Ophthalmology 2016; 52: 471-475 (IGR: 18-1)


69300 The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts
Fujimoto T
Experimental Eye Research 2016; 149: 107-115 (IGR: 18-1)


68994 Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study
Peace J
American Journal of Ophthalmology 2016; 168: 250-259 (IGR: 18-1)


69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Munisvaradass R
Eye 2016; 30: 1293-1309 (IGR: 18-1)


69268 Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma
Wordinger YH
Chinese Journal of Ophthalmology 2016; 52: 471-475 (IGR: 18-1)


69392 Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours
Vittitow JL
American Journal of Ophthalmology 2016; 169: 249-257 (IGR: 18-1)


69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Nitta E
Advances in Therapy 2016; 33: 1628-1634 (IGR: 18-1)


69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Weinreb RN
Advances in Therapy 2016; 33: 1612-1627 (IGR: 18-1)


69373 Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury
Wang Y
Experimental Eye Research 2017; 158: 33-42 (IGR: 18-1)


69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Koh EH
Eye 2016; 30: 1293-1309 (IGR: 18-1)


69268 Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma
Clark AF
Chinese Journal of Ophthalmology 2016; 52: 471-475 (IGR: 18-1)


69373 Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury
Ho D
Experimental Eye Research 2017; 158: 33-42 (IGR: 18-1)


69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Ukegawa K
Advances in Therapy 2016; 33: 1628-1634 (IGR: 18-1)


69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
Araie M
Advances in Therapy 2016; 33: 1612-1627 (IGR: 18-1)


69300 The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts
Inoue-Mochita M
Experimental Eye Research 2016; 149: 107-115 (IGR: 18-1)


69392 Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours
Scassellati Sforzolini B
American Journal of Ophthalmology 2016; 169: 249-257 (IGR: 18-1)


68994 Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study
Scassellati Sforzolini B
American Journal of Ophthalmology 2016; 168: 250-259 (IGR: 18-1)


69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Bastion ML
Eye 2016; 30: 1293-1309 (IGR: 18-1)


69268 Novel therapeutic targets for reduction of intraocular pressure in primary open angle glaucoma
Pang IH
Chinese Journal of Ophthalmology 2016; 52: 471-475 (IGR: 18-1)


69393 Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study

Advances in Therapy 2016; 33: 1612-1627 (IGR: 18-1)


68994 Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study
Vittitow JL
American Journal of Ophthalmology 2016; 168: 250-259 (IGR: 18-1)


69373 Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury
Douglas C
Experimental Eye Research 2017; 158: 33-42 (IGR: 18-1)


69300 The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts
Kawai M
Experimental Eye Research 2016; 149: 107-115 (IGR: 18-1)


69364 Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Tsujikawa A
Advances in Therapy 2016; 33: 1628-1634 (IGR: 18-1)


69392 Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours
Weinreb RN
American Journal of Ophthalmology 2016; 169: 249-257 (IGR: 18-1)


69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Then KY
Eye 2016; 30: 1293-1309 (IGR: 18-1)


69373 Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury
Dia L
Experimental Eye Research 2017; 158: 33-42 (IGR: 18-1)


69300 The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts
Tanihara H
Experimental Eye Research 2016; 149: 107-115 (IGR: 18-1)


68994 Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study
Weinreb RN
American Journal of Ophthalmology 2016; 168: 250-259 (IGR: 18-1)


69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Kumar S
Eye 2016; 30: 1293-1309 (IGR: 18-1)


69373 Topical administration of a Rock/Net inhibitor promotes retinal ganglion cell survival and axon regeneration after optic nerve injury
Goldberg JL
Experimental Eye Research 2017; 158: 33-42 (IGR: 18-1)


69132 Revisiting the role of erythropoietin for treatment of ocular disorders
Mok PL
Eye 2016; 30: 1293-1309 (IGR: 18-1)


67545 Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes
Li G
European Journal of Pharmacology 2016; 787: 20-31 (IGR: 17-4)


66716 The Effect of A2A Receptor Antagonist on Microglial Activation in Experimental Glaucoma
Liu X
Investigative Ophthalmology and Visual Science 2016; 57: 776-786 (IGR: 17-4)


67164 Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
Sturdivant JM
Bioorganic and Medicinal Chemistry Letters 2016; 26: 2475-2480 (IGR: 17-4)


67122 Neuroprotective effect of systemic and/or intravitreal rosuvastatin administration in rat glaucoma model
Unlu M
International Journal of Ophthalmology 2016; 9: 340-347 (IGR: 17-4)


67460 Pirfenidone inhibits fibrosis in foreign body reaction after glaucoma drainage device implantation
Jung KI
Drug design, development and therapy 2016; 10: 1477-1488 (IGR: 17-4)


66700 Paclitaxel Associated With Lipid Nanoparticles as a New Antiscarring Agent in Experimental Glaucoma Surgery
Occhiutto ML
Investigative Ophthalmology and Visual Science 2016; 57: 971-978 (IGR: 17-4)


67316 Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice
Martínez-Águila A
Journal of Pharmacology and Experimental Therapeutics 2016; 357: 293-299 (IGR: 17-4)


66840 Cannabinoids for treatment of glaucoma
Novack GD
Current Opinions in Ophthalmology 2016; 27: 146-150 (IGR: 17-4)


66794 Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study
Weinreb RN
Ophthalmology 2016; 123: 965-973 (IGR: 17-4)


67559 Ocular Erythropoietin Penetration after Subconjunctival Administration in Glaucomatous Rats
Resende AP
Ophthalmic Research 2016; 56: 104-110 (IGR: 17-4)


67228 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma
Myers JS
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 555-562 (IGR: 17-4)


67476 ATP sensitive potassium channel openers: A new class of ocular hypotensive agents
Roy Chowdhury U
Experimental Eye Research 2017; 158: 85-93 (IGR: 17-4)


67228 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma
Sall KN
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 555-562 (IGR: 17-4)


67316 Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice
Fonseca B
Journal of Pharmacology and Experimental Therapeutics 2016; 357: 293-299 (IGR: 17-4)


67545 Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes
Mukherjee D
European Journal of Pharmacology 2016; 787: 20-31 (IGR: 17-4)


66700 Paclitaxel Associated With Lipid Nanoparticles as a New Antiscarring Agent in Experimental Glaucoma Surgery
Freitas FR
Investigative Ophthalmology and Visual Science 2016; 57: 971-978 (IGR: 17-4)


67559 Ocular Erythropoietin Penetration after Subconjunctival Administration in Glaucomatous Rats
São Braz B
Ophthalmic Research 2016; 56: 104-110 (IGR: 17-4)


66716 The Effect of A2A Receptor Antagonist on Microglial Activation in Experimental Glaucoma
Huang P
Investigative Ophthalmology and Visual Science 2016; 57: 776-786 (IGR: 17-4)


67476 ATP sensitive potassium channel openers: A new class of ocular hypotensive agents
Dosa PI
Experimental Eye Research 2017; 158: 85-93 (IGR: 17-4)


67122 Neuroprotective effect of systemic and/or intravitreal rosuvastatin administration in rat glaucoma model
Aktas Z
International Journal of Ophthalmology 2016; 9: 340-347 (IGR: 17-4)


67460 Pirfenidone inhibits fibrosis in foreign body reaction after glaucoma drainage device implantation
Park CK
Drug design, development and therapy 2016; 10: 1477-1488 (IGR: 17-4)


66794 Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study
Scassellati Sforzolini B
Ophthalmology 2016; 123: 965-973 (IGR: 17-4)


67164 Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
Royalty SM
Bioorganic and Medicinal Chemistry Letters 2016; 26: 2475-2480 (IGR: 17-4)


66700 Paclitaxel Associated With Lipid Nanoparticles as a New Antiscarring Agent in Experimental Glaucoma Surgery
Lima PP
Investigative Ophthalmology and Visual Science 2016; 57: 971-978 (IGR: 17-4)


66794 Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study
Vittitow J
Ophthalmology 2016; 123: 965-973 (IGR: 17-4)


67122 Neuroprotective effect of systemic and/or intravitreal rosuvastatin administration in rat glaucoma model
Gocun PU
International Journal of Ophthalmology 2016; 9: 340-347 (IGR: 17-4)


67476 ATP sensitive potassium channel openers: A new class of ocular hypotensive agents
Fautsch MP
Experimental Eye Research 2017; 158: 85-93 (IGR: 17-4)


67228 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma
DuBiner H
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 555-562 (IGR: 17-4)


67164 Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
Lin CW
Bioorganic and Medicinal Chemistry Letters 2016; 26: 2475-2480 (IGR: 17-4)


66716 The Effect of A2A Receptor Antagonist on Microglial Activation in Experimental Glaucoma
Wang J
Investigative Ophthalmology and Visual Science 2016; 57: 776-786 (IGR: 17-4)


67316 Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice
Pérez de Lara MJ
Journal of Pharmacology and Experimental Therapeutics 2016; 357: 293-299 (IGR: 17-4)


67545 Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes
Navarro I
European Journal of Pharmacology 2016; 787: 20-31 (IGR: 17-4)


67559 Ocular Erythropoietin Penetration after Subconjunctival Administration in Glaucomatous Rats
Delgado E
Ophthalmic Research 2016; 56: 104-110 (IGR: 17-4)


67228 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma
Slomowitz N
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 555-562 (IGR: 17-4)


66716 The Effect of A2A Receptor Antagonist on Microglial Activation in Experimental Glaucoma
Yang Z
Investigative Ophthalmology and Visual Science 2016; 57: 776-786 (IGR: 17-4)


67545 Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes
Ashpole NE
European Journal of Pharmacology 2016; 787: 20-31 (IGR: 17-4)


67164 Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
Moore LA
Bioorganic and Medicinal Chemistry Letters 2016; 26: 2475-2480 (IGR: 17-4)


66794 Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study
Liebmann J
Ophthalmology 2016; 123: 965-973 (IGR: 17-4)


66700 Paclitaxel Associated With Lipid Nanoparticles as a New Antiscarring Agent in Experimental Glaucoma Surgery
Maranhão RC
Investigative Ophthalmology and Visual Science 2016; 57: 971-978 (IGR: 17-4)


67316 Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice
Pintor J
Journal of Pharmacology and Experimental Therapeutics 2016; 357: 293-299 (IGR: 17-4)


67122 Neuroprotective effect of systemic and/or intravitreal rosuvastatin administration in rat glaucoma model
Ilhan SO
International Journal of Ophthalmology 2016; 9: 340-347 (IGR: 17-4)


67164 Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
Yingling JD
Bioorganic and Medicinal Chemistry Letters 2016; 26: 2475-2480 (IGR: 17-4)


67545 Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes
Sherwood JM
European Journal of Pharmacology 2016; 787: 20-31 (IGR: 17-4)


66700 Paclitaxel Associated With Lipid Nanoparticles as a New Antiscarring Agent in Experimental Glaucoma Surgery
Costa VP
Investigative Ophthalmology and Visual Science 2016; 57: 971-978 (IGR: 17-4)


67228 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma
McVicar W
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 555-562 (IGR: 17-4)


66716 The Effect of A2A Receptor Antagonist on Microglial Activation in Experimental Glaucoma
Huang S
Investigative Ophthalmology and Visual Science 2016; 57: 776-786 (IGR: 17-4)


67122 Neuroprotective effect of systemic and/or intravitreal rosuvastatin administration in rat glaucoma model
Hasanreisoglu M
International Journal of Ophthalmology 2016; 9: 340-347 (IGR: 17-4)


66716 The Effect of A2A Receptor Antagonist on Microglial Activation in Experimental Glaucoma
Luo X
Investigative Ophthalmology and Visual Science 2016; 57: 776-786 (IGR: 17-4)


67122 Neuroprotective effect of systemic and/or intravitreal rosuvastatin administration in rat glaucoma model
Hasanreisoglu B
International Journal of Ophthalmology 2016; 9: 340-347 (IGR: 17-4)


67228 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma
Rich CC
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 555-562 (IGR: 17-4)


67164 Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
Laethem CL
Bioorganic and Medicinal Chemistry Letters 2016; 26: 2475-2480 (IGR: 17-4)


67545 Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes
Chang J
European Journal of Pharmacology 2016; 787: 20-31 (IGR: 17-4)


67164 Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
Sherman B
Bioorganic and Medicinal Chemistry Letters 2016; 26: 2475-2480 (IGR: 17-4)


67545 Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes
Overby DR
European Journal of Pharmacology 2016; 787: 20-31 (IGR: 17-4)


67228 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma
Baumgartner RA
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 555-562 (IGR: 17-4)


66716 The Effect of A2A Receptor Antagonist on Microglial Activation in Experimental Glaucoma
Qi J
Investigative Ophthalmology and Visual Science 2016; 57: 776-786 (IGR: 17-4)


67545 Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes
Yuan F
European Journal of Pharmacology 2016; 787: 20-31 (IGR: 17-4)


66716 The Effect of A2A Receptor Antagonist on Microglial Activation in Experimental Glaucoma
Shen X
Investigative Ophthalmology and Visual Science 2016; 57: 776-786 (IGR: 17-4)


67164 Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
Heintzelman GR; Kopczynski CC
Bioorganic and Medicinal Chemistry Letters 2016; 26: 2475-2480 (IGR: 17-4)


67545 Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes
Gonzalez P
European Journal of Pharmacology 2016; 787: 20-31 (IGR: 17-4)


66716 The Effect of A2A Receptor Antagonist on Microglial Activation in Experimental Glaucoma
Zhong Y
Investigative Ophthalmology and Visual Science 2016; 57: 776-786 (IGR: 17-4)


67545 Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes
Kopczynski CC
European Journal of Pharmacology 2016; 787: 20-31 (IGR: 17-4)


67164 Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma
deLong MA
Bioorganic and Medicinal Chemistry Letters 2016; 26: 2475-2480 (IGR: 17-4)


67545 Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes
Farsiu S; Stamer WD
European Journal of Pharmacology 2016; 787: 20-31 (IGR: 17-4)


66338 Extraction (DSX) from Erigeron breviscapus modulates outward potassium currents in rat retinal ganglion cells
Yin S
International Journal of Ophthalmology 2015; 8: 1101-1106 (IGR: 17-3)


65953 Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-(2S)-2-Aminopropyl-8,9-dihydro-7H-pyrano2,3-gindazol-8-ol a Selective 5-HT2 Receptor Agonist
May JA
Journal of Medicinal Chemistry 2015; 58: 8818-8833 (IGR: 17-3)


65815 Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure-induced transient ischemic injury
Madeira MH
Translational research : the journal of laboratory and clinical medicine 2016; 169: 112-128 (IGR: 17-3)


66557 Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells
Kaneko Y
Scientific reports 2016; 6: 19640 (IGR: 17-3)


65828 Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy
Keppel Hesselink JM
Journal of Ophthalmology 2015; 2015: 430596 (IGR: 17-3)


66221 Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease
Kokona D
Neural plasticity 2016; 2016: 8373020 (IGR: 17-3)


66257 Inhibition by a retinoic acid receptor γ agonist of extracellular matrix remodeling mediated by human Tenon fibroblasts
Liu Y
Molecular Vision 2015; 21: 1368-1377 (IGR: 17-3)


65831 New drugs and preparations for open-angle glaucoma in adults

Drug and therapeutics bulletin 2015; 53: 141-144 (IGR: 17-3)


65857 Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives
Roberti G
International journal of molecular sciences 2015; 16: 28401-28417 (IGR: 17-3)


66506 Neuroprotective effect of lignans extracted from Eucommia ulmoides Oliv. on glaucoma-related neurodegeneration
Li CP
Neurological Sciences 2016; 37: 755-762 (IGR: 17-3)


66220 The Endocannabinoid System as a Therapeutic Target in Glaucoma
Cairns EA
Neural plasticity 2016; 2016: 9364091 (IGR: 17-3)


65800 A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers
Suto F
Investigative Ophthalmology and Visual Science 2015; 56: 7963-7970 (IGR: 17-3)


65985 Ocular Hypotensive Effects of the ATP-Sensitive Potassium Channel Opener Cromakalim in Human and Murine Experimental Model Systems
Roy Chowdhury U
PLoS ONE 2015; 10: e0141783 (IGR: 17-3)


66236 Design and synthesis of novel hybrid sydnonimine and prodrug useful for glaucomatous optic neuropathy
Acharya S
Bioorganic and Medicinal Chemistry Letters 2016; 26: 1490-1494 (IGR: 17-3)


65926 Seeing over the horizon - targeting the endocannabinoid system for the treatment of ocular disease
Cairns EA
Journal of basic and clinical physiology and pharmacology 2016; 27: 253-265 (IGR: 17-3)


66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Pakravan M
American Journal of Therapeutics 2017; 24: e676-e680 (IGR: 17-3)


65820 Rho kinase inhibitors for glaucoma treatment - Review
Germano RA
Arquivos Brasileiros de Oftalmologia 2015; 78: 388-391 (IGR: 17-3)


66506 Neuroprotective effect of lignans extracted from Eucommia ulmoides Oliv. on glaucoma-related neurodegeneration
Qiu GZ
Neurological Sciences 2016; 37: 755-762 (IGR: 17-3)


66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Beni AN
American Journal of Therapeutics 2017; 24: e676-e680 (IGR: 17-3)


66221 Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease
Georgiou PC
Neural plasticity 2016; 2016: 8373020 (IGR: 17-3)


66220 The Endocannabinoid System as a Therapeutic Target in Glaucoma
Baldridge WH
Neural plasticity 2016; 2016: 9364091 (IGR: 17-3)


65985 Ocular Hypotensive Effects of the ATP-Sensitive Potassium Channel Opener Cromakalim in Human and Murine Experimental Model Systems
Bahler CK
PLoS ONE 2015; 10: e0141783 (IGR: 17-3)


65820 Rho kinase inhibitors for glaucoma treatment - Review
Finzi S
Arquivos Brasileiros de Oftalmologia 2015; 78: 388-391 (IGR: 17-3)


66338 Extraction (DSX) from Erigeron breviscapus modulates outward potassium currents in rat retinal ganglion cells
Wang ZF
International Journal of Ophthalmology 2015; 8: 1101-1106 (IGR: 17-3)


65800 A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers
Rowe-Rendleman CL
Investigative Ophthalmology and Visual Science 2015; 56: 7963-7970 (IGR: 17-3)


65953 Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-(2S)-2-Aminopropyl-8,9-dihydro-7H-pyrano2,3-gindazol-8-ol a Selective 5-HT2 Receptor Agonist
Sharif NA
Journal of Medicinal Chemistry 2015; 58: 8818-8833 (IGR: 17-3)


65815 Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure-induced transient ischemic injury
Boia R
Translational research : the journal of laboratory and clinical medicine 2016; 169: 112-128 (IGR: 17-3)


65828 Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy
Costagliola C
Journal of Ophthalmology 2015; 2015: 430596 (IGR: 17-3)


65926 Seeing over the horizon - targeting the endocannabinoid system for the treatment of ocular disease
Toguri JT
Journal of basic and clinical physiology and pharmacology 2016; 27: 253-265 (IGR: 17-3)


66257 Inhibition by a retinoic acid receptor γ agonist of extracellular matrix remodeling mediated by human Tenon fibroblasts
Kimura K
Molecular Vision 2015; 21: 1368-1377 (IGR: 17-3)


66557 Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells
Ohta M
Scientific reports 2016; 6: 19640 (IGR: 17-3)


66236 Design and synthesis of novel hybrid sydnonimine and prodrug useful for glaucomatous optic neuropathy
Rogers P
Bioorganic and Medicinal Chemistry Letters 2016; 26: 1490-1494 (IGR: 17-3)


65857 Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives
Tanga L
International journal of molecular sciences 2015; 16: 28401-28417 (IGR: 17-3)


65800 A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers
Ouchi T
Investigative Ophthalmology and Visual Science 2015; 56: 7963-7970 (IGR: 17-3)


65926 Seeing over the horizon - targeting the endocannabinoid system for the treatment of ocular disease
Porter RF
Journal of basic and clinical physiology and pharmacology 2016; 27: 253-265 (IGR: 17-3)


65815 Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure-induced transient ischemic injury
Elvas F
Translational research : the journal of laboratory and clinical medicine 2016; 169: 112-128 (IGR: 17-3)


66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Ghahari E
American Journal of Therapeutics 2017; 24: e676-e680 (IGR: 17-3)


66236 Design and synthesis of novel hybrid sydnonimine and prodrug useful for glaucomatous optic neuropathy
Krishnamoorthy RR
Bioorganic and Medicinal Chemistry Letters 2016; 26: 1490-1494 (IGR: 17-3)


65820 Rho kinase inhibitors for glaucoma treatment - Review
Challa P
Arquivos Brasileiros de Oftalmologia 2015; 78: 388-391 (IGR: 17-3)


65857 Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives
Michelessi M
International journal of molecular sciences 2015; 16: 28401-28417 (IGR: 17-3)


65953 Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-(2S)-2-Aminopropyl-8,9-dihydro-7H-pyrano2,3-gindazol-8-ol a Selective 5-HT2 Receptor Agonist
McLaughlin MA
Journal of Medicinal Chemistry 2015; 58: 8818-8833 (IGR: 17-3)


66338 Extraction (DSX) from Erigeron breviscapus modulates outward potassium currents in rat retinal ganglion cells
Duan JG
International Journal of Ophthalmology 2015; 8: 1101-1106 (IGR: 17-3)


66221 Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease
Kounenidakis M
Neural plasticity 2016; 2016: 8373020 (IGR: 17-3)


66220 The Endocannabinoid System as a Therapeutic Target in Glaucoma
Kelly ME
Neural plasticity 2016; 2016: 9364091 (IGR: 17-3)


65828 Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy
Fakhry J
Journal of Ophthalmology 2015; 2015: 430596 (IGR: 17-3)


66257 Inhibition by a retinoic acid receptor γ agonist of extracellular matrix remodeling mediated by human Tenon fibroblasts
Orita T
Molecular Vision 2015; 21: 1368-1377 (IGR: 17-3)


66506 Neuroprotective effect of lignans extracted from Eucommia ulmoides Oliv. on glaucoma-related neurodegeneration
Liu B
Neurological Sciences 2016; 37: 755-762 (IGR: 17-3)


66557 Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells
Inoue T
Scientific reports 2016; 6: 19640 (IGR: 17-3)


65985 Ocular Hypotensive Effects of the ATP-Sensitive Potassium Channel Opener Cromakalim in Human and Murine Experimental Model Systems
Holman BH
PLoS ONE 2015; 10: e0141783 (IGR: 17-3)


66257 Inhibition by a retinoic acid receptor γ agonist of extracellular matrix remodeling mediated by human Tenon fibroblasts
Suzuki K
Molecular Vision 2015; 21: 1368-1377 (IGR: 17-3)


66236 Design and synthesis of novel hybrid sydnonimine and prodrug useful for glaucomatous optic neuropathy
Stankowska DL
Bioorganic and Medicinal Chemistry Letters 2016; 26: 1490-1494 (IGR: 17-3)


65800 A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers
Jamil A
Investigative Ophthalmology and Visual Science 2015; 56: 7963-7970 (IGR: 17-3)


66557 Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells
Mizuno K
Scientific reports 2016; 6: 19640 (IGR: 17-3)


65953 Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-(2S)-2-Aminopropyl-8,9-dihydro-7H-pyrano2,3-gindazol-8-ol a Selective 5-HT2 Receptor Agonist
Chen HH
Journal of Medicinal Chemistry 2015; 58: 8818-8833 (IGR: 17-3)


65985 Ocular Hypotensive Effects of the ATP-Sensitive Potassium Channel Opener Cromakalim in Human and Murine Experimental Model Systems
Dosa PI
PLoS ONE 2015; 10: e0141783 (IGR: 17-3)


66338 Extraction (DSX) from Erigeron breviscapus modulates outward potassium currents in rat retinal ganglion cells
Ji L
International Journal of Ophthalmology 2015; 8: 1101-1106 (IGR: 17-3)


66221 Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease
Kiagiadaki F
Neural plasticity 2016; 2016: 8373020 (IGR: 17-3)


65828 Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy
Kopsky DJ
Journal of Ophthalmology 2015; 2015: 430596 (IGR: 17-3)


66506 Neuroprotective effect of lignans extracted from Eucommia ulmoides Oliv. on glaucoma-related neurodegeneration
Chen JL
Neurological Sciences 2016; 37: 755-762 (IGR: 17-3)


65820 Rho kinase inhibitors for glaucoma treatment - Review
Susanna Junior R
Arquivos Brasileiros de Oftalmologia 2015; 78: 388-391 (IGR: 17-3)


65857 Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives
Quaranta L
International journal of molecular sciences 2015; 16: 28401-28417 (IGR: 17-3)


66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Varshochian R
American Journal of Therapeutics 2017; 24: e676-e680 (IGR: 17-3)


65815 Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure-induced transient ischemic injury
Martins T
Translational research : the journal of laboratory and clinical medicine 2016; 169: 112-128 (IGR: 17-3)


65926 Seeing over the horizon - targeting the endocannabinoid system for the treatment of ocular disease
Szczesniak AM
Journal of basic and clinical physiology and pharmacology 2016; 27: 253-265 (IGR: 17-3)


65857 Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives
Parisi V
International journal of molecular sciences 2015; 16: 28401-28417 (IGR: 17-3)


65926 Seeing over the horizon - targeting the endocannabinoid system for the treatment of ocular disease
Kelly ME
Journal of basic and clinical physiology and pharmacology 2016; 27: 253-265 (IGR: 17-3)


66257 Inhibition by a retinoic acid receptor γ agonist of extracellular matrix remodeling mediated by human Tenon fibroblasts
Teranishi S
Molecular Vision 2015; 21: 1368-1377 (IGR: 17-3)


66338 Extraction (DSX) from Erigeron breviscapus modulates outward potassium currents in rat retinal ganglion cells
Lu XJ
International Journal of Ophthalmology 2015; 8: 1101-1106 (IGR: 17-3)


66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Yazdani S
American Journal of Therapeutics 2017; 24: e676-e680 (IGR: 17-3)


66221 Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease
Thermos K
Neural plasticity 2016; 2016: 8373020 (IGR: 17-3)


66557 Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells
Isobe T
Scientific reports 2016; 6: 19640 (IGR: 17-3)


65985 Ocular Hypotensive Effects of the ATP-Sensitive Potassium Channel Opener Cromakalim in Human and Murine Experimental Model Systems
Fautsch MP
PLoS ONE 2015; 10: e0141783 (IGR: 17-3)


66236 Design and synthesis of novel hybrid sydnonimine and prodrug useful for glaucomatous optic neuropathy
Dias HV
Bioorganic and Medicinal Chemistry Letters 2016; 26: 1490-1494 (IGR: 17-3)


66506 Neuroprotective effect of lignans extracted from Eucommia ulmoides Oliv. on glaucoma-related neurodegeneration
Fu HT
Neurological Sciences 2016; 37: 755-762 (IGR: 17-3)


65953 Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-(2S)-2-Aminopropyl-8,9-dihydro-7H-pyrano2,3-gindazol-8-ol a Selective 5-HT2 Receptor Agonist
Severns BS
Journal of Medicinal Chemistry 2015; 58: 8818-8833 (IGR: 17-3)


65800 A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers
Wood A
Investigative Ophthalmology and Visual Science 2015; 56: 7963-7970 (IGR: 17-3)


65815 Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure-induced transient ischemic injury
Cunha RA
Translational research : the journal of laboratory and clinical medicine 2016; 169: 112-128 (IGR: 17-3)


65857 Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives
Manni G
International journal of molecular sciences 2015; 16: 28401-28417 (IGR: 17-3)


65815 Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure-induced transient ischemic injury
Ambrósio AF
Translational research : the journal of laboratory and clinical medicine 2016; 169: 112-128 (IGR: 17-3)


66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Esfandiari H
American Journal of Therapeutics 2017; 24: e676-e680 (IGR: 17-3)


66257 Inhibition by a retinoic acid receptor γ agonist of extracellular matrix remodeling mediated by human Tenon fibroblasts
Mori T
Molecular Vision 2015; 21: 1368-1377 (IGR: 17-3)


66557 Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells
Tanabe S
Scientific reports 2016; 6: 19640 (IGR: 17-3)


65800 A Novel Dual Agonist of EP3 and FP Receptors for OAG and OHT: Safety, Pharmacokinetics, and Pharmacodynamics of ONO-9054 in Healthy Volunteers
Ward CL
Investigative Ophthalmology and Visual Science 2015; 56: 7963-7970 (IGR: 17-3)


65953 Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-(2S)-2-Aminopropyl-8,9-dihydro-7H-pyrano2,3-gindazol-8-ol a Selective 5-HT2 Receptor Agonist
Kelly CR
Journal of Medicinal Chemistry 2015; 58: 8818-8833 (IGR: 17-3)


66236 Design and synthesis of novel hybrid sydnonimine and prodrug useful for glaucomatous optic neuropathy
Yorio T
Bioorganic and Medicinal Chemistry Letters 2016; 26: 1490-1494 (IGR: 17-3)


65953 Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-(2S)-2-Aminopropyl-8,9-dihydro-7H-pyrano2,3-gindazol-8-ol a Selective 5-HT2 Receptor Agonist
Holt WF
Journal of Medicinal Chemistry 2015; 58: 8818-8833 (IGR: 17-3)


66257 Inhibition by a retinoic acid receptor γ agonist of extracellular matrix remodeling mediated by human Tenon fibroblasts
Sonoda KH
Molecular Vision 2015; 21: 1368-1377 (IGR: 17-3)


65857 Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives
Oddone F
International journal of molecular sciences 2015; 16: 28401-28417 (IGR: 17-3)


66557 Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm's canal endothelial cells
Tanihara H
Scientific reports 2016; 6: 19640 (IGR: 17-3)


65815 Selective A2A receptor antagonist prevents microglia-mediated neuroinflammation and protects retinal ganglion cells from high intraocular pressure-induced transient ischemic injury
Santiago AR
Translational research : the journal of laboratory and clinical medicine 2016; 169: 112-128 (IGR: 17-3)


66508 The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma
Ahmadieh H
American Journal of Therapeutics 2017; 24: e676-e680 (IGR: 17-3)


65953 Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-(2S)-2-Aminopropyl-8,9-dihydro-7H-pyrano2,3-gindazol-8-ol a Selective 5-HT2 Receptor Agonist
Young R; Glennon RA; Hellberg MR; Dean TR
Journal of Medicinal Chemistry 2015; 58: 8818-8833 (IGR: 17-3)


61378 Neuroprotective and antioxidant effects of ghrelin in an experimental glaucoma model
Can N
Drug design, development and therapy 2015; 9: 2819-2829 (IGR: 17-1)


61021 The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients
Tokuda N
Journal of Ophthalmology 2015; 2015: 689076 (IGR: 17-1)


61089 Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma
Parisi V
Graefe's Archive for Clinical and Experimental Ophthalmology 2015; 253: 1327-1340 (IGR: 17-1)


61535 Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension
Lewis RA
British Journal of Ophthalmology 2016; 100: 339-344 (IGR: 17-1)


61406 Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models
Yang Z
Scientific reports 2015; 5: 11294 (IGR: 17-1)


61594 Raf-1 Kinase Inhibitory Protein (RKIP) Promotes Retinal Ganglion Cell Survival and Axonal Regeneration Following Optic Nerve Crush
Wei J
Journal of Molecular Neuroscience 2015; 57: 243-248 (IGR: 17-1)


61292 Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury
Russo R
Molecular Vision 2015; 21: 718-729 (IGR: 17-1)


60986 Application of Cornelian Cherry Iridoid-Polyphenolic Fraction and Loganic Acid to Reduce Intraocular Pressure
Szumny D
Evidence-based Complementary and Alternative Medicine 2015; 2015: 939402 (IGR: 17-1)


61726 Neuroprotective effect of edaravone in experimental glaucoma model in rats: a immunofluorescence and biochemical analysis
Aksar AT
International Journal of Ophthalmology 2015; 8: 239-244 (IGR: 17-1)


61419 Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma
Shen C
Neuroscience Letters 2015; 600: 132-136 (IGR: 17-1)


61802 Spermidine promotes retinal ganglion cell survival and optic nerve regeneration in adult mice following optic nerve injury
Noro T
Cell Death and Disease 2015; 6: e1720 (IGR: 17-1)


61825 Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications
Saini M
Eye 2015; 29: 808-814 (IGR: 17-1)


61425 Effect of SCH442416 on glutamate uptake in retinal Müller cells at increased hydrostatic pressure
Li Y
Molecular medicine reports 2015; 12: 3993-3998 (IGR: 17-1)


61527 Therapeutic potential of cannabis-related drugs
Alexander SP
Progress in neuro-psychopharmacology & biological psychiatry 2016; 64: 157-166 (IGR: 17-1)


61781 The Suppression of Wound Healing Response with Sirolimus and Sunitinib Following Experimental Trabeculectomy in a Rabbit Model
Eren K
Current Eye Research 2015; 0: 1-10 (IGR: 17-1)


61441 Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials
Tanihara H
JAMA ophthalmology 2015; 133: 755-761 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Foureaux G
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


61299 Efficacy and safety of 1% forskolin eye drops in open angle glaucoma - An open label study
Majeed M
Saudi Journal of Ophthalmology 2015; 29: 197-200 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Marshall J
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


61784 Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders
Belendiuk KA
Addiction science & clinical practice 2015; 10: 10 (IGR: 17-1)


61357 Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics
Van de Velde S
Progress in Neurobiology 2015; 131: 105-119 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting PF
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


61412 Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure
Madeira MH
Journal of Neuroinflammation 2015; 12: 115 (IGR: 17-1)


61261 Spermidine Ameliorates Neurodegeneration in a Mouse Model of Normal Tension Glaucoma
Noro T
Investigative Ophthalmology and Visual Science 2015; 56: 5012-5019 (IGR: 17-1)


61420 Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes
Kaja S
Experimental Eye Research 2015; 138: 159-166 (IGR: 17-1)


61366 Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study
Prabhasawat P
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 323-329 (IGR: 17-1)


61016 Decorin Reduces Intraocular Pressure and Retinal Ganglion Cell Loss in Rodents Through Fibrolysis of the Scarred Trabecular Meshwork
Hill LJ
Investigative Ophthalmology and Visual Science 2015; 56: 3743-3757 (IGR: 17-1)


61623 Association of Geroprotective Effects of Metformin and Risk of Open-Angle Glaucoma in Persons With Diabetes Mellitus
Lin HC
JAMA ophthalmology 2015; 133: 915-923 (IGR: 17-1)


61784 Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders
Baldini LL
Addiction science & clinical practice 2015; 10: 10 (IGR: 17-1)


61412 Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure
Elvas F
Journal of Neuroinflammation 2015; 12: 115 (IGR: 17-1)


61357 Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics
De Groef L
Progress in Neurobiology 2015; 131: 105-119 (IGR: 17-1)


61802 Spermidine promotes retinal ganglion cell survival and optic nerve regeneration in adult mice following optic nerve injury
Namekata K
Cell Death and Disease 2015; 6: e1720 (IGR: 17-1)


61292 Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury
Adornetto A
Molecular Vision 2015; 21: 718-729 (IGR: 17-1)


61425 Effect of SCH442416 on glutamate uptake in retinal Müller cells at increased hydrostatic pressure
Liu X
Molecular medicine reports 2015; 12: 3993-3998 (IGR: 17-1)


61781 The Suppression of Wound Healing Response with Sirolimus and Sunitinib Following Experimental Trabeculectomy in a Rabbit Model
Turgut B
Current Eye Research 2015; 0: 1-10 (IGR: 17-1)


60986 Application of Cornelian Cherry Iridoid-Polyphenolic Fraction and Loganic Acid to Reduce Intraocular Pressure
Sozański T
Evidence-based Complementary and Alternative Medicine 2015; 2015: 939402 (IGR: 17-1)


61366 Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study
Ruangvaravate N
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 323-329 (IGR: 17-1)


61623 Association of Geroprotective Effects of Metformin and Risk of Open-Angle Glaucoma in Persons With Diabetes Mellitus
Stein JD
JAMA ophthalmology 2015; 133: 915-923 (IGR: 17-1)


61441 Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials
Inoue T
JAMA ophthalmology 2015; 133: 755-761 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Franca JR
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


61419 Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma
Chen L
Neuroscience Letters 2015; 600: 132-136 (IGR: 17-1)


61016 Decorin Reduces Intraocular Pressure and Retinal Ganglion Cell Loss in Rodents Through Fibrolysis of the Scarred Trabecular Meshwork
Mead B
Investigative Ophthalmology and Visual Science 2015; 56: 3743-3757 (IGR: 17-1)


61299 Efficacy and safety of 1% forskolin eye drops in open angle glaucoma - An open label study
Nagabhushanam K
Saudi Journal of Ophthalmology 2015; 29: 197-200 (IGR: 17-1)


61261 Spermidine Ameliorates Neurodegeneration in a Mouse Model of Normal Tension Glaucoma
Namekata K
Investigative Ophthalmology and Visual Science 2015; 56: 5012-5019 (IGR: 17-1)


61378 Neuroprotective and antioxidant effects of ghrelin in an experimental glaucoma model
Catak O
Drug design, development and therapy 2015; 9: 2819-2829 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Wolff RF
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


61089 Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma
Centofanti M
Graefe's Archive for Clinical and Experimental Ophthalmology 2015; 253: 1327-1340 (IGR: 17-1)


61726 Neuroprotective effect of edaravone in experimental glaucoma model in rats: a immunofluorescence and biochemical analysis
Yuksel N
International Journal of Ophthalmology 2015; 8: 239-244 (IGR: 17-1)


61594 Raf-1 Kinase Inhibitory Protein (RKIP) Promotes Retinal Ganglion Cell Survival and Axonal Regeneration Following Optic Nerve Crush
Jiang H
Journal of Molecular Neuroscience 2015; 57: 243-248 (IGR: 17-1)


61420 Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes
Payne AJ
Experimental Eye Research 2015; 138: 159-166 (IGR: 17-1)


61535 Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension
Levy B
British Journal of Ophthalmology 2016; 100: 339-344 (IGR: 17-1)


61406 Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models
Huang P
Scientific reports 2015; 5: 11294 (IGR: 17-1)


61825 Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications
Dhiman R
Eye 2015; 29: 808-814 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Wong KY
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


61021 The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients
Kitaoka Y
Journal of Ophthalmology 2015; 2015: 689076 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Rupasinghe CN
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Nogueira JC
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


61378 Neuroprotective and antioxidant effects of ghrelin in an experimental glaucoma model
Turgut B
Drug design, development and therapy 2015; 9: 2819-2829 (IGR: 17-1)


61406 Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models
Liu X
Scientific reports 2015; 5: 11294 (IGR: 17-1)


61412 Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure
Boia R
Journal of Neuroinflammation 2015; 12: 115 (IGR: 17-1)


61292 Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury
Cavaliere F
Molecular Vision 2015; 21: 718-729 (IGR: 17-1)


61425 Effect of SCH442416 on glutamate uptake in retinal Müller cells at increased hydrostatic pressure
Huang S
Molecular medicine reports 2015; 12: 3993-3998 (IGR: 17-1)


60986 Application of Cornelian Cherry Iridoid-Polyphenolic Fraction and Loganic Acid to Reduce Intraocular Pressure
Kucharska AZ
Evidence-based Complementary and Alternative Medicine 2015; 2015: 939402 (IGR: 17-1)


61781 The Suppression of Wound Healing Response with Sirolimus and Sunitinib Following Experimental Trabeculectomy in a Rabbit Model
Akin MM
Current Eye Research 2015; 0: 1-10 (IGR: 17-1)


61261 Spermidine Ameliorates Neurodegeneration in a Mouse Model of Normal Tension Glaucoma
Azuchi Y
Investigative Ophthalmology and Visual Science 2015; 56: 5012-5019 (IGR: 17-1)


61802 Spermidine promotes retinal ganglion cell survival and optic nerve regeneration in adult mice following optic nerve injury
Kimura A
Cell Death and Disease 2015; 6: e1720 (IGR: 17-1)


61420 Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes
Naumchuk Y
Experimental Eye Research 2015; 138: 159-166 (IGR: 17-1)


61623 Association of Geroprotective Effects of Metformin and Risk of Open-Angle Glaucoma in Persons With Diabetes Mellitus
Nan B
JAMA ophthalmology 2015; 133: 915-923 (IGR: 17-1)


61089 Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma
Ziccardi L
Graefe's Archive for Clinical and Experimental Ophthalmology 2015; 253: 1327-1340 (IGR: 17-1)


61784 Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders
Bonn-Miller MO
Addiction science & clinical practice 2015; 10: 10 (IGR: 17-1)


61016 Decorin Reduces Intraocular Pressure and Retinal Ganglion Cell Loss in Rodents Through Fibrolysis of the Scarred Trabecular Meshwork
Blanch RJ
Investigative Ophthalmology and Visual Science 2015; 56: 3743-3757 (IGR: 17-1)


61299 Efficacy and safety of 1% forskolin eye drops in open angle glaucoma - An open label study
Natarajan S
Saudi Journal of Ophthalmology 2015; 29: 197-200 (IGR: 17-1)


61021 The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients
Matsuzawa A
Journal of Ophthalmology 2015; 2015: 689076 (IGR: 17-1)


61535 Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension
Ramirez N
British Journal of Ophthalmology 2016; 100: 339-344 (IGR: 17-1)


61357 Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics
Stalmans I
Progress in Neurobiology 2015; 131: 105-119 (IGR: 17-1)


61366 Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study
Tesavibul N
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 323-329 (IGR: 17-1)


61825 Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications
Dada T
Eye 2015; 29: 808-814 (IGR: 17-1)


61726 Neuroprotective effect of edaravone in experimental glaucoma model in rats: a immunofluorescence and biochemical analysis
Gok M
International Journal of Ophthalmology 2015; 8: 239-244 (IGR: 17-1)


61441 Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials
Yamamoto T
JAMA ophthalmology 2015; 133: 755-761 (IGR: 17-1)


61419 Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma
Jiang L
Neuroscience Letters 2015; 600: 132-136 (IGR: 17-1)


61594 Raf-1 Kinase Inhibitory Protein (RKIP) Promotes Retinal Ganglion Cell Survival and Axonal Regeneration Following Optic Nerve Crush
Gao H
Journal of Molecular Neuroscience 2015; 57: 243-248 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Deshpande S
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


61726 Neuroprotective effect of edaravone in experimental glaucoma model in rats: a immunofluorescence and biochemical analysis
Cekmen M
International Journal of Ophthalmology 2015; 8: 239-244 (IGR: 17-1)


61425 Effect of SCH442416 on glutamate uptake in retinal Müller cells at increased hydrostatic pressure
Huang P
Molecular medicine reports 2015; 12: 3993-3998 (IGR: 17-1)


61406 Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models
Huang S
Scientific reports 2015; 5: 11294 (IGR: 17-1)


61419 Neuroprotective effect of epigallocatechin-3-gallate in a mouse model of chronic glaucoma
Lai TY
Neuroscience Letters 2015; 600: 132-136 (IGR: 17-1)


61594 Raf-1 Kinase Inhibitory Protein (RKIP) Promotes Retinal Ganglion Cell Survival and Axonal Regeneration Following Optic Nerve Crush
Wang G
Journal of Molecular Neuroscience 2015; 57: 243-248 (IGR: 17-1)


61021 The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients
Miyamoto J
Journal of Ophthalmology 2015; 2015: 689076 (IGR: 17-1)


61623 Association of Geroprotective Effects of Metformin and Risk of Open-Angle Glaucoma in Persons With Diabetes Mellitus
Childers D
JAMA ophthalmology 2015; 133: 915-923 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Tiwari R
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


61299 Efficacy and safety of 1% forskolin eye drops in open angle glaucoma - An open label study
Vaidyanathan P
Saudi Journal of Ophthalmology 2015; 29: 197-200 (IGR: 17-1)


61420 Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes
Levy D
Experimental Eye Research 2015; 138: 159-166 (IGR: 17-1)


61357 Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics
Moons L
Progress in Neurobiology 2015; 131: 105-119 (IGR: 17-1)


61016 Decorin Reduces Intraocular Pressure and Retinal Ganglion Cell Loss in Rodents Through Fibrolysis of the Scarred Trabecular Meshwork
Ahmed Z
Investigative Ophthalmology and Visual Science 2015; 56: 3743-3757 (IGR: 17-1)


61366 Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran Versus 0.18% Sodium Hyaluronate in the Treatment of Ocular Surface Disease in Glaucoma Patients: A Randomized, Double-Blind, and Controlled Study
Thewthong M
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 323-329 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Di Nisio M
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


61825 Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications
Tandon R
Eye 2015; 29: 808-814 (IGR: 17-1)


61441 Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials
Kuwayama Y
JAMA ophthalmology 2015; 133: 755-761 (IGR: 17-1)


60986 Application of Cornelian Cherry Iridoid-Polyphenolic Fraction and Loganic Acid to Reduce Intraocular Pressure
Dziewiszek W
Evidence-based Complementary and Alternative Medicine 2015; 2015: 939402 (IGR: 17-1)


61412 Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure
Gonçalves FQ
Journal of Neuroinflammation 2015; 12: 115 (IGR: 17-1)


61802 Spermidine promotes retinal ganglion cell survival and optic nerve regeneration in adult mice following optic nerve injury
Guo X
Cell Death and Disease 2015; 6: e1720 (IGR: 17-1)


61089 Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma
Tanga L
Graefe's Archive for Clinical and Experimental Ophthalmology 2015; 253: 1327-1340 (IGR: 17-1)


61261 Spermidine Ameliorates Neurodegeneration in a Mouse Model of Normal Tension Glaucoma
Kimura A
Investigative Ophthalmology and Visual Science 2015; 56: 5012-5019 (IGR: 17-1)


61378 Neuroprotective and antioxidant effects of ghrelin in an experimental glaucoma model
Demir T
Drug design, development and therapy 2015; 9: 2819-2829 (IGR: 17-1)


61292 Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury
Varano GP
Molecular Vision 2015; 21: 718-729 (IGR: 17-1)


61781 The Suppression of Wound Healing Response with Sirolimus and Sunitinib Following Experimental Trabeculectomy in a Rabbit Model
Demir T
Current Eye Research 2015; 0: 1-10 (IGR: 17-1)


61535 Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension
C Kopczynski C
British Journal of Ophthalmology 2016; 100: 339-344 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Fulgêncio Gde O
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


61261 Spermidine Ameliorates Neurodegeneration in a Mouse Model of Normal Tension Glaucoma
Guo X
Investigative Ophthalmology and Visual Science 2015; 56: 5012-5019 (IGR: 17-1)


61825 Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications
Vanathi M
Eye 2015; 29: 808-814 (IGR: 17-1)


61089 Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma
Michelessi M
Graefe's Archive for Clinical and Experimental Ophthalmology 2015; 253: 1327-1340 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Ribeiro TG
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


61016 Decorin Reduces Intraocular Pressure and Retinal Ganglion Cell Loss in Rodents Through Fibrolysis of the Scarred Trabecular Meshwork
De Cogan F
Investigative Ophthalmology and Visual Science 2015; 56: 3743-3757 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Zhao X
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


61726 Neuroprotective effect of edaravone in experimental glaucoma model in rats: a immunofluorescence and biochemical analysis
Caglar Y
International Journal of Ophthalmology 2015; 8: 239-244 (IGR: 17-1)


61420 Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes
Zaidi DH
Experimental Eye Research 2015; 138: 159-166 (IGR: 17-1)


61535 Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension
Usner DW
British Journal of Ophthalmology 2016; 100: 339-344 (IGR: 17-1)


60986 Application of Cornelian Cherry Iridoid-Polyphenolic Fraction and Loganic Acid to Reduce Intraocular Pressure
Piórecki N
Evidence-based Complementary and Alternative Medicine 2015; 2015: 939402 (IGR: 17-1)


61357 Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics
Van Hove I
Progress in Neurobiology 2015; 131: 105-119 (IGR: 17-1)


61292 Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury
Rusciano D
Molecular Vision 2015; 21: 718-729 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Duffy S
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


61623 Association of Geroprotective Effects of Metformin and Risk of Open-Angle Glaucoma in Persons With Diabetes Mellitus
Newman-Casey PA
JAMA ophthalmology 2015; 133: 915-923 (IGR: 17-1)


61412 Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure
Cunha RA
Journal of Neuroinflammation 2015; 12: 115 (IGR: 17-1)


61021 The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients
Sakae S
Journal of Ophthalmology 2015; 2015: 689076 (IGR: 17-1)


61425 Effect of SCH442416 on glutamate uptake in retinal Müller cells at increased hydrostatic pressure
Zhong Y
Molecular medicine reports 2015; 12: 3993-3998 (IGR: 17-1)


61441 Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials
Abe H
JAMA ophthalmology 2015; 133: 755-761 (IGR: 17-1)


61406 Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models
Deng L
Scientific reports 2015; 5: 11294 (IGR: 17-1)


61802 Spermidine promotes retinal ganglion cell survival and optic nerve regeneration in adult mice following optic nerve injury
Azuchi Y
Cell Death and Disease 2015; 6: e1720 (IGR: 17-1)


61378 Neuroprotective and antioxidant effects of ghrelin in an experimental glaucoma model
Ilhan N
Drug design, development and therapy 2015; 9: 2819-2829 (IGR: 17-1)


61299 Efficacy and safety of 1% forskolin eye drops in open angle glaucoma - An open label study
Karri SK
Saudi Journal of Ophthalmology 2015; 29: 197-200 (IGR: 17-1)


61535 Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension
Novack GD
British Journal of Ophthalmology 2016; 100: 339-344 (IGR: 17-1)


61420 Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes
Altman AM
Experimental Eye Research 2015; 138: 159-166 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Hernandez AV
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


61016 Decorin Reduces Intraocular Pressure and Retinal Ganglion Cell Loss in Rodents Through Fibrolysis of the Scarred Trabecular Meshwork
Morgan-Warren PJ
Investigative Ophthalmology and Visual Science 2015; 56: 3743-3757 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Berberoglu ED
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


61299 Efficacy and safety of 1% forskolin eye drops in open angle glaucoma - An open label study
Jose JA
Saudi Journal of Ophthalmology 2015; 29: 197-200 (IGR: 17-1)


61261 Spermidine Ameliorates Neurodegeneration in a Mouse Model of Normal Tension Glaucoma
Harada C
Investigative Ophthalmology and Visual Science 2015; 56: 5012-5019 (IGR: 17-1)


61412 Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure
Ambrósio AF
Journal of Neuroinflammation 2015; 12: 115 (IGR: 17-1)


61406 Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models
Jin Z
Scientific reports 2015; 5: 11294 (IGR: 17-1)


61021 The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients
Munemasa Y
Journal of Ophthalmology 2015; 2015: 689076 (IGR: 17-1)


61378 Neuroprotective and antioxidant effects of ghrelin in an experimental glaucoma model
Kuloglu T
Drug design, development and therapy 2015; 9: 2819-2829 (IGR: 17-1)


60986 Application of Cornelian Cherry Iridoid-Polyphenolic Fraction and Loganic Acid to Reduce Intraocular Pressure
Magdalan J
Evidence-based Complementary and Alternative Medicine 2015; 2015: 939402 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Castilho RO
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


61292 Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury
Morrone LA
Molecular Vision 2015; 21: 718-729 (IGR: 17-1)


61623 Association of Geroprotective Effects of Metformin and Risk of Open-Angle Glaucoma in Persons With Diabetes Mellitus
Thompson DA
JAMA ophthalmology 2015; 133: 915-923 (IGR: 17-1)


61441 Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials
Suganami H
JAMA ophthalmology 2015; 133: 755-761 (IGR: 17-1)


61089 Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma
Roberti G
Graefe's Archive for Clinical and Experimental Ophthalmology 2015; 253: 1327-1340 (IGR: 17-1)


61802 Spermidine promotes retinal ganglion cell survival and optic nerve regeneration in adult mice following optic nerve injury
Harada C
Cell Death and Disease 2015; 6: e1720 (IGR: 17-1)


61089 Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma
Manni G
Graefe's Archive for Clinical and Experimental Ophthalmology 2015; 253: 1327-1340 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Yoshida MI
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


61441 Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials
Araie M
JAMA ophthalmology 2015; 133: 755-761 (IGR: 17-1)


61535 Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension

British Journal of Ophthalmology 2016; 100: 339-344 (IGR: 17-1)


61406 Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models
Xu S
Scientific reports 2015; 5: 11294 (IGR: 17-1)


61802 Spermidine promotes retinal ganglion cell survival and optic nerve regeneration in adult mice following optic nerve injury
Nakano T
Cell Death and Disease 2015; 6: e1720 (IGR: 17-1)


61021 The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients
Takagi H
Journal of Ophthalmology 2015; 2015: 689076 (IGR: 17-1)


61378 Neuroprotective and antioxidant effects of ghrelin in an experimental glaucoma model
Ozercan IH
Drug design, development and therapy 2015; 9: 2819-2829 (IGR: 17-1)


61412 Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure
Santiago AR
Journal of Neuroinflammation 2015; 12: 115 (IGR: 17-1)


61623 Association of Geroprotective Effects of Metformin and Risk of Open-Angle Glaucoma in Persons With Diabetes Mellitus
Richards JE
JAMA ophthalmology 2015; 133: 915-923 (IGR: 17-1)


61261 Spermidine Ameliorates Neurodegeneration in a Mouse Model of Normal Tension Glaucoma
Nakano T
Investigative Ophthalmology and Visual Science 2015; 56: 5012-5019 (IGR: 17-1)


61016 Decorin Reduces Intraocular Pressure and Retinal Ganglion Cell Loss in Rodents Through Fibrolysis of the Scarred Trabecular Meshwork
Mohamed S
Investigative Ophthalmology and Visual Science 2015; 56: 3743-3757 (IGR: 17-1)


61420 Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes
Nawazish S
Experimental Eye Research 2015; 138: 159-166 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Sinkler C
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Keurentjes JC
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


60986 Application of Cornelian Cherry Iridoid-Polyphenolic Fraction and Loganic Acid to Reduce Intraocular Pressure
Chlebda-Sieragowska E
Evidence-based Complementary and Alternative Medicine 2015; 2015: 939402 (IGR: 17-1)


61292 Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury
Corasaniti MT
Molecular Vision 2015; 21: 718-729 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Liu J
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


60986 Application of Cornelian Cherry Iridoid-Polyphenolic Fraction and Loganic Acid to Reduce Intraocular Pressure
Kupczynski R
Evidence-based Complementary and Alternative Medicine 2015; 2015: 939402 (IGR: 17-1)


61441 Additive Intraocular Pressure-Lowering Effects of the Rho Kinase Inhibitor Ripasudil (K-115) Combined With Timolol or Latanoprost: A Report of 2 Randomized Clinical Trials

JAMA ophthalmology 2015; 133: 755-761 (IGR: 17-1)


61802 Spermidine promotes retinal ganglion cell survival and optic nerve regeneration in adult mice following optic nerve injury
Tsuneoka H
Cell Death and Disease 2015; 6: e1720 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Lang S
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Fuscaldi LL
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


61292 Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury
Bagetta G
Molecular Vision 2015; 21: 718-729 (IGR: 17-1)


61420 Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes
Ghuman JK
Experimental Eye Research 2015; 138: 159-166 (IGR: 17-1)


61406 Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models
Shen X
Scientific reports 2015; 5: 11294 (IGR: 17-1)


61261 Spermidine Ameliorates Neurodegeneration in a Mouse Model of Normal Tension Glaucoma
Tsuneoka H
Investigative Ophthalmology and Visual Science 2015; 56: 5012-5019 (IGR: 17-1)


61016 Decorin Reduces Intraocular Pressure and Retinal Ganglion Cell Loss in Rodents Through Fibrolysis of the Scarred Trabecular Meshwork
Leadbeater W
Investigative Ophthalmology and Visual Science 2015; 56: 3743-3757 (IGR: 17-1)


61292 Intravitreal injection of forskolin, homotaurine, and L-carnosine affords neuroprotection to retinal ganglion cells following retinal ischemic injury
Nucci C
Molecular Vision 2015; 21: 718-729 (IGR: 17-1)


60986 Application of Cornelian Cherry Iridoid-Polyphenolic Fraction and Loganic Acid to Reduce Intraocular Pressure
Szeląg A
Evidence-based Complementary and Alternative Medicine 2015; 2015: 939402 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Fernandes SO
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


61261 Spermidine Ameliorates Neurodegeneration in a Mouse Model of Normal Tension Glaucoma
Harada T
Investigative Ophthalmology and Visual Science 2015; 56: 5012-5019 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Lee I
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


61406 Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models
Luo X
Scientific reports 2015; 5: 11294 (IGR: 17-1)


61802 Spermidine promotes retinal ganglion cell survival and optic nerve regeneration in adult mice following optic nerve injury
Harada T
Cell Death and Disease 2015; 6: e1720 (IGR: 17-1)


61420 Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes
Gerdes BC
Experimental Eye Research 2015; 138: 159-166 (IGR: 17-1)


61016 Decorin Reduces Intraocular Pressure and Retinal Ganglion Cell Loss in Rodents Through Fibrolysis of the Scarred Trabecular Meshwork
Scott RA
Investigative Ophthalmology and Visual Science 2015; 56: 3743-3757 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Misso K
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


61016 Decorin Reduces Intraocular Pressure and Retinal Ganglion Cell Loss in Rodents Through Fibrolysis of the Scarred Trabecular Meshwork
Berry M
Investigative Ophthalmology and Visual Science 2015; 56: 3743-3757 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Parang K
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Ryder S
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Cardoso VN
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


61406 Effect of adenosine and adenosine receptor antagonist on Müller cell potassium channel in Rat chronic ocular hypertension models
Zhong Y
Scientific reports 2015; 5: 11294 (IGR: 17-1)


60986 Application of Cornelian Cherry Iridoid-Polyphenolic Fraction and Loganic Acid to Reduce Intraocular Pressure
Szumny A
Evidence-based Complementary and Alternative Medicine 2015; 2015: 939402 (IGR: 17-1)


61420 Plate reader-based cell viability assays for glioprotection using primary rat optic nerve head astrocytes
Moore MA; Koulen P
Experimental Eye Research 2015; 138: 159-166 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Cronemberger S
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Schmidlkofer S
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Spaller MR
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


61016 Decorin Reduces Intraocular Pressure and Retinal Ganglion Cell Loss in Rodents Through Fibrolysis of the Scarred Trabecular Meshwork
Logan A
Investigative Ophthalmology and Visual Science 2015; 56: 3743-3757 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Westwood M
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Faraco AA
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Hüttemann M
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


61345 Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Kleijnen J
JAMA (Journal of the American Medical Association) 2015; 313: 2456-2473 (IGR: 17-1)


61346 Inhibition of N-Methyl-D-Aspartate-Induced Retinal Neuronal Death by Polyarginine Peptides is Linked to the Attenuation of Stress-Induced Hyperpolarization of the Inner Mitochondrial Membrane Potential
Goebel DJ
Journal of Biological Chemistry 2015; 290: 22030-22048 (IGR: 17-1)


61540 Ocular Inserts for Sustained Release of the Angiotensin-Converting Enzyme 2 Activator, Diminazene Aceturate, to Treat Glaucoma in Rats
Ferreira AJ
PLoS ONE 2015; 10: e0133149 (IGR: 17-1)


60791 Bupropion Use and Risk of Open-Angle Glaucoma among Enrollees in a Large U.S. Managed Care Network
Stein JD
PLoS ONE 2015; 10: e0123682 (IGR: 16-4)


60768 Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action
Bozdag M
Bio-organic and Medicinal Chemistry 2015; 23: 2368-2376 (IGR: 16-4)


60505 Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency
Loma P
Experimental Eye Research 2015; 134: 141-147 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Nagai N
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Tanihara H
Acta Ophthalmologica 2015; 93: e254-e260 (IGR: 16-4)


60639 Protection of injured retinal ganglion cell dendrites and unfolded protein response resolution after long-term dietary resveratrol
Lindsey JD
Neurobiology of Aging 2015; 0: (IGR: 16-4)


60621 Effect of AR-13324 on Episcleral Venous Pressure in Dutch Belted Rabbits
Kiel JW
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 146-151 (IGR: 16-4)


60683 P2X7 receptor antagonists protect against N-methyl-d-aspartic acid-induced neuronal injury in the rat retina
Sakamoto K
European Journal of Pharmacology 2015; 756: 52-58 (IGR: 16-4)


60436 Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma
Pirhan D
Current Eye Research 2015; 0: 1-11 (IGR: 16-4)


60296 Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients
Pescosolido N
Ophthalmic and Physiological Optics 2015; 35: 201-205 (IGR: 16-4)


60786 Options for prolonging the hypotensive effect of trabeculectomy

Vestnik Oftalmologii 2015; 131: 75-78, 80-81 (IGR: 16-4)


60457 Neuroprotection in the treatment of glaucoma - A focus on connexin43 gap junction channel blockers
Chen YS
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 182-193 (IGR: 16-4)


60538 A Model-Based Dose-Response Meta-Analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma
Raber S
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 189-197 (IGR: 16-4)


60098 Rosmarinic Acid Suppresses Subconjunctival Neovascularization in Experimental Glaucoma Surgery
Ferreira JD
Current Eye Research 2014; 0: 1-7 (IGR: 16-4)


60664 Arundic acid attenuates retinal ganglion cell death by increasing glutamate/aspartate transporter expression in a model of normal tension glaucoma
Yanagisawa M
Cell Death and Disease 2015; 6: e1693 (IGR: 16-4)


60295 Novel potential treatment modalities for ocular hypertension: focus on Angiotensin and bradykinin system axes
Sharif NA
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 131-145 (IGR: 16-4)


60162 Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes
Wang RF
Journal of Glaucoma 2015; 24: 51-54 (IGR: 16-4)


60275 Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
Harrison BA
ACS Medicinal Chemistry Letters 2015; 6: 84-88 (IGR: 16-4)


60362 MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
Parsons CG
Neuropharmacology 2015; 92: 158-169 (IGR: 16-4)


60356 Retinal ganglion cell neuroprotection by an angiotensin II blocker in an ex vivo retinal explant model
White AJ
Journal of the renin-angiotensin-aldosterone system : JRAAS 2015; 16: 1193-1201 (IGR: 16-4)


60210 Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits
Iomdina EN
Front Biosci 2015; 20: 892-901 (IGR: 16-4)


60570 BDNF Rescues RGCs But Not Intrinsically Photosensitive RGCs in Ocular Hypertensive Albino Rat Retinas
Valiente-Soriano FJ
Investigative Ophthalmology and Visual Science 2015; 56: 1924-1936 (IGR: 16-4)


60429 Intravitreal delivery of human NgR-Fc decoy protein regenerates axons after optic nerve crush and protects ganglion cells in glaucoma models
Wang X
Investigative Ophthalmology and Visual Science 2015; 56: 1357-1366 (IGR: 16-4)


60083 A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
Weinreb RN
British Journal of Ophthalmology 2015; 99: 738-745 (IGR: 16-4)


60664 Arundic acid attenuates retinal ganglion cell death by increasing glutamate/aspartate transporter expression in a model of normal tension glaucoma
Aida T
Cell Death and Disease 2015; 6: e1693 (IGR: 16-4)


60098 Rosmarinic Acid Suppresses Subconjunctival Neovascularization in Experimental Glaucoma Surgery
Chahud F
Current Eye Research 2014; 0: 1-7 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Yoshioka C
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60505 Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency
Guzman-Aranguez A
Experimental Eye Research 2015; 134: 141-147 (IGR: 16-4)


60210 Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits
Khoroshilova-Maslova IP
Front Biosci 2015; 20: 892-901 (IGR: 16-4)


60429 Intravitreal delivery of human NgR-Fc decoy protein regenerates axons after optic nerve crush and protects ganglion cells in glaucoma models
Lin J
Investigative Ophthalmology and Visual Science 2015; 56: 1357-1366 (IGR: 16-4)


60570 BDNF Rescues RGCs But Not Intrinsically Photosensitive RGCs in Ocular Hypertensive Albino Rat Retinas
Nadal-Nicolás FM
Investigative Ophthalmology and Visual Science 2015; 56: 1924-1936 (IGR: 16-4)


60457 Neuroprotection in the treatment of glaucoma - A focus on connexin43 gap junction channel blockers
Green CR
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 182-193 (IGR: 16-4)


60356 Retinal ganglion cell neuroprotection by an angiotensin II blocker in an ex vivo retinal explant model
Heller JP
Journal of the renin-angiotensin-aldosterone system : JRAAS 2015; 16: 1193-1201 (IGR: 16-4)


60362 MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
Ruitenberg M
Neuropharmacology 2015; 92: 158-169 (IGR: 16-4)


60296 Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients
Gatto V
Ophthalmic and Physiological Optics 2015; 35: 201-205 (IGR: 16-4)


60768 Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action
Carta F
Bio-organic and Medicinal Chemistry 2015; 23: 2368-2376 (IGR: 16-4)


60162 Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes
Williamson JE
Journal of Glaucoma 2015; 24: 51-54 (IGR: 16-4)


60275 Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
Almstead ZY
ACS Medicinal Chemistry Letters 2015; 6: 84-88 (IGR: 16-4)


60683 P2X7 receptor antagonists protect against N-methyl-d-aspartic acid-induced neuronal injury in the rat retina
Endo K
European Journal of Pharmacology 2015; 756: 52-58 (IGR: 16-4)


60791 Bupropion Use and Risk of Open-Angle Glaucoma among Enrollees in a Large U.S. Managed Care Network
Talwar N
PLoS ONE 2015; 10: e0123682 (IGR: 16-4)


60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Inoue T
Acta Ophthalmologica 2015; 93: e254-e260 (IGR: 16-4)


60639 Protection of injured retinal ganglion cell dendrites and unfolded protein response resolution after long-term dietary resveratrol
Duong-Polk KX
Neurobiology of Aging 2015; 0: (IGR: 16-4)


60083 A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
Ong T
British Journal of Ophthalmology 2015; 99: 738-745 (IGR: 16-4)


60621 Effect of AR-13324 on Episcleral Venous Pressure in Dutch Belted Rabbits
Kopczynski CC
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 146-151 (IGR: 16-4)


60538 A Model-Based Dose-Response Meta-Analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma
Mandema JW
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 189-197 (IGR: 16-4)


60436 Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma
Yüksel N
Current Eye Research 2015; 0: 1-11 (IGR: 16-4)


60570 BDNF Rescues RGCs But Not Intrinsically Photosensitive RGCs in Ocular Hypertensive Albino Rat Retinas
Salinas-Navarro M
Investigative Ophthalmology and Visual Science 2015; 56: 1924-1936 (IGR: 16-4)


60768 Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action
Vullo D
Bio-organic and Medicinal Chemistry 2015; 23: 2368-2376 (IGR: 16-4)


60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Yamamoto T
Acta Ophthalmologica 2015; 93: e254-e260 (IGR: 16-4)


60683 P2X7 receptor antagonists protect against N-methyl-d-aspartic acid-induced neuronal injury in the rat retina
Suzuki T
European Journal of Pharmacology 2015; 756: 52-58 (IGR: 16-4)


60083 A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
Scassellati Sforzolini B
British Journal of Ophthalmology 2015; 99: 738-745 (IGR: 16-4)


60296 Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients
Stefanucci A
Ophthalmic and Physiological Optics 2015; 35: 201-205 (IGR: 16-4)


60791 Bupropion Use and Risk of Open-Angle Glaucoma among Enrollees in a Large U.S. Managed Care Network
Kang JH
PLoS ONE 2015; 10: e0123682 (IGR: 16-4)


60538 A Model-Based Dose-Response Meta-Analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma
Li H
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 189-197 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Mano Y
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60210 Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits
Robustova OV
Front Biosci 2015; 20: 892-901 (IGR: 16-4)


60639 Protection of injured retinal ganglion cell dendrites and unfolded protein response resolution after long-term dietary resveratrol
Hammond D
Neurobiology of Aging 2015; 0: (IGR: 16-4)


60436 Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma
Emre E
Current Eye Research 2015; 0: 1-11 (IGR: 16-4)


60275 Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
Burgoon H
ACS Medicinal Chemistry Letters 2015; 6: 84-88 (IGR: 16-4)


60457 Neuroprotection in the treatment of glaucoma - A focus on connexin43 gap junction channel blockers
Danesh-Meyer HV
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 182-193 (IGR: 16-4)


60505 Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency
Perez De Lara MJ
Experimental Eye Research 2015; 134: 141-147 (IGR: 16-4)


60362 MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
Freitag CE
Neuropharmacology 2015; 92: 158-169 (IGR: 16-4)


60664 Arundic acid attenuates retinal ganglion cell death by increasing glutamate/aspartate transporter expression in a model of normal tension glaucoma
Takeda T
Cell Death and Disease 2015; 6: e1693 (IGR: 16-4)


60429 Intravitreal delivery of human NgR-Fc decoy protein regenerates axons after optic nerve crush and protects ganglion cells in glaucoma models
Arzeno A
Investigative Ophthalmology and Visual Science 2015; 56: 1357-1366 (IGR: 16-4)


60356 Retinal ganglion cell neuroprotection by an angiotensin II blocker in an ex vivo retinal explant model
Leung J
Journal of the renin-angiotensin-aldosterone system : JRAAS 2015; 16: 1193-1201 (IGR: 16-4)


60162 Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes
Kopczynski C
Journal of Glaucoma 2015; 24: 51-54 (IGR: 16-4)


60098 Rosmarinic Acid Suppresses Subconjunctival Neovascularization in Experimental Glaucoma Surgery
Ramalho LN
Current Eye Research 2014; 0: 1-7 (IGR: 16-4)


60429 Intravitreal delivery of human NgR-Fc decoy protein regenerates axons after optic nerve crush and protects ganglion cells in glaucoma models
Choi JY
Investigative Ophthalmology and Visual Science 2015; 56: 1357-1366 (IGR: 16-4)


60356 Retinal ganglion cell neuroprotection by an angiotensin II blocker in an ex vivo retinal explant model
Tassoni A
Journal of the renin-angiotensin-aldosterone system : JRAAS 2015; 16: 1193-1201 (IGR: 16-4)


60162 Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes
Serle JB
Journal of Glaucoma 2015; 24: 51-54 (IGR: 16-4)


60664 Arundic acid attenuates retinal ganglion cell death by increasing glutamate/aspartate transporter expression in a model of normal tension glaucoma
Namekata K
Cell Death and Disease 2015; 6: e1693 (IGR: 16-4)


60362 MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
Sroka-Saidi K
Neuropharmacology 2015; 92: 158-169 (IGR: 16-4)


60683 P2X7 receptor antagonists protect against N-methyl-d-aspartic acid-induced neuronal injury in the rat retina
Fujimura K
European Journal of Pharmacology 2015; 756: 52-58 (IGR: 16-4)


60768 Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action
Akdemir A
Bio-organic and Medicinal Chemistry 2015; 23: 2368-2376 (IGR: 16-4)


60275 Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
Gardyan M
ACS Medicinal Chemistry Letters 2015; 6: 84-88 (IGR: 16-4)


60083 A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
Vittitow JL
British Journal of Ophthalmology 2015; 99: 738-745 (IGR: 16-4)


60791 Bupropion Use and Risk of Open-Angle Glaucoma among Enrollees in a Large U.S. Managed Care Network
Okereke OI
PLoS ONE 2015; 10: e0123682 (IGR: 16-4)


60505 Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency
Pintor J
Experimental Eye Research 2015; 134: 141-147 (IGR: 16-4)


60538 A Model-Based Dose-Response Meta-Analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma
Nickens DJ
Journal of Ocular Pharmacology and Therapeutics 2015; 31: 189-197 (IGR: 16-4)


60639 Protection of injured retinal ganglion cell dendrites and unfolded protein response resolution after long-term dietary resveratrol
Leung CK
Neurobiology of Aging 2015; 0: (IGR: 16-4)


60570 BDNF Rescues RGCs But Not Intrinsically Photosensitive RGCs in Ocular Hypertensive Albino Rat Retinas
Jiménez-López M
Investigative Ophthalmology and Visual Science 2015; 56: 1924-1936 (IGR: 16-4)


60098 Rosmarinic Acid Suppresses Subconjunctival Neovascularization in Experimental Glaucoma Surgery
Modulo CM
Current Eye Research 2014; 0: 1-7 (IGR: 16-4)


60210 Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits
Averina OA
Front Biosci 2015; 20: 892-901 (IGR: 16-4)


60436 Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma
Cengiz A
Current Eye Research 2015; 0: 1-11 (IGR: 16-4)


60296 Oral treatment with the melatonin agonist agomelatine lowers the intraocular pressure of glaucoma patients
Rusciano D
Ophthalmic and Physiological Optics 2015; 35: 201-205 (IGR: 16-4)


60457 Neuroprotection in the treatment of glaucoma - A focus on connexin43 gap junction channel blockers
Rupenthal ID
European Journal of Pharmaceutics and Biopharmaceutics 2015; 95: 182-193 (IGR: 16-4)


60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Kuwayama Y
Acta Ophthalmologica 2015; 93: e254-e260 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Tnabe W
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60362 MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
Russ H
Neuropharmacology 2015; 92: 158-169 (IGR: 16-4)


60083 A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
Singh K
British Journal of Ophthalmology 2015; 99: 738-745 (IGR: 16-4)


60429 Intravitreal delivery of human NgR-Fc decoy protein regenerates axons after optic nerve crush and protects ganglion cells in glaucoma models
Boccio J
Investigative Ophthalmology and Visual Science 2015; 56: 1357-1366 (IGR: 16-4)


60436 Riluzole- and Resveratrol-Induced Delay of Retinal Ganglion Cell Death in an Experimental Model of Glaucoma
Kürşat Yıldız D
Current Eye Research 2015; 0: 1-11 (IGR: 16-4)


60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Abe H
Acta Ophthalmologica 2015; 93: e254-e260 (IGR: 16-4)


60639 Protection of injured retinal ganglion cell dendrites and unfolded protein response resolution after long-term dietary resveratrol
Weinreb RN
Neurobiology of Aging 2015; 0: (IGR: 16-4)


60275 Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
Goodwin NC
ACS Medicinal Chemistry Letters 2015; 6: 84-88 (IGR: 16-4)


60210 Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits
Kovaleva NA
Front Biosci 2015; 20: 892-901 (IGR: 16-4)


60683 P2X7 receptor antagonists protect against N-methyl-d-aspartic acid-induced neuronal injury in the rat retina
Kurauchi Y
European Journal of Pharmacology 2015; 756: 52-58 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Ito Y
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60664 Arundic acid attenuates retinal ganglion cell death by increasing glutamate/aspartate transporter expression in a model of normal tension glaucoma
Harada T
Cell Death and Disease 2015; 6: e1693 (IGR: 16-4)


60098 Rosmarinic Acid Suppresses Subconjunctival Neovascularization in Experimental Glaucoma Surgery
Vieira LC
Current Eye Research 2014; 0: 1-7 (IGR: 16-4)


60768 Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action
Isik S
Bio-organic and Medicinal Chemistry 2015; 23: 2368-2376 (IGR: 16-4)


60791 Bupropion Use and Risk of Open-Angle Glaucoma among Enrollees in a Large U.S. Managed Care Network
Wiggs JL
PLoS ONE 2015; 10: e0123682 (IGR: 16-4)


60570 BDNF Rescues RGCs But Not Intrinsically Photosensitive RGCs in Ocular Hypertensive Albino Rat Retinas
Bernal-Garro JM
Investigative Ophthalmology and Visual Science 2015; 56: 1924-1936 (IGR: 16-4)


60356 Retinal ganglion cell neuroprotection by an angiotensin II blocker in an ex vivo retinal explant model
Martin KR
Journal of the renin-angiotensin-aldosterone system : JRAAS 2015; 16: 1193-1201 (IGR: 16-4)


60275 Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
Healy J
ACS Medicinal Chemistry Letters 2015; 6: 84-88 (IGR: 16-4)


60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Suganami H
Acta Ophthalmologica 2015; 93: e254-e260 (IGR: 16-4)


60570 BDNF Rescues RGCs But Not Intrinsically Photosensitive RGCs in Ocular Hypertensive Albino Rat Retinas
Villegas-Pérez MP
Investigative Ophthalmology and Visual Science 2015; 56: 1924-1936 (IGR: 16-4)


60362 MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD)
Rammes G
Neuropharmacology 2015; 92: 158-169 (IGR: 16-4)


60664 Arundic acid attenuates retinal ganglion cell death by increasing glutamate/aspartate transporter expression in a model of normal tension glaucoma
Shinagawa R
Cell Death and Disease 2015; 6: e1693 (IGR: 16-4)


60098 Rosmarinic Acid Suppresses Subconjunctival Neovascularization in Experimental Glaucoma Surgery
Reinach PS
Current Eye Research 2014; 0: 1-7 (IGR: 16-4)


60791 Bupropion Use and Risk of Open-Angle Glaucoma among Enrollees in a Large U.S. Managed Care Network
Pasquale LR
PLoS ONE 2015; 10: e0123682 (IGR: 16-4)


60083 A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
Kaufman PL
British Journal of Ophthalmology 2015; 99: 738-745 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Okamoto N
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60683 P2X7 receptor antagonists protect against N-methyl-d-aspartic acid-induced neuronal injury in the rat retina
Mori A
European Journal of Pharmacology 2015; 756: 52-58 (IGR: 16-4)


60768 Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action
Lanzi C
Bio-organic and Medicinal Chemistry 2015; 23: 2368-2376 (IGR: 16-4)


60429 Intravitreal delivery of human NgR-Fc decoy protein regenerates axons after optic nerve crush and protects ganglion cells in glaucoma models
Frieden E
Investigative Ophthalmology and Visual Science 2015; 56: 1357-1366 (IGR: 16-4)


60210 Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits
Aliev G; Reddy VP
Front Biosci 2015; 20: 892-901 (IGR: 16-4)


60275 Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
Liu Y
ACS Medicinal Chemistry Letters 2015; 6: 84-88 (IGR: 16-4)


60359 A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure
Shimomura Y
Experimental Eye Research 2015; 132: 115-123 (IGR: 16-4)


60683 P2X7 receptor antagonists protect against N-methyl-d-aspartic acid-induced neuronal injury in the rat retina
Nakahara T
European Journal of Pharmacology 2015; 756: 52-58 (IGR: 16-4)


60098 Rosmarinic Acid Suppresses Subconjunctival Neovascularization in Experimental Glaucoma Surgery
Rodrigues MD
Current Eye Research 2014; 0: 1-7 (IGR: 16-4)


60570 BDNF Rescues RGCs But Not Intrinsically Photosensitive RGCs in Ocular Hypertensive Albino Rat Retinas
Agudo-Barriuso M
Investigative Ophthalmology and Visual Science 2015; 56: 1924-1936 (IGR: 16-4)


60429 Intravitreal delivery of human NgR-Fc decoy protein regenerates axons after optic nerve crush and protects ganglion cells in glaucoma models
Bhargava A
Investigative Ophthalmology and Visual Science 2015; 56: 1357-1366 (IGR: 16-4)


60083 A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study

British Journal of Ophthalmology 2015; 99: 738-745 (IGR: 16-4)


60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study
Araie M
Acta Ophthalmologica 2015; 93: e254-e260 (IGR: 16-4)


60664 Arundic acid attenuates retinal ganglion cell death by increasing glutamate/aspartate transporter expression in a model of normal tension glaucoma
Tanaka K
Cell Death and Disease 2015; 6: e1693 (IGR: 16-4)


60768 Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action
Scozzafava A
Bio-organic and Medicinal Chemistry 2015; 23: 2368-2376 (IGR: 16-4)


60210 Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits
Zamyatnin AA
Front Biosci 2015; 20: 892-901 (IGR: 16-4)


60275 Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
Mabon R
ACS Medicinal Chemistry Letters 2015; 6: 84-88 (IGR: 16-4)


60570 BDNF Rescues RGCs But Not Intrinsically Photosensitive RGCs in Ocular Hypertensive Albino Rat Retinas
Vidal-Sanz M
Investigative Ophthalmology and Visual Science 2015; 56: 1924-1936 (IGR: 16-4)


60077 Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study

Acta Ophthalmologica 2015; 93: e254-e260 (IGR: 16-4)


60429 Intravitreal delivery of human NgR-Fc decoy protein regenerates axons after optic nerve crush and protects ganglion cells in glaucoma models
Maynard G
Investigative Ophthalmology and Visual Science 2015; 56: 1357-1366 (IGR: 16-4)


60768 Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action
Masini E
Bio-organic and Medicinal Chemistry 2015; 23: 2368-2376 (IGR: 16-4)


60098 Rosmarinic Acid Suppresses Subconjunctival Neovascularization in Experimental Glaucoma Surgery
Cunha AS
Current Eye Research 2014; 0: 1-7 (IGR: 16-4)


60683 P2X7 receptor antagonists protect against N-methyl-d-aspartic acid-induced neuronal injury in the rat retina
Ishii K
European Journal of Pharmacology 2015; 756: 52-58 (IGR: 16-4)


60768 Synthesis of a new series of dithiocarbamates with effective human carbonic anhydrase inhibitory activity and antiglaucoma action
Supuran CT
Bio-organic and Medicinal Chemistry 2015; 23: 2368-2376 (IGR: 16-4)


60210 Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits
Skulachev MV
Front Biosci 2015; 20: 892-901 (IGR: 16-4)


60429 Intravitreal delivery of human NgR-Fc decoy protein regenerates axons after optic nerve crush and protects ganglion cells in glaucoma models
Tsai JC
Investigative Ophthalmology and Visual Science 2015; 56: 1357-1366 (IGR: 16-4)


60275 Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
Marinelli B
ACS Medicinal Chemistry Letters 2015; 6: 84-88 (IGR: 16-4)


60098 Rosmarinic Acid Suppresses Subconjunctival Neovascularization in Experimental Glaucoma Surgery
Paula JS
Current Eye Research 2014; 0: 1-7 (IGR: 16-4)


60275 Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
Samala L
ACS Medicinal Chemistry Letters 2015; 6: 84-88 (IGR: 16-4)


60429 Intravitreal delivery of human NgR-Fc decoy protein regenerates axons after optic nerve crush and protects ganglion cells in glaucoma models
Strittmatter SM
Investigative Ophthalmology and Visual Science 2015; 56: 1357-1366 (IGR: 16-4)


60210 Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits
Senin II; Skulachev VP
Front Biosci 2015; 20: 892-901 (IGR: 16-4)


60275 Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma
Zhang Y; Stouch TR; Whitlock NA; Gopinathan S; McKnight B; Wang S; Patel N; Wilson AG; Hamman BD; Rice DS; Rawlins DB
ACS Medicinal Chemistry Letters 2015; 6: 84-88 (IGR: 16-4)


58916 Effect of the Aβ aggregation modulator MRZ-99030 on retinal damage in an animal model of glaucoma
Salt TE; Nizari S; Cordeiro MF; Russ H; Danysz W
Neurotoxicity research 2014; 26: 440-446 (IGR: 16-3)


58772 Renin-angiotensin system regulates neurodegeneration in a mouse model of normal tension glaucoma
Semba K; Namekata K; Guo X; Harada C; Harada T; Mitamura Y
Cell Death and Disease 2014; 5: e1333 (IGR: 16-3)


58506 Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits
Isobe T; Mizuno K; Kaneko Y; Ohta M; Koide T; Tanabe S
Current Eye Research 2014; 39: 813-822 (IGR: 16-3)


58860 Effects of coenzyme Q10 in conjunction with vitamin E on retinal-evoked and cortical-evoked responses in patients with open-angle glaucoma
Parisi V; Centofanti M; Gandolfi S; Marangoni D; Rossetti L; Tanga L; Tardini M; Traina S; Ungaro N; Vetrugno M; Falsini B
Journal of Glaucoma 2014; 23: 391-404 (IGR: 16-3)


59314 Tissue plasminogen activator reduces the elevated intraocular pressure induced by prednisolone in sheep
Candia OA; Gerometta RM; Danias J
Experimental Eye Research 2014; 128: 114-116 (IGR: 16-3)


59438 Neuroprotective and neurite outgrowth effects of maltol on retinal ganglion cells under oxidative stress
Hong S; Iizuka Y; Lee T; Kim CY; Seong GJ
Molecular Vision 2014; 20: 1456-1462 (IGR: 16-3)


59266 The Novel Rho Kinase (ROCK) Inhibitor K-115: A New Candidate Drug for Neuroprotective Treatment in Glaucoma
Yamamoto K; Maruyama K; Himori N; Omodaka K; Yokoyama Y; Shiga Y; Morin R; Nakazawa T
Investigative Ophthalmology and Visual Science 2014; 55: 7126-7136 (IGR: 16-3)


59294 Neuroprotection of a novel cyclopeptide C*HSDGIC* from the cyclization of PACAP (1-5) in cellular and rodent models of retinal ganglion cell apoptosis
Cheng H; Ding Y; Yu R; Chen J; Wu C
PLoS ONE 2014; 9: e108090 (IGR: 16-3)


58505 Nerve growth factor modulation of retinal ganglion cell physiology
Roberti G; Mantelli F; Macchi I; Massaro-Giordano M; Centofanti M
Journal of Cellular Physiology 2014; 229: 1130-1133 (IGR: 16-3)


59530 Neurosteroids are endogenous neuroprotectants in an ex vivo glaucoma model
Ishikawa M; Yoshitomi T; Zorumski CF; Izumi Y
Investigative Ophthalmology and Visual Science 2014; 0: (IGR: 16-3)


59535 Tumor necrosis factor alpha has an early protective effect on retinal ganglion cells after optic nerve crush
Mac Nair CE; Fernandes KA; Schlamp CL; Libby RT; Nickells RW
Journal of Neuroinflammation 2014; 11: 194 (IGR: 16-3)


59389 Effect of Eye Drops Containing Disulfiram and Low-Substituted Methylcellulose in Reducing Intraocular Pressure in Rabbit Models
Nagai N; Yoshioka C; Mano Y; Ito Y; Okamoto N; Shimomura Y
Current Eye Research 2014; 0: 1-11 (IGR: 16-3)


58752 Dock GEFs and their therapeutic potential: neuroprotection and axon regeneration
Namekata K; Kimura A; Kawamura K; Harada C; Harada T
Progress in Retinal and Eye Research 2014; 43: 1-16 (IGR: 16-3)


59231 Double-masked, Randomized, Dose-Response Study of AR-13324 versus Latanoprost in Patients with Elevated Intraocular Pressure
Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
Ophthalmology 2015; 122: 302-307 (IGR: 16-3)


59385 Hybrid formulations of liposomes and bioadhesive polymers improve the hypotensive effect of the melatonin analogue 5-MCA-NAT in rabbit eyes
Quinteros D; Vicario-de-la-Torre M; Andrés-Guerrero V; Palma S; Allemandi D; Herrero-Vanrell R; Molina-Martínez IT
PLoS ONE 2014; 9: e110344 (IGR: 16-3)


59157 Latrunculin B Reduces Intraocular Pressure in Human Ocular Hypertension and Primary Open-Angle Glaucoma
Rasmussen CA; Kaufman PL; Ritch R; Haque R; Brazzell RK; Vittitow JL
Translational vision science & technology 2014; 3: 1 (IGR: 16-3)


59332 Application of Retinalamin for the treatment of glaucomatous optic neuropathy
Makashova NV; Vasil'eva AE; Morozova NE; Ronzina IA
Vestnik Oftalmologii 2014; 130: 71-76, 78-80 (IGR: 16-3)


59443 A Class of 4-Sulfamoylphenyl-ω-aminoalkyl Ethers with Effective Carbonic Anhydrase Inhibitory Action and Antiglaucoma Effects
Bozdag M; Pinard M; Carta F; Masini E; Scozzafava A; McKenna R; Supuran CT
Journal of Medicinal Chemistry 2014; 57: 9673-9686 (IGR: 16-3)


59343 Conjunctival matrix metalloproteinases and their inhibitors in glaucoma patients
Helin-Toiviainen M; Rönkkö S; Puustjärvi T; Rekonen P; Ollikainen M; Uusitalo H
Acta Ophthalmologica 2015; 93: 165-171 (IGR: 16-3)


59335 Preclinical pharmacology, ocular tolerability and ocular hypotensive efficacy of a novel non-peptide bradykinin mimetic small molecule
Sharif NA; Li L; Katoli P; Xu S; Veltman J; Li B; Scott D; Wax M; Gallar J; Acosta C; Belmonte C
Experimental Eye Research 2014; 128: 170-180 (IGR: 16-3)


59536 Cannabinoids: New Promising Agents in the Treatment of Neurological Diseases
Giacoppo S; Mandolino G; Galuppo M; Bramanti P; Mazzon E
Molecules 2014; 19: 18781-18816 (IGR: 16-3)


58815 Reduction of conjunctival fibrosis after trabeculectomy using topical α-lipoic acid in rabbit eyes
Ekinci M; Cagatay HH; Ceylan E; Keles S; Koban Y; Gokce G; Huseyinoğlu U; Ozcan E; Oba ME
Journal of Glaucoma 2014; 23: 372-379 (IGR: 16-3)


59364 The ocular hypotensive effect of saffron extract in primary open angle glaucoma: a pilot study
Jabbarpoor Bonyadi MH; Yazdani S; Saadat S
BMC complementary and alternative medicine 2014; 14: 399 (IGR: 16-3)


57497 Furazan and furoxan sulfonamides are strong α-carbonic anhydrase inhibitors and potential antiglaucoma agents
Chegaev K; Lazzarato L; Tamboli Y; Boschi D; Blangetti M; Scozzafava A; Carta F; Masini E; Fruttero R; Supuran CT; Gasco A
Bio-organic and Medicinal Chemistry 2014; 22: 3913-3921 (IGR: 16-2)


57130 CSM Enhances the Filtration Bleb Survival in Rabbit Model of Experimental Glaucoma Surgery
Ma J; Li X; Zhang W; Huang L; Chen M; Xi L; Zhang Z; Duan L; Quan D; Ge J
Current Eye Research 2014; 39: 982-988 (IGR: 16-2)


57159 The effect of oral solifenacin succinate treatment on intraocular pressure: glaucoma paradox during overactive bladder treatment
Sekeroglu MA; Hekimoglu E; Petricli IS; Tasci Y; Dolen I; Arslan U
International urogynecology journal 2014; 25: 1479-1482 (IGR: 16-2)


57022 Investigation of ocular events associated with taprenepag isopropyl, a topical EP2 agonist in development for treatment of glaucoma
Yanochko GM; Affolter T; Eighmy JJ; Evans MG; Khoh-Reiter S; Lee D; Miller PE; Shiue MH; Trajkovic D; Jessen BA
Journal of Ocular Pharmacology and Therapeutics 2014; 30: 429-439 (IGR: 16-2)


57305 A preliminary study of the neuroprotective role of citicoline eye drops in glaucomatous optic neuropathy
Roberti G; Tanga L; Parisi V; Sampalmieri M; Centofanti M; Manni G
Indian Journal of Ophthalmology 2014; 62: 549-553 (IGR: 16-2)


57150 Critical neuroprotective roles of heme oxygenase-1 induction against axonal injury-induced retinal ganglion cell death
Himori N; Maruyama K; Yamamoto K; Yasuda M; Ryu M; Omodaka K; Shiga Y; Tanaka Y; Nakazawa T
Journal of Neuroscience Research 2014; 92: 1134-1142 (IGR: 16-2)


57024 Taurine: the comeback of a neutraceutical in the prevention of retinal degenerations
Froger N; Moutsimilli L; Cadetti L; Jammoul F; Wang QP; Fan Y; Gaucher D; Rosolen SG; Neveux N; Cynober L; Sahel JA; Picaud S
Progress in Retinal and Eye Research 2014; 41: 44-63 (IGR: 16-2)


57202 Effect of Palmitoylethanolamide on Visual Field Damage Progression in Normal Tension Glaucoma Patients: Results of an Open-Label Six-Month Follow-Up
Costagliola C; Romano MR; dell'Omo R; Russo A; Mastropasqua R; Semeraro F
Journal of medicinal food 2014; 17: 949-954 (IGR: 16-2)


57115 Identification of the ghrelin-GHSR 1 system and its influence in the modulation of induced ocular hypertension in rabbit and rat eyes
Rocha-Sousa A; Pereira-Silva P; Tavares-Silva M; Azevedo-Pinto S; Rodrigues-Araújo J; Pinho S; Avelino A; Falcão-Reis F; Leite-Moreira A
Peptides 2014; 57: 59-66 (IGR: 16-2)


57146 Intracameral triamcinolone acetonide in glaucoma surgery: a prospective randomized controlled trial
Koval MS; Moster MR; Freidl KB; Waisbourd M; Jain SG; Ichhpujani P; Myers JS; Pro MJ
American Journal of Ophthalmology 2014; 158: 395-401.e2 (IGR: 16-2)


57154 Impact of trastuzumab on wound healing in experimental glaucoma surgery
Turgut B; Eren K; Akin MM; Bilir Can N; Demir T
Clinical and Experimental Ophthalmology 2015; 43: 67-76 (IGR: 16-2)


56422 Investigation of the Rho-kinase Gene Polymorphism in Primary Open-angle Glaucoma
Demiryürek S; Okumus S; Bozgeyik I; Oztuzcu S; Coskun E; Mat E; Durucu E; Tatar MG; Erbagci I; Gürler B; Demiryürek AT
Ophthalmic Genetics 2015; 0: 4-jan (IGR: 16-1)


56432 Aquaporins: important but elusive drug targets
Verkman AS; Anderson MO; Papadopoulos MC
Nature Reviews Drug Discovery 2014; 13: 259-277 (IGR: 16-1)


55998 Effect of Ginkgo biloba on visual field and contrast sensitivity in Chinese patients with normal tension glaucoma: a randomized, crossover clinical trial
Guo X; Kong X; Huang R; Jin L; Ding X; He M; Liu X; Patel MC; Congdon NG
Investigative Ophthalmology and Visual Science 2014; 55: 110-116 (IGR: 16-1)


56445 Cyclosporine a protects RGC-5 cells from excitotoxic cell death
Schultheiss M; Schnichels S; Mlynczak T; Dipl-Ing JH; Bartz-Schmidt KU; Szurman P; Spitzer MS
Journal of Glaucoma 2014; 23: 219-224 (IGR: 16-1)


56122 Minocycline mechanism of neuroprotection involves the Bcl-2 gene family in optic nerve transection
Levkovitch-Verbin H; Waserzoog Y; Vander S; Makarovsky D; Ilia P
The International Journal of Neuroscience 2014; 124: 755-761 (IGR: 16-1)


56239 Neuroprotective properties of citicoline: facts, doubts and unresolved issues
Grieb P
CNS Drugs 2014; 28: 185-193 (IGR: 16-1)


56525 In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma
Chen HH; Namil A; Severns B; Ward J; Kelly C; Drace C; McLaughlin MA; Yacoub S; Li B; Patil R; Sharif N; Hellberg MR; Rusinko A; Pang IH; Combrink KD
Bioorganic and Medicinal Chemistry Letters 2014; 24: 1875-1879 (IGR: 16-1)


56207 AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia
Van de Velde S; Van Bergen T; Sijnave D; Hollanders K; Castermans K; Defert O; Leysen D; Vandewalle E; Moons L; Stalmans I
Investigative Ophthalmology and Visual Science 2014; 55: 1006-1016 (IGR: 16-1)


56471 Resveratrol and the eye: activity and molecular mechanisms
Bola C; Bartlett H; Eperjesi F
Graefe's Archive for Clinical and Experimental Ophthalmology 2014; 252: 699-713 (IGR: 16-1)


56655 An emerging treatment option for glaucoma: Rho kinase inhibitors
Wang SK; Chang RT
Clinical Ophthalmology 2014; 8: 883-890 (IGR: 16-1)


55315 Anti-connective tissue growth factor antibody treatment reduces extracellular matrix production in trabecular meshwork and lamina cribrosa cells
Wallace DM; Clark AF; Lipson KE; Andrews D; Crean JK; O'brien CJ
Investigative Ophthalmology and Visual Science 2013; 54: 7836-7848 (IGR: 15-4)


55283 Identification of retinal ganglion cell neuroprotection conferred by platelet-derived growth factor through analysis of the mesenchymal stem cell secretome
Johnson TV; Dekorver NW; Levasseur VA; Osborne A; Tassoni A; Lorber B; Heller JP; Villasmil R; Bull ND; Martin KR; Tomarev SI
Brain 2014; 137: 503-519 (IGR: 15-4)


55282 Reduction of steroid-induced intraocular pressure elevation in sheep by tissue plasminogen activator
Gerometta R; Kumar S; Shah S; Alvarez L; Candia O; Danias J
Investigative Ophthalmology and Visual Science 2013; 54: 7903-7909 (IGR: 15-4)


55441 Calcium channels and their blockers in intraocular pressure and glaucoma
Mayama C
European Journal of Pharmacology 2014; 739: 96-105 (IGR: 15-4)


55687 γ-Synuclein antibodies have neuroprotective potential on neuroretinal cells via proteins of the mitochondrial apoptosis pathway
Wilding C; Bell K; Beck S; Funke S; Pfeiffer N; Grus FH
PLoS ONE 2014; 9: e90737 (IGR: 15-4)


55481 Curcumin: therapeutical potential in ophthalmology
Pescosolido N; Giannotti R; Plateroti AM; Pascarella A; Nebbioso M
Planta Medica 2014; 80: 249-254 (IGR: 15-4)


55709 The effectiveness of endonasal electrophoresis of neuroprotective agents used in the rehabilitative treatment of the patients presenting with primary open angle glaucoma
Nazarova GA; Konchugova TV; Iurova OV; Sichinava NV; Turova EA; Rassulova MA; Morozova NE
Voprosy kurortologii, fizioterapii, i lechebno? fizichesko? kultury 2013; 0: 27-30 (IGR: 15-4)


55169 Rho-kinase inhibitors offer a new approach in the treatment of glaucoma
Challa P; Arnold JJ
Expert Opinion on Investigational Drugs 2014; 23: 81-95 (IGR: 15-4)


55428 Bioactive lysophospholipids: role in regulation of aqueous humor outflow and intraocular pressure in the context of pathobiology and therapy of glaucoma
Rao PV
Journal of Ocular Pharmacology and Therapeutics 2014; 30: 181-190 (IGR: 15-4)


55376 Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients With Existing Superficial Punctate Keratitis
Suzuki K; Teranishi S; Sagara T; Yoshino H; Nakayama M; Enoki M; Nuno Y; Hirano S; Wakuta M; Takahashi N; Tokuhisa K; Kondo Y; Shiraishi R; Ishida Y; Sonoda KH;
Journal of Glaucoma 2015; 24: e145-e150 (IGR: 15-4)


55192 Inhibition of placental growth factor improves surgical outcome of glaucoma surgery
Van Bergen T; Jonckx B; Hollanders K; Sijnave D; Van de Velde S; Vandewalle E; Moons L; Stassen JM; Stalmans I
Journal of cellular and molecular medicine 2013; 17: 1632-1643 (IGR: 15-4)


55343 Interferon-alpha and interferon-gamma modulate Fas-mediated apoptosis in mitomycin-C-resistant human Tenon's fibroblasts
Wang XY; Crowston JG; White AJ; Zoellner H; Healey PR
Clinical and Experimental Ophthalmology 2014; 42: 529-538 (IGR: 15-4)


55435 RNA Interference Targeting Connective Tissue Growth Factor Inhibits the Transforming Growth Factor- β 2 Induced Proliferation in Human Tenon Capsule Fibroblasts
Jing J; Li P; Li T; Sun Y; Guan H
Journal of Ophthalmology 2013; 2013: 354798 (IGR: 15-4)


55431 Effect of poly(DL-lactide-co-glycolide) on scar formation after glaucoma filtration surgery
DU LQ; Yang HL; Wu XY; Wang SG; Li Y
Chinese Medical Journal 2013; 126: 4528-4535 (IGR: 15-4)


54709 In Vitro and In Vivo Efficacy of SYL040012, a Novel siRNA Compound for Treatment of Glaucoma
Martí,nez T; Gonzá,lez MV; Roehl I; Wright N; Pañ,eda C; Jimé,nez AI
Molecular Therapy 2014; 22: 81-91 (IGR: 15-3)


54424 17β-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma
Prokai-Tatrai K; Xin H; Nguyen V; Szarka S; Blazics B; Prokai L; Koulen P
Molecular pharmaceutics 2013; 10: 3253-3261 (IGR: 15-3)


54397 Neuroprotective Effects of Bis(7)-tacrine in a Rat Model of Pressure-Induced Retinal Ischemia
Li JB; Lu ZG; Xu L; Wang Q; Zhang ZH; Fang JH
Cell biochemistry and biophysics 2014; 68: 275-282 (IGR: 15-3)


54418 VEGF-A165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro
Beazley-Long N; Hua J; Jehle T; Hulse RP; Dersch R; Lehrling C; Bevan H; Qiu Y; Lagrè,ze WA; Wynick D; Churchill AJ; Kehoe P; Harper SJ; Bates DO; Donaldson LF
American Journal of Pathology 2013; 183: 918-929 (IGR: 15-3)


54508 Lycium barbarum (wolfberry) reduces secondary degeneration and oxidative stress, and inhibits JNK pathway in retina after partial optic nerve transection
Li H; Liang Y; Chiu K; Yuan Q; Lin B; Chang RC; So KF
PLoS ONE 2013; 8: e68881 (IGR: 15-3)


54722 Leptin as a neuroprotective agent in glaucoma
Gupta A
Medical Hypotheses 2013; 81: 797-802 (IGR: 15-3)


54395 Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
American Journal of Ophthalmology 2013; 156: 731-736 (IGR: 15-3)


54599 Regulation of intraocular pressure in mice: structural analysis of dopaminergic and serotonergic systems in response to cabergoline
Platania CB; Leggio GM; Drago F; Salomone S; Bucolo C
Biochemical Pharmacology 2013; 86: 1347-1356 (IGR: 15-3)


54664 Investigation on novel chitosan nanoparticle-aptamer complexes targeting TGF-β receptor II
Chen X; Zhu X; Li L; Xian G; Wang W; Ma D; Xie L
International Journal of Pharmaceutics 2013; 456: 499-507 (IGR: 15-3)


54348 Sustained release of matrix metalloproteinase-3 to trabecular meshwork cells using biodegradable PLGA microparticles
Turturro S; Sunoqrot S; Ying H; Hong S; Yue BY
Molecular pharmaceutics 2013; 10: 3023-3032 (IGR: 15-3)


54406 The Effects of Remifentanil and Esmolol on Increase in Intraocular Pressure Due to Laryngoscopy and Tracheal Intubation: A Double-Blind, Randomized Clinical Trial
Tuzcu K; Tuzcu EA; Karcioglu M; Davarci I; Coskun M; Ilhan O; Daglioglu MC; Turhanoglu S
Journal of Glaucoma 2015; 24: 372-376 (IGR: 15-3)


53973 Ethyl pyruvate treatment mitigates oxidative stress damage in cultured trabecular meshwork cells
Famili A; Ammar DA; Kahook MY
Molecular Vision 2013; 19: 1304-1309 (IGR: 15-2)


53825 Substratum stiffness and latrunculin B modulate the gene expression of the mechanotransducers YAP and TAZ in human trabecular meshwork cells
Thomasy SM; Morgan JT; Wood JA; Murphy CJ; Russell P
Experimental Eye Research 2013; 113: 66-73 (IGR: 15-2)


53533 Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors
Yin Y; Lin L; Ruiz C; Khan S; Cameron MD; Grant W; Pocas J; Eid N; Park H; Schröter T; Lograsso PV; Feng Y
Journal of Medicinal Chemistry 2013; 56: 3568-3581 (IGR: 15-2)


53708 Idebenone prevents human optic nerve head astrocytes from oxidative stress, apoptosis, and senescence by stabilizing BAX/Bcl-2 ratio
Kernt M; Arend N; Buerger A; Mann T; Haritoglou C; Ulbig MW; Kampik A; Hirneiss C
Journal of Glaucoma 2013; 22: 404-412 (IGR: 15-2)


53856 An Effective Prodrug Strategy to Selectively Enhance Ocular Exposure of a Cannabinoid Receptor (CB1/2) Agonist
Mainolfi N; Powers J; Amin J; Long D; Lee W; McLaughlin ME; Jaffee B; Brain CT; Elliott J; Sivak JM
Journal of Medicinal Chemistry 2013; 0: (IGR: 15-2)


53523 Targeting the A3 adenosine receptor for glaucoma treatment (review)
Fishman P; Cohen S; Bar-Yehuda S
Molecular medicine reports 2013; 7: 1723-1725 (IGR: 15-2)


54004 Functional and structural evaluation of lamotrigine treatment in rat models of acute and chronic ocular hypertension
Sandalon S; Könnecke B; Levkovitch-Verbin H; Simons M; Hein K; Sättler MB; Bähr M; Ofri R
Experimental Eye Research 2013; 115: 47-56 (IGR: 15-2)


53977 Deficiency of complement component 5 ameliorates glaucoma in DBA/2J mice
Howell GR; Soto I; Ryan M; Graham LC; Smith RS; John SW
Journal of Neuroinflammation 2013; 10: 76 (IGR: 15-2)


53903 Intravitreal cidofovir injection for the management of chronic glaucoma in dogs
Low MC; Landis ML; Peiffer RL
Veterinary Ophthalmology 2014; 17: 201-206 (IGR: 15-2)


53780 Effect of intranasal budesonide irrigations on intraocular pressure
Seiberling KA; Chang DF; Nyirady J; Park F; Church CA
International forum of allergy & rhinology 2013; 3: 704-707 (IGR: 15-2)


53500 Effects of thailanstatins on glucocorticoid response in trabecular meshwork and steroid-induced glaucoma
Jain A; Liu X; Wordinger RJ; Yorio T; Cheng YQ; Clark AF
Investigative Ophthalmology and Visual Science 2013; 54: 3137-3142 (IGR: 15-2)


53933 Nerve growth factor: basic studies and possible therapeutic applications
Manni L; Rocco ML; Bianchi P; Soligo M; Guaragna M; Barbaro SP; Aloe L
Growth Factors 2013; 31: 115-122 (IGR: 15-2)


53472 Dynamic mobilization of PGC-1α mediates mitochondrial biogenesis for the protection of RGC-5 cells by resveratrol during serum deprivation
Chen S; Fan Q; Li A; Liao D; Ge J; Laties AM; Zhang X
Apoptosis 2013; 18: 786-799 (IGR: 15-2)


53695 Xanthates and trithiocarbonates strongly inhibit carbonic anhydrases and show antiglaucoma effects in vivo
Carta F; Akdemir A; Scozzafava A; Masini E; Supuran CT
Journal of Medicinal Chemistry 2013; 56: 4691-4700 (IGR: 15-2)


53778 Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2
Foureaux G; Nogueira JC; Nogueira BS; Fulgêncio GO; Menezes GB; Fernandes SO; Cardoso VN; Fernandes RS; Oliveira GP; Franca JR; Faraco AA; Raizada MK; Ferreira AJ
Investigative Ophthalmology and Visual Science 2013; 54: 4296-4306 (IGR: 15-2)


53553 Randomized, Double-Masked, Placebo-Controlled Study to Assess the Ocular Safety of Mirabegron in Healthy Volunteers
Novack GD; Lewis RA; Vogel R; Sheth N; Swearingen D; Rasmussen S; Hantsbarger G; Martin NE
Journal of Ocular Pharmacology and Therapeutics 2013; 29: 674-680 (IGR: 15-2)


54058 Effect of 0.004% travoprost and 2% carteolol on intraocular pressure in patients with ocular hypertension after laser peripheral iridotomy or trabeculectomy in primary angle-closure glaucoma
Yao BQ; Pang YY; Li YX
Chinese Journal of Ophthalmology 2013; 49: 340-344 (IGR: 15-2)


53948 Phase 1 Clinical Trials of a Selective Rho Kinase Inhibitor, K-115
Tanihara H; Inoue T; Yamamoto T; Kuwayama Y; Abe H; Araie M;
JAMA ophthalmology 2013; 0: 1-8 (IGR: 15-2)


53559 Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma
Crooke A; Huete-Toral F; Martínez-Águila A; Martín-Gil A; Pintor J
Journal of Pharmacology and Experimental Therapeutics 2013; 346: 138-145 (IGR: 15-2)


54052 Role of dopaminergic receptors in glaucomatous disease modulation
Pescosolido N; Parisi F; Russo P; Buomprisco G; Nebbioso M
BioMed research international 2013; 2013: 193048 (IGR: 15-2)


53924 Rho-associated kinase inhibitors: A novel glaucoma therapy
Inoue T; Tanihara H
Progress in Retinal and Eye Research 2013; 37: 1-12 (IGR: 15-2)


52969 Protective effects of a compound isolated from Alnus japonica on oxidative stress-induced death in transformed retinal ganglion cells
Jo H; Choi SJ; Jung SH
Food and Chemical Toxicology 2013; 56: 425-435 (IGR: 15-1)


53096 The role of transforming growth factor β in glaucoma and the therapeutic implications
Prendes MA; Harris A; Wirostko BM; Gerber AL; Siesky B
British Journal of Ophthalmology 2013; 97: 680-686 (IGR: 15-1)


52709 Delta-opioid agonist SNC-121 protects retinal ganglion cell function in a chronic ocular hypertensive rat model
Abdul Y; Akhter N; Husain S
Investigative Ophthalmology and Visual Science 2013; 54: 1816-1828 (IGR: 15-1)


53246 Stanniocalcin-1 protects retinal ganglion cells by inhibiting apoptosis and oxidative damage
Kim SJ; Ko JH; Yun JH; Kim JA; Kim TE; Lee HJ; Kim SH; Park KH; Oh JY
PLoS ONE 2013; 8: e63749 (IGR: 15-1)


52941 Attenuation of choroidal neovascularization by β(2)-adrenoreceptor antagonism
Lavine JA; Sang Y; Wang S; Ip MS; Sheibani N
JAMA ophthalmology 2013; 131: 376-382 (IGR: 15-1)


53207 Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells
Chindasub P; Lindsey JD; Duong-Polk K; Leung CK; Weinreb RN
Investigative Ophthalmology and Visual Science 2013; 54: 96-102 (IGR: 15-1)


52789 The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches
Cheong SL; Federico S; Venkatesan G; Mandel AL; Shao YM; Moro S; Spalluto G; Pastorin G
Medicinal Research Reviews 2013; 33: 235-335 (IGR: 15-1)


52537 The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate
Arnold JJ; Hansen MS; Gorman GS; Inoue T; Rao V; Spellen S; Hunsinger RN; Chapleau CA; Pozzo-Miller L; Stamer WD; Challa P
Investigative Ophthalmology and Visual Science 2013; 54: 1118-1126 (IGR: 15-1)


53035 Identification of PDE6D as a molecular target of anecortave acetate via a methotrexate-anchored yeast three-hybrid screen
Shepard AR; Conrow RE; Pang IH; Jacobson N; Rezwan M; Rutschmann K; Auerbach D; Sriramaratnam R; Cornish VW
ACS Chemical Biology 2013; 8: 549-558 (IGR: 15-1)


52837 Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs
Fischer KM; Ward DA; Hendrix DV
American Journal of Veterinary Research 2013; 74: 275-280 (IGR: 15-1)


53128 Oxidative stress and potential applications of free radical scavengers in glaucoma
Aslan M; Dogan S; Kucuksayan E
Redox report : communications in free radical research 2013; 18: 76-87 (IGR: 15-1)


52750 Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X
Stamer WD; Hoffman EA; Kurali E; Krauss AH
Investigative Ophthalmology and Visual Science 2013; 54: 2100-2107 (IGR: 15-1)


52528 Protective effects of the compounds isolated from the seed of Psoralea corylifolia on oxidative stress-induced retinal damage
Kim KA; Shim SH; Ahn HR; Jung SH
Toxicology and applied pharmacology 2013; 269: 109-120 (IGR: 15-1)


51647 Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism
Suntharalingam A; Abisambra JF; O'Leary JC; Koren J; Zhang B; Joe MK; Blair LJ; Hill SE; Jinwal UK; Cockman M; Duerfeldt AS; Tomarev S; Blagg BS; Lieberman RL; Dickey CA
Journal of Biological Chemistry 2012; 287: 40661-40669 (IGR: 14-4)


51658 The activity of lowering intraocular pressure of cassiae seed extract in a DBA/2J mouse glaucoma model
Horng CT; Tsai ML; Chien ST; Kao WT; Tsai MK; Chang TH; Chen FA
Journal of Ocular Pharmacology and Therapeutics 2013; 29: 48-54 (IGR: 14-4)


51996 Melatonin analogue agomelatine reduces rabbit's intraocular pressure in normotensive and hypertensive conditions
Martínez-Águila A; Fonseca B; Bergua A; Pintor J
European Journal of Pharmacology 2013; 701: 213-217 (IGR: 14-4)


51640 Comparison of single versus multiple injections of the protein saratin for prolonging bleb survival in a rabbit model
Min J; Lukowski ZL; Levine MA; Meyers CA; Beattie AR; Schultz GS; Samuelson DA; Sherwood MB
Investigative Ophthalmology and Visual Science 2012; 53: 7625-7630 (IGR: 14-4)


52046 A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma
Long DD; Frieman B; Hegde SS; Hill CM; Jiang L; Kintz S; Marquess DG; Purkey H; Shaw JP; Steinfeld T; Wilson MS; Wrench K
Bioorganic and Medicinal Chemistry Letters 2013; 23: 939-943 (IGR: 14-4)


51739 Protection of retinal ganglion cells and retinal vasculature by Lycium barbarum polysaccharides in a mouse model of acute ocular hypertension
Mi XS; Feng Q; Lo AC; Chang RC; Lin B; Chung SK; So KF
PLoS ONE 2012; 7: e45469 (IGR: 14-4)


51754 Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities
Pertwee RG
Philosophical transactions of the Royal Society of London. Series B, Biological sciences 2012; 367: 3353-3363 (IGR: 14-4)


51990 Poloxamine micellar solubilization of α-tocopherol for topical ocular treatment
Ribeiro A; Sandez-Macho I; Casas M; Alvarez-Pérez S; Alvarez-Lorenzo C; Concheiro A
Colloids and surfaces. B, Biointerfaces 2013; 103: 550-557 (IGR: 14-4)


52002 Effects of roscovitine, a cell cycling-dependent kinase inhibitor, on intraocular pressure of rabbit and retinal ganglion cell damage
Kasai H; Imamura T; Tsuruma K; Takahashi Y; Kurasawa T; Hirata H; Shimazawa M; Hara H
Neuroscience Letters 2013; 535: 95-99 (IGR: 14-4)


51668 Effects of black currant anthocyanins on intraocular pressure in healthy volunteers and patients with glaucoma
Ohguro H; Ohguro I; Yagi S
Journal of Ocular Pharmacology and Therapeutics 2013; 29: 61-67 (IGR: 14-4)


51626 The effects of transforming growth factor-β2 on the expression of follistatin and activin A in normal and glaucomatous human trabecular meshwork cells and tissues
Fitzgerald AM; Benz C; Clark AF; Wordinger RJ
Investigative Ophthalmology and Visual Science 2012; 53: 7358-7369 (IGR: 14-4)


52099 Decrease in Corneal Damage due to Benzalkonium Chloride by the Addition of Sericin into Timolol Maleate Eye Drops
Nagai N; Ito Y; Okamoto N; Shimomura Y
Journal of oleo science 2013; 62: 159-166 (IGR: 14-4)


51235 Melatonin: an underappreciated player in retinal physiology and pathophysiology
Tosini G; Baba K; Hwang CK; Iuvone PM
Experimental Eye Research 2012; 103: 82-89 (IGR: 14-3)


51142 Ginkgolide B promotes axonal growth of retina ganglion cells by anti-apoptosis in vitro
Wang ZY; Mo XF; Jiang XH; Rong XF; Miao HM
Acta physiologica Sinica 2012; 64: 417-424 (IGR: 14-3)


51340 8-Hydroxycalamenene isolated from the rhizomes of Reynoutria elliptica exerts neuroprotective effects both in vitro and in vivo
Jo H; Lee HJ; Kim CY; Son JK; Jung SH
Food and Chemical Toxicology 2012; 51: 231-241 (IGR: 14-3)


51298 The influence of water soluble antioxidant agent (mexidol) on optic nerve and blood flow velocity in ocular and orbital arteries in patients with primary open-angle glaucoma
Volchegorskiĭ IA; Tur EV; Soliannikova OV; Rykun VS; Berdnikova EV; Sumina MS; Dmitrienko VN
Vestnik Oftalmologii 2012; 128: 35-38, 41 (IGR: 14-3)


51245 Protective effects of the β3-adrenoceptor agonist CL316243 against N-methyl-D-aspartate-induced retinal neurotoxicity
Oikawa F; Nakahara T; Akanuma K; Ueda K; Mori A; Sakamoto K; Ishii K
Naunyn-Schmiedeberg's archives of pharmacology 2012; 385: 1077-1081 (IGR: 14-3)


51375 Oxidative stress in the closed-eyelid test: management of glaucoma
Pescosolido N; Malagola R; Scarsella G; Lenarduzzi F; Dapoto L; Nebbioso M
European review for medical and pharmacological sciences 2012; 16: 1453-1457 (IGR: 14-3)


51163 Modeling of LIM-Kinase 2 Inhibitory Activity of Pyrrolopyrimidine Analogues: Useful in Treatment of Ocular Hypertension and Glaucoma
Singh G; Gupta MK; Kumar V; Prabhakar YS
Medicinal Chemistry 2013; 9: 402-409 (IGR: 14-3)


50884 Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets
Nakagawa S; Usui T; Yokoo S; Omichi S; Kimakura M; Mori Y; Miyata K; Aihara M; Amano S; Araie M
Investigative Ophthalmology and Visual Science 2012; 53: 5154-5160 (IGR: 14-3)


51152 Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure
Iyer P; Lalane R; Morris C; Challa P; Vann R; Rao PV
PLoS ONE 2012; 7: e42627 (IGR: 14-3)


50283 Potential role of Rho-associated protein kinase inhibitors for glaucoma treatment
Colligris B; Crooke A; Huete F; Pintor J
Recent patents on endocrine, metabolic & immune drug discovery 2012; 6: 89-98 (IGR: 14-2)


50494 CXCR3 antagonism of SDF-1(5-67) restores trabecular function and prevents retinal neurodegeneration in a rat model of ocular hypertension
Denoyer A; Godefroy D; Cé,lé,rier I; Frugier J; Degardin J; Harrison JK; Brignole-Baudouin F; Picaud S; Baleux F; Sahel JA; Rostè,ne W; Baudouin C
PLoS ONE 2012; 7: e37873 (IGR: 14-2)


50499 Effect of diinosine polyphosphates on intraocular pressure in normotensive rabbits
Guzman-Aranguez A; Dí,ez LM; Martí,n-Gil A; Gualix J; Miras-Portugal MT; Pintor J
Experimental Eye Research 2012; 101: 49-55 (IGR: 14-2)


50553 Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues
Crooke A; Colligris B; Pintor J
Current Medicinal Chemistry 2012; 19: 3508-3522 (IGR: 14-2)


50578 Is low dose of Estrogen beneficial for prevention of glaucoma?
Wei X; Cai SP; Zhang X; Li X; Chen X; Liu X
Medical Hypotheses 2012; 79: 377-380 (IGR: 14-2)


50539 Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma
Zhang K; Zhang L; Weinreb RN
Nature Reviews Drug Discovery 2012; 11: 541-559 (IGR: 14-2)


50585 Oral Administration of Forskolin and Rutin Contributes to Intraocular Pressure Control in Primary Open Angle Glaucoma Patients Under Maximum Tolerated Medical Therapy
Vetrugno M; Uva MG; Russo V; Iester M; Ciancaglini M; Brusini P; Centofanti M; Rossetti LM
Journal of Ocular Pharmacology and Therapeutics 2012; 28: 536-541 (IGR: 14-2)


50214 Single and mixed poloxamine micelles as nanocarriers for solubilization and sustained release of ethoxzolamide for topical glaucoma therapy
Ribeiro A; Sosnik A; Chiappetta DA; Veiga F; Concheiro A; Alvarez-Lorenzo C
Journal of the Royal Society, Interface / the Royal Society 2012; 9: 2059-2069 (IGR: 14-2)


50603 Curcuminoids in Neurodegenerative Diseases
Kim DS; Kim JY; Han Y
Recent Patents on CNS Drug Discovery 2012; 7: 184-204 (IGR: 14-2)


49014 Preventive effects of omega-3 and omega-6 Fatty acids on peroxide mediated oxidative stress responses in primary human trabecular meshwork cells
Tourtas T; Birke MT; Kruse FE; Welge-Lü,ssen UC; Birke K
PLoS ONE 2012; 7: e31340 (IGR: 14-1)


49000 Glutamate oxidative injury to RGC-5 cells in culture is necrostatin sensitive and blunted by a hydrogen sulfide (H2S)-releasing derivative of aspirin (ACS14)
Osborne NN; Ji D; Majid AS; Del Soldata P; Sparatore A
Neurochemistry International 2012; 60: 365-378 (IGR: 14-1)


48816 Guanylate cyclase activators, cell volume changes and IOP reduction
Ellis DZ
Cellular Physiology and Biochemistry 2011; 28: 1145-1154 (IGR: 14-1)


49030 Topical ocular sodium 4-phenylbutyrate rescues glaucoma in a myocilin mouse model of primary open-angle glaucoma
Zode GS; Bugge KE; Mohan K; Grozdanic SD; Peters JC; Koehn DR; Anderson MG; Kardon RH; Stone EM; Sheffield VC
Investigative Ophthalmology and Visual Science 2012; 53: 1557-1565 (IGR: 14-1)


48840 1α,25-Dihydroxyvitamin D(3) and its analog, 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD), suppress intraocular pressure in non-human primates
Kutuzova GD; Gabelt BT; Kiland JA; Hennes-Beann EA; Kaufman PL; DeLuca HF
Archives of Biochemistry and Biophysics 2012; 518: 53-60 (IGR: 14-1)


49142 Norrin: Molecular and functional properties of an angiogenic and neuroprotective growth factor
Ohlmann A; Tamm ER
Progress in Retinal and Eye Research 2012; 31: 243-257 (IGR: 14-1)


48967 Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action in vivo
Carta F; Aggarwal M; Maresca A; Scozzafava A; McKenna R; Masini E; Supuran CT
Journal of Medicinal Chemistry 2012; 55: 1721-1730 (IGR: 14-1)


48812 Effect of SPP 635, a renin inhibitor, on intraocular pressure in glaucomatous monkey eyes
Wang RF; Podos SM; Serle JB; Baltatu OC
Experimental Eye Research 2012; 94: 146-149 (IGR: 14-1)


49004 Pregnenolone sulfate decreases intraocular pressure and changes expression of sigma receptor in a model of chronic ocular hypertension
Sun X; Cheng F; Meng B; Yang B; Song W; Yuan H
Molecular Biology Reports 2012; 39: 6607-6614 (IGR: 14-1)


49359 Renin-Angiotensin system hyperactivation can induce inflammation and retinal neural dysfunction
Kurihara T; Ozawa Y; Ishida S; Okano H; Tsubota K
International Journal of Inflammation 2012; 2012: 581695 (IGR: 14-1)


48814 Dopamine-₃ receptor modulates intraocular pressure: implications for glaucoma
Bucolo C; Leggio GM; Maltese A; Castorina A; D'Agata V; Drago F
Biochemical Pharmacology 2012; 83: 680-686 (IGR: 14-1)


48525 A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties Mechanism of action and preliminary pharmacology
Fabrizi F; Mincione F; Somma T; Scozzafava G; Galassi F; Masini E; Impagnatiello F; Supuran CT
Journal of Enzyme Inhibition and Medicinal Chemistry 2012; 27: 138-147 (IGR: 14-1)


48529 Palmitoylethanolamide effects on intraocular pressure after Nd:YAG laser iridotomy: an experimental clinical study
Pescosolido N; Librando A; Puzzono M; Nebbioso M
Journal of Ocular Pharmacology and Therapeutics 2011; 27: 629-635 (IGR: 14-1)


48532 A cannabinoid ligand, anandamide, exacerbates endotoxin-induced uveitis in rabbits
Altinsoy A; Dilekö,z E; Kul O; Ilhan SÖ,; Tunccan OG; Seven I; Bagriacik EU; Sarioglu Y; Or M; Ercan ZS
Journal of Ocular Pharmacology and Therapeutics 2011; 27: 545-552 (IGR: 14-1)


48620 Effect of ion pairing on in vitro transcorneal permeability of a Δ(9) -tetrahydrocannabinol prodrug: potential in glaucoma therapy
Hingorani T; Gul W; Elsohly M; Repka MA; Majumdar S
Journal of Pharmaceutical Sciences 2012; 101: 616-626 (IGR: 14-1)


49130 Two-Year Randomized, Placebo-Controlled Study of Black Currant Anthocyanins on Visual Field in Glaucoma
Ohguro H; Ohguro I; Katai M; Tanaka S
Ophthalmologica 2012; 228: 26-35 (IGR: 14-1)


49109 Effect of tetrandrine on bax, bcl-2 and TGF-β2 mRNA expressions in cultured human Tenon's capsule fibroblasts
Li D; Sun M; Li Q; Yang F; Lin S; Wu K
Journal of Southern Medical University 2012; 32: 97-100 (IGR: 14-1)


48825 Clinical study on interferon treatment of early scarring in filtering bleb
Wang WH; Zhang JL; Huang Y; Huang JX; Jiang JH
Eye Science 2011; 26: 197-200 (IGR: 14-1)


49053 Modulation of postoperative scarring with tacrolimus and octreotide in experimental glaucoma filtration surgery
Arslan S; Aydemir O; Gü,ler M; DaÄŸlı AF
Current Eye Research 2012; 37: 228-233 (IGR: 14-1)


47577 Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma
Zode GS; Kuehn MH; Nishimura DY; Searby CC; Mohan K; Grozdanic SD; Bugge K; Anderson MG; Clark AF; Stone EM
Journal of Clinical Investigation 2011; 121: 3542-3553 (IGR: 13-4)


48136 Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease
Bakalash S; Pham M; Koronyo Y; Salumbides BC; Kramerov A; Seidenberg H; Berel D; Black KL; Koronyo-Hamaoui M
Investigative Ophthalmology and Visual Science 2011; 52: 9033-9046 (IGR: 13-4)


47581 Indirect sympatholytic actions at (beta)-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists
Hudson BD; Beazley M; Szczesniak A-M; Straiker A; Kelly MEM
Journal of Pharmacology and Experimental Therapeutics 2011; 339: 757-767 (IGR: 13-4)


48001 Effect of recombinant human erythropoietin on bcl-2 protein expression in the retina in a rabbit model of acute high intraocular pressure
Wang JM; Song YP; Sun NX; Hui N; Zhao SP; Hu K
Journal of Southern Medical University 2010; 30: 552-554 (IGR: 13-4)


47924 Tafluprost for glaucoma
Papadia M; Bagnis A; Scotto R; Traverso CE
Expert Opinion in Pharmacotherapy 2011; 12: 2393-2401 (IGR: 13-4)


47679 The role of neurotrophins and mimetics in the treatment of ocular diseases
Bai Y; Ge J; Saragovi HU; Zhuo Y
Drugs of the Future 2011; 36: 123-131 (IGR: 13-4)


48421 Simvastatin upregulates Bcl-2 expression and protects retinal neurons from early ischemia/reperfusion injury in the rat retina
Ko ML; Chen CF; Peng PH; Peng YH
Experimental Eye Research 2011; 93: 580-585 (IGR: 13-4)


48338 Down-regulation of matrix metalloproteinase-9 by pyrrolidine dithiocarbamate prevented retinal ganglion cell death after transection of optic nerve in rats
Sun MH; Chen KJ; Tsao YP; Kao LY; Han WH; Lin KK; Pang JH
Current Eye Research 2011; 36: 1053-1063 (IGR: 13-4)


48260 Neuroprotective effects of tempol acyl esters against retinal ganglion cell death in a rat partial optic nerve crush model
Thaler S; Fiedorowicz M; Grieb P; Wypych Z; Knap N; Borowik T; Zawada K; Kaminski J; Wozniak M; Rejdak R
Acta Ophthalmologica 2011; 89: 555-560 (IGR: 13-4)


47600 Cannabinoids and their possible use in the treatment of glaucoma
Aldana BZ; Rodriguez IM; Pineda NT
Revista Cubana de Farmacia 2011; 45: 439-448 (IGR: 13-4)


47596 Effect of Ketorolac Add-On Treatment on Intra-Ocular Pressure in Glaucoma Patients Receiving Prostaglandin Analogues
Turan-Vural E; Torun-Acar B; Acar S
Ophthalmologica 2011; (IGR: 13-4)


47896 Adenosine receptor targeting in health and disease
Gessi S; Merighi S; Fazzi D; Stefanelli A; Varani K; Borea PA
Expert Opinion on Investigational Drugs 2011; 20: 1591-1609 (IGR: 13-4)


47824 Pharmacokinetics of pirfenidone after topical administration in rabbit eye
Sun G; Lin X; Zhong H; Yang Y; Qiu X; Ye C; Wu K; Yu M
Molecular Vision 2011; 17: 2191-2196 (IGR: 13-4)


47678 Novel therapeutic approaches for glaucoma
Rasmussen CA; Kaufman PL
Drugs of the Future 2011; 36: 287-300 (IGR: 13-4)


48329 Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats
Tokushige H; Waki M; Takayama Y; Tanihara H
Current Eye Research 2011; 36: 964-970 (IGR: 13-4)


47664 Ocular and systemic distribution of ino-8875, a selective adenosine A1 receptor agonist, in rabbits by quantitative whole body autoradiography (QWBA) and tissue analysis
Prescott E; Struble C; Denissen J; Kim N
Drug Metabolism Reviews 2011; 43: 78-79 (IGR: 13-4)


48242 Efficacy and tolerability of topical 0 0.5% flunarizine in patients with open-angle glaucoma or ocular hypertension-a pilot study
Mansouri K; Silva SE; Shaarawy T
Journal of Glaucoma 2011; 20: 519-522 (IGR: 13-4)


48283 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2? agonist, in preclinical models
Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
Experimental Eye Research 2011; 93: 250-255 (IGR: 13-4)


48323 Similar hydrodynamic and morphological changes in the aqueous humor outflow pathway after washout and Y27632 treatment in monkey eyes
Lu Z; Zhang Y; Freddo TF; Gong H
Experimental Eye Research 2011; 93: 397-404 (IGR: 13-4)


47580 Effect of ion pairing on in vitro transcorneal permeability of a (Delta)(9)-tetrahydrocannabinol prodrug: Potential in glaucoma therapy
Hingorani T; Gul W; Elsohly M; Repka MA; Majumdar S
Journal of Pharmaceutical Sciences 2011; (IGR: 13-4)


48334 Evaluation of Sustained Release of PLC-Loaded Prednisolone Acetate Microfilm on Postoperative Inflammation in an Experimental Model of Glaucoma Filtration Surgery
Ang M; Yan P; Zhen M; Foo S; Venkatraman SS; Wong TT
Current Eye Research 2011; 36: 1123-1128 (IGR: 13-4)


47803 Prevention of ocular scarring after glaucoma filtering surgery using the monoclonal antibody LT1009 (Sonepcizumab) in a rabbit model
Lukowski ZL; Min J; Beattie AR; Meyers CA; Levine MA; Stoller G; Schultz GS; Samuelson DA; Sherwood MB
Journal of Glaucoma 2011; (IGR: 13-4)


47123 Oral administration of an association of forskolin, rutin and vitamins B1 and B2 potentiates the hypotonising effects of pharmacological treatments in POAG patients
Pescosolido N; Librando A
Clinica Terapeutica 2010; 161: 81-85 (IGR: 13-3)


46864 Glycyrrhizin could reduce ocular hypertension induced by triamcinolone acetonide in rabbits
Song Z; Gong Y; Liu H; Ren Q; Sun X
Molecular Vision 2011; 17: 2056-2064 (IGR: 13-3)


46998 Effect of topical 0.03% flurbiprofen and 0.005% latanoprost, alone and in combination, on normal canine eyes
Pirie CG; Maranda LS; Pizzirani S
Veterinary Ophthalmology 2011; 14: 71-79 (IGR: 13-3)


46956 Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea
Okamoto N; Ito Y; Nagai N; Murao T; Takiguchi Y; Kurimoto T; Mimura O
Journal of oleo science 2010; 59: 423-430 (IGR: 13-3)


46688 A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension
Schachar RA; Raber S; Courtney R; Zhang M
Current Eye Research 2011; 36: 809-817 (IGR: 13-3)


47128 Structural and functional neuroprotection in glaucoma: role of galantamine-mediated activation of muscarinic acetylcholine receptors
Almasieh M; Zhou Y; Kelly ME; Casanova C; Di Polo A
Cell Death and Disease 2010; 1: 27 (IGR: 13-3)


46464 Ocular Hypotensive Effect of the Rho Kinase Inhibitor AR-12286 in Patients with Glaucoma and Ocular Hypertension
Williams RD; Novack GD; Van Haarlem T; Kopczynski C
American Journal of Ophthalmology 2011; (IGR: 13-3)


46716 Cannabinoid applications in glaucoma
Pinar-Sueiro S; Rodriguez-Puertas R; Vecino E
Archivos de la Sociedad Española de Oftalmologia 2011; 86: 16-23 (IGR: 13-3)


46757 Manganese porphyrin reduces retinal injury induced by ocular hypertension
Dogan S; Baranowska K; Walankiewicz M; Yargicoglu P; Unal M; Spasojevic I; Haberle IB; Aslan M
Free Radical Biology and-Medicine 2010; 49: S176-S177 (IGR: 13-3)


46613 Ocular hypotensive effect of oral palmitoyl-ethanolamide: A clinical trial
Gagliano C; Ortisi E; Pulvirenti L; Reibaldi M; Scollo D; Amato R; Avitabile T; Longo A
Investigative Ophthalmology and Visual Science 2011; 52: 6096-6100 (IGR: 13-3)


46906 Novel ocular antihypertensive compounds in clinical trials
Chen J; Runyan SA; Robinson MR
Clinical Ophthalmology 2011; 5: 667-677 (IGR: 13-3)


47065 Local Ocular Renin-Angiotensin System - A Target for Glaucoma Therapy?
Vaajanen A; Vapaatalo H
Basic and Clinical Pharmacology and Toxicology 2011; (IGR: 13-3)


46750 Biomarkers and special features of oxidative stress in the anterior segment of the eye linked to lens cataract and the trabecular meshwork injury in primary open-angle glaucoma: Challenges of dual combination therapy with N-acetylcarnosine lubricant eye d
Babizhayev MA
Fundamental and Clinical Pharmacology 2011; (IGR: 13-3)


46546 Effects of Rho-associated protein kinase inhibitors Y-27632 and Y-39983 on isolated rabbit ciliary arteries
Watabe H; Abe S; Yoshitomi T
Japanese Journal of Ophthalmology 2011; (IGR: 13-3)


46668 Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure
Checa-Casalengua P; Jiang C; Bravo-Osuna I; Tucker BA; Molina-Martinez IT; Young MJ; Herrero-Vanrell R
Journal of Controlled Release 2011; (IGR: 13-3)


46997 Evaluation of the ocular penetration of topical alpha-luminol (Galavit((registered trademark))/GVT((registered trademark)))
da Silva EG; Gionfriddo JR; Hudachek SF; Gustafson DL; Olea-Popelka FJ; Scofield VL; Powell CC; Hill AE
Veterinary Ophthalmology 2011; 14: 180-185 (IGR: 13-3)


47018 Can topical ketorolac 0.5% improve the function of Ahmed glaucoma drainage devices?
Scott GR; Weizer JS; Moroi SE; Bruno CA; Musch DC; Niziol LM; Lee PP; Stein JD
Ophthalmic Surgery Lasers and Imaging 2011; 42: 190-195 (IGR: 13-3)


46446 Monoclonal antibodies in ophthalmology
Biswas NR; Das GK; Dubey AK
Nepalese journal of ophthalmology : a biannual peer-reviewed academic journal of the Nepal Ophthalmic Society : NEPJOPH 2010; 12: 264-271 (IGR: 13-3)


45634 Real-time measurements of nicotinamide adenine dinucleotide in live human trabecular meshwork cells: Effects of acute oxidative stress
Masihzadeh O; Ammar DA; Lei TC; Gibson EA; Kahook MY
Experimental Eye Research 2011; (IGR: 13-2)


46301 Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death
Gregory MS; Hackett CG; Abernathy EF; Lee KS; Saff RR; Hohlbaum AM; Moody KL; Hobson MW; Jones A; Kolovou P
PLoS ONE 2011; 6: e17659 (IGR: 13-2)


46168 Current and emerging medical therapies in the treatment of glaucoma
Bagnis A; Papadia M; Scotto R; Traverso CE
Expert Opinion on Emerging Drugs 2011; 16: 293-307 (IGR: 13-2)


46112 Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
Duncan RS; Xin H; Goad DL; Chapman KD; Koulen P
Clinical Ophthalmology 2011; 5: 543-548 (IGR: 13-2)


45491 Rasagiline-induced Delay of Retinal Ganglion Cell Death in Experimental Glaucoma in Rats
Levkovitch-Verbin H; Vander S; Melamed S
Journal of Glaucoma 2011; 20: 273-277 (IGR: 13-2)


45733 A selective inhibitor of Drp1, Mdivi-1, increases retinal ganglion cell survival in acute ischemic mouse retina
Park SW; Kim K-Y; Lindsey JD; Dai Y; Heo H; Nguyen DH; Ellisman MH; Weinreb RN; Ju W-K
Investigative Ophthalmology and Visual Science 2011; 52: 2837-2843 (IGR: 13-2)


46102 Closed gateways- Can neuroprotectants shield the retina in glaucoma?
Velpandian T
Drugs in R&D 2010; 10: 93-96 (IGR: 13-2)


46103 Visual field protective effect of erigeron breviscapus (vant.) hand. mazz. extract on glaucoma with controlled intraocular pressure: A randomized, double-blind, clinical trial
Zhong Y; Xiang M; Ye W; Cheng Y; Jiang Y
Drugs in R&D 2010; 10: 75-82 (IGR: 13-2)


45658 Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits
Alarma-Estrany P; Guzman-Aranguez A; Huete F; Peral A; Plourde Jr R; Pelaez T; Yerxa B; Pintor J
Journal of Pharmacology and Experimental Therapeutics 2011; 337: 703-709 (IGR: 13-2)


46317 Asymmetric synthesis of potent chroman-based Rho kinase (ROCK-II) inhibitors
Chen YT; Vojkovsky T; Fang X; Pocas JR; Grant W; Handy AMW; Schroter T; LoGrasso P; Bannister TD; Feng Y
MedChemComm 2011; 2: 73-75 (IGR: 13-2)


45942 Biological activity of quinoxaline derivatives
Deepika Y; Nath PS; Sachin K; Shewta S
International Journal of Current Pharmaceutical Review and Research 2011; 2: 33-46 (IGR: 13-2)


45630 A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs
Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WKM; Prasanna G; Chiroli V
Experimental Eye Research 2011; (IGR: 13-2)


45627 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F2(alpha) agonist, in preclinical models
Krauss AHP; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WKM; Carreiro ST; Ongini E
Experimental Eye Research 2011; (IGR: 13-2)


45922 Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action
Mincione F; Benedini F; Biondi S; Cecchi A; Temperini C; Formicola G; Pacileo I; Scozzafava A; Masini E; Supuran CT
Bioorganic and Medicinal Chemistry Letters 2011; 21: 3216-3221 (IGR: 13-2)


45628 Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma
Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D
Experimental Eye Research 2011; (IGR: 13-2)


46130 (alpha)2C-adrenoceptor modulators: A patent review
Quaglia W; Del Bello F; Giannella M; Piergentili A; Pigini M
Expert Opinion on Therapeutic Patents 2011; 21: 455-481 (IGR: 13-2)


45687 Combined treatment in patients with unstabilized glaucoma
Shtilerman AL; Mikhal'skii EA; Lysiak IV
Vestnik Oftalmologii 2010; 126: 28-31 (IGR: 13-2)


46063 Protective effect of a JNK inhibitor against retinal ganglion cell loss induced by acute moderate ocular hypertension
Sun H; Wang Y; Pang I-H; Shen J; Tang X; Li Y; Liu C; Li B
Molecular Vision 2011; 17: 864-875 (IGR: 13-2)


45642 Functional and morphological effects of (beta)-estradiol in eyes with N-methyl-d-Aspartate-induced retinal neurotoxicity in rats
Yamashita H; Yamada-Nakayama C; Sugihara K; Tsuji S; Sakurai T; Ban Y; Tsutsumi S; Sato Y
Experimental Eye Research 2011; (IGR: 13-2)


45734 The use of mucoadhesive polymers to enhance the hypotensive effect of a melatonin analogue, 5-MCA-NAT, in rabbit eyes
Andres-Guerrero V; Molina-Martinez IT; Pera A; de las Heras B; Pintor J; Herrero-Vanrell R
Investigative Ophthalmology and Visual Science 2011; 52: 1507-1515 (IGR: 13-2)


46186 Enhanced Solubility, Stability, and Transcorneal Permeability of Delta-8-Tetrahydrocannabinol in the Presence of Cyclodextrins
Hippalgaonkar K; Gul W; Elsohly MA; Repka MA; Majumdar S
AAPS PharmSciTech 2011; (IGR: 13-2)


45947 Inhibition of TGF beta 2 shRNA on human Tenon's capsular fibroblasts
Luo W; Sun L; Li J-M
Chinese Ophthalmic Research 2010; 28: 1150-1153 (IGR: 13-2)


45945 Inhibition effect of P27 tumor suppressor gene transfection on human Tenon's fibroblast cells
Sun L; Luo W; Li J-M
Chinese Ophthalmic Research 2010; 28: 1119-1123 (IGR: 13-2)


45944 Effects of huoxuehuayu prescription on retina with acute intraocular hypertension
Zhang C; Wang D-B; Fang J; Shang W-W
Chinese Ophthalmic Research 2010; 28: 1129-1133 (IGR: 13-2)


28116 Cationic nano-copolymers mediated IKK(beta) targeting siRNA to modulate wound healing in a monkey model of glaucoma filtration surgery
Ye H; Qian Y; Lin M; Duan Y; Sun X; Zhuo Y; Ge J
Molecular Vision 2010; 16: 2502-2510 (IGR: 13-1)


27917 The effect of biophysical attributes of the ocular trabecular meshwork associated with glaucoma on the cell response to therapeutic agents
McKee CT; Wood JA; Shah NM; Fischer ME; Reilly CM; Murphy CJ; Russell P
Biomaterials 2011; 32: 2417-2423 (IGR: 13-1)


27850 Endothelin antagonism as an active principle for glaucoma therapy
Rosenthal R; Fromm M
British Journal of Pharmacology 2011; 162: 806-816 (IGR: 13-1)


27706 Lack of protective effect of local administration of triamcinolone or systemic treatment with methylprednisolone against damages caused by optic nerve crush in rats
Huang TL; Chang CH; Lin KH; Sheu MM; Tsai RK
Experimental Eye Research 2011; 92: 112-119 (IGR: 13-1)


27688 Efficacy of tetrandrine on lowering intraocular pressure in animal model with ocular hypertension
Huang P; Xu Y; Wei R; Li H; Tang Y; Liu J; Zhang SS; Zhang C
Journal of Glaucoma 2011; 20: 183-188 (IGR: 13-1)


27676 Alpha-Crystallin Promotes Rat Retinal Neurite Growth on Myelin Substrates in vitro
Wang YH; Wang DW; Wu N; Wang Y; Yin ZQ
Ophthalmic Research 2010; 45: 164-168 (IGR: 13-1)


27958 Effect of SPP 301, an endothelin antagonist, on intraocular pressure in glaucomatous monkey eyes
Wang R-F; Podos SM; Serle JB; Baltatu OC
Current Eye Research 2011; 36: 41-46 (IGR: 13-1)


27741 Cytokine-Dependent ELAM-1 Induction and Concomitant Intraocular Pressure Regulation in Porcine Anterior Eye Perfusion Culture
Birke MT; Birke K; Lütjen-Drecoll E; Schlötzer-Schrehardt U; Hammer CH
Investigative Ophthalmology and Visual Science 2011; 52: 468-475 (IGR: 13-1)


27960 Effect of avosentan (SPP-301) in porcine ciliary arteries
Konieczka K; Meyer P; Schoetzau A; Neutzner A; Mozaffarieh M; Flammer J
Current Eye Research 2011; 36: 118-124 (IGR: 13-1)


28157 Management of chronic anterior uveitis relapses: Efficacy of oral phospholipidic curcumin treatment. Long-term follow-up
Allegri P; Mastromarino A; Neri P
Clinical Ophthalmology 2010; 4: 1201-1206 (IGR: 13-1)


28205 Pharmacotherapies for glaucoma
Toris CB
Current Molecular Medicine 2010; 10: 824-840 (IGR: 13-1)


28149 Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
Pozarowska D
Clinical Ophthalmology 2010; 4: 1229-1236 (IGR: 13-1)


28150 Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
Schnober D; Hofmann G; Maier H; Scherzer M-L; Ogundele AB; Jasek MC
Clinical Ophthalmology 2010; 4: 1459-1463 (IGR: 13-1)


27999 Similarities and differences between primary and secondary degeneration of the optic nerve and the effect of minocycline
Levkovitch-Verbin H; Spierer O; Vander S; Dardik R
Graefe's Archive for Clinical and Experimental Ophthalmology 2011; 1-9 (IGR: 13-1)


28068 Ocular application of nerve growth factor protects degenerating retinal ganglion cells in a rat model of glaucoma
Colafrancesco V; Parisi V; Sposato V; Rossi S; Russo MA; Coassin M; Lambiase A; Aloe L
Journal of Glaucoma 2011; 20: 100-108 (IGR: 13-1)


27938 Secretoneurin and the tachykinins substance P and neurokinin-A/B in NMDA-induced excitotoxicity in the rat retina
Teuchner B; Dimmer A; Troger J; Fischer-Colbrie R; Schmid E; Kieselbach G; Dietrich H; Bechrakis N
Regulatory Peptides 2010; 165: 123-127 (IGR: 13-1)


28019 Neuroprotective effect of PACAP against NMDA-induced retinal damage in the mouse
Endo K; Nakamachi T; Seki T; Kagami N; Wada Y; Nakamura K; Kishimoto K; Hori M; Tsuchikawa D; Shinntani N
Journal of Molecular Neuroscience 2011; 43: 22-29 (IGR: 13-1)


28048 Neuro-protective effects of yiyanming solution on visual function of glaucoma patient
Wang Y; Qiu B; Zhang C-X; Ou Y; Pang L; Li Z-P
Chinese Ophthalmic Research 2010; 28: 1087-1090 (IGR: 13-1)


28035 Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors
Fang X; Chen YT; Sessions EH; Chowdhury S; Vojkovsky T; Yin Y; Pocas JR; Grant W; Schroter T; Lin L
Bioorganic and Medicinal Chemistry Letters 2011; 21:1844-1848 (IGR: 13-1)


28165 Use of calcium channel blockers for glaucoma
Araie M; Mayama C
Progress in Retinal and Eye Research 2011; 30: 54-71 (IGR: 13-1)


27758 Quercetin Induces the Expression of Peroxiredoxins 3 and 5 via the Nrf2/NRF1 Transcription Pathway
Miyamoto N; Izumi H; Miyamoto R; Kondo H; Tawara A; Sasaguri Y; Kohno K
Investigative Ophthalmology and Visual Science 2011; 52: 1055-1063 (IGR: 13-1)


28181 Emerging drugs for ocular hypertension
Lee AJ; Goldberg I
Expert Opinion on Emerging Drugs 2011; 16: 137-161 (IGR: 13-1)


28222 Role of nitric oxide in the regulation of intraocular pressure: A possibility for glaucoma treatment
Vapaatalo H; Kotikoski H; Oksala O
Expert Review of Ophthalmology 2010; 5: 751-758 (IGR: 13-1)


28185 Future possibilities in glaucoma therapy
Wierzbowska J; Robaszkiewicz J; Figurska M; Stankiewicz A
Case Reports and Clinical Practice Review 2010; 16: 252-259 (IGR: 13-1)


27737 Effects of Fasudil, a Rho-Associated Protein Kinase Inhibitor, on Optic Nerve Head Blood Flow in Rabbits
Sugiyama T; Shibata M; Kajiura S; Okuno T; Tonari M; Oku H; IkedaT
Investigative Ophthalmology and Visual Science 2011; 52: 64-69 (IGR: 13-1)


28215 Potential for serotonergic agents to treat elevated intraocular pressure and glaucoma: Focus on 5-HT(2) receptor agonists
Sharif NA; May JA
Expert Review of Ophthalmology 2011; 6: 105-120 (IGR: 13-1)


28227 Prevention of filtering surgery failure by subconjunctival injection of a novel peptide hydrogel into rabbit eyes
Liang L; Xu XD; Zhang XZ; Feng M; Peng C; Jiang FG
Biomedical Materials 2010; 5: 045008) (IGR: 13-1)


28229 Therapeutic potential of new hydrogen sulfide-releasing hybrids
Sparatore A; Santus G; Giustarini D; Rossi R; Del Soldato P
Expert Review of Clinical Pharmacology 2011; 4: 109-121 (IGR: 13-1)


27957 A potential new therapeutic system for glaucoma: Solid lipid nanoparticles containing methazolamide
Li R; Jiang S; Liu D; Bi X; Wang F; Zhang Q; Xu Q
Journal of Microencapsulation 2011; 28: 134-141 (IGR: 13-1)


28209 Ophthalmic drug-loaded N,O-carboxymethyl chitosan hydrogels: Synthesis, in vitro and in vivo evaluation
Yang L-Q; Lan Y-Q; Guo H; Cheng L-Z; Fan J-Z; Cai X; Zhang L-M; Chen R-F; Zhou H-S
Acta Pharmacologica Sinica 2010; 31: 1625-1634 (IGR: 13-1)


27265 Sulbutiamine counteracts trophic factor deprivation induced apoptotic cell death in transformed retinal ganglion cells
Kang KD; Abdul Majid AS; Kim K-A; Kang K; Ahn HR; Nho CW; Jung SH
Neurochemical Research 2010; 35: 1828-1839 (IGR: 12-4)


27496 Topical administration of adrenergic receptor pharmaceutics and nerve growth factor
Steinle JJ
Clinical Ophthalmology 2010; 4: 605-610 (IGR: 12-4)


27222 Synthesis, characterization and antiglaucoma activity of some novel pyrazole derivatives of 5-amino-1,3,4-thiadiazole-2-sulfonamide
Kasmoullar R; Bulbul M; Arslan BS; Goke B
European Journal of Medicinal Chemistry 2010; 45: 4769-4773 (IGR: 12-4)


26972 Intravitreal Injections of Neurotrophic Factors Secreting Mesenchymal Stem Cells Are Neuroprotective in Rat Eyes following Optic Nerve Transection.
Levkovitch-Verbin H; Sadan O; Vander S; Rosner M; Barhum Y; Melamed E; Offen D; Melamed S
Investigative Ophthalmology and Visual Science 2010; 51: 6394-6400 (IGR: 12-4)


27635 Calcium channel blockers: Their use in normal tension glaucoma
Mozaffarieh M; Konieczka K; Flammer J
Expert Review of Ophthalmology 2010; 5: 617-625 (IGR: 12-4)


27492 Mirtogenol((registered trademark)) potentiates latanoprost in lowering intraocular pressure and improves ocular blood flow in asymptomatic subjects
Steigerwalt Jr RD; Belcaro G; Morazzoni P; Bombardelli E; Burki C; Schonlau F
Clinical Ophthalmology 2010; 4: 471-476 (IGR: 12-4)


27577 An agonistic TrkB mAb causes sustained TrkB activation, delays RGC death, and protects the retinal structure in optic nerve axotomy and in glaucoma
Bai Y; Xu J; Brahimi F; Zhuo Y; Sarunic MV; Saragovi HU
Investigative ophthalmology & visual science 2010; 51: 4722-4731 (IGR: 12-4)


26983 TRPC6 channel protects retinal ganglion cells in a rat model of retinal ischemia/reperfusion-induced cell death.
Wang X; Teng L; Li A; Ge J; Laties AM; Zhang X
Investigative Ophthalmology and Visual Science 2010; 51: 5751-5758 (IGR: 12-4)


27070 Neuroprotection by acetoacetate and ?-hydroxybutyrate against NMDA-induced RGC damage in rat--possible involvement of kynurenic acid.
Thaler S; Choragiewicz TJ; Rejdak R; Fiedorowicz M; Turski WA; Tulidowicz-Bielak M; Zrenner E; Schuettauf F; Zarnowski T
Graefe's Archive for Clinical and Experimental Ophthalmology 2010; 248: 1729-1735 (IGR: 12-4)


27274 Hypotensive action of naturally occurring diterpenes: A therapeutic promise for the treatment of hypertension
Tirapelli CR; Ambrosio SR; De Oliveira AM; Tostes RC
Fitoterapia 2010; 81: 690-702 (IGR: 12-4)


27319 Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-(beta)-cyclodextrin in rabbit
Ito Y; Nagai N; Shimomura Y
Biological & Pharmaceutical Bulletin 2010; 33: 1574-1578 (IGR: 12-4)


27275 Therapeutic targets for glaucoma
Sorbera LA; Aravamudan J; Dulsat C; Rosa E
Drugs of the Future 2010; 35: 585-592 (IGR: 12-4)


27365 Effect of topically applied moxonidine on intraocular pressure and blood pressure
Zhang Q; Sun N-X; Liu J
Chinese Ophthalmic Research 2010; 28: 611-615 (IGR: 12-4)


27220 Isoquercitrin is the most effective antioxidant in the plant Thuja orientalis and able to counteract oxidative-induced damage to a transformed cell line (RGC-5 cells)
Jung SH; Kim BJ; Lee EH; Osborne NN
Neurochemistry International 2010; 57: 713-721 (IGR: 12-4)


27650 Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action
Sharif NA
Current Drug Targets 2010; 11: 978-993 (IGR: 12-4)


27410 Efficacy and tolerability of topical 0.05% flunarizine in patients with open-angle glaucoma or ocular hypertension-a pilot study
Mansouri K; Silva SE; Shaarawy T
Journal of Glaucoma 2010; (IGR: 12-4)


27029 Sodium orthovanadate effect on outflow facility and intraocular pressure in live monkeys.
Tan JC; Kiland JA; Gonzalez JM; Gabelt BT; Peters DM; Kaufman PL
Experimental Eye Research 2010; 91: 486-490 (IGR: 12-4)


26974 Potentiation of Bortezomib-Induced Apoptosis by TGF-{beta} in Cultured Human Tenon's Fibroblasts: Contribution of the PI3K/Akt Signaling Pathway.
Chung EJ; Moon SW; Jung SA; Cho YJ; Kim SW; Lee JH
Investigative Ophthalmology and Visual Science 2010; 51: 6232-6237 (IGR: 12-4)


27033 The effect of adjuvant dimethylenastron, a mitotic Kinesin eg5 inhibitor, in experimental glaucoma filtration surgery.
Lüke J; Nassar K; Lüke M; Tura A; Merz H; Giannis A; Grisanti S
Current Eye Research 2010; 35: 1090-1098 (IGR: 12-4)


27572 Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis
Klocek MS; Sassani JW; Donahue RN; McLaughlin PJ; Zagon IS
Investigative ophthalmology & visual science 2010; 51: 5054-5061 (IGR: 12-4)


26425 Cyclooxygenase-2 and tissue inhibitor of matrix metalloproteinases-1 confer the antimigratory effect of cannabinoids on human trabecular meshwork cells
Ramer R; Hinz B
Biochemical Pharmacology 2010; 80: 846-857 (IGR: 12-3)


26369 In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells
Kahook MY; Ammar DA
Journal of Glaucoma 2010; 19: 437-441 (IGR: 12-3)


26446 The calcineurin inhibitor, FK506, does not alter glutamate transport in the ischaemic mouse retina
Holcombe DJ; Gole GA; Barnett NL
Experimental Eye Research 2010; 91: 315-319 (IGR: 12-3)


26382 Dietary deficiency of vitamin E aggravates retinal ganglion cell death in experimental glaucoma of rats
Ko ML; Peng PH; Hsu SY; Chen CF
Current Eye Research 2010; 35: 842-849 (IGR: 12-3)


26332 The effect of ginkgo biloba on the rat retinal ganglion cell survival in the optic nerve crush model
Ma K; Xu L; Zhang H; Zhang S; Pu M; Jonas JB
Acta Ophthalmologica 2010; 88: 553-557 (IGR: 12-3)


26315 Neuroprotective effects of C-type natriuretic peptide on rat retinal ganglion cells
Ma J; Yu W; Wang Y; Cao G; Cai S; Chen X; Yan N; Yuan Y; Zeng H; Fleenor DL
Investigative Ophthalmology and Visual Science 2010; 51: 3544-3553 (IGR: 12-3)


26391 Retinal protection from acute glaucoma-induced ischemia-reperfusion injury through pharmacologic induction of heme oxygenase-1
Sun MH; Pang JH; Chen SL; Han WH; Ho TC; Chen KJ; Kao LY; Lin KK; Tsao YP
Investigative Ophthalmology and Visual Science 2010; 51: 4798-4808 (IGR: 12-3)


26869 Protective effects of nerve regeneration factor and brain-derived neurotrophic factor on retinal ganglion cells in a rabbit model of acute hyper-intraocular pressure
Huang Z; Guan H; Ding F; Gu X
Neural Regeneration Research 2010; 5: 445-449 (IGR: 12-3)


26777 Gene delivery of erythropoietin protects retinal ganglion cells in DBA/2J glaucomatous mice
Sullivan TA; Geisert EE; Rex TS
Molecular Therapy 2010; 18: S171 (IGR: 12-3)


26880 Pharmacology of pre-versus postsynaptic A(2)-adrenoceptors
Hein L; Gilsbach R; Haubold M; Albarran-Juarez J; Schneider J
Basic and Clinical Pharmacology and Toxicology 2010; 107: 42-43 (IGR: 12-3)


26825 Effect of Latrunculin-B on rabbit uveoscleral outflow
Li W-G; He X-Z
International Journal of Ophthalmology 2010; 10: 1277-1280 (IGR: 12-3)


26878 Focused Conference Group: P02 - Transmembrane transport: Perspectives for disease and drug discovery calcium signal passway-based on to research the neuroprotection of effective components of traditional chinese medicine
Zhang Y; Lai X; Zhang J
Basic and Clinical Pharmacology and Toxicology 2010; 107: 687 (IGR: 12-3)


26439 Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits
Mehta A; Iyer L; Parmar S; Shah G; Goyal R
Canadian Journal of Physiology and Pharmacology 2010; 88: 595-600 (IGR: 12-3)


26829 Protective effect of Ginaton and fleabane on retinal ganglion cells
Wang M-L; Fei Z-G; Li H; He M-N
International Journal of Ophthalmology 2010; 10: 850-852 (IGR: 12-3)


26771 An overview of satavaptan: A selective V2 receptor antagonist
Farah J; Daifallah S; Zmily H; Ghali JK
Therapy 2010; 7: 409-422 (IGR: 12-3)


26752 Association for research in vision and ophthalmology (ARVO) - 2010 annual meeting. for sight: The future of eye and vision research - Part 2
Hookes L
Idrugs 2010; 13: 430-432 (IGR: 12-3)


26460 Tetrahydroisoquinoline derivatives as highly selective and potent rho kinase inhibitors
Fang X; Yin Y; Chen YT; Yao L; Wang B; Cameron MD; Lin L; Khan S; Ruiz C; Schroter T
Journal of Medicinal Chemistry 2010; 53: 5727-5737 (IGR: 12-3)


26751 Association for research in vision and ophthalmology (ARVO) - 2010 annual meeting. for sight: The future of eye and vision research - Part 1
Hookes L
Idrugs 2010; 13: 427-429 (IGR: 12-3)


26905 Discovery of potent and selective urea-based ROCK inhibitors and their effects on intraocular pressure in rats
Yin Y; Cameron MD; Lin L; Khan S; Schroter T; Grant W; Pocas J; Chen YT; Schurer S; Pachori A
ACS Medicinal Chemistry Letters 2010; 1: 175-179 (IGR: 12-3)


26623 Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma
Davis RL; Kahraman M; Prins TJ; Beaver Y; Cook TG; Cramp J; Cayanan CS; Gardiner EMM; McLaughlin MA; Clark AF
Bioorganic and Medicinal Chemistry Letters 2010; 20: 3361-3366 (IGR: 12-3)


26775 Numerical simulations of ethacrynic acid transport from precorneal region to trabecular meshwork
Lin CW; Yuan F
Annals of Biomedical Engineering 2010; 38: 935-944 (IGR: 12-3)


26049 Effects of recombinant human erythropoietin on hypoxia inducible factor-1alpha expression in the retina of rabbits with acute high intraocular pressure
Wang JM; Song YP; Sun NX; Hui N; Zhao SP; Hu K
Journal of Southern Medical University 2009; 29: 271-273 (IGR: 12-2)


25750 Melatonin: A novel neuroprotectant for the treatment of glaucoma
Belforte NA; Moreno MC; de Zavalia N; Sande PH; Chianelli MS; Keller Sarmiento MI; Rosenstein RE
Journal of Pineal Research 2010; 48: 353-364 (IGR: 12-2)


25948 Neuroprotective effects of bis(7)-tacrine against glutamate-induced retinal ganglion cells damage
Fang JH; Wang XH; Xu ZR; Jiang FG
BMC Neuroscience 2010; 11: 31 (IGR: 12-2)


26055 Diadenosine tetraphosphate protects sympathetic terminals from 6-hydroxydopamine-induced degeneration in the eye
Hoyle CHV; Pintor JJ
Acta Physiologica 2010; 199: 205-210 (IGR: 12-2)


25830 Copolymer-1 immunization reduces damage in retinal ganglion cells under high intraocular pressure through altering the expression of retinal neurotrophins
Yang B; Shan L; Song W; Xiao Z; Shi L; Yuan H
Journal of Ocular Pharmacology and Therapeutics 2010; 26: 11-19 (IGR: 12-2)


25839 A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma
Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WKM; Gale DC; Kucera DJ
Journal of Ocular Pharmacology and Therapeutics 2010; 26: 125-131 (IGR: 12-2)


25994 Rescue of glaucoma-causing mutant myocilin thermal stability by chemical chaperones
Burns JN; Orwig SD; Harris JL; Watkins JD; Vollrath D; Lieberman RL
ACS Chemical Biology 2010; 5: 477-487 (IGR: 12-2)


25768 Interaction of endocannabinoid receptors with biological membranes
Dainese E; Oddi S; Maccarrone M
Current Medicinal Chemistry 2010; 17: 1487-1499 (IGR: 12-2)


25658 2-MeS-(beta),(gamma)-CCl(2)-ATP is a potent agent for reducing intraocular pressure
Eliahu S; Martin-Gil A; Perez De Lara MJ; Pintor J; Camden J; Weisman GA; Lecka J; Sevigny J; Fischer B
Journal of Medicinal Chemistry 2010; 53: 3305-3319 (IGR: 12-2)


25834 Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN((registered trademark)) or TRAVATAN((registered trademark))
Faulkner R; Sharif NA; Orr S; Sall K; DuBiner H; Whitson JT; Moster M; Craven ER; Curtis M; Pailliotet C
Journal of Ocular Pharmacology and Therapeutics 2010; 26: 147-156 (IGR: 12-2)


25648 Advances in eicosanoid research, novel therapeutic implications
Haeggstrom JZ; Rinaldo-Matthis A; Wheelock CE; Wetterholm A
Biochemical and Biophysical Research Communications 2010; 396: 135-139 (IGR: 12-2)


25987 Effect of the Age Cross-Link Breaker Alagebrium on Anterior Segment Physiology, Morphology, and Ocular Age and Rage
Kiland JA; Gabelt BT; Tezel G; Lutjen-Drecoll E; Kaufman PL
Transactions of the American Ophthalmological Society 2009; 107: 146-158 (IGR: 12-2)


26277 Enalaprilat and enalapril maleate eyedrops lower intraocular pressure in rabbits
Loftsson T; Thorisdóttir S; Fridriksdóttir H; Stefánsson E
Acta Ophthalmologica 2010; 88: 337-341 (IGR: 12-2)


26057 Design and application of locally delivered agonists of the adenosine A(2A) receptor
Mantell S; Jones R; Trevethick M
Expert Review of Clinical Pharmacology 2010; 3: 55-72 (IGR: 12-2)


26030 Effects of bushenhuoxue on protecting the visual function of rat with chronic intraocular hypertension
Mao X; Li X
International Journal of Ophthalmology 2010; 10: 238-240 (IGR: 12-2)


25737 New developments in glaucoma medical treatment
Munoz-Negrete FJ; Perez-Lopez M; Won Kim HR; Rebolleda G
Archivos de la Sociedad Española de Oftalmologia 2009; 84: 491-500 (IGR: 12-2)


25817 Intraocular hypotensive effect and action on aqueous humor dynamics of (alpha)-ergocryptine in ocular normotensive and in (alpha)-chymotrypsin-induced ocular hypertensive rabbits
Puras G; Garcia VB; Rivera G
Revista Mexicana de Ciencias Farmaceuticas 2009; 40: 22-29 (IGR: 12-2)


25783 The development of benzimidazoles as selective rho kinase inhibitors
Sessions EH; Smolinski M; Wang B; Frackowiak B; Chowdhury S; Yin Y; Chen YT; Ruiz C; Lin L; Pocas J
Bioorganic and Medicinal Chemistry Letters 2010; 20: 1939-1943 (IGR: 12-2)


25828 A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of tafluprost compared with latanoprost
Traverso CE; Ropo A; Papadia M; Uusitalo H
Journal of Ocular Pharmacology and Therapeutics 2010; 26: 97-104 (IGR: 12-2)


25785 Thioether benzenesulfonamide inhibitors of carbonic anhydrases II and IV: Structure-based drug design, synthesis, and biological evaluation
Vernier W; Chong W; Rewolinski D; Greasley S; Pauly T; Shaw M; Dinh D; Ferre RA; Nukui S; Ornelas M
Bio-organic and Medicinal Chemistry 2010; 18: 3307-3319 (IGR: 12-2)


25832 A pilot study for the effects of donepezil therapy on cerebral and optic nerve head blood flow, visual field defect in normal-tension glaucoma
Yoshida Y; Sugiyama T; Utsunomiya K; Ogura Y; Ikeda T
Journal of Ocular Pharmacology and Therapeutics 2010; 26: 187-192 (IGR: 12-2)


25674 Methazolamide calcium phosphate nanoparticles in an ocular delivery system
Chen R; Qian Y; Li R; Zhang Q; Liu D; Wang M; Xu Q
Yakugaku Zasshi 2010; 130: 419-424 (IGR: 12-2)


25761 Preparation and evaluation of a contact lens vehicle for puerarin delivery
Xu J; Li X; Sun F
Journal of Biomaterials Science, Polymer Edition 2010; 21: 271-288 (IGR: 12-2)


25918 Diclofenac prevents temporal increase of intraocular pressure after uneventful cataract surgery with longer operation time
Shimura M; Nakazawa T; Yasuda K; Shiono T; Nishida K
Clinical Ophthalmology 2009; 3: 95-101 (IGR: 12-2)


25021 Effects of chemical inhibition of N-WASP, a critical regulator of actin polymerization on aqueous humor outflow through the conventional pathway
Inoue T; Pattabiraman PP; Epstein DL; Vasantha Rao P
Experimental Eye Research 2010; 90: 360-367 (IGR: 12-1)


25217 Episcleral Venous Pressure Responses to Topical Nitroprusside and N-Nitro-L-arginine Methyl Ester
Zamora DO; Kiel JW
Investigative Ophthalmology and Visual Science 2010; 51: 1614-1620 (IGR: 12-1)


25584 Modulation of morphological changes of microglia and neuroprotection by monocyte chemoattractant protein-1 in experimental glaucoma
Chiu K; Yeung S -C; So K -F; Chang R C -C
Cellular and Molecular Immunology 2010; 7: 61-68 (IGR: 12-1)


25148 ACS67, a hydrogen sulfide-releasing derivative of latanoprost acid, attenuates retinal ischemia and oxidative stress to RGC-5 cells in culture
Osborne NN; Ji D; Abdul Majid AS; Fawcett RJ; Sparatore A; Del Soldato P
Investigative Ophthalmology and Visual Science 2010; 51: 284-294 (IGR: 12-1)


25077 Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species
Wang Z; Do CW; Avila MY; Peterson-Yantorno K; Stone RA; Gao ZG; Joshi B; Besada P; Jeong LS; Jacobson KA
Experimental Eye Research 2010; 90: 146-154 (IGR: 12-1)


25187 Reduced myocilin expression in cultured monkey trabecular meshwork cells induced by a selective glucocorticoid receptor agonist: comparison with steroids
Pfeffer BA; DeWitt CA; Salvador-Silva M; Cavet ME; López FJ; Ward KW
Investigative Ophthalmology and Visual Science 2010; 51: 437-446 (IGR: 12-1)


25583 Effects of qingguangan on retinal structure and apoptosis in rabbit eyes with acute ocular hypertension
Dong C -X; Peng J; Peng Q -H; Zeng Z -C
International Journal of Ophthalmology 2010; 10: 51-54 (IGR: 12-1)


25543 Effect of orally administered zingiber officinale on the intra ocular pressure of experimental rabbits
Akpalaba R U E; Agu G C; Adeleke O O; Asonye C C
International Journal of Health Research 2009; 2: 273-278 (IGR: 12-1)


25572 Experimental study on the protective effects of qingguangan granule on optic nerve axons in rabbit eyes with acute ocular hypertension
Zhao H -B; Peng Q -H; Wu Q -L; Zeng Z -C
International Journal of Ophthalmology 2009; 9: 2318-2321 (IGR: 12-1)


25393 The effect of forskolin ophthalmic inserts on intraocular pressure in rabbit eyes
Wagh V D; Wagh K V; Inamdar B; Samanta M K
International Journal of Pharmacy and Pharmaceutical Sciences 2009; 146-155 (IGR: 12-1)


25180 Combined application of BDNF to the eye and brain enhances ganglion cell survival and function in the cat after optic nerve injury
Weber AJ; Viswanáthan S; Ramanathan C; Harman CD
Investigative Ophthalmology and Visual Science 2010; 51: 327-334 (IGR: 12-1)


25570 Experimental study about the effect of qingguangan suspel on the structure and function of lamina cribrosa in rabbit eye with chronic hypertension
Li X -J; Peng Q -H; Zeng Z -C; Li J -C
International Journal of Ophthalmology 2009; 9: 2310-2314 (IGR: 12-1)


25202 The effect of oral magnesium therapy on visual field and ocular blood flow in normotensive glaucoma
Aydin B; Onol M; Hondur A; Kaya MG; Ozdemir H; Cengel A; Hasanreisoglu B
European Journal of Ophthalmology 2010; 20: 131-135 (IGR: 12-1)


25513 Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
Holland E J; Djalilian A R; Sanderson J P
Cornea 2009; 28: 1139-1143 (IGR: 12-1)


25158 Protection of retinal ganglion cells by caspase substrate-binding peptide IQACRG from N-methyl-D-aspartate receptor-mediated excitotoxicity
Seki M; Soussou W; Manabe S; Lipton SA
Investigative Ophthalmology and Visual Science 2010; 51: 1198-1207 (IGR: 12-1)


25022 Triamcinolone attenuates macrophage/microglia accumulation associated with NMDA-induced RGC death and facilitates survival of Müller stem cell grafts
Singhal S; Lawrence JM; Salt TE; Khaw PT; Limb GA
Experimental Eye Research 2010; 90: 308-315 (IGR: 12-1)


25168 Stimulation of axon regeneration in the mature optic nerve by intravitreal application of the toll-like receptor 2 agonist Pam3Cys
Hauk TG; Leibinger M; Müller A; Andreadaki A; Knippschild U; Fischer D
Investigative Ophthalmology and Visual Science 2010; 51: 459-464 (IGR: 12-1)


25179 Valproic acid-mediated neuroprotection and regeneration in injured retinal ganglion cells
Biermann J; Grieshaber P; Goebel U; Martin G; Thanos S; Di Giovanni S; Lagrèze WA
Investigative Ophthalmology and Visual Science 2010; 51: 526-534 (IGR: 12-1)


25367 NBCe1 (Slc4A4) functional dimer assembly
Chang M; Holmes H L; Ranatunga W K; Chen A; Romero M F
FASEB Journal 2009; 23: S1 (IGR: 12-1)


25351 Nucleoside-based adenosine A(3) receptor antagonists as drug candidates
Tosh D K; Jacobson K A; Jeong L S
Drugs of the Future 2009; 34: 43-52 (IGR: 12-1)


25392 Synthesis, characterization and antiglaucoma activity of a novel proton transfer compound and a mixed-ligand Zn(II) complex
Yenikaya C; Sari M; Bulbul M; Ilkimen H; Celik H; Buyukgungor O
Bio-organic and Medicinal Chemistry 2010; 18: 930-938 (IGR: 12-1)


25282 The possibility of selective Rho-associated kinase (ROCK) inhibitors as a medical treatment for glaucoma
Honjo M
Nippon Ganka Gakkai Zasshi 2009; 113: 1071-1081 (IGR: 12-1)


25142 Future target molecules in antiglaucoma therapy: tgf-Beta may have a role to play
Agarwal R; Agarwal P
Ophthalmic Research 2010; 3: 1-10 (IGR: 12-1)


25390 Nitric oxide-donating carbonic anhydrase inhibitors for the treatment of open-angle glaucoma
Steele R M; Benedini F; Biondi S; Borghi V; Carzaniga L; Impagnatiello F; Miglietta D; Chong W K M; Rajapakse R; Cecchi A
Bioorganic and Medicinal Chemistry Letters 2009; 19: 6565-6570 (IGR: 12-1)


25420 Comparative study of topical application of timolol and verapamil in patients with glaucoma within 6 months
Shayegan M R; Boloorian A A; Kianoush S
Journal of Ocular Pharmacology and Therapeutics 2009; 25: 551-553 (IGR: 12-1)


25345 Limited restoration of visual function after partial optic nerve injury; a time course study using the calcium channel blocker lomerizine
Selt M; Bartlett C A; Harvey A R; Dunlop S A; Fitzgerald M
Brain Research Bulletin 2010; 81: 467-471 (IGR: 12-1)


25388 3D-QSAR and docking studies on transforming growth factor (TGF)-(beta) receptor 1 antagonists
Geldenhuys W J; Nakamura H
Bioorganic and Medicinal Chemistry Letters 2010; 20: 1918-1923 (IGR: 12-1)


25389 2,3-Diaminopyrazines as rho kinase inhibitors
Henderson A J; Hadden M; Guo C; Douglas N; Decornez H; Hellberg M R; Rusinko A; McLaughlin M; Sharif N; Drace C
Bioorganic and Medicinal Chemistry Letters 2010; 20: 1137-1140 (IGR: 12-1)


25540 Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists.
Gerra G; Zaimovic A; Gerra M L; Ciccocioppo R; Cippitelli A; Serpelloni G; Somaini L
Recent Patents on CNS Drug Discovery 2010; 5: 46-52 (IGR: 12-1)


25258 Characterization of a novel non-steroidal glucocorticoid receptor antagonist
Li Q -Y; Zhang M; Hallis T M; DeRosier T A; Yue J -M; Ye Y; Mais D E; Wang M -W
Biochemical and Biophysical Research Communications 2010; 391: 1531-1536 (IGR: 12-1)


25512 Dual-Drug Delivery System Based on In Situ Gel-Forming Nanosuspension of Forskolin to Enhance Antiglaucoma Efficacy
Gupta S; Samanta M K; Raichur A M
AAPS PharmSciTech 2010; 1-14 (IGR: 12-1)


25093 Effects of postoperative cyclosporine ophthalmic emulsion 0.05% (Restasis) following glaucoma surgery
Fakhraie G; Lopes JF; Spaeth GL; Almodin J; Ichhpujani P; Moster MR
Clinical and Experimental Ophthalmology 2009; 37: 842-848 (IGR: 12-1)


25453 Intravitreal injection of tissue plasminogen activator as treatment for an occluded pars plana glaucoma tube
Tsui I; Airiani S; Wen A; El-Sawy T; Fine H F; Maris Jr P J G
Clinical Ophthalmology 2009; 3: 91-93 (IGR: 12-1)


25044 Paclitaxel inhibits growth, migration and collagen production of human Tenon's fibroblasts--potential use in drug-eluting glaucoma drainage devices
Choritz L; Grub J; Wegner M; Pfeiffer N; Thieme H
Graefe's Archive for Clinical and Experimental Ophthalmology 2010; 248: 197-206 (IGR: 12-1)


25398 Inhibitory effect of tetrandrine on the apoptosis of cultured human Tenon's capsule fibroblasts
Li D; Yang L; Lin S; Kaili W
Chinese Ophthalmic Research 2010; 28: 1-4 (IGR: 12-1)


25401 The prevention effect of pyrrolidine dithiocarbamate against scarring of filtering bleb in rats
Li X; Ma J; Wang N
Chinese Ophthalmic Research 2009; 27: 858-862 (IGR: 12-1)


25049 Antifibrotic effects of tocotrienols on human Tenon's fibroblasts
Tappeiner C; Meyenberg A; Goldblum D; Mojon D; Zingg JM; Nesaretnam K; Kilchenmann M; Frueh BE
Graefe's Archive for Clinical and Experimental Ophthalmology 2010; 248: 65-71 (IGR: 12-1)


24941 Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma
Yang H; Hirooka K; Fukuda K; Shiraga F
Investigative Ophthalmology and Visual Science 2009; 50: 5800-5804 (IGR: 11-4)


24835 Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models
Prasanna G; Fortner J; Xiang C; Zhang E; Carreiro S; Anderson S; Sartnurak S; Wu G; Gukasyan H; Niesman M
Experimental Eye Research 2009; 89: 608-617 (IGR: 11-4)


24950 Effect of systemic moxaverine on ocular blood flow in humans
Resch H; Weigert G; Karl K; Pemp B; Garhofer G; Schmetterer L
Acta Ophthalmologica 2009; 87: 731-735 (IGR: 11-4)


24626 Evaluation of a new lead for acetylcholinesterase inhibition
Khorana N; Markmee S; Ingkaninan K; Ruchirawat S; Kitbunnadaj R; Pullagurla MR
Medicinal Chemistry Research 2009; 18: 231-241 (IGR: 11-4)


24832 Secondary retinal ganglion cell death and the neuroprotective effects of the calcium channel blocker lomerizine
Fitzgerald M; Payne SC; Bartlett CA; Evill L; Harvey AR; Dunlop SA
Investigative Ophthalmology and Visual Science 2009; 50: 5456-5462 (IGR: 11-4)


24522 Neuroprotective effects of 5-S-GAD against oxidative stress-induced apoptosis in RGC-5 cells
Koriyama Y; Ohno M; Kimura T; Kato S
Brain Research 2009; 1296: 187-195 (IGR: 11-4)


24669 Endocannabinoid system: Emerging role from neurodevelopment to neurodegeneration
Basavarajappa BS; Nixon RA; Arancio O
Mini Reviews in Medicinal Chemistry 2009; 9: 448-462 (IGR: 11-4)


24715 Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications
Galal AM; Slade D; Gul W; El-Alfy AT; Ferreira D; Elsohly MA
Recent Patents on CNS Drug Discovery 2009; 4: 112-136 (IGR: 11-4)


24538 Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma
Harrison BA; Whitlock NA; Voronkov MV; Almstead ZY; Gu K-J; Mabon R; Gardyan M; Hamman BD; Allen J; Gopinathan S
Journal of Medicinal Chemistry 2009; 52: 6515-6518 (IGR: 11-4)


24756 Effect of dual endothelin receptor blockade on ocular blood flow in patients with glaucoma and healthy subjects
Garhofer G; Resch H; Wolzt M; Schmetterer L
Basic and Clinical Pharmacology and Toxicology 2009; 105 42 (IGR: 11-4)


24551 Intraocular pressure-lowering activity of topical application of Aegle marmelos fruit extract in experimental animal models
Agarwal R; Gupta SK; Srivastava S; Saxena R; Agrawal SS
Ophthalmic Research 2009; 42: 112-116 (IGR: 11-4)


24671 Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity
Hahmann C; Schroeter T
Cellular and Molecular Life Sciences 2009; 1-7 (IGR: 11-4)


24676 (alpha)-Luminol prevents decreases in glutamate, glutathione, and glutamine synthetase in the retinas of glaucomatous DBA/2J mice
Gionfriddo JR; Freeman KS; Groth A; Scofield VL; Alyahya K; Madl JE
Veterinary Ophthalmology 2009; 12: 325-332 (IGR: 11-4)


24770 BMP-7: Therapeutic target for ocular fibrotic disorders
Wang J-Y; Han G-g; Wang J; Mei H-F; Yang A-H
Bioscience Hypotheses 2009; 2: 413-416 (IGR: 11-4)


24755 Mitochondria-targeted rechargeable antioxidant SkQ1 prevents senescence in mammals
Skulachev V
FEBS Journal 2009; 276 35-36 (IGR: 11-4)


24119 Effects of platelet-derived growth factor on aqueous humor dynamics
Syriani E; Cuesto G; Abad E; Pelaez T; Gual A; Pintor J; Morales M; Gasull X
Investigative Ophthalmology and Visual Science 2009; 50: 3833-3839 (IGR: 11-3)


24068 Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow
Woodward DF; Nilsson SF; Toris CB; Kharlamb AB; Nieves AL; Krauss AH
Investigative Ophthalmology and Visual Science 2009; 50: 3320-3328 (IGR: 11-3)


24164 Analysis of alpha2-adrenergic receptors and effect of brimonidine on matrix metalloproteinases and their inhibitors in human ciliary body
Ooi YH; Oh DJ; Rhee DJ
Investigative Ophthalmology and Visual Science 2009; 50: 4237-4243 (IGR: 11-3)


24112 Cyclic mechanical stress and trabecular meshwork cell contractility
Ramos RF; Sumida GM; Stamer WD
Investigative Ophthalmology and Visual Science 2009; 50: 3826-3832 (IGR: 11-3)


24443 Effect of serum containing qingguang'an grains on pressurized human trabecular cells activity
Peng Q-H; Zeng Z-C; Li B; Zhuo Y-H
International Journal of Ophthalmology 2009; 9: 839-842 (IGR: 11-3)


24011 Correction of the disease phenotype of myocilin-causing glaucoma by a natural osmolyte
Jia LY; Gong B; Pang CP; Huang Y; Lam DS; Wang N; Yam GH
Investigative Ophthalmology and Visual Science 2009; 50: 3743-3749 (IGR: 11-3)


24485 Melatonin modulates visual function and cell viability in the mouse retina via the MT1 melatonin receptor
Baba K; Pozdeyev N; Mazzoni F; Contreras-Alcantara S; Liu C; Kasamatsu M; Martinez-Merlos T; Strettoi E; Iuvone PM; Tosini G
Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 15043-15048 (IGR: 11-3)


24156 Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: a short-term study by pattern electroretinogram
Falsini B; Marangoni D; Salgarello T; Stifano G; Montrone L; Di Landro S; Guccione L; Balestrazzi E; Colotto A
Graefe's Archive for Clinical and Experimental Ophthalmology 2009; 247: 1223-1233 (IGR: 11-3)


24387 Both systemic and local application of Granulocyte-colony stimulating factor (G-CSF) is neuroprotective after retinal ganglion cell axotomy
Frank T; Schlachetzki JCM; Goricke B; Meuer K; Rohde G; Dietz GPH; Bahr M; Schneider A; Weishaupt JH
BMC Neuroscience 2009; 10: 49 (IGR: 11-3)


24268 Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma
Fu Q-L; Li X; Yip HK; Shao Z; Wu W; Mi S; So K-F
Neuroscience 2009; 162: 375-382 (IGR: 11-3)


24490 Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma
Lambiasea A; Aloe L; Centofanti M; Parisi V; Mantelli F; Colafrancesco V; Manni GL; Bucci MG; Bonini S; Levi-Montalcini R
Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 13469-13474 (IGR: 11-3)


24517 Pyroglutamic Acid Promotes Survival of Retinal Ganglion Cells after Optic Nerve Injury
Oono S; Kurimoto T; Nakazawa T; Miyoshi T; Okamoto N; Kashimoto R; Tagami Y; Ito Y; Mimura O
Current Eye Research 2009; 34: 598-605 (IGR: 11-3)


24080 Expression of prostaglandin PGE2 receptors under conditions of aging and stress and the protective effect of the EP2 agonist butaprost on retinal ischemia
Osborne NN; Li GY; Ji D; Andrade da Costa BL; Fawcett RJ; Kang KD; Rittenhouse KD
Investigative Ophthalmology and Visual Science 2009; 50: 3238-3248 (IGR: 11-3)


24343 Eyedrops containing SA9000 prodrugs result in sustained reductions in intraocular pressure in rabbits
Arnold JJ; Choksi Y; Chen X; Shimazaki A; Hatten J; Toone EJ; Epstein DL; Challa P
Journal of Ocular Pharmacology and Therapeutics 2009; 25: 179-186 (IGR: 11-3)


24203 Agmatine as retinal protection from ischemia-reperfusion injury in guinea pigs
Dastan A; Kocer I; Erdogan F; Ates O; KIzIltunc A
Japanese Journal of Ophthalmology 2009; 53: 219-224 (IGR: 11-3)


24304 The effect of H-1152 on IOP and trabecular meshwork structure in rabbit
Wang Y; Sun J; Cai S; Qiu J; Yu M; Cao G; Liu X; Li X
Chinese Ophthalmic Research 2009; 27: 453-456 (IGR: 11-3)


24238 Therapeutic applications of glycosidic carbonic anhydrase inhibitors
Winum J-Y; Poulsen S-A; Supuran CT
Medicinal Research Reviews 2009; 29: 419-435 (IGR: 11-3)


24122 Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro
Lin X; Yu M; Wu K; Yuan H; Zhong H
Investigative Ophthalmology and Visual Science 2009; 50: 3763-3770 (IGR: 11-3)


23667 Effect of moxonidine on the uveoscleral outflow: role of alpha2-adrenoceptors or i1 imidazoline receptors
Yang J; Sun N; Xiong Q; Yang R
Current Eye Research 2009; 34: 287-296 (IGR: 11-2)


23581 Pathophysiology of cyclooxygenase inhibition in animal models
Radi ZA
Toxicologic Pathology 2009; 37: 34-46 (IGR: 11-2)


23881 alpha-Crystallin Downregulates the Expression of TNF-alpha and iNOS by Activated Rat Retinal Microglia in vitro and in vivo
Wu N; Wang YH; Zhao HS; Liu DN; Ying X; Yin ZQ; Wang Y
Ophthalmic Research 2009; 42: 21-28 (IGR: 11-2)


23658 17Beta-estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
Russo R; Cavaliere F; Watanabe C; Nucci C; Bagetta G; Corasaniti MT; Sakurada S; Morrone LA
Progress in Brain Research 2008; 173:- 583-590 (IGR: 11-2)


23716 Histological protection by cilnidipine, a dual L/N-type Ca(2+) channel blocker, against neurotoxicity induced by ischemia-reperfusion in rat retina
Sakamoto K; Kawakami T; Shimada M; Yamaguchi A; Kuwagata M; Saito M; Nakahara T; Ishii K
Experimental Eye Research 2009; 88: 974-982 (IGR: 11-2)


23429 Lithium chloride protects retinal neurocytes from nutrient deprivation by promoting DNA non-homologous end-joining
Zhuang J; Li F; Liu X; Liu Z; Lin J; Ge Y; Kaminski JM; Summers JB; Wang Z; Ge J
Biochemical and Biophysical Research Communications 2009; 380: 650-654 (IGR: 11-2)


23492 New prostaglandin derivative for glaucoma treatment
Perrino E; Uliva C; Lanzi C; Soldato PD; Masini E; Sparatore A
Bioorganic and Medicinal Chemistry Letters 2009; 19: 1639-1642 (IGR: 11-2)


23590 Safety of intravitreally administered recombinant erythropoietin (an AOS thesis)
Tsai JC
Transactions of the American Ophthalmological Society 2008; 106:- 459-472 (IGR: 11-2)


23526 Alpha-tocopherol: Looking beyond an antioxidant
Engin KN
Molecular Vision 2009; 15:- 855-860 (IGR: 11-2)


23825 Antiglaucoma drug GLC756 and its effect on cellular cAMP and tumor necrosis factor alpha release in vitro of activated human monocytic leukemia cells
Laengle UW; Markstein R; Cazaubon C; Roman D
Japanese Journal of Ophthalmology 2009; 53: 159-163 (IGR: 11-2)


23605 New treatments for ocular hypertension
Mediero A; Alarma-Estrany P; Pintor J
Auton Neuroscience 2009; 147:-2 14-19 (IGR: 11-2)


23569 LA-419, a nitric-oxide donor for the treatment of cardiovascular disorders
Megson IL; Leslie SJ
Current Opinion in Investigational Drugs 2009; 10: 276-285 (IGR: 11-2)


23541 The aging eye and the role of L-carnitine and its derivatives
Pescosolido N; Imperatrice B; Karavitis P
Drugs in R&D 2008; 9 Suppl 1:- 3-14 (IGR: 11-2)


23793 Effects of some ophthalmic medications on pupil size: a literature review
Novitskaya ES; Dean SJ; Moore JE; Moore TC; Nagendran S; Sharma A
Canadian Journal of Ophthalmology 2009; 44: 193-197 (IGR: 11-2)


23666 The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes
Nishio M; Fukunaga T; Sugimoto M; Ikesugi K; Sumi K; Hidaka H; Uji Y
Current Eye Research 2009; 34: 282-286 (IGR: 11-2)


23872 Dietary Tocopherol Supplementation after Trabeculectomy and Phacotrabeculectomy: Double-Blind Randomized Placebo-Controlled Trial
Goldblum D; Meyenberg A; Mojon D; Tappeiner C; Frueh BE
Ophthalmologica 2009; 223: 226-230 (IGR: 11-2)


23957 SB-431542 inhibition of scar formation after filtration surgery and its potential mechanism
Xiao YQ; Liu K; Shen JF; Xu GT; Ye W
Investigative Ophthalmology and Visual Science 2009; 50: 1698-1706 (IGR: 11-2)


23823 Seprafilm as a new antifibrotic agent following trabeculectomy in rabbit eyes
Tsurumaru N; Arai M; Teruya K; Sueda J; Yamakawa R
Japanese Journal of Ophthalmology 2009; 53: 164-170 (IGR: 11-2)


23792 Diphenhydramine as a topical ocular anesthetic
Suffridge PJ; Wiggins MN; Landes RD; Harper RA
Canadian Journal of Ophthalmology 2009; 44: 181-184 (IGR: 11-2)


22717 Suppression of injury-induced conjunctiva scarring by peroxisome proliferator-activated receptor γ gene transfer in mice
Yamanaka O; Miyazaki K; Kitano A; Saika S; Nakajima Y; Ikeda K
Investigative Ophthalmology and Visual Science 2009; 50: 187-193 (IGR: 11-1)


23358 Rho-kinase, but not protein kinase C, is involved in generation of the spontaneous tone in the resting phase of the isolated pig iris sphincter muscle
Okano M; Uchikawa Y; Tanaka N; Mutoh J; Ohkura M; Hisa H; Yamamoto R
Current Eye Research 2009; 34: 177-183 (IGR: 11-1)


22778 Study on the influence of the treatment with some newly synthesized antiglaucoma prostamides on the hematological parameters on rats
Udeanu DI; Mihele D; Cocu F; Caraene G; Vulturescu V; Iova D
Farmacia 2008; 56: 669-674 (IGR: 11-1)


22905 Effect of WIN55, 212-2 on lowing rabbit IOP
Liu H; Wang W; Zhao J
Chinese Ophthalmic Research 2008; 26: 929-931 (IGR: 11-1)


22619 The effect of the Rho-associated protein kinase inhibitor, HA-1077, in the rabbit ocular hypertension model induced by water loading
Fukunaga T; Ikesugi K; Nishio M; Sugimoto M; Sasoh M; Hidaka H; Uji Y
Current Eye Research 2009; 34: 42-47 (IGR: 11-1)


22610 A water-soluble carbon monoxide-releasing molecule (CORM-3) lowers intraocular pressure in rabbits
Stagni E; Privitera MG; Bucolo C; Leggio GM; Motterlini R; Drago F
British Journal of Ophthalmology 2009; 93: 254-257 (IGR: 11-1)


22816 Effect of vasoactive drugs on visual functions and ocular hemodynamics in patients with primary open-angle glaucoma
Makashova NV; Kiseleva TN; Ronzina IA; Vasil'eva AE
Vestnik Oftalmologii 2008; 124: 55-59 (IGR: 11-1)


22936 Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: Critical role of p38 MAPK activation
El-Remessy AB; Tang Y; Zhu G; Matragoon S; Khalifa Y; Liu EK; Liu J-Y; Hanson E; Mian S; Fatteh N
Molecular Vision 2008; 14: 2190-2203 (IGR: 11-1)


23362 GABA agonists fail to protect the retina from ischemia-reperfusion injury
Traustason S; Eysteinsson T; Agnarsson BA; Stefánsson E
Experimental Eye Research 2009; 88: 361-366 (IGR: 11-1)


22558 Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma
Robin AL; Suan EP; Sjaarda RN; Callanan DG; Defaller J; Alcon Anecortave Acetate for IOP Research Team
Archives of Ophthalmology 2009; 127: 173-178 (IGR: 11-1)


22523 Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma
Egorov E; Ropo A; on behalf of the Investigators
European Journal of Ophthalmology 2009; 19: 214-222 (IGR: 11-1)


22897 Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: Synthesis and biological activity
Feng Z; Hellberg MR; Sharif NA; McLaughlin MA; Williams GW; Scott D; Wallace T
Bio-organic and Medicinal Chemistry 2009; 17: 576-584 (IGR: 11-1)


22896 Chroman-3-amides as potent Rho kinase inhibitors
Chen YT; Bannister TD; Weiser A; Griffin E; Lin L; Ruiz C; Cameron MD; Schurer S; Duckett D; Schroter T
Bioorganic and Medicinal Chemistry Letters 2008; 18: 6406-6409 (IGR: 11-1)


22921 The pleiotropic effects of ethacrynic acid
Somberg JC; Molnar J
American Journal of Therapeutics 2009; 16: 102-104 (IGR: 11-1)


23004 Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 4. Age-related eye disease. SkQ1 returns vision to blind animals
Neroev VV; Archipova MM; Bakeeva LE; Fursova AZ; Grigorian EN; Grishanova AY; Iomdina EN; Ivashchenko ZN; Katargina LA; Khoroshilova-Maslova IP
Biochemistry. Biokhimiia 2008; 73: 1317-1328 (IGR: 11-1)


22796 Possibilities of applying cannabinoids' in the treatment of glaucoma
Nadolska K; Gos R
Klinika Oczna 2008; 110:-9 314-317 (IGR: 11-1)


23365 Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT
Andrés-Guerrero V; Alarma-Estrany P; Molina-Martínez IT; Peral A; Herrero-Vanrell R; Pintor J
Experimental Eye Research 2009; 88: 504-511 (IGR: 11-1)


21832 Aqueous humor outflow effects of 2-arachidonylglycerol
Njie YF; He F; Qiao Z; Song ZH
Experimental Eye Research 2008; 87: 106-114 (IGR: 10-3)


21619 Expression of caspase-9 affected by AG on retina of rats with chronic IOP elevation
Nie Q-Z; Sha Q; Wang Y-S; Gui D-M; Liu Z-L; Gao D-W
International Journal of Ophthalmology 2008; 8: 1299-1303 (IGR: 10-3)


21829 Relaxing effect and mechanism of tafluprost on isolated rabbit ciliary arteries
Dong Y; Watabe H; Su G; Ishikawa H; Sato N; Yoshitomi T
Experimental Eye Research 2008; 87: 251-256 (IGR: 10-3)


21497 The mechanisms by which latanoprost free acid inhibits human carbonic anhydrase I and II
Sugimoto A; Ikeda H; Tsukamoto H; Kihira K; Takeda C; Hirose J; Hata T; Baba E; Ono Y
Biological & Pharmaceutical Bulletin 2008; 31: 796-801 (IGR: 10-3)


21668 Neuroprotection in glaucoma using calpain-1 inhibitors: Regional differences in calpain-1 activity in the trabecular meshwork, optic nerve and implications for therepeutics
Govindarajan B; Laird J; Sherman R; Salomon RG; Bhattacharya SK
CNS and Neurological Disorders - Drug Targets 2008; 7: 295-304 (IGR: 10-3)


21816 Neuroprotective effects of recombinant human granulocyte colony-stimulating factor (G-CSF) in neurodegeneration after optic nerve crush in rats
Tsai RK; Chang CH; Wang HZ
Experimental Eye Research 2008; 87: 242-250 (IGR: 10-3)


21434 Oculohypotensive effects of Foeniculum vulgare in experimental models of glaucoma
Agarwal R; Gupta SK; Agrawal SS; Srivastava S; Saxena R
Indian Journal of Physiology and Pharmacology 2008; 52: 77-83 (IGR: 10-3)


21727 Effects of endothelin-1 on calcium-independent contraction of bovine trabecular meshwork
Renieri G; Choritz L; Rosenthal R; Meissner S; Pfeiffer N; Thieme H
Graefe's Archive for Clinical and Experimental Ophthalmology 2008; 246: 1107-1115 (IGR: 10-3)


21842 Predictive value of the efficacy of glaucoma medications in regulatory trials: Phase I-III to post-marketing studies
Stewart WC; Jenkins JN
Eye 2008; 22: 985-988 (IGR: 10-3)


21618 Effect of endogenous AEA on the morphology and cytoskeleton of bovine trabecular meshwork cells cultured in vitro
Sun S-L; Zhang D-X; Guo B-X
International Journal of Ophthalmology 2008; 8: 1346-1349 (IGR: 10-3)


21495 Adverse effects of medical cannabinoids: A systematic review
Wang T; Collet J-P; Shapiro S; Ware MA
Canadian Medical Association Journal 2008; 178: 1669-1678 (IGR: 10-3)


21622 Effect of AEA on proliferation, adherence and immigration in cultured bovine trabecular cells
Yang X-G; Zhang D-X; Liu S-W; Chen L; Sun S-L
International Journal of Ophthalmology 2008; 8: 1343-1345 (IGR: 10-3)


21571 Scope and limitations of the co-drug approach to topical drug delivery
Lau WM; White AW; Gallagher SJ; Donaldson M; McNaughton G; Heard CM
Current Pharmaceutical Design 2008; 14: 794-802 (IGR: 10-3)


21780 Lovastatin inhibits TGF-β-induced myofibroblast transdifferentiation in human tenon fibroblasts
Meyer-Ter-Vehn T; Katzenberger B; Han H; Grehn F; Schlunck G
Investigative Ophthalmology and Visual Science 2008; 49: 3955-3960 (IGR: 10-3)


21287 Effect of cannabinoid (WIN55, 212-2) on glutamic acid concentration in vitreous body of chronic glaucoma rabbit model
Zhao J-H; Wang W-H
International Journal of Ophthalmology 2008; 8: 726-728 (IGR: 10-2)


21029 Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma
Bosco A; Inman DM; Steele MR; Wu G; Soto I; Marsh-Armstrong N; Hubbard WC; Calkins DJ; Horner PJ; Vetter ML
Investigative Ophthalmology and Visual Science 2008; 49: 1437-1446 (IGR: 10-2)


21254 Neuroprotection of progesterone on retinal ganglion cells in chronic ocular hypertension model rats
Xu S-L; Yin Y; Gu G-Z; Gao Z-Z
Journal of Jilin University Medicine Edition 2008; 34: 226-229 (IGR: 10-2)


21292 Studies on corneal permeation and oculo-hypotensive effect of benazepril in chronic and acute models of glaucoma
Sharma S; Pathak D; Goyal R
Iranian Journal of Pharmacology and Therapeutics 2006; 5: 145-149 (IGR: 10-2)


21045 Orally administered epigallocatechin gallate attenuates retinal neuronal death in vivo and light-induced apoptosis in vitro
Zhang B; Rusciano D; Osborne NN
Brain Research 2008; 1198: 141-152 (IGR: 10-2)


20477 Hypotensive effect of UDP on intraocular pressure in rabbits
Markovskaya A; Crooke A; Guzman-Aranguez AI; Peral A; Ziganshin AU; Pintor J
European Journal of Pharmacology 2008; 579: 93-97 (IGR: 10-1)


20655 Cannabinoids in health and disease
Kogan NM; Mechoulam R
Dialogues in Clinical Neuroscience 2007; 9: 413-430 (IGR: 10-1)


20653 Cannabis sativa in the light of scientific research
Szulakowska A; Milnerowicz H
Advances in Clinical and Experimental Medicine 2007; 16: 807-815 (IGR: 10-1)


20522 Up-regulated endogenous erythropoietin/erythropoietin receptor system and exogenous erythropoietin rescue retinal ganglion cells after chronic ocular hypertension
Fu Q-L; Wu W; Wang H; Li X; Lee VWH; So K-F
Cellular and molecular neurobiology 2008; 28: 317-329 (IGR: 10-1)


20456 Effects of the topically applied calcium-channel blocker flunarizine on intraocular pressure in clinically normal dogs
Greller AL; Hoffman AR; Liu C; Ying G-S; Vudathala DK; Acland GM; Komaromy AM
American Journal of Veterinary Research 2008; 69: 273-278 (IGR: 10-1)


20473 Rabbit's intraocular pressure after instillation of timolol and aminoacid lysine, arginine, glycine or taurine mixture.
Olah Z; Veselovsky J
Bratisl Lek Listy 2007; 108: 283-286 (IGR: 10-1)


20615 Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action
Oltmanns MH; Samudre SS; Castillo IG; Hosseini A; Lichtman AH; Allen RC; Lattanzio Jr FA; Williams PB
Journal of Ocular Pharmacology and Therapeutics 2008; 24: 104-115 (IGR: 10-1)


20766 Intraocular Pressure-Lowering Effects and Safety of Topical Administration of a Selective ROCK Inhibitor, SNJ-1656, in Healthy Volunteers
Tanihara H; Inatani M; Honjo M; Tokushige H; Azuma J; Araie M
Archives of Ophthalmology 2008; 126: 309-315 (IGR: 10-1)


20602 Curative effect of acupuncture separation combined with injection of recombinant human Interferon αZb around Bulbar conjunctiva on encapsulated filtering bled
Wang Y; Shao-Lin X; Cheng Z
Chinese Journal of Biologicals 2007; 20: 457-458 (IGR: 10-1)


20596 Effect of TGF-β1 on proliferation of Tenon capsule fibroblasts and expression of heat shock protein 47
Pan R; Chen X; Li M; Liu D
Chinese Ophthalmic Research 2007; 25: 933-936 (IGR: 10-1)


20686 Interpretation of uniocular and binocular trials of glaucoma medications: An observational case series
Leffler CT; Amini L
BMC Ophthalmology 2007; 7: 17 (IGR: 10-1)


19804 Aquaporins as targets for drug discovery
Frigeri A; Nicchia GP; Svelto M
Current Pharmaceutical Design 2007; 13: 2421-2427 (IGR: 9-4)


20069 Promotion of neurite outgrowth and protective effect of erythropoietin on the retinal neurons of rats
Zhong Y; Yao H; Deng L; Cheng Y; Zhou X
Graefe's Archive for Clinical and Experimental Ophthalmology 2007; 245: 1859-1867 (IGR: 9-4)


19706 Pitavastatin: Protection against neuronal retinal damage induced by ischemia-reperfusion injury in rats
Kawaji T; Inomata Y; Takano A; Sagara N; Inatani M; Fukushima M; Tanihara H; Honjo M
Current Eye Research 2007; 32: 991-997 (IGR: 9-4)


19833 Effects of ZX-5 and its optical isomers on ocular blood flow in rabbits and retinal function recovery in rats
Peng J; Zou Y-H; Jiang W; Zhang Y-H; Ji X-B; Shen Z-L; Peng S-X; Chiou GCY
International Journal of Ophthalmology 2007; 7: 1197-1201 (IGR: 9-4)


19785 Characterization of the effects of anti-aging medicine Fructus lycii on β-amyloid peptide neurotoxicity
Yu MS; Lai CS; Ho YS; Zee SY; So KF; Yuen WH; Chang RC
International Journal of Molecular Medicine 2007; 20: 261-268 (IGR: 9-4)


19828 Requirement of intact sympathetic transmission for the ocular hypotensive effects of melatonin and 5-MCA-NAT
Alarma-Estrany P; Crooke A; Peral A; Pintor J
Auton Neuroscience 2007; 137: 63-66 (IGR: 9-4)


20037 Dinucleoside polyphosphates in the eye: from physiology to therapeutics
Guzmán-Aranguez A; Crooke A; Peral A; Hoyle CH; Pintor J
Progress in Retinal and Eye Research 2007; 26: 674-687 (IGR: 9-4)


20065 Potential role of rho-associated protein kinase inhibitor y-27632 in glaucoma filtration surgery
Honjo M; Tanihara H; Kameda T; Kawaji T; Yoshimura N; Araie M
Investigative Ophthalmology and Visual Science 2007; 48: 5549-5557 (IGR: 9-4)


20077 Effects of latanoprost, timolol and GLC756, a novel dopamine D2 agonist and D1 antagonist on LTC4 release after rat mast cell activation
Laengle UW; Markstein R; Pralet D; Seewald W; Roman D
Clinical and Experimental Ophthalmology 2007; 35: 645-650 (IGR: 9-4)


19835 Hypericin's effects on retinal glutamate in acute ocular hypertension of rabbits
Li L-L; Jiang F-G; Li S
International Journal of Ophthalmology 2007; 7: 1308-1310 (IGR: 9-4)


20080 A comparative study of topical natural ergot alkaloids on the intraocular pressure and aqueous humor dynamics in oclular normotensive and α-chymotrypsin-induced ocular hypertensive rabbits
Puras G; Santafé J; Segarra J; Garrido M; Melena J
Graefe's Archive for Clinical and Experimental Ophthalmology 2007; 245: 1559-1567 (IGR: 9-4)


19705 Effects of MISA A on actin cytoskeleton of cultured HTM cells and intraocular pressure of rats and glaucomatous monkeys
Wang H; Liu X; Guo L; Gabelt BT; Lee P-Y; Podos SM; Kaufman PL; Wang N
Current Eye Research 2007; 32: 843-850 (IGR: 9-4)


20043 A phase III study of subconjunctival human anti-transforming growth factor β2 monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy
CAT-152 0102 Trabeculectomy Study Group; Khaw P; Grehn F; Holló G; Overton B; Wilson R; Vogel R; Smith Z
Ophthalmology 2007; 114: 1822-1830 (IGR: 9-4)


20042 Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor β2, CAT-152
CAT-152 Trabeculectomy Study Group; Grehn F; Holló G; Khaw P; Overton B; au; Wilson R; Vogel R; Smith Z
Ophthalmology 2007; 114: 1831-1838 (IGR: 9-4)


19342 Effect of hypericin on retinal glutamate levels in chronic ocular hypertension rabbits
Li S; Jiang F
Chinese Ophthalmic Research 2007; 25: 370-372 (IGR: 9-3)


19246 Hypotensive effect of profilin on rabbit intraocular pressure
Morales M; Gomez-Cabrero A; Peral A; Gasull X; Pintor J
European Journal of Pharmacology 2007; 567: 145-148 (IGR: 9-3)


19295 Survival and axonal regeneration of off-center retinal ganglion cells of adult cats are promoted with an anti-glaucoma drug, nipradilol, but not BDNF and CNTF
Yata T; Nakamura M; Sagawa H; Tokita Y; Terasaki H; Watanabe M
Neuroscience 2007; 148: 53-64 (IGR: 9-3)


19523 Effects of dopamine on retinal and choroidal blood flow parameters in humans
Huemer KH; Zawinka C; Garhöfer G; Golestani E; Litschauer B; Dorner GT; Schmetterer L
British Journal of Ophthalmology 2007; 91: 1194-1198 (IGR: 9-3)


19413 The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents
Mincione F; Scozzafava A; Supuran CT
Current Topics in Medicinal Chemistry 2007; 7: 849-854 (IGR: 9-3)


19476 Clinical evaluation of the neuroprotective effect of alpha-tocopherol against glaucomatous damage
Engin KN; Engin G; Kucuksahin H; Oncu M; Guvener B
European Journal of Ophthalmology 2007; 17: 528-533 (IGR: 9-3)


19343 Effect of nerve regeneration factor on expression of inducible-nitric oxide synthase in retina with experimental intraocular hypertension
Guan H; Huang Z; Ding F; Gu X
Chinese Ophthalmic Research 2007; 25: 325-328 (IGR: 9-3)


19383 Pathologically-activated therapeutics for neuroprotection: Mechanism of NMDA receptor block by memantine and S-nitrosylation
Lipton SA
Current Drug Targets 2007; 8: 621-632 (IGR: 9-3)


19266 Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders
Lipton SA; Gu Z; Nakamura T
International review of neurobiology 2007; 82: 1-27 (IGR: 9-3)


19557 Erythropoietin: A candidate neuroprotective agent in the treatment of glaucoma
Tsai JC; Song BJ; Wu L; Forbes M
Journal of Glaucoma 2007; 16: 567-571 (IGR: 9-3)


19392 Fixed-combination and emerging glaucoma therapies
Woodward DF; Chen J
Expert Opinion on Emerging Drugs 2007; 12: 313-327 (IGR: 9-3)


19341 Effects of low dose of latrunculin-A on actin cytoskeleton and extracellular matrix protein TSP-1 in dexamethasone-induced bovine TMCs
Cao J; Zhang D
Chinese Ophthalmic Research 2007; 25: 502-505 (IGR: 9-3)


19424 Research progress on application of ET-1 on eyes
Cao W-J; Zhou Y-H
International Journal of Ophthalmology 2007; 7: 782-783 (IGR: 9-3)


19333 Novel benzodifuran analogs as potent 5-HT(2A) receptor agonists with ocular hypotensive activity
Feng Z; Mohapatra S; Klimko PG; Hellberg MR; May JA; Kelly C; Williams G; McLaughlin MA; Sharif NA
Bioorganic and Medicinal Chemistry Letters 2007; 17: 2998-3002 (IGR: 9-3)


19421 The protective function of erythropoietin to the rat retina after acute intraocular hypertension
Guo Y; Wang W-H
International Journal of Ophthalmology 2007; 7: 688-691 (IGR: 9-3)


19431 Protective effect on visual functions of long-term use of trimetazidine in treatment of primary open angle glaucoma and degenerative myopia
Nowak MS; Wybor K; Gos R; Zeman-Miecznik A; Waszczykowska A; Pastuszka M; Klysik A; Gajdowska A
Archives of Medical Science 2007; 3: 152-156 (IGR: 9-3)


19359 Hemin, an inducer of heme oxygenase-1, lowers intraocular pressure in rabbits
Privitera MG; Potenza M; Bucolo C; Leggio GM; Drago F
Journal of Ocular Pharmacology and Therapeutics 2007; 23: 232-239 (IGR: 9-3)


19376 Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma
Rao VP; Epstein DL
BioDrugs 2007; 21: 167-177 (IGR: 9-3)


19434 Therapeutic potential of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the treatment of retinal and eye diseases
Schmeer C; Kretz A; Isenmann S
CNS and Neurological Disorders - Drug Targets 2007; 6: 282-287 (IGR: 9-3)


19634 Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys
Tokushige H; Inatani M; Nemoto S; Sakaki H; Katayama K; Uehata M; Tanihara H
Investigative Ophthalmology and Visual Science 2007; 48: 3216-3222 (IGR: 9-3)


19411 Metal binding functions in the design of carbonic anhydrase inhibitors
Winum J-Y; Scozzafava A; Montero J-L; Supuran CT
Current Topics in Medicinal Chemistry 2007; 7: 835-848 (IGR: 9-3)


18202 Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis
Yam GH; Gaplovska-Kysela K; Zuber C; Roth J
Investigative Ophthalmology and Visual Science 2007; 48: 1683-1690 (IGR: 9-2)


17455 Analysis of human carbonic anhydrase II: Docking reliability and receptor-based 3D-QSAR study
Tuccinardi T; Nuti E; Ortore G; Supuran CT; Rossello A; Martinelli A
Journal of Chemical Information and Modeling 2007; 47: 515-525 (IGR: 9-2)


17633 Implication of cannabinoids in neurological diseases
Alsasua del Valle A
Cellular and molecular neurobiology 2006; 26: 579-591 (IGR: 9-2)


17567 Structure-activity relationships, and drug metabolism and pharmacokinetic properties for indazole piperazine and indazole piperidine inhibitors of ROCK-II
Feng Y; Cameron MD; Frackowiak B; Griffin E; Lin L; Ruiz C; Schroter T; LoGrasso P
Bioorganic and Medicinal Chemistry Letters 2007; 17: 2355-2360 (IGR: 9-2)


17568 Carbonic anhydrase inhibitors: Binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties
Fiore AD; Scozzafava A; Winum J-Y; Montero J-L; Pedone C; Supuran CT; De Simone G
Bioorganic and Medicinal Chemistry Letters 2007; 17: 1726-1731 (IGR: 9-2)


17648 Synthesis and ocular hypotensive activity of magnolol
Huang W-H; Lin I-H; Tan K-I; Chiang C-H; Lee A-R
Chinese Pharmaceutical Journal 2006; 58: 115-122 (IGR: 9-2)


17622 New ocular therapeutics: a view from the patenting perspective
Mucke HA
Idrugs 2007; 10: 37-41 (IGR: 9-2)


18096 The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice
Ota T; Aihara M; Saeki T; Narumiya S; Araie M
British Journal of Ophthalmology 2007; 91: 673-676 (IGR: 9-2)


17608 Pigment epithelium-derived factor protects retinal ganglion cells
Pang I-H; Zeng H; Fleenor DL; Clark AF
BMC Neuroscience 2007; 8: 11 (IGR: 9-2)


17529 AL-34662: A potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist
Sharif NA; McLaughlin MA; Kelly CR
Journal of Ocular Pharmacology and Therapeutics 2007; 23: 1-13 (IGR: 9-2)


18169 The Rho-kinase inhibitor H-1152P suppresses the wound-healing activities of human Tenon's capsule fibroblasts in vitro
Tura A; Grisanti S; Petermeier K; Henke-Fahle S
Investigative Ophthalmology and Visual Science 2007; 48: 2152-2161 (IGR: 9-2)


17601 Experimental study of TGF-β(2) antisense oligodeoxynucleotide as an anti-scarring agent in glaucoma surgery
Li J-Y; Fu P; Yang Q
International Journal of Ophthalmology 2007; 7: 10-14 (IGR: 9-2)


16815 Morphine-stimulated nitric oxide release in rabbit aqueous humor
Dortch-Carnes J; Russell K
Experimental Eye Research 2007; 84: 185-190 (IGR: 9-1)


16945 Neuroprotective and intraocular pressure-lowering effects of (-)delta-tetrahydrocannabinol in a rat model of glaucoma
Crandall J; Matragoon S; Khalifa YM; Borlongan C; Tsai NT; Caldwell RB; Liou GI
Ophthalmic Research 2007; 39: 69-75 (IGR: 9-1)


17167 The function of the selective inhibitors of cycloxygenase 2
Luan Y; Xu W
Mini Reviews in Medicinal Chemistry 2006; 6: 1375-1381 (IGR: 9-1)


17078 New perspectives in ocular pharmacology: Nucleotides as therapeutic agents
Pintor J
Anales de la Real Academia Nacional de Farmacia 2006; 72: 519-538 (IGR: 9-1)


16859 Dronabinol and retinal hemodynamics in humans
Plange N; Arend KO; Kaup M; Doehmen B; Adams H; Hendricks S; Cordes A; Huth J; Sponsel WE; Remky A
American Journal of Ophthalmology 2007; 143: 173-174 (IGR: 9-1)


16958 Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice
Zhong L; Bradley J; Schubert W; Ahmed E; Adamis AP; Shima DT; Robinson GS; Ng YS
Investigative Ophthalmology and Visual Science 2007; 48: 1212-1218 (IGR: 9-1)


15272 Citicoline and lithium rescue retinal ganglion cells following partial optic nerve crush in the rat
Schuettauf F; Rejdak R; Thaler S; Bolz S; Lehaci C; Mankowska A; Zarnowski T; Junemann A; Zagorski Z; Zrenner E
Experimental Eye Research 2006; 83: 1128-1134 (IGR: 8-4)


15264 Synthesis and characterization of a novel class of reducing agents that are highly neuroprotective for retinal ganglion cells
Schlieve CR; Tam A; Nilsson BL; Lieven CJ; Raines RT; Levin LA
Experimental Eye Research 2006; 83: 1252-1259 (IGR: 8-4)


15253 Intravitreal bevacizumab (Avastin®) in the treatment of neovascular glaucoma
Iliev ME; Domig D; Wolf-Schnurrbursch U; Wolf S; Sarra GM
American Journal of Ophthalmology 2006; 142: 1054-1056 (IGR: 8-4)


14489 The effect of glycine with timoptol on the rabbit IOP physiological values
Veselovsky J; Olah Z; Vesela A; Gressnerova S
?eska a Slovenska Oftalmologie 2006; 62: 247-254 (IGR: 8-4)


15120 Cortisol promotes survival and regeneration of axotomised retinal ganglion cells and enhances effects of aurintricarboxylic acid
Heiduschka P; Thanos S
Graefe's Archive for Clinical and Experimental Ophthalmology 2006; 244: 1512-1521 (IGR: 8-4)


15054 Morphine-induced reduction of intraocular pressure and pupil diameter: role of nitric oxide
Dortch Carnes J; Russell KR
Pharmacology 2006; 77: 17-24 (IGR: 8-4)


15205 A topical nitric oxide-releasing dexamethasone derivative: effects on intraocular pressure and ocular haemodynamics in a rabbit glaucoma model
Galassi F; Masini E; Giambene B; Fabrizi F; Uliva C; Bolla M; Ongini E
British Journal of Ophthalmology 2006; 90: 1414-1419 (IGR: 8-4)


15265 Effect of GLC756, a novel mixed dopamine D1 receptor antagonist and dopamine D2 receptor agonist, on TNF-α release in vitro from activated rat mast cells
Laengle UW; Markstein R; Pralet D; Seewald W; Roman D
Experimental Eye Research 2006; 83: 1335-1339 (IGR: 8-4)


14782 Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbo nyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester
Oka T; Walkup RD; Tamada Y; Nakajima E; Tochigi A; Shearer TR; Azuma M
Neuroscience 2006; 141: 2139-2145 (IGR: 8-4)


14718 Ocular hypotensive effects of an intratracheally delivered liposomal Δ9-tetrahydrocannabinol preparation in rats
Szczesniak A-M; Kelly MEM; Whynot S; Shek PN; Hung O
Journal of Ocular Pharmacology and Therapeutics 2006; 22: 160-167 (IGR: 8-4)


15202 Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study
Tomida I; Azuara-Blanco A; House H; Flint M; Pertwee RG; Robson PJ
Journal of Glaucoma 2006; 15: 349-353 (IGR: 8-4)


15263 Short-term exposure to transforming growth factor β induces long-term fibrotic responses
Wormstone IM; Anderson IK; Eldred JA; Dawes LJ; Duncan G
Experimental Eye Research 2006; 83: 1238-1245 (IGR: 8-4)


14143 Effects of endothelin-1 and flunarizine on human trabecular meshwork cell contraction
Cellini M; Versura P; Zamparini E; Bendo E; Campos EC
Experimental Biology and Medicine (Maywood, N.J.) 2006; 231: 1081-1084 (IGR: 8-3)


14171 Possible involvement of nitric oxide in morphine-induced miosis and reduction of intraocular pressure in rabbits
Bonfiglio V; Bucolo C; Camillieri G; Drago F
European Journal of Pharmacology 2006; 534: 227-232 (IGR: 8-3)


13898 Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes
Ethier CR; Read AT; Chan DW
Investigative Ophthalmology and Visual Science 2006; 47: 1991-1998 (IGR: 8-2)


13899 Chronic topical administration of WIN-55-212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects
Hosseini A; Lattanzio FA; Williams PB; Tibbs D; Samudre SS; Allen RC
Experimental Eye Research 2006; 82: 753-759 (IGR: 8-2)


13900 Effects of antiglaucoma drugs GLC756, a novel dopamine D2 agonist and D1 antagonist, and timolol on endotoxin-induced TNF-α release in serum of rats
Laengle UW; Markstein R; Schneider V; Roman D
European Journal of Ophthalmology 2006; 16: 401-406 (IGR: 8-2)


13897 Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility
Njie YF; Kumar A; Qiao Z; Zhong L; Song ZH
Investigative Ophthalmology and Visual Science 2006; 47: 1999-2005 (IGR: 8-2)


13590 The pharmacology of cannabinoid receptors and their ligands: An overview
Pertwee RG
International Journal of Obesity 2006; 30: S13-S18 (IGR: 8-2)


13626 R(+)-methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells
Rosch S; Ramer R; Brune K; Hinz B
Journal of Pharmacology and Experimental Therapeutics 2006; 316: 1219-1228 (IGR: 8-2)


13567 Reduction of the physiologic IOP value after instilation of the mixture of the 2 amino acids (L-lysine and L-arginine) in Timoptol - Experiment on rabbits
Veselovsky J; Olah Z; Vesela A; Gressnerova S
?eska a Slovenska Oftalmologie 2006; 62: 3-10 (IGR: 8-2)


13364 Effects of latanoprost and GLC756, a novel dopamine D2 agonist and D1 antagonist, on cultured normal human dermal fibroblasts
Laengle UW; Markstein R; Pralet D; Greiner B; Roman D
European Journal of Ophthalmology 2006; 16: 67-72 (IGR: 8-1)


13361 Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells
Koga T; Awai M; Tsutsui J; Yue BY; Tanihara H
Experimental Eye Research 2006; 82: 362-370 (IGR: 8-1)


13320 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity
May JA; Dantanarayana AP; Zinke PW; McLaughlin MA; Sharif NA
Journal of Medicinal Chemistry 2006; 49: 318-328 (IGR: 8-1)


13311 Effects of novel ethacrynic acid derivatives on human trabecular meshwork cell shape, actin cytoskeletal organization, and transcellular fluid flow
Rao PV; Shimazaki A; Ichikawa M; Alvarado JA; Epstein DL
Biological & Pharmaceutical Bulletin 2005; 28: 2189-2196 (IGR: 8-1)


13359 Latrunculin B effects on trabecular meshwork and corneal endothelial morphology in monkeys
Sabanay I; Tian B; Gabelt BT; Geiger B; Kaufman PL
Experimental Eye Research 2006; 82: 236-246 (IGR: 8-1)


13488 Increased glutamate uptake and GLAST expression by cyclic AMP in retinal glial cells
Sakai T; Yoshitoshi T; Nagai Y; Kitahara K
Graefe's Archive for Clinical and Experimental Ophthalmology 2006; 244: 359-363 (IGR: 8-1)


13299 Development of specific Rho-kinase inhibitors and their clinical application
Tamura M; Nakao H; Yoshizaki H; Shiratsuchi M; Shigyo H; Yamada H; Ozawa T; Totsuka J; Hidaka H
Biochimica et Biophysica Acta Proteins and Proteomics 2005; 1754: 245-252 (IGR: 8-1)


13527 Endothelin Antagonism: Effects of FP Receptor Agonists Prostaglandin F2α and Fluprostenol on Trabecular Meshwork Contractility
Thieme H; Schimmat C; Munzer G; Boxberger M; Fromm M; Pfeiffer N; Rosenthal R
Investigative Ophthalmology and Visual Science 2006; 47: 938-945 (IGR: 8-1)


13027 Aqueous humor dynamics in monkeys after topical R-DOI
Gabelt BT; Okka M; Dean TR; Kaufman PL
Investigative Ophthalmology and Visual Science 2005; 46: 4691-4696 (IGR: 7-3)


12594 Effects of anti-glaucoma drugs timolol and GLC756, a novel mixed dopamine D2 receptor agonist and D1 receptor antagonist, on endotoxin-induced-uveitis and -arthritis in rats
Laengle UW; Court M; Markstein R; Germann PG; Nogues V; Roman D
Experimental and Toxicologic Pathology 2005; 57: 127-134 (IGR: 7-3)


13176 Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats
Lambiase A; Tirassa P; Micera A; Aloe L; Bonini S
Investigative Ophthalmology and Visual Science 2005; 46: 3800-3806 (IGR: 7-3)


12593 Ocular pharmacology of bicyclic hexahydroaporphines
Ohia SE; Zhan GL; Leday AM; Opere CA; Kulkarni KH; Harris LC; Roche VF
Methods and Findings in Experimental and Clinical Pharmacology 2005; 27: 87-93 (IGR: 7-3)


12590 Expression of dominant negative Rho-binding domain of Rho-kinase in organ cultured human eye anterior segments increases aqueous humor outflow
Rao PV; Deng P; Maddala R; Epstein DL; Li C-Y; Shimokawa H
Molecular Vision 2005; 11: 288-297 (IGR: 7-3)


12589 Effects of dinucleoside polyphosphates on trabecular meshwork cells and aqueous humor outflow facility
Soto D; Pintor J; Peral A; Gual A; Gasull X
Journal of Pharmacology and Experimental Therapeutics 2005; 314: 1042-1051 (IGR: 7-3)


13180 Blebbistatin, a novel inhibitor of myosin II ATPase activity, increases aqueous humor outflow facility in perfused enucleated porcine eyes
Zhang M; Rao PV
Investigative Ophthalmology and Visual Science 2005; 46: 4130-4138 (IGR: 7-3)


12520 CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility
Zhong L; Geng L; Njie Y; Feng W; Song ZH
Investigative Ophthalmology and Visual Science 2005; 46: 1988-1992 (IGR: 7-2)


12348 Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes
Wang RF; Podos SM; Mittag TW; Yokoyoma T
Experimental Eye Research 2005; 80: 629-632 (IGR: 7-2)


12299 The rabbit IOP and pupil values after application of aminoacid L-lysine and antiglaucomatic Timoptol mixture
Veselovsky J; Olah Z; Gressnerova S; Vesela A
?eska a Slovenska Oftalmologie 2005; 61: 88-95 (IGR: 7-2)


12148 Preparation and characterization of demeclocycline liposomal formulations and assessment of their intraocular pressure-lowering effects
Afouna MI; Khattab IS; Reddy IK
Journal of Toxicology – Cutaneous and Ocular Toxiclogy 2005; 24: 111-124 (IGR: 7-2)


12163 Finding of endocannabinoids in human eye tissues: implications for glaucoma
Chen J; Matias I; Dinh T; Lu T; Venezia S; Nieves A; Woodward DF; Di-Marzo V
Biochemical and Biophysical Research Communications 2005; 330: 1062-1067 (IGR: 7-2)


12169 Novel antiglaucoma prodrugs and codrugs of ethacrynic acid
Cynkowska G; Cynkowski T; Al-Ghananeem AA; Guo H; Ashton P; Crooks PA
Bioorganic and Medicinal Chemistry Letters 2005; 15: 3524-3527 (IGR: 7-2)


12192 Ocular hypotensive effect of bunazosin hydrochloride as the third concomitant topical medication
Hashimoto T; Kara T; Kubota S; Kubota M; Tsuru T
Japanese Journal of Clinical Ophthalmology 2005; 59: 359-362 (IGR: 7-2)


12354 Effects of antiglaucoma drugs timolol and GLC756, a novel dopamine D2 agonist and D1 antagonist, on endotoxin-induced-uveitis in rats
Laengle UW; Markstein R; Schneider V; Greiner B; Roman D
Experimental Eye Research 2005; 80: 847-852 (IGR: 7-2)


12242 Contribution of ROCK in contraction of trabecular meshwork: Proposed mechanism for regulating aqueous outflow in monkey and human eyes
Nakajima E; Nakajima T; Minagawa Y; Shearer TR; Azuma MM
Journal of Pharmaceutical Sciences 2005; 94: 701-708 (IGR: 7-2)


12245 Synthesis, hydrolysis, and intraocular pressure lowering effects of fadolmidine prodrugs
Niemi R; Huuskonen J; Laine K; Jarvinen T
International Journal of Pharmaceutics 2005; 13: 121-127 (IGR: 7-2)


12247 Effects of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and miotic and accommodative responses to pilocarpine in monkeys
Okka M; Tian B; Kaufman PL
Transactions of the American Ophthalmological Society 2004; 102: 251-259 (IGR: 7-2)


12249 Synthesis and ocular effects of imidazole nitrolic acids
Oresmaa L; Kotikoski H; Haukka M; Salminen J; Oksala O; Pohjala E; Moilanen E; Vapaatalo H; Vainiotalo P; Aulaskari P
Journal of Medicinal Chemistry 2005; 48: 4231-4236 (IGR: 7-2)


12353 Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork
Rosenthal R; Choritz L; Schlott S; Bechrakis NE; Jaroszewski J; Wiederholt M; Thieme H
Experimental Eye Research 2005; 80: 837-845 (IGR: 7-2)


12277 Cyclic GMP, sodium nitroprusside and sodium azide reduce aqueous humour formation in the isolated arterially perfused pig eye
Shahidullah M; Yap M; To CH
British Journal of Pharmacology 2005; 145: 84-92 (IGR: 7-2)


12282 Additive effect of bunazosin hydrochloride on intraocular pressure and disc circulation in patients of normal-tension glaucoma treated by latanoprost
Shimizu M; Kon No-S; Maeda S; Matsumoto H; Ohtsuka K
Japanese Journal of Clinical Ophthalmology 2005; 59: 283-287 (IGR: 7-2)


11965 Fadolmidine-induced ocular hypotension in normotensive rabbits
Savolainen J; Niemi R; Mantyla A; Huuskonen J; Jarvinen T
Journal of Pharmacy and Pharmacology 2005; 57: 191-195 (IGR: 7-1)


12105 The anandamide membrane transporter and the therapeutic implications of its inhibition
Battista N; Gasperi V; Fezza F; Maccarrone M
Therapy 2005; 2: 141-150 (IGR: 7-1)


11770 β-oxygenated analogues of the 5-HT2A serotonin receptor agonist 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane
Glennon RA; Bondarev ML; Khorana N; Young R; May JA; Hellberg MR; McLaughlin MA; Sharif NA
Journal of Medicinal Chemistry 2004; 47: 6034-6041 (IGR: 7-1)


11917 The rabbit's IOP after instillation of antiglaucomatic COSOPT and aminoacid L-argininin. HCL mixture in the conjunctival sac
Olah Z; Veselovsky J; Gressnerova S; Vesela A
?eska a Slovenska Oftalmologie 2005; 61: 3-12 (IGR: 7-1)


11934 Adenine nucleotides and dinucleotides as new substances for the treatment of ocular hypertension and glaucoma
Pintor J
Current Opinion in Investigational Drugs 2005; 6: 76-80 (IGR: 7-1)


11976 Molecular pharmacology of the DP/EP2 class prostaglandin AL-6598 and quantitative autoradiographic visualization of DP and EP2 receptor sites in human eyes
Sharif NA; Williams GW; Crider JY; Xu SX; Davis TL
Journal of Ocular Pharmacology and Therapeutics 2004; 20: 489-508 (IGR: 7-1)


12005 Effects of the Rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys
Tian B; Kaufman PL
Experimental Eye Research 2005; 80: 215-225 (IGR: 7-1)


11294 Effects of adenosine on optic nerve head circulation in rabbits
Hirao M; Oku H; Goto W; Sugiyama T; Kobayashi T; Ikeda T
Experimental Eye Research 2004; 79: 729-735 (IGR: 6-3)


11336 Inhibition of NHE-1 Na+/H+ exchanger by natriuretic peptides in ocular nonpigmented ciliary epithelium
Fidzinski P; Salvador Silva M; Choritz L; Geibel J; Coca Prados M
American Journal of Physiology and Cell Physiology 2004; 287: C655-663 (IGR: 6-3)


11476 Effects of topically instilled bunazosin, an α1-adrenoceptor antagonist, on constrictions induced by phenylephrine and ET-1 in rabbit retinal arteries
Ichikawa M; Okada Y; Asai Y; Hara H; Ishii K; Araie M
Investigative Ophthalmology and Visual Science 2004; 45: 4041-4048 (IGR: 6-3)


11439 Effect of low-dose latrunculin B on anterior segment physiologic features in themonkey eye
Okka M; Tian B; Kaufman PL
Archives of Ophthalmology 2004; 122: 1482-1488 (IGR: 6-3)


11265 Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes
Serle JB; Wang RF; Peterson WM; Plourde R; Yerxa BR
Journal of Glaucoma 2004; 13: 385-388 (IGR: 6-3)


11557 The mechanism of ocular hypotensive effect of CS-088, angiotensin II type I receptor blocker, in pigmented rabbit - Investigation of central ocular hypotensive effect
Yoshida M; Ueda T; Noda T; Shimada S; Koide R; Shi Yu G; Hisamitsu T; Oguchi K
Journal of the Showa Medical Association 2004; 64: 199-205 (IGR: 6-3)


10587 The effect of verapamil on expression of transforming growth factor-β in bovine trabecular meshwork cells
Chen F; Wei H; Zeng Y; Lu Y; Zhang Y
Chinese Ophthalmic Research 2004; 22: 156-160 (IGR: 6-2)


10641 H-7 effect on outflow facility after trabecular obstruction following long-term echothiophate treatment in monkeys
Gabelt BT; Hennes EA; Seeman JL; Tian B; Kaufman PL
Investigative Ophthalmology and Visual Science 2004; 45: 2732-6 (IGR: 6-2)


10532 Effects of bunazosin hydrochloride on ciliary muscle constriction and matrix metalloproteinase activities
Akaishi T; Takagi Y; Matsugi T; Ishida N; Hara H; Kashiwagi K
Journal of Glaucoma 2004; 13: 312-8 (IGR: 6-2)


10550 Pharmacologic disruption of Schlemm's canal cells and outflow facility in anterior segments of human eyes
Bahler CK; Hann CR; Fautsch MP; Johnson DH
Investigative Ophthalmology and Visual Science 2004; 45: 2246-54 (IGR: 6-2)


10578 The inhibitory effect of tranilast on transforming growth factor-β2 expression in cultured human trabecular meshwork cells
Cao Y; Da BH; Wei HR
Chinese Journal of Ophthalmology 2004; 40: 254-7 (IGR: 6-2)


10595 SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms
Costagliola C; Parmeggiani F; Sebastiani A
CNS Drugs 2004; 18: 475-484 (IGR: 6-2)


10710 Role of adenosine in intraocular pressure
Konno T
Nippon yakurigaku zasshi 2004; 123: 289-294 (IGR: 6-2)


10763 Effect of rilmenidine on intraocular pressure in rabbits, interaction with efaroxan and rauwolscine
Misiuk Hojlo M; Szalinski M; Merwid Lad A; Trocha M; Piesniewska M
Klinika Oczna 2004; 106: 7-10 (IGR: 6-2)


10795 Structure-activity relationships of adenosine A3 receptor ligands: New potential therapy for the treatment of glaucoma
Okamura T; Kurogi Y; Hashimoto K; Sato S; Nishikawa H; Kiryu K; Nagao Y
Bioorganic and Medicinal Chemistry Letters 2004; 14: 3775-3779 (IGR: 6-2)


10811 Bremazocine increases C-type natriuretic peptide levels in aqueous humor and enhances outflow facility
Potter DE; Russell KR; Manhiani M
Journal of Pharmacology and Experimental Therapeutics 2004; 309: 548-53 (IGR: 6-2)


10875 Effects of Topical H-7 on Outflow Facility, Intraocular Pressure, and Corneal Thickness in Monkeys
Tian B; Wang R-F; Podos SM; Kaufman PL
Archives of Ophthalmology 2004; 122: 1171-1177 (IGR: 6-2)


10878 Cannabinoids and glaucoma
Tomida I; Pertwee RG; Azuara-Blanco A
British Journal of Ophthalmology 2004; 88: 708-13 (IGR: 6-2)


10893 Intraocular pressure in rabbits after administration of 10% L-arginine HCl in 2% Trusopt
Veselovsky J; Olah Z; Vesela A; Gressnerova S
?eska a Slovenska Oftalmologie 2004; 60: 81-8 (IGR: 6-2)


10892 The amino acid 10% L-arginin.HCl combined with 0.5% timoptol and with 2% trusopt: Effectivity check and comparison with the single compounds - Experiment on rabbits
Veselovsky J; Olah Z; Vesela A; Gressnerova S
?eska a Slovenska Oftalmologie 2004; 60: 163-170 (IGR: 6-2)


10477 Effects of 2-alkynyladenosine derivatives on intraocular pressure in rabbits
Konno T; Ohnuma SY; Uemoto K; Uchibori T; Nagai A; Kogi K; Endo K; Hosokawa T; Nakahata N
European Journal of Pharmacology 2004; 486: 307-316 (IGR: 6-1)


10511 Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment
Wang Y; Challa P; Epstein DL; Yuan F
Biomaterials 2004; 25: 4279-4285 (IGR: 6-1)


9945 Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma
Flach AJ; Anderson DR; Spaeth GL; Cantor LB
Transactions of the American Ophthalmological Society 2002; 100: 215-224 (IGR: 5-3)


9946 A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole
May JA; Chen HH; Rusinko A; Lynch VM; Sharif NA; McLaughlin MA
Journal of Medicinal Chemistry 2003; 46: 4188-4195 (IGR: 5-3)


9944 4-Aminopyridine transiently increases intraocular pressure in rabbits
Socci RR; Chu E; Bayorh MA; Chu TC
Pharmacology 2003; 69: 108-114 (IGR: 5-3)


9948 A combination of timoptol and L-arginine HCl: a regulator of intraocular pressure in rabbits
Veselovsky J; Olah Z; Vesela A; Gressnerova S
?eska a Slovenska Oftalmologie 2003; 59: 295-302 (IGR: 5-3)


8874 Nitric oxide and cyclic GMP enhance aqueous humor outflow facility in rabbits
Kotikoski H; Vapaatalo H; Oksala O
Current Eye Research 2003; 26: 119-123 (IGR: 5-2)


8937 Omega conotoxin: a subtype specific calcium channel ligand with therapeutic potential in glaucoma?
Chu TC; Potter DE
Research Communications in Pharmacology and Toxicology 2001; 6: 263-275 (IGR: 5-2)


8933 Pharmacokinetic profile of topical flunarizine in rabbit eye and plasma
Maltese A; Bucolo C
Journal of Ocular Pharmacology and Therapeutics 2003; 19: 171-179 (IGR: 5-2)


8934 Evaluation of the ocular hypotensive response of serotonin 5 HT1A and 5 HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys
May JA; McLaughlin MA; Sharif NA; Hellberg MR; Dean TR
Journal of Pharmacology and Experimental Therapeutics 2003; 306: 301-309 (IGR: 5-2)


8932 Effects of adenosine on intraocular pressure, optic nerve head blood flow, and choroidal blood flow in healthy humans
Polska E; Ehrlich P; Luksch A; Fuchsjager-Mayrl G; Schmetterer L
Investigative Ophthalmology and Visual Science 2003; 44: 3110-3114 (IGR: 5-2)


8939 Inhibition of 11β hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension
Rauz S; Cheung CM; Wood PJ; Coca-Prados M; Walker EA; Murray PI; Stewart PM
Quarterly Journal of Medicine 2003; 96: 481-490 (IGR: 5-2)


8935 A novel D2 dopaminergic and α2 adrenoceptor receptor agonist induces substantial and prolonged IOP decrease in normotensive rabbits
Savolainen J; Rautio J; Razzetti R; Jarvinen T
Journal of Pharmacy and Pharmacology 2003; 55: 789-794 (IGR: 5-2)


8385 Effects of ion transport and channel-blocking drugs on aqueous humor formation in isolated bovine eye
Shahidullah M; Wilson WS; Yap M; To CH
Investigative Ophthalmology and Visual Science 2003; 44: 1185-1191 (IGR: 5-1)


8525 Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys
Chien FY; Wang RF; Mittag TW; Podos SM
Archives of Ophthalmology 2003; 121: 87-90 (IGR: 5-1)


8526 Dexanabinol (HU-211) has a beneficial effect on axonal sprouting and survival after rat optic nerve crush injury
Zalish M; Lavie V
Vision Research 2003; 43: 237-242 (IGR: 5-1)


8419 Autonomic function in mice lacking alpha5 neuronal nicotinic acetylcholine receptor subunit
Wang N; Orr-Urtreger A; Chapman J; Rabinowitz R; Nachman R; Korczyn AD
Journal of Physiology 2002; 542: 347-354 (IGR: 5-1)


8532 Effects of olprinone hydrochloride on intraocular pressure and ocular blood flow in patients after cardiac surgery under cardiopulmonary bypass
Goto K; Hasegawa A; Shingu C; Hayano Y; Yoshitake S; Noguchi T
Japanese Journal of Anesthesiology 2002; 51: 1212-1216 (IGR: 5-1)


8678 Iganidipine, a new water-soluble Ca2+ antagonist: ocular and periocular penetration after instillation
Ishii K; Matsuo H; Fukaya Y; Tanaka S; Sakaki H; Waki M; Araie M
Investigative Ophthalmology and Visual Science 2003; 44: 1169-1177 (IGR: 5-1)


8531 Presence of diadenosine polyphosphates in the aqueous humor: their effect on intraocular pressure
Pintor J; Peral A; Pelaez T; Martin S; Hoyle CH
Journal of Pharmacology and Experimental Therapeutics 2003; 304: 342-348 (IGR: 5-1)


8298 Ocular hypotensive action of topical flunarizine in the rabbit: role of sigma 1 recognition sites
Campana G; Bucolo C; Murari G; Spampinato S
Journal of Pharmacology and Experimental Therapeutics 2002; 303: 1086-1094 (IGR: 4-3)


8060 Endothelin-A receptor antagonist BQ-485 protects against intraocular pressure spike induced by laser trabeculoplasty in the rabbit
Holló G; Kóthy P; Lakatos P; Vargha P
Ophthalmologica 2002; 216: 459-462 (IGR: 4-3)


8339 Cannabinoids in the treatment of glaucoma
Jarvinen T; Pate DW; Laine K
Pharmacology and Therapeutics 2002; 95: 203-220 (IGR: 4-3)


8301 Topically administered CB2-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits
Laine K; Jarvinen K; Jarvinen T
Life Sciences 2003; 72: 837-842 (IGR: 4-3)


8059 Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid
Laine K; Jarvinen K; Mechoulam R; Breuer A; Jarvinen T
Investigative Ophthalmology and Visual Science 2002; 43(10): 3216-3222 (IGR: 4-3)


8062 The influence of nitric synthase inhibitor (L-NAME) on the intraocular pressure in endotoxin induced uveitis in rats
Szymaniec S; Misiuk-Hojlo M
Klinika Oczna 2002; 104: 87-88 (IGR: 4-3)


8330 Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway
Tomita H; Nakazawa T; Sugano E; Abe T; Tamai M
European Journal of Pharmacology 2002; 452: 263-268 (IGR: 4-3)


3452 Aquaporin deletion in mice reduces intraocular pressure and aqueous fluid production
Zhang D; Vetrivel L; Verkman AS
Journal of General Physiology 2002; 119: 561-569 (IGR: 4-2)


3591 Inhibitors of NHE-1 Na+/H+ exchange reduce mouse intraocular pressure
Avila MY; Seidler RW; Stone RA; Civan MM
Investigative Ophthalmology and Visual Science 2002; 43: 1897-1902 (IGR: 4-2)


3592 Adenylyl cyclase activity mediated by β-adrenoceptors in immortalized human trabecular meshwork and non-pigmented ciliary epithelial cells
Crider JY; Sharif NA
Journal of Ocular Pharmacology and Therapeutics 2002; 18: 221-230 (IGR: 4-2)


3593 A myosin light chain kinase inhibitor, ML-9, lowers the intraocular pressure in rabbit eyes
Honjo M; Inatani M; Kido N; Sawamura T; Yue BY; Honda Y; Tanihara H
Experimental Eye Research 2002; 75: 135-142 (IGR: 4-2)


3594 The effects of several vasopressin receptor antagonists on normal intraocular pressure and the intraocular distribution of vasopressin receptor subtypes
Naito A; Kurasawa T; Ohtake Y; Toyoda Y; Ezure Y; Koike K; Shigenobu K
Biological & Pharmaceutical Bulletin 2002; 25: 251-255 (IGR: 4-2)


3595 Chronic cannabis use in the Compassionate Investigational New Drug program: an examination of benefits and adverse effects of legal clinical cannabis
Russo E; Mathre ML; Byrne A; Velin R; Bach PJ; Sanchez Ramos J; Kirlin KA
Journal of Cannabis Therapeutics 2002; 2: 3-57 (IGR: 4-2)


6600 Aqueous humor adrenomedullin levels differ in patients with different types of glaucoma
Evereklioglu C; Doganay S; Er H; Yurekli M
Japanese Journal of Ophthalmology 2002; 46: 203-208 (IGR: 4-1)


6847 Relaxing effect of CEDO 8956 and hydralazine HCl in cultured smooth muscle cells versus pericytes: a preliminary study
Haefliger IO; Pedrini M; Anderson DR
Klinische Monatsblätter für Augenheilkunde 2002; 219: 277-280 (IGR: 4-1)


6858 Nitric oxide is proangiogenic in the retina and choroid
Ando A; Yang A; Mori K; Yamada H; Yamada E; Takahashi K; Saikia J; Kim M; Melia M; Fishman M
Journal of Cellular Physiology 2002; 191: 116-124 (IGR: 4-1)


6859 Soft cannabinoid analogues as potential anti-glaucoma agents
Buchwald A; Derendorf H; Ji F; Nagaraja NY; Wu WM; Bodor N
Pharmazie 2002; 57: 108-114 (IGR: 4-1)


6860 Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: Role of cyclic GMP
Kotikoski H; Alajuuma P; Moilanen E; Salmenpera P; Oksala O; Laippala P; Vapaatalo H
Journal of Ocular Pharmacology and Therapeutics 2002; 18: 11-23 (IGR: 4-1)


6861 Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides
Laine K; Jarvinen K; Pate DW; Urtti A; Jarvinen T
Investigative Ophthalmology and Visual Science 2002; 43: 393-397 (IGR: 4-1)


6862 Forskolin upregulation of NOS I protein expression in porcine ciliary processes: a new aspect of aqueous humor regulation
Liu R; Flammer J; Haefliger IO
Klinische Monatsblätter für Augenheilkunde 2002; 219: 281-283 (IGR: 4-1)


6863 Potentiation of sympathetic neurotransmission in bovine isolated irides by isoprostanes
Opere CA; Awe SO; Harris LC; Leday AM; Ohia SE
Free Radical Research 2001; 35: 257-264 (IGR: 4-1)


6864 Ocular hypotensive and aqueous outflow-enhancing effects of AL-3037A (sodium ferri ethylenediaminetetraacetate)
Pang IH; Moll H; McLaughlin M; Knepper PA; De Santis L; Epstein DL; Clark AF
Experimental Eye Research 2001; 73: 815-825 (IGR: 4-1)


6865 The effect of topical natural ergot alkaloids on the intraocular pressure and aqueous humor dynamics in rabbits with α-chymotrypsin-induced ocular hypertension
Puras G; Santafe J; Segarra J; Garrido M; Melena J
Graefe's Archive for Clinical and Experimental Ophthalmology 2002; 240: 322-328 (IGR: 4-1)


6866 Flufenamic acid enhances current through maxi-K channels in the trabecular meshwork of the eye
Stumpff F; Boxberger M; Thieme H; Strauss O; Wiederholt M
Current Eye Research 2001; 22: 427-437 (IGR: 4-1)


6867 Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase
Waki M; Yoshida Y; Oka T; Azuma M
Current Eye Research 2001; 22: 470-474 (IGR: 4-1)


6868 Effects of two forskolin analogues on the elevation of ocular pressure in human
Yang W; Li X; Chen Z; Nie L; Li L; Lie W
Chinese Ophthalmic Research 2001; 19: 556-559 (IGR: 4-1)


18333 Activation of p42/p44 mitogen-activated protein kinase and contraction by prostaglandin F2α, ionomycin, and thapsigargin in cat iris sphincter smooth muscle: inhibition by PD98059, KN-93, and isoproterenol
Ansari HR; Husain S; Abdel-Latif AA
Journal of Pharmacology and Experimental Therapeutics 2001; 299: 178-186 (IGR: 3-3)


18332 Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes
Maihöfner C; Schlötzer-Schrehardt U; Gübring H; Zeilhofer HU; Naumann GOH; Pahl A; Mardin CY; Tamm ER; Brune K
Investigative Ophthalmology and Visual Science 2001; 42: 2616-2624 (IGR: 3-3)


18331 Assessment of the intraocular pressure-lowering activity of bicyclic derivatives of 1-substituted benzyloctahydroisoquinoline
Saha SL; Igbo IN; Opere CA; Zhan GL; Taniyama J; Ohia SE; Roche VF
Journal of Ocular Pharmacology and Therapeutics 2001; 17: 413-420 (IGR: 3-3)


18330 Effects of the marine macrolides swinholide A and jasplakinolide on outflow facility in monkeys
Tian B; Kiland JA; Kaufman PL
Investigative Ophthalmology and Visual Science 2001; 42: 3187-3192 (IGR: 3-3)


6321 Effect of H-7 on cultured human trabecular meshwork cells
Liu X; Cai S; Glasser A; Volberg T; Polansky JR; Fauss DJ; Brandt CR; Geiger B; Kaufman PL
Molecular Vision 2001; 7: 145-153 (IGR: 3-2)


6332 Nitric oxide attenuates α2-adrenergic receptors by ADP-ribosylation of GIα in ciliary epithelium
Moroi SE; Sitaramayya A
Investigative Ophthalmology and Visual Science 2001; 42: 2056-2062 (IGR: 3-2)


6363 Intraocular pressure responses to the adenosine agonist cyclohexyladenosine: evidence for a dual mechanism of action
Crosson CE
Investigative Ophthalmology and Visual Science 2001; 42: 1837-1840 (IGR: 3-2)


6368 Intraocular pressure-lowering activity and in vivo disposition of dipivalyl terbutalone in rabbits
Reddy IK; Vaithiyalingam SR; Khan MA; Bodor NS
Drug Development and Industrial Pharmacy 2001; 27: 137-141 (IGR: 3-2)


6516 Cationic ferritin changes outflow facility in human eyes whereas anionic ferritin does not
Ethier CR; Chan DWH
Investigative Ophthalmology and Visual Science 2001; 42: 1795-1802 (IGR: 3-2)


6517 Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes
Honjo M; Inatani M; Kido N; Sawamura T; Yue BYJT; Honda Y; Tanihara H
Archives of Ophthalmology 2001; 119: 1171-1178 (IGR: 3-2)


19152 Effects of Rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility
Honjo M; Tanihara H; Inatani M; Kido N; Sawamura T; Yue BYJT; Narumiya S; Honda Y
Investigative Ophthalmology and Visual Science 2001; 42: 137-144 (IGR: 3-1)


19153 The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies
Porcella A; Maxia C; Gessa GL; Pani L
European Journal of Neuroscience 2001; 13: 409-412 (IGR: 3-1)


19154 Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632
Rao PV; Deng PF; Kumar J; Epstein DL
Investigative Ophthalmology and Visual Science 2001; 42: 1029-1037 (IGR: 3-1)


19155 The changes on free radical and catalase in ocular tissue of rabbits undergoing acute ocular hypertension status
Weirong S; Qingkang M; Yanyan L
Chinese Ophthalmic Research 2001; 19: 104-106 (IGR: 3-1)


15661 Mechanism related to reduction of intraocular pressure by melanocortins in rabbits
Naveh N; Kaplan-Messas A; Marshall J
British Journal of Ophthalmology 2000; 84: 1411-1414 (IGR: 2-3)


15660 Effect of ifenprodil on aqueous humor dynamics and optic nerve head circulation in rabbits
Muta K; Tamaki Y; Araie M; Matsubara M
Journal of Ocular Pharmacology and Therapeutics 2000; 16: 241-250 (IGR: 2-3)


15920 Pharmacology of the intraocular pressure (IOP) lowering effect of systemic dexanabinol (HU-211), a non-psychotropic cannabinoid
Beilin M; Neumann R; Belkin M; Green K; Bar-Ilan A
Journal of Ocular Pharmacology and Therapeutics 2000; 16: 217-230 (IGR: 2-3)


15788 Ocular effects associated with the chronic administration of the adenosine A(1) agonist cyclohexyladenosine
Crosson CE; Niazi Z
Current Eye Research 2000; 21: 808-813 (IGR: 2-3)


15773 In vitro and ex vivo hydrolysis rates of ethacrynate esters and their relationship to intraocular pressure in the rabbit eye
Deshpande G; Schoenwald RD; Barfknecht CF; Duffel MW
Journal of Ocular Pharmacology and Therapeutics 2000; 16: 539-556 (IGR: 2-3)


15779 Effect of CO2 pneumoperitoneum on early cellular markers of retinal ischemia in rabbits with alpha-chymotrypsin-induced glaucoma
Lentschener C; Fredi-Reygrobellet D; Bouaziz H; Mazoit JX; Niessen F; Benhamou D
Surgical Endoscopy 2000; 14: 1057-1061 (IGR: 2-3)


16004 Suppressing effect of isoforskolin and forskolin on ocular hypertension in rabbits
Li X; Nie L; Yang W
Chinese Journal of Ophthalmology 2000; 36: 292 (IGR: 2-3)


15748 The ocular pharmacokinetics of ketanserin and its metabolite, ketanserinol, in albino rabbits
Schoenwald RD; Zhu J
Journal of Ocular Pharmacology and Therapeutics 2000; 16: 481-495 (IGR: 2-3)


15769 Mediation of calcium-independent contraction in trabecular meshwork through protein kinase C and rho-A
Thieme H; Nuskovski M; Nass JU; Pleyer U; Strauss O; Wiederholt M
Investigative Ophthalmology and Visual Science 2000; 41: 4240-4246 (IGR: 2-3)


15892 ML-7, chelerythrine and phorbol ester increase outflow facility in the monkey eye
Tian B; Brumback LC; Kaufman PL
Experimental Eye Research 2000; 71: 551-556 (IGR: 2-3)


5982 H-7 effects on the structure and fluid conductance of monkey trabecular meshwork
Sabanay I; Gabelt BT; Tian B; Kaufman PL; Geiger B
Archives of Ophthalmology 2000; 118: 955-962 (IGR: 2-2)


5991 The role of NaKCl cotransport in blood-to-aqueous chloride fluxes across rabbit ciliary epithelium
Crook RB; Takahashi K; Mead A; Dunn JJ; Sears ML
Investigative Ophthalmology and Visual Science 2000; 41: 2574-2583 (IGR: 2-2)


6212 Effect of latrunculin-A on morphology and actin-associated adhesions of cultured human trabecular meshwork cells
Cai S; Liu X; Glasser A; Volberg T; Filla M; Geiger B; Polansky JR; Kaufman PL
Molecular Vision 2000; 6: 132-143 (IGR: 2-2)


6213 The effect of L-arginine on intraocular pressure in the human eye
Chuman H; Chuman T; Nao-i N; Sawada A
Current Eye Research 2000; 20: 511-516 (IGR: 2-2)


6214 Effect of fluoxetine on intraocular pressure in the rabbit
Costagliola C; Mastropasqua L; Capone D; Verolino M; Ciancaglini M; Pisanti N
Experimental Eye Research 2000; 70: 551-555 (IGR: 2-2)


6215 Effect of SR121463, a selective non-peptide vasopressin V sub(2) receptor antagonist, in a rabbit model of ocular hypertension
Lacheretz F; Barbier A; Serradeil-Le Gal C; Elena PP; Maffrand JP; Le Fur G
Journal of Ocular Pharmacology and Therapeutics 2000; 16: 203-216 (IGR: 2-2)


6216 Latrunculins' effects on intraocular pressure, aqueous humor flow, and corneal endothelium
Peterson JA; Tian B; McLaren JW; Hubbard WC; Geiger B; Kaufman PL
Investigative Ophthalmology and Visual Science 2000; 41: 1749-1758 (IGR: 2-2)


5626 Influence of muscarinic agonists and tyrosine kinase inhibitors on L-type Ca(2+)Channels in human and bovine trabecular meshwork cells
Steinhausen K; Stumpff F; Strauss O; Thieme H; Wiederholt M
Experimental Eye Research 2000; 70: 285-293 (IGR: 2-1)


5630 Effect of latrunculin-B on outflow facility in monkeys
Peterson JA; Tian B; Geiger B; Kaufman PL
Experimental Eye Research 2000; 70: 307-313 (IGR: 2-1)


5837 Kinase independent function of EphB receptors in retinal axon pathfinding to the optic disc from dorsal but not ventral retina
Birgbauer E; Cowan CA; Sretavan DW; Henkemeyer M
Development 2000; 127: 1231-1241 (IGR: 2-1)


5838 Acetylsalicylic acid does not reduce the intraocular pressure variation in ocular hypertension or glaucoma
Linden C; Alm A
Experimental Eye Research 2000; 70: 281-283 (IGR: 2-1)


5839 Laboratory investigation: A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits
Naveh N; Weissman C; Muchtar S; Benita S; Mechoulam R
Graefe's Archive for Clinical and Experimental Ophthalmology 2000; 238: 334-338 (IGR: 2-1)


5840 Expression of adenylate cyclase subtypes II and IV in the human outflow pathway
Zhang X; Wang N; Schroeder A; Erickson KA
Investigative Ophthalmology and Visual Science 2000; 41: 998-1005 (IGR: 2-1)


15544 Advances in glaucoma diagnosis and therapy for the next millennium: new drugs for trabecular and uveoscleral outflow
Kaufman PL; Gabelt B; Tian B; Liu X
Seminars in Ophthalmology 1999; 14: 130-143 (IGR: 1-3)


15546 Atriopeptin, sodium azide and cyclic GMP reduce secretion of aqueous humour and inhibit intracellular calcium release in bovine cultured ciliary epithelium
Shahidullah M; Wilson WS
British Journal of Pharmacology 1999; 127: 1438-1446 (IGR: 1-3)


15547 Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2
Song ZH; Slowey CA
Journal of Pharmacology and Experimental Therapeutics 2000; 292: 136-139 (IGR: 1-3)


15548 Ocular effects of adrenomedullin
Taniguchi T; Kawase K; Gu Z-B; Kimura M; Okano Y; Kawakami H; Tsuji A; Kitazawa Y
Experimental Eye Research 1999; 69: 467-474 (IGR: 1-3)


15549 Biphasic intraocular pressure response to calcitonin gene-related peptide
Taniguchi T; Nakai Y; Karim Z; Gu Z-B; Kawase K; Kitazawa Y
Current Eye Research 1999; 5: 432-438 (IGR: 1-3)


15550 The effects of protein kinase C on trabecular meshwork and ciliary muscle contractility
Thieme H; Nass JU; Nuskovski M; Bechrakis NE; Stumpff F; Strauss O; Wiederholt M
Investigative Ophthalmology and Visual Science 1999; 40: 3254-3261 (IGR: 1-3)


5191 Stimulation of maxi-K channels in trabecular meshwork by tyrosine kinase inhibitors.
Stumpff F; Que Y; Boxberger M; Strauss O; Wiederholt M
Investigative Ophthalmology and Visual Science 1999; 40: 1404-1417 (IGR: 1-2)


5231 The effect of topical dihydroergocristine on the intraocular pressure in alpha-chymotrypsin-induced ocular hypertensive rabbits.
Melena J; Santafe J; Segarra J
Methods and Findings in Experimental and Clinical Pharmacology 1998; 20: 861-867 (IGR: 1-2)


5235 Ocular hypotensive effect of ramiprilat in chronic and acute models of glaucoma in rabbits
Shah GB; Harma S; Mehta AA; Goyal RK
Indian Journal of Pharmacology 1999; 31: 110-115 (IGR: 1-2)


5290 Sympathetic vasoconstriction in the rat anterior choroid is mediated by alpha1-adrenoceptors
Kawarai M; Koss MC
European Journal of Pharmacology 1999; 363: 35-40 (IGR: 1-2)


5456 Sigma1 recognition sites in rabbit iris-ciliary body: topical sigma1-site agonists lower intraocular pressure.
Bucolo C; Campana G; Di Toro R; Cacciaguerra S; Spampinato S
Journal of Pharmacology and Experimental Therapeutics 1999; 289: 1362-1369 (IGR: 1-2)


5457 Effects of ethacrynic acid on Schlemm's canal inner wall and outflow facility in human eyes.
Ethier CR; Coloma FM
Investigative Ophthalmology and Visual Science 1999; 40: 1599-1607 (IGR: 1-2)


5458 Enthacrynic and acid effects on inner wall pores in living monkeys.
Ethier CR; Croft MA; Coloma FM; Gangnon RE; Ladd W; Kaufman PL
Investigative Ophthalmology and Visual Science 1999; 40: 1382-1391 (IGR: 1-2)


5459 Effects of adenosinergic agents on the vascular resistance and on the optic nerve response in the perfused cat eye.
Kaelin-Lang A; Jurklies B; Niemeyer G
Vision Research 1999; 39: 1059-1068 (IGR: 1-2)


5460 Effects of ethacrynic acid on intraocular pressure of anesthetized rats.
Searles RV; Johnson M; Shikher V; Balaban CD; Severs WB
Proceedings of the Society for Experimental Biology and Medicine 1999; 220: 184-188 (IGR: 1-2)


5461 Safety and ocular hypotensive efficacy of a single dose of metoclopramide or droperidol in healthy subjects
Shu Lang Liao; Por Tying Hung; Yi Chun Chen; Wei Lun Lan
Journal of Ocular Pharmacology and Therapeutics 1999; 15: 117-121 (IGR: 1-2)


5462 8OH-DPAT-Induced ocular hypotension: Sites and mechanisms of action
Teh-Ching Chu; Miller J; Ogidigben; Potter DE
Experimental Eye Research 1999; 69: 227-238 (IGR: 1-2)


5463 Combined effects of H-7 and cytochalasin B on outflow facility in monkeys
Tian B; Gabelt BT; Geiger B; Kaufman PL
Experimental Eye Research 1999; 66: 649-655 (IGR: 1-2)



11.8 Neuroprotection (3947 abstracts found)


84549 Possible therapeutic effect of magnesium in ocular diseases
Ajith TA
Journal of basic and clinical physiology and pharmacology 2019; 31: (IGR: 21-1)


85110 Recent Research Efforts to Achieve Neuroprotection, Progression and Treatment of Glaucoma
Jacobi A
Klinische Monatsblätter für Augenheilkunde 2020; 237: 133-139 (IGR: 21-1)


84510 Intravitreal S100B Injection Triggers a Time-Dependent Microglia Response in a Pro-Inflammatory Manner in Retina and Optic Nerve
Grotegut P
Molecular Neurobiology 2020; 57: 1186-1202 (IGR: 21-1)


84974 Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina
Nascimento-Dos-Santos G
Biochimica et Biophysica Acta - Molecular Basis of Disease 2020; 1866: 165686 (IGR: 21-1)


84973 Bio-tactics for neuroprotection of retinal ganglion cells in the treatment of glaucoma
Yadav KS
Life Sciences 2020; 243: 117303 (IGR: 21-1)


84995 Current State of Primary Neuroprotection in Glaucoma
Reinehr S
Klinische Monatsblätter für Augenheilkunde 2020; 237: 143-149 (IGR: 21-1)


84756 Potential mechanisms of retinal ganglion cell type-specific vulnerability in glaucoma
Wang AY
Clinical and Experimental Optometry 2019; 0: (IGR: 21-1)


85159 Pathogenic roles of retinal glia in glaucoma
Shinozaki Y
Nippon yakurigaku zasshi 2020; 155: 87-92 (IGR: 21-1)


85210 The Role of Autophagy in Glaucomatous Optic Neuropathy
Adornetto A
Frontiers in cell and developmental biology 2020; 8: 121 (IGR: 21-1)


84701 Neuroprotective effects of DAAO are mediated via the ERK1/2 signaling pathway in a glaucomatous animal model
Zhang X
Experimental Eye Research 2020; 190: 107892 (IGR: 21-1)


84393 Silencing of GAS5 Alleviates Glaucoma in Rat Models by Reducing Retinal Ganglion Cell Apoptosis
Zhou RR
Human Genetics and Therapeutics 2019; 30: 1505-1519 (IGR: 21-1)


84615 Secondary Neuroprotection in Glaucoma by Reduction of Intraocular Pressure
Unterlauft JD
Klinische Monatsblätter für Augenheilkunde 2020; 237: 150-157 (IGR: 21-1)


84974 Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina
Nascimento-Dos-Santos G
Biochimica et Biophysica Acta - Molecular Basis of Disease 2020; 1866: 165686 (IGR: 21-1)


84756 Potential mechanisms of retinal ganglion cell type-specific vulnerability in glaucoma
Wang AY
Clinical and Experimental Optometry 2019; 0: (IGR: 21-1)


85112 Secondary Neuroprotection in Glaucoma Through the Concepts of Complementary Drug Therapy
Erb C
Klinische Monatsblätter für Augenheilkunde 2020; 237: 163-174 (IGR: 21-1)


84764 TRPC5 regulates axonal outgrowth in developing retinal ganglion cells
Oda M
Laboratory Investigation 2020; 100: 297-310 (IGR: 21-1)


84903 Resveratrol Protects Optic Nerve Head Astrocytes from Oxidative Stress-Induced Cell Death by Preventing Caspase-3 Activation, Tau Dephosphorylation at Ser and Formation of Misfolded Protein Aggregates
Means JC
Cellular and molecular neurobiology 2020; 0: (IGR: 21-1)


84808 Piezo channel plays a part in retinal ganglion cell damage
Morozumi W
Experimental Eye Research 2020; 191: 107900 (IGR: 21-1)


84736 Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications
Fu L
BioMed research international 2019; 2019: 8397521 (IGR: 21-1)


84559 Elevated ocular pressure reduces voltage-gated sodium channel NaV1.2 protein expression in retinal ganglion cell axons
Risner ML
Experimental Eye Research 2020; 190: 107873 (IGR: 21-1)


84863 SIRT1 is required for the neuroprotection of resveratrol on retinal ganglion cells after retinal ischemia-reperfusion injury in mice
Luo J
Graefe's Archive for Clinical and Experimental Ophthalmology 2020; 258: 335-344 (IGR: 21-1)


85111 Secondary Neuroprotection in Glaucoma from Change in Lifestyle
Rüfer F
Klinische Monatsblätter für Augenheilkunde 2020; 237: 158-162 (IGR: 21-1)


84628 Inhibition of cAMP/PKA Pathway Protects Optic Nerve Head Astrocytes against Oxidative Stress by Akt/Bax Phosphorylation-Mediated Mfn1/2 Oligomerization
Ju WK
Oxidative medicine and cellular longevity 2019; 2019: 8060962 (IGR: 21-1)


85227 Arginase Pathway in Acute Retina and Brain Injury: Therapeutic Opportunities and Unexplored Avenues
Fouda AY
Frontiers in pharmacology 2020; 11: 277 (IGR: 21-1)


84973 Bio-tactics for neuroprotection of retinal ganglion cells in the treatment of glaucoma
Yadav KS
Life Sciences 2020; 243: 117303 (IGR: 21-1)


84774 Intravitreal Therapy Against the Complement Factor C5 Prevents Retinal Degeneration in an Experimental Autoimmune Glaucoma Model
Reinehr S
Frontiers in pharmacology 2019; 10: 1381 (IGR: 21-1)


84852 Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma
Tribble JR
Brain communications 2019; 1: fcz035 (IGR: 21-1)


84793 Lycium Barbarum Exerts Protection against Glaucoma-Like Injury Via Inhibition of MMP-9 Signaling In Vitro
Xu S
Medical Science Monitor 2019; 25: 9794-9800 (IGR: 21-1)


84852 Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma
Vasalauskaite A
Brain communications 2019; 1: fcz035 (IGR: 21-1)


84764 TRPC5 regulates axonal outgrowth in developing retinal ganglion cells
Yamamoto H
Laboratory Investigation 2020; 100: 297-310 (IGR: 21-1)


85227 Arginase Pathway in Acute Retina and Brain Injury: Therapeutic Opportunities and Unexplored Avenues
Eldahshan W
Frontiers in pharmacology 2020; 11: 277 (IGR: 21-1)


84559 Elevated ocular pressure reduces voltage-gated sodium channel NaV1.2 protein expression in retinal ganglion cell axons
McGrady NR
Experimental Eye Research 2020; 190: 107873 (IGR: 21-1)


84628 Inhibition of cAMP/PKA Pathway Protects Optic Nerve Head Astrocytes against Oxidative Stress by Akt/Bax Phosphorylation-Mediated Mfn1/2 Oligomerization
Shim MS
Oxidative medicine and cellular longevity 2019; 2019: 8060962 (IGR: 21-1)


85110 Recent Research Efforts to Achieve Neuroprotection, Progression and Treatment of Glaucoma
van Zyl T
Klinische Monatsblätter für Augenheilkunde 2020; 237: 133-139 (IGR: 21-1)


84510 Intravitreal S100B Injection Triggers a Time-Dependent Microglia Response in a Pro-Inflammatory Manner in Retina and Optic Nerve
Kuehn S
Molecular Neurobiology 2020; 57: 1186-1202 (IGR: 21-1)


84973 Bio-tactics for neuroprotection of retinal ganglion cells in the treatment of glaucoma
Sharma S
Life Sciences 2020; 243: 117303 (IGR: 21-1)


84393 Silencing of GAS5 Alleviates Glaucoma in Rat Models by Reducing Retinal Ganglion Cell Apoptosis
Li HB
Human Genetics and Therapeutics 2019; 30: 1505-1519 (IGR: 21-1)


84793 Lycium Barbarum Exerts Protection against Glaucoma-Like Injury Via Inhibition of MMP-9 Signaling In Vitro
Liu S
Medical Science Monitor 2019; 25: 9794-9800 (IGR: 21-1)


85210 The Role of Autophagy in Glaucomatous Optic Neuropathy
Parisi V
Frontiers in cell and developmental biology 2020; 8: 121 (IGR: 21-1)


84701 Neuroprotective effects of DAAO are mediated via the ERK1/2 signaling pathway in a glaucomatous animal model
Zhang R
Experimental Eye Research 2020; 190: 107892 (IGR: 21-1)


84736 Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications
Kwok SS
BioMed research international 2019; 2019: 8397521 (IGR: 21-1)


84774 Intravitreal Therapy Against the Complement Factor C5 Prevents Retinal Degeneration in an Experimental Autoimmune Glaucoma Model
Gomes SC
Frontiers in pharmacology 2019; 10: 1381 (IGR: 21-1)


84863 SIRT1 is required for the neuroprotection of resveratrol on retinal ganglion cells after retinal ischemia-reperfusion injury in mice
He T
Graefe's Archive for Clinical and Experimental Ophthalmology 2020; 258: 335-344 (IGR: 21-1)


84903 Resveratrol Protects Optic Nerve Head Astrocytes from Oxidative Stress-Induced Cell Death by Preventing Caspase-3 Activation, Tau Dephosphorylation at Ser and Formation of Misfolded Protein Aggregates
Lopez AA
Cellular and molecular neurobiology 2020; 0: (IGR: 21-1)


84808 Piezo channel plays a part in retinal ganglion cell damage
Inagaki S
Experimental Eye Research 2020; 191: 107900 (IGR: 21-1)


84974 Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina
de-Souza-Ferreira E
Biochimica et Biophysica Acta - Molecular Basis of Disease 2020; 1866: 165686 (IGR: 21-1)


84756 Potential mechanisms of retinal ganglion cell type-specific vulnerability in glaucoma
Lee PY
Clinical and Experimental Optometry 2019; 0: (IGR: 21-1)


84995 Current State of Primary Neuroprotection in Glaucoma
Grotegut P
Klinische Monatsblätter für Augenheilkunde 2020; 237: 143-149 (IGR: 21-1)


85159 Pathogenic roles of retinal glia in glaucoma
Koizumi S
Nippon yakurigaku zasshi 2020; 155: 87-92 (IGR: 21-1)


84774 Intravitreal Therapy Against the Complement Factor C5 Prevents Retinal Degeneration in an Experimental Autoimmune Glaucoma Model
Gassel CJ
Frontiers in pharmacology 2019; 10: 1381 (IGR: 21-1)


84903 Resveratrol Protects Optic Nerve Head Astrocytes from Oxidative Stress-Induced Cell Death by Preventing Caspase-3 Activation, Tau Dephosphorylation at Ser and Formation of Misfolded Protein Aggregates
Koulen P
Cellular and molecular neurobiology 2020; 0: (IGR: 21-1)


84756 Potential mechanisms of retinal ganglion cell type-specific vulnerability in glaucoma
Bui BV
Clinical and Experimental Optometry 2019; 0: (IGR: 21-1)


84793 Lycium Barbarum Exerts Protection against Glaucoma-Like Injury Via Inhibition of MMP-9 Signaling In Vitro
Yan G
Medical Science Monitor 2019; 25: 9794-9800 (IGR: 21-1)


84808 Piezo channel plays a part in retinal ganglion cell damage
Iwata Y
Experimental Eye Research 2020; 191: 107900 (IGR: 21-1)


84393 Silencing of GAS5 Alleviates Glaucoma in Rat Models by Reducing Retinal Ganglion Cell Apoptosis
You QS
Human Genetics and Therapeutics 2019; 30: 1505-1519 (IGR: 21-1)


85210 The Role of Autophagy in Glaucomatous Optic Neuropathy
Morrone LA
Frontiers in cell and developmental biology 2020; 8: 121 (IGR: 21-1)


84995 Current State of Primary Neuroprotection in Glaucoma
Tsai T
Klinische Monatsblätter für Augenheilkunde 2020; 237: 143-149 (IGR: 21-1)


84852 Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma
Redmond T
Brain communications 2019; 1: fcz035 (IGR: 21-1)


84628 Inhibition of cAMP/PKA Pathway Protects Optic Nerve Head Astrocytes against Oxidative Stress by Akt/Bax Phosphorylation-Mediated Mfn1/2 Oligomerization
Kim KY
Oxidative medicine and cellular longevity 2019; 2019: 8060962 (IGR: 21-1)


84701 Neuroprotective effects of DAAO are mediated via the ERK1/2 signaling pathway in a glaucomatous animal model
Chen J
Experimental Eye Research 2020; 190: 107892 (IGR: 21-1)


85227 Arginase Pathway in Acute Retina and Brain Injury: Therapeutic Opportunities and Unexplored Avenues
Narayanan SP
Frontiers in pharmacology 2020; 11: 277 (IGR: 21-1)


84973 Bio-tactics for neuroprotection of retinal ganglion cells in the treatment of glaucoma
Londhe VY
Life Sciences 2020; 243: 117303 (IGR: 21-1)


84764 TRPC5 regulates axonal outgrowth in developing retinal ganglion cells
Matsumoto H
Laboratory Investigation 2020; 100: 297-310 (IGR: 21-1)


84510 Intravitreal S100B Injection Triggers a Time-Dependent Microglia Response in a Pro-Inflammatory Manner in Retina and Optic Nerve
Meißner W
Molecular Neurobiology 2020; 57: 1186-1202 (IGR: 21-1)


84736 Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications
Chan YK
BioMed research international 2019; 2019: 8397521 (IGR: 21-1)


84559 Elevated ocular pressure reduces voltage-gated sodium channel NaV1.2 protein expression in retinal ganglion cell axons
Pasini S
Experimental Eye Research 2020; 190: 107873 (IGR: 21-1)


84863 SIRT1 is required for the neuroprotection of resveratrol on retinal ganglion cells after retinal ischemia-reperfusion injury in mice
Yang J
Graefe's Archive for Clinical and Experimental Ophthalmology 2020; 258: 335-344 (IGR: 21-1)


84974 Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina
Lani R
Biochimica et Biophysica Acta - Molecular Basis of Disease 2020; 1866: 165686 (IGR: 21-1)


84756 Potential mechanisms of retinal ganglion cell type-specific vulnerability in glaucoma
Jobling AI
Clinical and Experimental Optometry 2019; 0: (IGR: 21-1)


84808 Piezo channel plays a part in retinal ganglion cell damage
Nakamura S
Experimental Eye Research 2020; 191: 107900 (IGR: 21-1)


84764 TRPC5 regulates axonal outgrowth in developing retinal ganglion cells
Ishizaki Y
Laboratory Investigation 2020; 100: 297-310 (IGR: 21-1)


84774 Intravitreal Therapy Against the Complement Factor C5 Prevents Retinal Degeneration in an Experimental Autoimmune Glaucoma Model
Asaad MA
Frontiers in pharmacology 2019; 10: 1381 (IGR: 21-1)


84863 SIRT1 is required for the neuroprotection of resveratrol on retinal ganglion cells after retinal ischemia-reperfusion injury in mice
Yang N
Graefe's Archive for Clinical and Experimental Ophthalmology 2020; 258: 335-344 (IGR: 21-1)


85227 Arginase Pathway in Acute Retina and Brain Injury: Therapeutic Opportunities and Unexplored Avenues
Caldwell RW
Frontiers in pharmacology 2020; 11: 277 (IGR: 21-1)


84736 Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications
Ming Lai JS
BioMed research international 2019; 2019: 8397521 (IGR: 21-1)


84559 Elevated ocular pressure reduces voltage-gated sodium channel NaV1.2 protein expression in retinal ganglion cell axons
Lambert WS
Experimental Eye Research 2020; 190: 107873 (IGR: 21-1)


84974 Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina
Faria CC
Biochimica et Biophysica Acta - Molecular Basis of Disease 2020; 1866: 165686 (IGR: 21-1)


84995 Current State of Primary Neuroprotection in Glaucoma
Wagner N
Klinische Monatsblätter für Augenheilkunde 2020; 237: 143-149 (IGR: 21-1)


84510 Intravitreal S100B Injection Triggers a Time-Dependent Microglia Response in a Pro-Inflammatory Manner in Retina and Optic Nerve
Dick HB
Molecular Neurobiology 2020; 57: 1186-1202 (IGR: 21-1)


84628 Inhibition of cAMP/PKA Pathway Protects Optic Nerve Head Astrocytes against Oxidative Stress by Akt/Bax Phosphorylation-Mediated Mfn1/2 Oligomerization
Park TL
Oxidative medicine and cellular longevity 2019; 2019: 8060962 (IGR: 21-1)


84852 Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma
Young RD
Brain communications 2019; 1: fcz035 (IGR: 21-1)


85210 The Role of Autophagy in Glaucomatous Optic Neuropathy
Corasaniti MT
Frontiers in cell and developmental biology 2020; 8: 121 (IGR: 21-1)


84393 Silencing of GAS5 Alleviates Glaucoma in Rat Models by Reducing Retinal Ganglion Cell Apoptosis
Rong R
Human Genetics and Therapeutics 2019; 30: 1505-1519 (IGR: 21-1)


84701 Neuroprotective effects of DAAO are mediated via the ERK1/2 signaling pathway in a glaucomatous animal model
Wu J
Experimental Eye Research 2020; 190: 107892 (IGR: 21-1)


85210 The Role of Autophagy in Glaucomatous Optic Neuropathy
Bagetta G
Frontiers in cell and developmental biology 2020; 8: 121 (IGR: 21-1)


84974 Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina
Araújo VG
Biochimica et Biophysica Acta - Molecular Basis of Disease 2020; 1866: 165686 (IGR: 21-1)


84863 SIRT1 is required for the neuroprotection of resveratrol on retinal ganglion cells after retinal ischemia-reperfusion injury in mice
Li Z
Graefe's Archive for Clinical and Experimental Ophthalmology 2020; 258: 335-344 (IGR: 21-1)


84852 Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma
Hassan S
Brain communications 2019; 1: fcz035 (IGR: 21-1)


84974 Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina
Araújo VG
Biochimica et Biophysica Acta - Molecular Basis of Disease 2020; 1866: 165686 (IGR: 21-1)


84628 Inhibition of cAMP/PKA Pathway Protects Optic Nerve Head Astrocytes against Oxidative Stress by Akt/Bax Phosphorylation-Mediated Mfn1/2 Oligomerization
Ahn S
Oxidative medicine and cellular longevity 2019; 2019: 8060962 (IGR: 21-1)


84774 Intravitreal Therapy Against the Complement Factor C5 Prevents Retinal Degeneration in an Experimental Autoimmune Glaucoma Model
Stute G
Frontiers in pharmacology 2019; 10: 1381 (IGR: 21-1)


84393 Silencing of GAS5 Alleviates Glaucoma in Rat Models by Reducing Retinal Ganglion Cell Apoptosis
You ML
Human Genetics and Therapeutics 2019; 30: 1505-1519 (IGR: 21-1)


84808 Piezo channel plays a part in retinal ganglion cell damage
Hara H
Experimental Eye Research 2020; 191: 107900 (IGR: 21-1)


85227 Arginase Pathway in Acute Retina and Brain Injury: Therapeutic Opportunities and Unexplored Avenues
Caldwell RB
Frontiers in pharmacology 2020; 11: 277 (IGR: 21-1)


84995 Current State of Primary Neuroprotection in Glaucoma
Joachim SC
Klinische Monatsblätter für Augenheilkunde 2020; 237: 143-149 (IGR: 21-1)


84756 Potential mechanisms of retinal ganglion cell type-specific vulnerability in glaucoma
Greferath U
Clinical and Experimental Optometry 2019; 0: (IGR: 21-1)


84559 Elevated ocular pressure reduces voltage-gated sodium channel NaV1.2 protein expression in retinal ganglion cell axons
Calkins DJ
Experimental Eye Research 2020; 190: 107873 (IGR: 21-1)


84764 TRPC5 regulates axonal outgrowth in developing retinal ganglion cells
Shibasaki K
Laboratory Investigation 2020; 100: 297-310 (IGR: 21-1)


84510 Intravitreal S100B Injection Triggers a Time-Dependent Microglia Response in a Pro-Inflammatory Manner in Retina and Optic Nerve
Joachim SC
Molecular Neurobiology 2020; 57: 1186-1202 (IGR: 21-1)


84736 Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications
Pan W
BioMed research international 2019; 2019: 8397521 (IGR: 21-1)


84852 Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma
Fautsch MP
Brain communications 2019; 1: fcz035 (IGR: 21-1)


84736 Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications
Nie L
BioMed research international 2019; 2019: 8397521 (IGR: 21-1)


84774 Intravitreal Therapy Against the Complement Factor C5 Prevents Retinal Degeneration in an Experimental Autoimmune Glaucoma Model
Schargus M
Frontiers in pharmacology 2019; 10: 1381 (IGR: 21-1)


84974 Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina
Teixeira-Pinheiro LC
Biochimica et Biophysica Acta - Molecular Basis of Disease 2020; 1866: 165686 (IGR: 21-1)


84808 Piezo channel plays a part in retinal ganglion cell damage
Shimazawa M
Experimental Eye Research 2020; 191: 107900 (IGR: 21-1)


84863 SIRT1 is required for the neuroprotection of resveratrol on retinal ganglion cells after retinal ischemia-reperfusion injury in mice
Xing Y
Graefe's Archive for Clinical and Experimental Ophthalmology 2020; 258: 335-344 (IGR: 21-1)


84393 Silencing of GAS5 Alleviates Glaucoma in Rat Models by Reducing Retinal Ganglion Cell Apoptosis
Xiong K
Human Genetics and Therapeutics 2019; 30: 1505-1519 (IGR: 21-1)


84756 Potential mechanisms of retinal ganglion cell type-specific vulnerability in glaucoma
Brandli A
Clinical and Experimental Optometry 2019; 0: (IGR: 21-1)


84628 Inhibition of cAMP/PKA Pathway Protects Optic Nerve Head Astrocytes against Oxidative Stress by Akt/Bax Phosphorylation-Mediated Mfn1/2 Oligomerization
Edwards G
Oxidative medicine and cellular longevity 2019; 2019: 8060962 (IGR: 21-1)


85210 The Role of Autophagy in Glaucomatous Optic Neuropathy
Tonin P
Frontiers in cell and developmental biology 2020; 8: 121 (IGR: 21-1)


84974 Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina
Vasconcelos T
Biochimica et Biophysica Acta - Molecular Basis of Disease 2020; 1866: 165686 (IGR: 21-1)


84628 Inhibition of cAMP/PKA Pathway Protects Optic Nerve Head Astrocytes against Oxidative Stress by Akt/Bax Phosphorylation-Mediated Mfn1/2 Oligomerization
Weinreb RN
Oxidative medicine and cellular longevity 2019; 2019: 8060962 (IGR: 21-1)


84393 Silencing of GAS5 Alleviates Glaucoma in Rat Models by Reducing Retinal Ganglion Cell Apoptosis
Huang JF
Human Genetics and Therapeutics 2019; 30: 1505-1519 (IGR: 21-1)


84736 Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications
Shih KC
BioMed research international 2019; 2019: 8397521 (IGR: 21-1)


84774 Intravitreal Therapy Against the Complement Factor C5 Prevents Retinal Degeneration in an Experimental Autoimmune Glaucoma Model
Dick HB
Frontiers in pharmacology 2019; 10: 1381 (IGR: 21-1)


85210 The Role of Autophagy in Glaucomatous Optic Neuropathy
Russo R
Frontiers in cell and developmental biology 2020; 8: 121 (IGR: 21-1)


84852 Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma
Sengpiel F
Brain communications 2019; 1: fcz035 (IGR: 21-1)


84756 Potential mechanisms of retinal ganglion cell type-specific vulnerability in glaucoma
Dixon MA
Clinical and Experimental Optometry 2019; 0: (IGR: 21-1)


84393 Silencing of GAS5 Alleviates Glaucoma in Rat Models by Reducing Retinal Ganglion Cell Apoptosis
Xia XB
Human Genetics and Therapeutics 2019; 30: 1505-1519 (IGR: 21-1)


84852 Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma
Williams PA
Brain communications 2019; 1: fcz035 (IGR: 21-1)


84756 Potential mechanisms of retinal ganglion cell type-specific vulnerability in glaucoma
Findlay Q
Clinical and Experimental Optometry 2019; 0: (IGR: 21-1)


84774 Intravitreal Therapy Against the Complement Factor C5 Prevents Retinal Degeneration in an Experimental Autoimmune Glaucoma Model
Joachim SC
Frontiers in pharmacology 2019; 10: 1381 (IGR: 21-1)


84974 Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina
Gonçalo T; Gonçalo T; Santiago MF
Biochimica et Biophysica Acta - Molecular Basis of Disease 2020; 1866: 165686 (IGR: 21-1)


84852 Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma
Morgan JE
Brain communications 2019; 1: fcz035 (IGR: 21-1)


84756 Potential mechanisms of retinal ganglion cell type-specific vulnerability in glaucoma
Fletcher EL
Clinical and Experimental Optometry 2019; 0: (IGR: 21-1)


84393 Silencing of GAS5 Alleviates Glaucoma in Rat Models by Reducing Retinal Ganglion Cell Apoptosis
Ji D
Human Genetics and Therapeutics 2019; 30: 1505-1519 (IGR: 21-1)


84756 Potential mechanisms of retinal ganglion cell type-specific vulnerability in glaucoma
Vessey KA
Clinical and Experimental Optometry 2019; 0: (IGR: 21-1)


84974 Neuroprotection from optic nerve injury and modulation of oxidative metabolism by transplantation of active mitochondria to the retina
Linden R; Galina A; Petrs-Silva H; Petrs-Silva H
Biochimica et Biophysica Acta - Molecular Basis of Disease 2020; 1866: 165686 (IGR: 21-1)


82700 Neuroprotective Potential of Pituitary Adenylate Cyclase Activating Polypeptide in Retinal Degenerations of Metabolic Origin
Gábriel R
Frontiers in neuroscience 2019; 13: 1031 (IGR: 20-4)


82130 Meox2 Haploinsufficiency Accelerates Axonal Degeneration in DBA/2J Glaucoma
Buchanan RA
Investigative Ophthalmology and Visual Science 2019; 60: 3283-3296 (IGR: 20-4)


82633 Targeting the vascular-specific phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma
Thomson BR
eLife 2019; 8: (IGR: 20-4)


82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Quaranta L
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)


82459 Immune Mediated Degeneration and Possible Protection in Glaucoma
Tsai T
Frontiers in neuroscience 2019; 13: 931 (IGR: 20-4)


82619 Brimonidine enhances inhibitory postsynaptic activity of OFF- and ON-type retinal ganglion cells in a Wistar rat chronic glaucoma model
Zhou X
Experimental Eye Research 2019; 189: 107833 (IGR: 20-4)


82151 IL-1 Family Members Mediate Cell Death, Inflammation and Angiogenesis in Retinal Degenerative Diseases
Wooff Y
Frontiers in immunology 2019; 10: 1618 (IGR: 20-4)


81992 The effects of endothelium-specific CYP2J2 overexpression on the attenuation of retinal ganglion cell apoptosis in a glaucoma rat model
Huang J
FASEB Journal 2019; 33: 11194-11209 (IGR: 20-4)


82354 Survival of Alpha and Intrinsically Photosensitive Retinal Ganglion Cells in NMDA-Induced Neurotoxicity and a Mouse Model of Normal Tension Glaucoma
Honda S
Investigative Ophthalmology and Visual Science 2019; 60: 3696-3707 (IGR: 20-4)


82660 Role of Heat Shock Proteins in Glaucoma
Tsai T
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Krishnan A
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)


82820 The effects of intravitreal H S application on apoptosis in the retina and cornea in experimental glaucoma model
Erisgin Z
International journal of experimental pathology 2019; 100: 330-336 (IGR: 20-4)


82563 Enriched environment provides neuroprotection against experimental glaucoma
González Fleitas MF
Journal of Neurochemistry 2020; 152: 103-121 (IGR: 20-4)


82686 Tetrahedral framework nucleic acids prevent retina ischemia-reperfusion injury from oxidative stress via activating the Akt/Nrf2 pathway
Qin X
Nanoscale 2019; 11: 20667-20675 (IGR: 20-4)


82707 Potential Impact of DARC Technology in Neuroprotective Therapies
Pahlitzsch M
Klinische Monatsblätter für Augenheilkunde 2020; 237: 140-142 (IGR: 20-4)


81949 Neuroprotective Effect of Ginkgo Biloba Extract Against Hypoxic Retinal Ganglion Cell Degeneration and
Cho HK
Journal of medicinal food 2019; 22: 771-778 (IGR: 20-4)


82800 Human Umbilical Cord Mesenchymal Stem Cells Attenuate Ocular Hypertension-Induced Retinal Neuroinflammation via Toll-Like Receptor 4 Pathway
Ji S
Stem cells international 2019; 2019: 9274585 (IGR: 20-4)


82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Guo Y
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)


82639 Extracellular Signal-Regulated Kinase 1/2 Pathway Is Insufficiently Involved in the Neuroprotective Effect by Hydrogen Sulfide Supplement in Experimental Glaucoma
Huang S
Investigative Ophthalmology and Visual Science 2019; 60: 4346-4359 (IGR: 20-4)


82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Chițu I
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)


82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Choi KJ
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)


82799 Impairment of Membrane Repolarization Accompanies Axon Transport Deficits in Glaucoma
Fischer RA
Frontiers in neuroscience 2019; 13: 1139 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Fernández-Albarral JA
International journal of molecular sciences 2019; 20: (IGR: 20-4)


81958 Human retinal ganglion cell axon regeneration by recapitulating developmental mechanisms: effects of recruitment of the mTOR pathway
Teotia P
Development 2019; 146: (IGR: 20-4)


82093 Betulinic acid derivatives can protect human Müller cells from glutamate-induced oxidative stress
Cheng Z
Experimental Cell Research 2019; 383: 111509 (IGR: 20-4)


81980 Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: implications for neuroprotection in glaucoma
Stankowska DL
Cell death discovery 2019; 5: 112 (IGR: 20-4)


82336 Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine
Khatib TZ
Current Eye Research 2020; 45: 327-338 (IGR: 20-4)


82102 microRNA dysregulation in neurodegenerative diseases: A systematic review
Juźwik CA
Progress in Neurobiology 2019; 182: 101664 (IGR: 20-4)


82655 DDIT3 (CHOP) contributes to retinal ganglion cell somal loss but not axonal degeneration in DBA/2J mice
Marola OJ
Cell death discovery 2019; 5: 140 (IGR: 20-4)


82001 Axon injury signaling and compartmentalized injury response in glaucoma
Syc-Mazurek SB
Progress in Retinal and Eye Research 2019; 73: 100769 (IGR: 20-4)


82313 The Neuroprotective Effect of the Adiponectin Receptor Agonist AdipoRon on Glutamate-Induced Cell Death in Rat Primary Retinal Ganglion Cells
Uchida T
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 535-541 (IGR: 20-4)


82152 Green Tea Extract Ameliorates Ischemia-Induced Retinal Ganglion Cell Degeneration in Rats
Yang Y
Oxidative medicine and cellular longevity 2019; 2019: 8407206 (IGR: 20-4)


82347 Target-Derived Neurotrophic Factor Deprivation Puts Retinal Ganglion Cells on Death Row: Cold Hard Evidence and Caveats
Claes M
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82152 Green Tea Extract Ameliorates Ischemia-Induced Retinal Ganglion Cell Degeneration in Rats
Xu C
Oxidative medicine and cellular longevity 2019; 2019: 8407206 (IGR: 20-4)


82639 Extracellular Signal-Regulated Kinase 1/2 Pathway Is Insufficiently Involved in the Neuroprotective Effect by Hydrogen Sulfide Supplement in Experimental Glaucoma
Huang P
Investigative Ophthalmology and Visual Science 2019; 60: 4346-4359 (IGR: 20-4)


82102 microRNA dysregulation in neurodegenerative diseases: A systematic review
S Drake S
Progress in Neurobiology 2019; 182: 101664 (IGR: 20-4)


82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Na YJ
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)


81949 Neuroprotective Effect of Ginkgo Biloba Extract Against Hypoxic Retinal Ganglion Cell Degeneration and
Kim S
Journal of medicinal food 2019; 22: 771-778 (IGR: 20-4)


82336 Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine
Martin KR
Current Eye Research 2020; 45: 327-338 (IGR: 20-4)


82093 Betulinic acid derivatives can protect human Müller cells from glutamate-induced oxidative stress
Zhang T
Experimental Cell Research 2019; 383: 111509 (IGR: 20-4)


82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Voinea LM
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)


82655 DDIT3 (CHOP) contributes to retinal ganglion cell somal loss but not axonal degeneration in DBA/2J mice
Syc-Mazurek SB
Cell death discovery 2019; 5: 140 (IGR: 20-4)


82799 Impairment of Membrane Repolarization Accompanies Axon Transport Deficits in Glaucoma
Risner ML
Frontiers in neuroscience 2019; 13: 1139 (IGR: 20-4)


82001 Axon injury signaling and compartmentalized injury response in glaucoma
Libby RT
Progress in Retinal and Eye Research 2019; 73: 100769 (IGR: 20-4)


82686 Tetrahedral framework nucleic acids prevent retina ischemia-reperfusion injury from oxidative stress via activating the Akt/Nrf2 pathway
Li N
Nanoscale 2019; 11: 20667-20675 (IGR: 20-4)


82800 Human Umbilical Cord Mesenchymal Stem Cells Attenuate Ocular Hypertension-Induced Retinal Neuroinflammation via Toll-Like Receptor 4 Pathway
Xiao J
Stem cells international 2019; 2019: 9274585 (IGR: 20-4)


82347 Target-Derived Neurotrophic Factor Deprivation Puts Retinal Ganglion Cells on Death Row: Cold Hard Evidence and Caveats
De Groef L
International journal of molecular sciences 2019; 20: (IGR: 20-4)


81958 Human retinal ganglion cell axon regeneration by recapitulating developmental mechanisms: effects of recruitment of the mTOR pathway
Van Hook MJ
Development 2019; 146: (IGR: 20-4)


82313 The Neuroprotective Effect of the Adiponectin Receptor Agonist AdipoRon on Glutamate-Induced Cell Death in Rat Primary Retinal Ganglion Cells
Ueta T
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 535-541 (IGR: 20-4)


81980 Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: implications for neuroprotection in glaucoma
Nam MH
Cell death discovery 2019; 5: 112 (IGR: 20-4)


82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Kocab AJ
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)


82130 Meox2 Haploinsufficiency Accelerates Axonal Degeneration in DBA/2J Glaucoma
Foley KE
Investigative Ophthalmology and Visual Science 2019; 60: 3283-3296 (IGR: 20-4)


82563 Enriched environment provides neuroprotection against experimental glaucoma
Devouassoux JD
Journal of Neurochemistry 2020; 152: 103-121 (IGR: 20-4)


82633 Targeting the vascular-specific phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma
Carota IA
eLife 2019; 8: (IGR: 20-4)


82619 Brimonidine enhances inhibitory postsynaptic activity of OFF- and ON-type retinal ganglion cells in a Wistar rat chronic glaucoma model
Zhang T
Experimental Eye Research 2019; 189: 107833 (IGR: 20-4)


82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Mehrabian Z
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)


82700 Neuroprotective Potential of Pituitary Adenylate Cyclase Activating Polypeptide in Retinal Degenerations of Metabolic Origin
Pöstyéni E
Frontiers in neuroscience 2019; 13: 1031 (IGR: 20-4)


81992 The effects of endothelium-specific CYP2J2 overexpression on the attenuation of retinal ganglion cell apoptosis in a glaucoma rat model
Zhao Q
FASEB Journal 2019; 33: 11194-11209 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
Ramírez AI
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82660 Role of Heat Shock Proteins in Glaucoma
Grotegut P
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82151 IL-1 Family Members Mediate Cell Death, Inflammation and Angiogenesis in Retinal Degenerative Diseases
Man SM
Frontiers in immunology 2019; 10: 1618 (IGR: 20-4)


82354 Survival of Alpha and Intrinsically Photosensitive Retinal Ganglion Cells in NMDA-Induced Neurotoxicity and a Mouse Model of Normal Tension Glaucoma
Namekata K
Investigative Ophthalmology and Visual Science 2019; 60: 3696-3707 (IGR: 20-4)


82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Riva I
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)


82459 Immune Mediated Degeneration and Possible Protection in Glaucoma
Reinehr S
Frontiers in neuroscience 2019; 13: 931 (IGR: 20-4)


82820 The effects of intravitreal H S application on apoptosis in the retina and cornea in experimental glaucoma model
Ozer MA
International journal of experimental pathology 2019; 100: 330-336 (IGR: 20-4)


82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Istrate S
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)


82000 Evaluating the Effects of an Ophthalmic Solution of Coenzyme Q10 and Vitamin E in Open-Angle Glaucoma Patients: A Study Protocol
Biagioli E
Advances in Therapy 2019; 36: 2506-2514 (IGR: 20-4)


82660 Role of Heat Shock Proteins in Glaucoma
Reinehr S
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82563 Enriched environment provides neuroprotection against experimental glaucoma
Aranda ML
Journal of Neurochemistry 2020; 152: 103-121 (IGR: 20-4)


82354 Survival of Alpha and Intrinsically Photosensitive Retinal Ganglion Cells in NMDA-Induced Neurotoxicity and a Mouse Model of Normal Tension Glaucoma
Kimura A
Investigative Ophthalmology and Visual Science 2019; 60: 3696-3707 (IGR: 20-4)


82093 Betulinic acid derivatives can protect human Müller cells from glutamate-induced oxidative stress
Zheng J
Experimental Cell Research 2019; 383: 111509 (IGR: 20-4)


82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Johnson MA
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)


82700 Neuroprotective Potential of Pituitary Adenylate Cyclase Activating Polypeptide in Retinal Degenerations of Metabolic Origin
Dénes V
Frontiers in neuroscience 2019; 13: 1031 (IGR: 20-4)


82102 microRNA dysregulation in neurodegenerative diseases: A systematic review
Zhang Y
Progress in Neurobiology 2019; 182: 101664 (IGR: 20-4)


82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Jung WH
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)


82799 Impairment of Membrane Repolarization Accompanies Axon Transport Deficits in Glaucoma
Roux AL
Frontiers in neuroscience 2019; 13: 1139 (IGR: 20-4)


82151 IL-1 Family Members Mediate Cell Death, Inflammation and Angiogenesis in Retinal Degenerative Diseases
Aggio-Bruce R
Frontiers in immunology 2019; 10: 1618 (IGR: 20-4)


82152 Green Tea Extract Ameliorates Ischemia-Induced Retinal Ganglion Cell Degeneration in Rats
Chen Y
Oxidative medicine and cellular longevity 2019; 2019: 8407206 (IGR: 20-4)


82655 DDIT3 (CHOP) contributes to retinal ganglion cell somal loss but not axonal degeneration in DBA/2J mice
Libby RT
Cell death discovery 2019; 5: 140 (IGR: 20-4)


82686 Tetrahedral framework nucleic acids prevent retina ischemia-reperfusion injury from oxidative stress via activating the Akt/Nrf2 pathway
Zhang M
Nanoscale 2019; 11: 20667-20675 (IGR: 20-4)


82347 Target-Derived Neurotrophic Factor Deprivation Puts Retinal Ganglion Cells on Death Row: Cold Hard Evidence and Caveats
Moons L
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
de Hoz R
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82459 Immune Mediated Degeneration and Possible Protection in Glaucoma
Maliha AM
Frontiers in neuroscience 2019; 13: 931 (IGR: 20-4)


82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Zacks DN
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)


82130 Meox2 Haploinsufficiency Accelerates Axonal Degeneration in DBA/2J Glaucoma
Pepper KW
Investigative Ophthalmology and Visual Science 2019; 60: 3283-3296 (IGR: 20-4)


82820 The effects of intravitreal H S application on apoptosis in the retina and cornea in experimental glaucoma model
Tosun M
International journal of experimental pathology 2019; 100: 330-336 (IGR: 20-4)


82313 The Neuroprotective Effect of the Adiponectin Receptor Agonist AdipoRon on Glutamate-Induced Cell Death in Rat Primary Retinal Ganglion Cells
Honjo M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 535-541 (IGR: 20-4)


81980 Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: implications for neuroprotection in glaucoma
Nahomi RB
Cell death discovery 2019; 5: 112 (IGR: 20-4)


82639 Extracellular Signal-Regulated Kinase 1/2 Pathway Is Insufficiently Involved in the Neuroprotective Effect by Hydrogen Sulfide Supplement in Experimental Glaucoma
Yu H
Investigative Ophthalmology and Visual Science 2019; 60: 4346-4359 (IGR: 20-4)


81949 Neuroprotective Effect of Ginkgo Biloba Extract Against Hypoxic Retinal Ganglion Cell Degeneration and
Lee EJ
Journal of medicinal food 2019; 22: 771-778 (IGR: 20-4)


82800 Human Umbilical Cord Mesenchymal Stem Cells Attenuate Ocular Hypertension-Induced Retinal Neuroinflammation via Toll-Like Receptor 4 Pathway
Liu J
Stem cells international 2019; 2019: 9274585 (IGR: 20-4)


82633 Targeting the vascular-specific phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma
Souma T
eLife 2019; 8: (IGR: 20-4)


81992 The effects of endothelium-specific CYP2J2 overexpression on the attenuation of retinal ganglion cell apoptosis in a glaucoma rat model
Li M
FASEB Journal 2019; 33: 11194-11209 (IGR: 20-4)


81958 Human retinal ganglion cell axon regeneration by recapitulating developmental mechanisms: effects of recruitment of the mTOR pathway
Fischer D
Development 2019; 146: (IGR: 20-4)


82619 Brimonidine enhances inhibitory postsynaptic activity of OFF- and ON-type retinal ganglion cells in a Wistar rat chronic glaucoma model
Wu J
Experimental Eye Research 2019; 189: 107833 (IGR: 20-4)


82800 Human Umbilical Cord Mesenchymal Stem Cells Attenuate Ocular Hypertension-Induced Retinal Neuroinflammation via Toll-Like Receptor 4 Pathway
Tang S
Stem cells international 2019; 2019: 9274585 (IGR: 20-4)


82282 Neuroprotective and Anti-Inflammatory Effects of a Hydrophilic Saffron Extract in a Model of Glaucoma
López-Villarín N
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82820 The effects of intravitreal H S application on apoptosis in the retina and cornea in experimental glaucoma model
Ozen S
International journal of experimental pathology 2019; 100: 330-336 (IGR: 20-4)


82372 Protective effect of a novel selective 11β-HSD1 inhibitor on eye ischemia-reperfusion induced glaucoma
Park SB
Biochemical Pharmacology 2019; 169: 113632 (IGR: 20-4)


81958 Human retinal ganglion cell axon regeneration by recapitulating developmental mechanisms: effects of recruitment of the mTOR pathway
Ahmad I
Development 2019; 146: (IGR: 20-4)


82313 The Neuroprotective Effect of the Adiponectin Receptor Agonist AdipoRon on Glutamate-Induced Cell Death in Rat Primary Retinal Ganglion Cells
Aihara M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 535-541 (IGR: 20-4)


82633 Targeting the vascular-specific phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma
Soman S
eLife 2019; 8: (IGR: 20-4)


82639 Extracellular Signal-Regulated Kinase 1/2 Pathway Is Insufficiently Involved in the Neuroprotective Effect by Hydrogen Sulfide Supplement in Experimental Glaucoma
Lin Z
Investigative Ophthalmology and Visual Science 2019; 60: 4346-4359 (IGR: 20-4)


82102 microRNA dysregulation in neurodegenerative diseases: A systematic review
Paradis-Isler N
Progress in Neurobiology 2019; 182: 101664 (IGR: 20-4)


81949 Neuroprotective Effect of Ginkgo Biloba Extract Against Hypoxic Retinal Ganglion Cell Degeneration and
Kee C
Journal of medicinal food 2019; 22: 771-778 (IGR: 20-4)


82130 Meox2 Haploinsufficiency Accelerates Axonal Degeneration in DBA/2J Glaucoma
Reagan AM
Investigative Ophthalmology and Visual Science 2019; 60: 3283-3296 (IGR: 20-4)


82354 Survival of Alpha and Intrinsically Photosensitive Retinal Ganglion Cells in NMDA-Induced Neurotoxicity and a Mouse Model of Normal Tension Glaucoma
Guo X
Investigative Ophthalmology and Visual Science 2019; 60: 3696-3707 (IGR: 20-4)


81992 The effects of endothelium-specific CYP2J2 overexpression on the attenuation of retinal ganglion cell apoptosis in a glaucoma rat model
Duan Q
FASEB Journal 2019; 33: 11194-11209 (IGR: 20-4)


82459 Immune Mediated Degeneration and Possible Protection in Glaucoma
Joachim SC
Frontiers in neuroscience 2019; 13: 931 (IGR: 20-4)


82686 Tetrahedral framework nucleic acids prevent retina ischemia-reperfusion injury from oxidative stress via activating the Akt/Nrf2 pathway
Lin S
Nanoscale 2019; 11: 20667-20675 (IGR: 20-4)


82151 IL-1 Family Members Mediate Cell Death, Inflammation and Angiogenesis in Retinal Degenerative Diseases
Natoli R
Frontiers in immunology 2019; 10: 1618 (IGR: 20-4)


81980 Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: implications for neuroprotection in glaucoma
Chaphalkar RM
Cell death discovery 2019; 5: 112 (IGR: 20-4)


82660 Role of Heat Shock Proteins in Glaucoma
Joachim SC
International journal of molecular sciences 2019; 20: (IGR: 20-4)


82757 The neuroprotective role of citicoline treatment in glaucoma - 6 months results of a prospective therapeutic trial
Vrapciu A
Romanian journal of ophthalmology 2019; 63: 222-230 (IGR: 20-4)


82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Marshak-Rothstein A
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)


82563 Enriched environment provides neuroprotection against experimental glaucoma
Calanni JS
Journal of Neurochemistry 2020; 152: 103-121 (IGR: 20-4)


82093 Betulinic acid derivatives can protect human Müller cells from glutamate-induced oxidative stress
Ding W
Experimental Cell Research 2019; 383: 111509 (IGR: 20-4)


82843 Topical Trabodenoson Is Neuroprotective in a Rodent Model of Anterior Ischemic Optic Neuropathy (rNAION)
Albers DS
Translational vision science & technology 2019; 8: 47 (IGR: 20-4)


82152 Green Tea Extract Ameliorates Ischemia-Induced Retinal Ganglion Cell Degeneration in Rats
Liang JJ
Oxidative medicine and cellular longevity 2019; 2019: 8407206 (IGR: 20-4)


82799 Impairment of Membrane Repolarization Accompanies Axon Transport Deficits in Glaucoma
Wareham LK
Frontiers in neuroscience 2019; 13: 1139 (IGR: 20-4)


82633 Targeting the vascular-specific phosphatase PTPRB protects against retinal ganglion cell loss in a pre-clinical model of glaucoma
Vestweber D
eLife 2019; 8: (IGR: 20-4)


81992 The effects of endothelium-specific CYP2J2 overexpression on the attenuation of retinal ganglion cell apoptosis in a glaucoma rat model
Zhao Y
FASEB Journal 2019; 33: 11194-11209 (IGR: 20-4)


82528 A small peptide antagonist of the Fas receptor inhibits neuroinflammation and prevents axon degeneration and retinal ganglion cell death in an inducible mouse model of glaucoma
Gregory-Ksander M
Journal of Neuroinflammation 2019; 16: 184 (IGR: 20-4)


82151 IL